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Résumé 
Cette thèse de doctorat porte sur la catalyse à partir de métaux de transition et sur la 
substitution homolytique aromatique favorisée par une base visant à former de nouvelles 
liaisons C–C, et à ainsi concevoir de nouvelles structures chimiques. Au cours des vingt 
dernières années, des nombreux efforts ont été réalisés afin de développer des méthodologies 
pour la fonctionnalisation de liens C–H, qui soient efficaces et sélectives, et ce à faible coût et 
en produisant le minimum de déchets. Le chapitre d'introduction donnera un aperçu de la 
fonctionnalisation directe de liens C–H sur des centres sp2 et sp3. Il sera également discuté 
dans cette partie de certains aspects de la chimie radicalaire reliés a ce sujet. Les travaux sur la 
fonctionnalisation d’imidazo[1,5-a]pyridines catalysée par des compleces de ruthénium seront 
présentés dans le chapitre 2. Malgré l'intérêt des imidazo[1,5-a]azines en chimie médicinale, 
ces composés n’ont reçu que peu d'attention dans le domaine de la fonctionnalisation de liens 
C–H. L'étendue de la réaction et l'influence des effets stériques et électroniques seront 
détaillés.  
Les cyclopropanes représentent les 10ème cycles carbonés les plus rencontrés dans les 
petites molécules d’intérêt pharmacologique. Ce sont aussi des intermédiaires de synthèse de 
choix pour la création de complexité chimique. Malgré de grands progrès dans le domaine de 
la fonctionnalisation de liens C(sp3)–H, l'étude des cyclopropanes comme substrats dans les 
transformations directes est relativement nouvelle. Le chapitre trois présentera l'arylation 
intramoléculaire directe de cyclopropanes. Cette réaction est réalisée en présence de 
palladium, en quantité catalytique, en combinaison avec des sels d’argent. Des études 
mécanistiques ont réfuté la formation d'un énolate de palladium et suggéreraient plutôt une 
étape de métallation - déprotonation concertée. En outre, les cycles de type benzoazepinone à 
sept chaînons ont été synthétisés par l'intermédiaire d'une séquence d'activation de 
cyclopropane/ouverture/cyclisation. Une arylation directe intermoléculaire des cyclopropanes 
a été réalisée en présence d'un auxiliaire de type  picolinamide (Chapitre 4). 
Les deux derniers chapitres de ce mémoire de thèse décriront nos études sur la 
substitution homolytique aromatique favorisée par une base. Le mécanisme de la réaction de 
cyclisation intramoléculaire d'halogénures d'aryle, réalisée en présence de tert-butylate de 
 ii 
potassium, a été élucidé et se produit via une voie radicalaire (Chapitre 5). La transformation, 
exempte de métaux de transition, ne nécessite que la présence d’une base et de pyridine 
comme solvant. Cette réaction radicalaire a été étendue à la cyclisation d'iodures d'alkyle non 
activés en présence d'un catalyseur à base de nickel et de bis(trimethylsilyl)amidure de sodium 
comme base (Chapitre 6). Des études de RMN DOSY ont démontré une association entre le 
catalyseur, la base et le matériel de départ. 
Mots-clés : catalyse, activation C–H, métal de transition, substitution homolitique aromatique, 
tert-butylate de potassium, phénanthridines, cyclopropanes, imidazo[1,5-a]azines. 
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Abstract 
The dissertation will focus on transition metal catalysis and base-promoted homolytic 
aromatic substitution as a means of forming new C–C bonds, and thus designing new chemical 
scaffolds. During the last twenty years, tremenduous efforts have been expended to achieve 
low-cost, waste-free, efficient and selective C–H bond functionalization methodologies. The 
introductory chapter will provide an overview of direct functionalization of C–H sp2 and sp3 
centers, as well as discuss relevant topics in radical chemistry. Work on the ruthenium-
catalyzed functionalization of imidazo[1,5-a]pyridines will be presented in Chapter 2. Despite 
interest from the medicinal chemistry field, imidazo[1,5-a]azines have received little attention 
in the C–H functionalization field. The scope of the reaction and, in particular, the influence of 
sterics and electronics will be detailed. 
Cyclopropanes represent the 10th most encountered rings in small drug synthesis. They 
are also valuable synthetic intermediates en route to more chemical complexity. Despite great 
advances in the field of C(sp3)–H functionalizations, the exploration of cyclopropanes as 
substrates in direct transformations is relatively novel. Chapter three will present the 
intramolecular direct arylation of cyclopropanes. A combination of palladium catalysis in 
presence of a silver salt was found to mediate the reaction. Mechanistic studies disproved the 
formation of a palladium-enolate and pointed towards a concerted metalation-deprotonation 
pathway. Furthermore, seven-membered benzoazepinone rings were synthesized via a 
cyclopropane activation/opening/cyclization sequence. An intermolecular direct arylation of 
cyclopropanes was achieved in presence of a picolinamide auxiliary (Chapter 4). 
The last two chapters of the thesis will describe our studies on base-promoted 
homolytic aromatic substitution. A potassium tert-butoxide-promoted intramolecular 
cyclization of aryl halides was shown to occur through a radical pathway (Chapter 5). The 
transition metal-free transformation occurred in the sole presence of the base and pyridine as 
the solvent. The radical process was extended to the cyclization of unactivated alkyl iodides in 
presence of a nickel catalyst and sodium hexamethyldisilzide as the base (Chapter 6). DOSY 
NMR studies demonstrated an association between the catalyst, base and starting material.  
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Keywords: catalysis, C–H functionalization, transition metal, homolytic aromatic substitution, 
potassium tert-butoxide, phenanthridines, cyclopropanes, imidazo[1,5-a]azines.  
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Chapter 1: C–C bond formation 
The rapid and efficient assembly of complex chemical structures is highly desired in 
organic synthesis. In the last two centuries, an enormous number of reactions and reagents 
have been developed in order to ease the process of chemical synthesis. In particular, carbon-
carbon bond forming reactions have played a significant role in shaping organic chemistry. 
For example, the Grignard,1 Diels-Alder2 or Wittig3 reactions have certainly changed the 
world of synthesis, and their contribution has been recognized by the Nobel Prize committee.4 
Cross-couplings represent a special category of carbon-carbon bond forming reactions, in 
which a transition metal, usually in a catalytic amount, is employed to combine two partners, 
which in some cases require to be synthesized. Cross-couplings have already shown 
tremendous applications in the synthesis of pharmaceuticals, herbicides, electronics, materials 
etc. (Figure 1).5 In 2010, the Nobel Prize in chemistry4 was awarded to three cross-coupling 
pioneers: Richard Heck, Eichii Negishi and Akira Suzuki. 
 
Figure 1. Examples of pharmaceuticals that employed a cross-coupling step in their synthesis 
 Cross-couplings are highly efficient reactions, they are run under mild conditions, and 
demonstrate excellent functional group tolerance and selectivity. One commonly encountered 
criticism to cross-couplings (except the Heck reaction) is the need for two pre-activated 
coupling partners, which is wasteful to the overall atom economy of the process. In addition, 
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the use of stoichiometric amounts of organometallic reagents with moderate to high toxicity 
(for example, organotin reagents) may affect the applicability of some of the transformations 
in the pharmaceutical industry. Despite the drawbacks, the number of publications and patents 
related to carbon-carbon bond formation via cross-couplings is on the rise, with the Suzuki-
Miyaura transformation being the most popular in an industrial setting.6 
 Sustainable chemistry, or green chemistry, refers to the design of processes that reduce 
or eliminate the use or generation of hazardous substances.7 The twelve principles of green 
chemistry also underline the importance of atom economy, catalysis and energy efficiency. 
Based on the principles, the ideal carbon-carbon bond forming reaction should involve the 
oxidative coupling of two C–H bonds in presence of a reusable catalyst. Oxidative couplings 
or cross-dehydrogenative couplings (CDC) have already been developed,8 but most often 
suffer from issues such as selectivity or high reaction temperature. Considerable effort has 
instead focused on the functionalization of C–H bonds with a pre-formed coupling partner 
(most often an aryl or alkyl halide). Figure 2 contains selected examples of total syntheses 
where C–H functionalization was applied.9 Such strategies for C–H functionalization were 
also the focus of a significant amount of work during the PhD research presented herein and 
will be further discussed.   
 
Figure 2. Selected examples of C–H activation in total synthesis 
 3 
A different approach for C–C bond formation is represented by radical reactions. In 
particular, homolytic aromatic substitution (HAS) has become a common methodology in 
organic synthesis.10 A number of natural products and current drug targets have been 
synthesized via HAS strategies (Figure 3).11 Of late, HAS promoted by a strong base, such as 
potassium tert-butoxide, has gathered a lot of attention in the chemical community,12 and the 
last part of the thesis will be dedicated to the advances of the methodology.  
 
Figure 3. Examples of natural products synthesized via an HAS reaction 
Scheme 1 provides a short summary of all the C–C bond forming strategies discussed 
thus far, exemplified by C(sp2)–R (where R = aryl, alkenyl, alkynyl, alkyl, M = metal, and X = 
halogen) bond formation. 
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Scheme 1. Approaches for the synthesis of C(sp2)–R bonds 
 
1.1 Direct arylation strategies  
In recent years, the direct coupling of an aryl C–H bond (bond dissociation energy 113 
kcal/mol for benzene)13 with a pre-activated arene partner has emerged as a reliable and 
efficient method for the synthesis of biaryl-containing molecules, both inter- and 
intramolecularly.14 A particular challenge is site selectivity, which refers to the preferred 
reaction of one C–H bond in the molecule versus all others. In an intramolecular system, 
regioselectivity is influenced by the use of a tether, which limits the degree of freedom in the 
system.14a In an intermolecular system a number of factors contribute to site selectivity, such 
as electronics of the arene, or the use of directing groups.14a The next sections will provide an 
overview of the strategies employed to improve efficiency and selectivity in direct 
transformations, as well as describe mechanistic considerations.  
1.1.1 Intramolecular direct arylation 
A couple of early examples of intramolecular arylation of a C–H bond were reported 
by the group of Ames.15 While attempting to functionalize bromocinnoline scaffold 1 via a 
Heck reaction, the only product observed was the five-membered ring 3 resulting from direct 
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arylation (55%, Scheme 2A).15a The former strategy was further applied to the synthesis of 
benzofurans and benzopyrans (Scheme 2B, example for benzopyran 5).15b,c In addition to the 
low yield, a significant problem with the reaction was the formation of high amounts of 
debrominated ether 6 (35% yield, Scheme 2B).  
Scheme 2. Ames’ early examples of intramolecular direct arylation15 
 
 Later, Fagnou’s group looked at improving the arylation-to-hydrodehalogenation 
ratio of Ames’ benzopyran system.16,17 Initial results revealed that the employment of 
PhDavePhos as a ligand for Pd in presence of the inorganic base potassium carbonate provided 
the products in 96% yield, with a 165 to 1 ratio of benzopyran 5 to dehalogenated product 6 
(Scheme 3).16a  
Scheme 3. Fagnou’s synthesis of benzopyran16a 
 
 Even though the system was ideal for the cyclization of aryl bromides, aryl chlorides 
showed poor reactivity. An in-depth look at ligand effects for the cyclization of aryl chloride 
4b showed that sterically hindered alkyl phosphines such as PCy3∙HBF4 and P(tBu)2Me∙HBF4 
led to higher reactivities than the previously employed aryl phosphines.17 A significant base 
effect was also noted and summarized in Table 1.17 K2CO3 was most effective (entry 1), while 
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other carbonate bases (Na2CO3 and Cs2CO3) provided low conversions and decreased 
selectivities (entries 2 and 3). KOAc provided good selectivity for the benzopyran product, but 
lower conversions (entry 4), while K3PO4 resulted in poor conversion and selectivity (entry 5). 
The strong, non-nucleophilic base KOtBu gave a good conversion, but significant amounts of 
hydrodehalogenated product 6 (entry 6). Aryl iodides of type 4 could also be cyclized; 
however, it was found necessary to add a silver additive (such as Ag2CO3 or AgOTf) in order 
to sequester the iodide produced. In absence of the silver additive, the iodide had been 
revealed to inhibit the palladium catalyst, thus shutting down the reaction.17 
Table 1. Base effects in the intramolecular direct arylation of simple arenes17 
 
entry base conversion (%) ratio 5:6 
1 K2CO3 100 >99:1 
2 Na2CO3 11 20:1 
3 Cs2CO3 25 15:1 
4 KOAc 81 >99:1 
5 K3PO4 13 5:1 
6 KOtBu 84 2.3:1 
It is worth going over several mechanistic possibilities for direct arylation reactions, as 
they will repeatedly be discussed throughout the introduction. All the reactions presented thus 
far follow a classic Pd0/II catalytic cycle, where the first and last steps are always oxidative 
addition and reductive elimination, while the middle steps have been the target of much debate 
over the last few decades (Scheme 4). Electrophilic aromatic substitution (SEAr, Scheme 4a), 
which involves attack of the arene onto the metal centre has been proposed by Ames in his 
studies.15  SEAr has also been confirmed to occur in several other direct arylation 
transformations, including the Pd-catalyzed, domino reaction first introduced by Catellani.18 
The concomitant formation of the M–C and X–H bonds is represented by σ-bond metathesis 
(Scheme 4b). DFT calculations have suggested the pathway to be common in direct 
arylation.19 A related process, concerted metalation-deprotonation (CMD), implies a 
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simultaneous metalation and intramolecular deprotonation mechanism and will be discussed in 
Section 1.1.3. An SE3 process is also plausible, where an external base is involved in the arene 
deprotonation step (Scheme 4c).17  Oxidative addition by two C–H bonds onto the metal 
centre is another possibility (Scheme 4d).8 Finally, a Heck-type mechanism (Scheme 4e) has 
also been suggested; however, the process implies a rare anti β-hydride elimination, or an 
isomerization followed by a syn β-hydride elimination.9c A variety of experiments can be 
employed to provide insights into the reaction mechanism, such as kinetic isotope effect (KIE) 
determination, labelling and competition studies, Hammett plots, etc. and these will be 
discussed according to each example presented. 
Scheme 4. Direct arylation pathways (exemplified in an intramolecular fashion) 
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Fagnou and co-workers determined a primary kinetic isotope effect of 4.25, and it was 
incorrectly suggested that the C–H bond breaking event is the limiting step of the 
transformation (Scheme 5a);17 the observation of a KIE in the intramolecular competition 
experiment in Scheme 5a cannot on its own predict that C–H cleavage is rate-determining.20 
Intramolecular competition experiments revealed a small selectivity for electron-rich rings 
(Scheme 5b), while Echavarren’s earlier findings were of no strong electronic bias in direct 
arylation reactions.21 A likely proposal for the mechanism is either σ-bond metathesis or an 
SE3 process, in which the base, potassium carbonate, deprotonates the arene (Scheme 5c).  
Scheme 5. Fagnou’s mechanistic studies and transition state proposals17 
 
1.1.2 Intermolecular direct arylation  
In intramolecular transformations, proximity of the two coupling partners induced by 
the use of a tether aids in product formation. That is not the case in intermolecular reactions, 
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thus several strategies have been explored in order to increase the yields and especially the 
selectivities. Figure 4 presents an overview of the strategies, divided into substrate and 
catalyst based-control.22 The metal-catalyzed, direct functionalization of simple, unactivated 
arenes is quite uncommon (due to their low nucleophilicity), hence the presence of a 
heteroatom in the ring or a substituent that may alter the pKa of the C–H bond to be 
functionalized plays an important role.14b Perhaps the most applied and, at the same time, most 
useful strategy is the employment of directing groups. The aforementioned strategy can be 
further divided into “proximal” effects, where, for example, the transformation takes place at 
the ortho position of an arene, or remote functionalizations, where the reaction takes place 
several bonds away from the directing group.22a Catalysts or ligands can also dictate selectivity 
and influence the reaction outcome. 
 
Figure 4. Strategies for intermolecular direct functionalizations22 
In 1989, Ohta and co-workers reported one of the first examples of heterocyclic direct 
arylation.23 Targeting the indole system, it was demonstrated that the N-protecting group can 
dictate the reaction outcome, as one can get a selective arylation at the C-2 position (if R = 
Me) or the C-3 position (if R = Ts, 50:1 ratio for the C-3 to the C-2 position) (Scheme 6).  
Scheme 6. Ohta’s strategy for indole arylation23 
N
R N
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R
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N
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2
3
 
Later, Sames described the Rh-catalyzed arylation of unprotected (free NH) indoles 
and pyrroles (Scheme 7).24 A selective C-2 arylation occurred in presence of [Rh(coe)2Cl]2 as 
the catalyst, triphenylphosphine as the ligand and the weak base cesium pivalate. Other 
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functionalities that were tolerated under the conditions included carbamate, carboxamide, and 
sulfonamide. The proposed mechanism involved a RhI/III catalytic cycle, in which CsOPiv 
activated the catalyst to form a rhodium pivalate species responsible for the C–H activation -
process.24 Itami and co-workers also employed a Rh catalyst for the direct arylation of the 
thiophene core with aryl iodides (Scheme 7).25 In Itami’s case, the use of a strongly π-acceptor 
phosphine ligand, P[OCH(CF3)2]3 was key to the transformation. Notably, the reaction is 
performed under microwave radiation and further arylation of the substrate can be suppressed 
by the addition of dimethoxyethane.  
Scheme 7. Rh-catalyzed arylation of heterocycles24,25 
 
 The direct arylation of other electron deficient heterocycles, such as pyridines, is 
challenging, due to their high Lewis basicity. The Fagnou group developed conditions for the 
direct functionalization of pyridine N-oxides instead (Scheme 8).26 The N-oxide functionality 
decreased the pKa of the 2-position of the heterocycle, and prevented binding of the transition 
metal to the pyridine nitrogen, which could cause catalyst poisoning. The Charette group 
explored N-iminopyridinium ylides in direct arylation, alkenylation and other 
transformations.27 The pyridinium ylide is easily installed in two steps, and its role is both in 
activating the pyridine ring and as a directing tool for the transition metal. Both the N-oxide 
and pyridinium ylide moieties could be deprotected under reductive conditions. 
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Scheme 8. Arylation of pyridine N-oxides and N-iminopyridinium ylides26,27 
 
 C–H bond acidity was further exploited by the Fagnou group in the arylation of 
pentafluorobenzene with aryl bromides (Scheme 9).28 The Pd-catalyzed transformation 
exhibited a complete reversal of activity from the SEAr pathway,29 as the more electron-
deficient arene reacted preferentially during competition experiments. Computational studies 
demonstrated that the C–H bond breaking event occurred through a concerted metalation-
deprotonation pathway, where the bicarbonate ion played an important role.28  
Scheme 9. Fagnou’s arylation of pentafluorobenzene28 
 
 Chemists have turned to the employment of directing groups to tackle the problem of 
C–H site selectivity.  Many such chelating groups have been made popular, including phenols, 
amides, amines, carbamates, sulfonamides, phosphates, pyridines, oxazoles, etc.14d,22 The 
above-mentioned groups are usually located in a proximal position to the site being targeted 
(for example, in the ortho position of the arene) and are strong σ-donors and π-acceptors. In 
fact, the directing group plays a dual role: it activates the arene, and also guides the transition 
metal to the desired reaction site.  Figure 5 provides an overview of the most used ortho-
directing groups in direct arylations.  
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Figure 5. An overview of ortho-directing groups in direct functionalizations 
The inspiration for directing groups originated from the isolation of the first 
metallacycle species (Figure 6). Upon heating azobenzene with dicyclopentadienylnickel, 
Kleiman and Dubeck isolated the first metallacycle in 1963.30 Two years later, Cope and 
Siekmann isolated the corresponding Pd and Pt metallacycles.31  
 
Figure 6. First isolated azobenzene metallocycles (Ni, then Pd and Pt)30,31 
Early work exploiting the just-mentioned findings is scarce;32 but, in 1997, Miura and 
co-workers reported the arylation of a phenolic substrate 8 under Pd0/II catalysis (Scheme 
10).33a It was speculated that key to the reaction was the formation of a Pd-phenolate 
intermediate, responsible for the C–H activation step. A diarylated product could also be 
obtained if large excess of the aryl iodide was used. The initial findings were followed by 
another report, where an acetanilide substrate 10 acted as a chelating group for Pd, to provide 
diarylated products from reaction with aryl triflates or bromides.33b Preliminary mechanistic 
investigations suggested that a free N–H group was important to the reaction outcome, and 
presumably involved in a chelation with the Pd catalyst. 
  
 13 
Scheme 10. Miura’s direct arylation of phenols and acetanilides33 
 
Interest in these types of transformations sparked when Sanford34 and Yu35 disclosed a 
direct acetoxylation and iodination, respectively (Scheme 11). In presence of two equivalents 
of the oxidant diacetoxyiodobenzene, benzo[h]quinoline 12 was functionalized via Pd 
catalysis. No over-oxidation was observed, but a mixture of acetoxylated and phenol products 
were isolated (13:14, 11:1).34 Employing a chiral oxazole auxiliary 15 derived from (S)-tert-
leucinol, the Yu group were successful in obtaining the iodinated product 16 in presence of 
one equivalent diacetoxyiodobenzene, iodine and catalytic palladium acetate.35 Daugulis and 
Zaitsev later disclosed an arylation utilizing an anilide chelating group (Scheme 11).36 Arene 
17 was arylated twice via Pd catalysis in presence of stoichiometric silver acetate, acting as a 
base. The previous three reactions are all presumed to occur via a PdII/IV catalytic cycle 
(Scheme 16, vide infra), although a PdII/III catalytic cycle cannot be excluded.37   
Scheme 11. Direct functionalizations employing chelating groups34,35,36 
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Scheme 12. Yu’s use of carboxylic acids as directing groups38 
 
The employment of carboxylic acids as directing groups for palladium was first 
disclosed by the group of Yu.22a An initial report looked at the functionalization of aryl 
carboxylates 19 with boronic esters as coupling partners, but the yields were modest and the 
substrate scope limited;38a a subsequent report by the same group improved the yields by 
utilizing potassium aryltrifluoroborates as coupling partners, while the reaction was promoted 
by air or oxygen, thus avoiding the use of a silver oxidant (Scheme 12).38b The reaction time 
(3 days) could be decreased if increased pressures of oxygen (20 atm) were applied. The 
reaction pathways were proposed to involve a PdII/0 cycle (Scheme 16, vide infra).  
In analogy to the oxygenation reactions employing PhI(OAc)2, the Sanford group 
sought to explore other iodine-based reagents for direct functionalizations.39 Iodonium (III) 
salts, such as 22, were found to be successful arylating agents for a variety of heterocyclic 
directing groups including pyridines, quinolines, pyrrolidinones and oxazolidinones (Scheme 
13). The iodonium salts were predicted to promote a PdIV species during the catalytic cycle, 
the step later being proved to be rate-limiting.39b Additionally, the reaction conditions showed 
high functional group tolerance, good regioselectivity and relatively mild conditions (the 
reaction could also be run under air). However, the disadvantage lies in synthesizing the 
iodonium arylating agents, as many of these are not commercially available.  
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Scheme 13. Iodonium arylating agents in direct functionalizations39 
 
In 2010, our group disclosed an Umpolung direct arylation (Scheme 14).40 The 
reaction exhibited an unusual reverse in polarity, whereby, in contrast with the reports 
described above, the aryl bromide was placed ortho to the directing group in order to aid with 
oxidative addition of the transition metal. As such, unactivated arenes (such as benzene or 
toluene) could be added in high yields to aryl bromides containing sensitive functional groups 
such as esters, amides, aldehydes and ketones. A key feature of the reaction was the 
requirement of catalytic acetate, the reaction shutting down in its absence. The reaction 
mechanism was presumed to occur via a PdII/IV cycle, where the silver additive aided in the 
oxidative addition step.40  
Scheme 14. Charette’s Umpolung direct arylation40 
 
Site-selective direct arylation of unactivated arenes was achieved by the Sanford group 
through catalyst-based control.41 Upon exploring a variety of diamine-ligated Pd catalysts in 
combination with iodonium salts for the arylation of naphthalene, a significant ligand effect 
was observed (Scheme 15). For example, diamine 26 gave excellent selectivity for product 24, 
but a low yield, while the Cl-substituted diimine 28 provided both good yields and selectivites. 
No significant correlation was found between the regioselectivities and the electronics or 
sterics of the ligands; however, studies into the mechanism supported a PdII/IV pathway, with 
oxidative addition being the rate limiting step (the KIE obtained was 1.0, thus C–H activation 
was not the rate-limiting step).41  
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Scheme 15. Regioselective arylation of naphthalene41 
 
Many of the intermolecular reactions discussed in the current section occurred through 
catalytic cycles different from the classical Pd0/II cross-coupling reaction. Scheme 16 depicts a 
summary of the proposed mechanistic pathways for many of the functionalization reactions 
described throughout the introduction. In Scheme 16, the details of the C–H activation step 
were omitted, as the possibilities were already depicted in Scheme 4. In-depth discussion 
about these mechanisms, as they relate to the work in the present thesis, will take place in later 
chapters. 
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Scheme 16. Catalytic cycles involving palladium catalysts 
  
1.1.3 Carboxylate-assisted direct arylation 
It has been long established that acetate bases promote the formation of Ir, Pt or Pd 
cyclometalated complexes.42 Acetate-assisted reactions have also been the target of extensive 
mechanistic and computational work, especially probing the nature of the transition state for 
C–H bond metalation.43 For the ortho-palladation of N,N-dimethylbenzylamines with 
palladium acetate, a reaction initially explored by Ryabov and co-workers, an electrophilic 
mechanism was proposed.44 The key features of the mechanism were: (i) the formation of a 
Wheland-like intermediate and (ii) the implication of an acetate group, coordinated to the Pd 
centre, in the deprotonation of the arene (Figure 7). Later, computational studies favoured 
agostic interactions in the transition state, over the Wheland-like intermediate (Figure 7).19 
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Figure 7. Proposed intermediates by Ryabov44 and Davies19 
In their arylation reaction with pentafluorobenzene (Scheme 9, vide supra), the Fagnou 
group determined that arene nucleophilicity was not important for reactivity, but the acidity of 
the C–H bond was.28 The observation led them to the application of carboxylic acids for C–H 
bond functionalization.45 The Pd-catalyzed coupling of benzene with 4-bromotoluene did not 
occur in the absence of an additive (Table 2, entry 1); per contra, the addition of 30 mol % 
acetic acid resulted in 20% conversion (entry 2). Moreover, catalytic pivalic acid provided 
100% conversion and 82% yield of the desired biaryl 29 (entry 3). Increasing the steric bulk of 
the additive (adamantyl carboxylic acid, entry 4) gave inferior results. Use of the base KOPiv 
in stoichiometric quantities (with the omission of K2CO3 and PivOH) led to the formation of 
toluene (through dehalogenation) and the homocoupled side product.45  DFT calculations 
determined that transition state 30, involving deprotonation by a bicarbonate ion, is higher in 
energy than transition state 31 with pivalic acid (26.2 versus 24.9 kcal/mol, Scheme 17).45 
Table 2. Screen of additives for the coupling of benzene with 4-bromotoluene45 
 
entry additive conversion yield 29 (%) 
1 --- <5 0 
2 AcOH 20 11 
3 PivOH 100 82 
4 1-AdCO2H 60 36 
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Scheme 17. Comparison of transition state energies45 
 
The beneficial effect of pivalic acid was applied to an intramolecular system,46 where 
Fagnou and co-workers were able to lower the reaction temperature to 45 °C, while still 
providing 100% conversion of 4a (Scheme 3, vide supra); it should be noted that the 
phosphine ligand used was P(p-FPh)3. Again, the result could be rationalized through the 
formation of a Pd-pivalate species, which could undergo the concerted metalation-
deprotonation step. A wide range of heterocycles such as thiophene, benzothiophene, furan, 
pyrrole, thiazole, triazole, imidazole, etc. also underwent direct arylation with aryl bromides in 
presence of catalytic pivalic acid at 100 °C; notably, only one equivalent of the heteroarene 
partner was used in the reaction.47 A great number of palladium-catalyzed direct arylations 
employing pivalic acid as an additive have now been reported in the literature.43 
Scheme 18. Use of carboxylates in Ru-catalyzed direct arylation48 
 
Ackermann promoted the use of carboxylates for ruthenium-catalyzed direct 
functionalizations (Scheme 18).48 While the majority of Ru-catalyzed reactions up to that 
point took place in the highly polar solvent N-methylpyrrolidinone (NMP), the implementation 
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of carboxylates allowed for the use of non-polar solvent toluene. Ruthenium-catalyzed C–H 
functionalization is discussed in detail in the next section. 
1.2 Ruthenium-catalyzed C–H functionalization 
With the use of palladium and rhodium catalysts for C–H functionalizations being well 
documented in synthesis, many groups initiated a search into the reactivity of other transition 
metals for these types of transformations. In 1993, the Chatani group reported a direct 
alkylation of aromatic ketone 32 in presence of RuH2(CO)(PPh3)3 as the catalyst (Scheme 
19).49 The above-mentioned catalyst was a stable precursor of a Ru0 species49b which mediated 
the addition of a variety of olefins to the ortho-position of aromatic ketones. The reaction 
proceeded with remarkable efficiency; traces of dialkylated products 34 were also isolated in 
cases where the second ortho-position was also sterically accessible. In terms of reaction 
pathway, it was proposed that coordination of the metal to the carbonyl enabled the activation 
of the C–H bond, followed by migratory insertion of the alkene, then reductive elimination 
(Scheme 19).49b,50 
Scheme 19. Ru-promoted alkylation of aromatic ketones49,50 
 
1.2.1 Catalysis with RuII and phosphine ligands 
Within the last decade, RuII catalysis has been vastly explored in relation to C-H bond 
activation.51,52 RuII catalysts are generally more stable to air than moisture than their Ru0 
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counterparts; in addition, their mechanism of C–H activation is similar to PdII catalysts, in 
terms of having a ligand on the metal or a base to perform the deprotonation step.  
 Inoue and Oi first reported the efficient functionalization of 2-phenylpyridine 35 with 
aryl halides in presence of a RuII catalyst.53 The reaction employed triphenylphosphine as the 
ligand (two per Ru atom), potassium carbonate as the base and occurred in the highly polar 
solvent NMP (Scheme 20). When only one equivalent of aryl halide was added, the major 
product was monoaryl 36; arylation of both ortho positions was observed when excess (three 
equivalents) of aryl halide were added, thus providing diaryl 37 in 77% yield. Aryl bromides, 
iodides or triflates provided good yields of the corresponding products, presumably due to 
easier oxidative addition into a Ru(II) complex, while chlorobenzene reacted poorly (Scheme 
20A). The rate of addition of the aryl halide corresponded to the trend: 
ArBr>ArI>ArOTf>>ArCl. The initial proposed mechanism involved oxidative addition to 
give ruthenate species 38, followed by an electrophilic addition to the arene to provide 
zwitterionic intermediate 39, then loss of HBr to provide 40, and finally reductive elimination 
to release the product and the RuII active species (Scheme 20B).  
Scheme 20. A. Inoue and Oi’s arylation of 2-phenylpyridine. B. Proposed mechanism53
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 Inoue and Oi next looked at using an imine group as a chelator for Ru.54 Employing the 
same catalyst as in their previous reaction, the influence of substitution on the arylimine 
moiety 41 for the ratio of mono 42 versus diarylation 43 was now explored (Table 3). The 
ratio was roughly 4:1 for monoaryl 42, when no substitution was present on the arylimine 
(41a), in presence of 1.2 equivalents bromobenzene. Interestingly, ortho-substitution (41b) led 
to a low 17% yield, which was explained through steric clash between the ortho-Me and the 
methyl on the imino group. Meta-substitution (Me, CF3 and naphthyl, 41c-e) offered 
exclusively monoaryl 42 in good to excellent yields, while the presence of a para-Me (41f) 
provided 42 in a modest 2:1 ratio. For the para-substitution, the diarylated product 43 could be 
targeted exclusively with excess aryl bromide. The above studies concluded that the Ru-
catalyzed direct arylation was highly influenced by sterics.  
Table 3. Influence of arene substitution on the reaction outcome54 
 
 To further expand the applicability of ruthenium catalysis in organic synthesis, Inoue 
and Oi developed a variant of the Mizoroki-Heck reaction.55 Intriguingly, the Z geometry of 
the isolated product 45 was in stark contrast to the E-alkene 46 produced via the classic Pd-
catalyzed Mizoroki-Heck reaction (Scheme 21A). The results were rationalized through the 
chelating effect of the pyridine nitrogen to the ruthenium centre (Scheme 21B), which enabled 
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a β-cis-ruthenation step to provide intermediate 47. The intermediate then underwent oxidative 
addition to give 48, followed by reductive elimination to afford the product. In contrast, the 
Pd-catalyzed Mizoroki-Heck reaction commenced with oxidative addition to provide 49, 
followed by syn migratory insertion (50), and rearrangement to enable syn-β-hydride 
elimination (Scheme 21C).  
Scheme 21. A. Comparison between Pd- and Ru-catalyzed Mizoroki-Heck reactions. B. 
Mechanism for the Ru-catalyzed reaction. C. Mechanism of the Pd-catalyzed transformation55 
 
 In 2005, Ackermann reported that through the use of a secondary phosphine oxide 
ligand, less reactive aryl chlorides could also be used as coupling partners for the direct 
arylation of 2-phenylpyridine 35 in presence of a ruthenium catalyst (Scheme 22).56 Aryl 
chlorides are less expensive and more widely available than the corresponding aryl bromides, 
so the research represented a critical discovery. After screening a series of secondary 
phosphine oxides of different sizes and electronics, the best yield was obtained with the bulky 
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diadamantyl phosphine oxide after heating for 24 h at 120 °C. In general, the latter system 
advanced by Ackermann was more efficient than the former PPh3/RuII system. The role of the 
secondary phosphine oxide was denoted as simply a ligand precursor, giving rise to a 
bimolecular bidentate ligand system through self-assembly (Scheme 22).57  
Scheme 22. Use of secondary phosphine oxides for the coupling of aryl chlorides56 
 
1.2.2 Carboxylate-assisted RuII catalysis 
The mechanism of direct arylation through Ru-catalysis was investigated 
computationally (DFT calculations) by Bruneau and Dixneuf.58 2-Phenylpyridine 35 was 
chosen as the starting material, and its interaction with a RuCl2(NHC) catalyst, and afterwards 
a base, was studied (Scheme 23). To start with, the cleavage of the C–H bond was examined. 
An agostic interaction between the catalyst and the aryl C–H bond (complex 52) was found 
28.2 kcal/mol lower in energy than RuIV complex 53, formed by direct oxidative addition of 
the arene C–H bond to a RuII species. To continue, the addition of a carbonate anion resulted 
in the favourable formation of a Ru adduct (54). Then, adduct 54 formed complex 56 through 
transition state 55, where the carbonate base was directly involved in the deprotonation step. 
Transition state 55 was calculated to have a barrier of 13.9 kcal/mol, while the overall 
transformation from 54 to 56 was exothermic by 13.7 kcal/mol. The DFT studies 
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demonstrated similarities between the mechanisms of arene C–H activation of Ru and Pd 
catalysts.  In consequence, it paved the way to the exploration of carboxylates as additives for 
Ru, as they had been previously shown to be successful in Pd catalysis (Section 1.1). 
Scheme 23. Dixneuf’s DFT calculations58 
 
As early as 2008, Ackermann demonstrated the utility of carboxylates as ligands for Ru 
(Scheme 18, vide supra). In particular, 2,4,6-trimethylbenzoic acid (MesCO2H) was shown to 
be effective for direct arylations with a variety of arenes containing directing groups (Figure 
8).48,59,60 In addition, the use of MesCO2H allowed for a change in solvent from the high 
boiling NMP (202 °C) to toluene (110 °C).  
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Figure 8. Directing groups for the carboxylate-assisted Ru activation 
 The working mode of the carboxylate-assisted Ru catalysis was also elucidated 
by the Ackermann group (Scheme 24).59 Firstly, Ru-carboxylate complex 57 was prepared 
and its structure confirmed by X-ray crystallography. Secondly, complex 57 was proven to be 
a competent catalyst in the arylation reaction with 2-arylpyridine 58, providing product 59 in 
80% yield. Thirdly, upon heating 57 in presence of 4-chloroanisole, no reaction was detected. 
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In contrast, upon reacting 57 with 2-arylpyridine 58, but no aryl chloride, the corresponding 
ruthenacycle complex 60 was isolated in 60%.59 
Deuterium experiments were also carried out; when reacting deuterated 2-
phenylpyridine, a D/H exchange in both the starting material and the product was clearly 
observed at 120 °C (Scheme 25).59 The result supported their hypothesis that the C–H 
activation (ruthenation step) was reversible. In addition, competition experiments with excess 
heteroarenes (not shown here) favoured the addition of an aryl chloride containing an electron 
withdrawing versus an electron donating group in either NMP or toluene as solvents, 
suggesting that oxidative addition is the rate-limiting step.59 
Scheme 24. Synthesis of complex 57 and its competence in arylation reactions59 
 
Scheme 25. Ackermann’s D/H exchange experiment59 
N
D
(2 equiv)
4-chloroanisole
(1 equiv)
57 (5 mol%)
K2CO3, PhMe, 120 °C
N
D/H
N
D/H Ar
50% D 35% D
100% D
61 62 63
 
 27 
 Based on experimental results, the following mechanism was proposed for the Ru-
catalyzed direct arylation (Scheme 26). Once formed in situ, complex 64 undergoes a 
reversible cyclometalation with 2-phenylpyridine, mediated by the carbonate base, and aided 
by the carboxylate, to provide complex 66. Rate-limiting oxidative addition provides RuIV 
complex 67, followed by reductive elimination to give the desired arylated product and release 
the active catalyst. The mechanism contrasts with the earlier proposed mechanism by Inoue 
and Oi,53 where oxidative addition preceded C–H ruthenation (Scheme 20, vide supra).  
Scheme 26. Ackermann’s proposed catalytic cycle59 
 
 Dixneuf and co-workers have shown that ruthenium catalysis could also tolerate water 
as solvent; interestingly, the reaction was more efficient in water than the previously used 
NMP.61  In presence of potassium pivalate as an additive, diarylation of 2-phenylpyridine 35 
with chlorobenzene was obtained as the sole product at 100 °C in only 2 h (Scheme 27). In 
contrast, potassium acetate or carbonate provided a mixture of mono and diarylation. The 
order of reactivity of the aryl coupling partner was PhCl>PhBr>PhI, correlating well with their 
water solubilities. The ability to perform catalysis in water without the use of a surfactant was 
a great step forward towards developing more environmentally friendly procedures. 
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Scheme 27. Water as solvent in Ru catalysis61  
 
1.2.3 Other Ru-catalyzed reactions 
Ruthenium(II) complexes have shown to be versatile catalysts for a plethora of 
transformations, including direct arylations, alkenylations, alkylations, as well as annulations 
with alkynes and alkenes.52 In addition, a few intriguing reports appeared in the literature 
describing oxidative homocoupling (Scheme 28). Inoue and Oi showed that, in presence of 2-
methylallyl acetate, 2-aryloxazolines 68 reacted with each other in 83% yield.62 The 
conditions were amenable to the dehydrogenative coupling of similar ortho-substituted 
imidazole, thiazole or indazole substrates. The group of Li disclosed the homocoupling of 
several substituted 2-phenylpyridines in presence of a Ru catalyst and FeCl3 as a 
substoichiometric oxidant.63 The mechanism proposed consisted of two sequential 
cyclometalations of 2-phenylpyridine (35) via a chelation-directed C–H activation step, with 
loss of two molecules of HCl (Scheme 29). Reductive elimination of complex 74 provided the 
homocoupled product, while Ru0 was oxidized back to RuII by ferric chloride. It was 
suggested that traces of oxygen present in the reaction might also be involved in the re-
oxidation of Ru0 to RuII.63 Finally, Ackermann noticed homocoupling of substituted triazole 
71 when ortho-substituted aryl halides (for example 72) were employed as coupling partners 
(Scheme 28).60a It was suggested that the sterically hindered aryl halide acted as a sacrificial 
oxidant.  
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Scheme 28. Ru-catalyzed oxidative homocoupling 
 
Scheme 29. Li’s proposed oxidative homocoupling mechanism63 
 
1.3 Functionalization at sp3 centers 
The following section will look at C–C bond formation at sp3 centers from two points 
of view: direct alkylation (the coupling of alkyl halides with arene C–H bonds), and direct 
C(sp3)–H functionalization, focusing on recent approaches featuring cyclopropanes.  
1.3.1 Direct alkylation 
The transformation of sp2 C–H bonds has received great attention from the organic 
synthetic community, with direct arylation (Sections 1.1 and 1.2), alkenylation64 and 
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alkynylation65 reactions being widespread. A less common activation mode is direct 
alkylation,66 due to the difficulty of alkyl halides to undergo oxidative addition and their 
propensity for undesired side reactions such as β-hydride elimination. In comparison, 
conventional cross-coupling strategies rely on the pre-formation of nucleophilic substrates as 
organometallic reagents, followed by the transition-metal catalyzed addition of an alkyl halide 
(Scheme 30). The disadvantages of the method have already been underlined at the start of the 
dissertation. Consequently, synthetic efforts are directed towards the development of 
appropriate conditions that allow for direct alkylation to occur. 
Scheme 30. Cross-coupling with alkyl halides versus direct alkylation66 
 
In 1984, Tremont and Rahman reported the alkylation of acetanilides in presence of 
excess Pd(OAc)2 (Scheme 31).67a The reaction was proposed to first undergo a directed ortho-
metalation, most likely followed by oxidative addition of methyl iodide, and reductive 
elimination to give the desired product. The only alkyl halides tested were methyl, ethyl and 
allyl iodide. A subsequent report from the same group looked at aryl imines as chelating 
groups for Pd in direct alkylations.67b  
Scheme 31. Tremont’s direct alkylation with excess Pd(OAc)267a 
 
A widely studied example of direct alkylation is the Catellani reaction,18 whose 
mechanism was fully elucidated by the pioneering work of Marta Catellani.68 In the reaction, 
norbornene acts as a scaffold on which the molecule is built and can be recovered at the end of 
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the reaction (Scheme 32). Three new C–C bonds result from this reaction, out of which two 
are C(sp2)–C(sp3). 
Scheme 32. The Catellani reaction18 
 
The oxindole scaffold, a motif widely found in medicinal chemistry, was easily 
accessed by a Pd-catalyzed cyclization of α-chloroacetanilides 77, in a report by Buchwald 
and Hennessy (Scheme 33A).69 Protection of the amide group was necessary, and both alkyl 
and aryl groups could be employed to provide good yields of the corresponding products 78a-
c. Investigations into the reaction mechanism revealed an intermolecular KIE of 1, while the 
intramolecular value was 4. After oxidative addition of Pd0 into the alkyl chloride bond to give 
a Pd enolate, two possible pathways are possible, one involving electrophilic substitution (A), 
and the other σ-bond metathesis (B) (Scheme 33B).  
Chang and co-workers disclosed an intramolecular direct alkylation employing benzyl 
chlorides for the synthesis of pyrrole-containing heterocycles (Scheme 34).70 The calculated 
KIE values were 1.4 (intramolecular) and 1.7 (intermolecular), implying a C–H activation or 
electrophilic substitution type mechanism. Furthermore, the transformation could be extended 
to the synthesis of fluorenones 83 by changing the ligand and base in the reaction (Scheme 
34).71 Hammett studies revealed a 0.42 ρ value, predicting a build-up of negative charge 
during the transition state, thus excluding an electrophilic pathway. The corresponding 
intermolecular KIE value was 2.1, and the reaction was found to be sensitive to base. Based on 
all these observations, the proposed mechanism involved a base-assisted deprotonation, as 
shown in transition state C (Scheme 34).71  
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Scheme 33. A. Buchwald’s synthesis of oxindoles. B. Possible mechanisms69 
 
Scheme 34. Chang’s intramolecular direct alkylation70,71 
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An intermolecular Pd-catalyzed benzylation was disclosed by Fagnou (Scheme 35).72 
Under the reaction conditions, a wide range of electron-deficient heterocycles (e.g. thiophenes, 
thiazoles, furans, indolizines etc) which proved difficult to alkylate under Friedel-Crafts type 
conditions, were reacted with benzyl chlorides to give the corresponding products in good to 
excellent yields. 
Scheme 35. Intermolecular benzylation of thiazoles72 
 
1.3.2 Direct functionalization of C(sp3)–H Bonds 
The direct functionalization of challenging C(sp3)–H bonds has attracted many 
chemical efforts.73 Although both sp2 and sp3 C–H bonds have high bond dissociation energies 
(BDE’s) (105 kcal/mol for methane, 113 kcal/mol for benzene),13 sp3 C–H centers lack π-
groups which may aid in interacting with transition metal centers. The direct oxidation of 
allylic or benzylic C–H bonds is much easier,13 due to the lower BDE values of these bonds 
(88.8 kcal/mol for allyl and 89.8 kcal/mol for benzyl C-H), but also as a result of interaction of 
the π-bonds to the metal centre. It should be noted that BDE is a measure of enthalpy change 
when a bond is cleaved in a homolytic fashion,13 thus it may not accurately depict the 
difficulty of C–H bond cleavage upon activation by a transition metal. Due to the ubiquity of 
C–H bonds in nature, site selectivity is also a major issue, thus chemists have again turned to 
directing groups to help them overcome the problem.  
1.3.2.1 Direct C-C bond formation 
In 2007, Fagnou and co-workers disclosed a pivalic acid-mediated, intramolecular sp3 
C–H activation in the synthesis of dihydrobenzofuran 85 (Scheme 36).74 High selectivity for a 
C–H methyl functionalization to form a five-membered ring was observed (compounds 86 and 
87), with one exception: when one of the substituents was an arene, there was a preferential 
reaction at the sp2 C–H bond to form a six-membered ring (compound 88). DFT calculations 
were performed to suggest a mechanistic pathway. The formation of a PdIV species (not 
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depicted here) was excluded, due to its high energy (47.7 kcal/mol). The value of the 
computed KIE was 3.6, coinciding well with the experimentally determined value of an 
intramolecular experiment (KIE 5.4 ± 0.3); however, the intramolecular KIE experiment could 
not support the conclusion that C–H bond cleavage is rate-limiting. Based on the DFT 
calculations and experimental evidence, a catalytic cycle involving a Pd0/II cycle seemed more 
plausible than a PdII/IV pathway (Scheme 16, vide supra). After oxidative addition, a concerted 
metalation-deprotonation step mediated by pivalic acid would take place. Transition state 89 
involving an agostic, three-center, two-electron interaction was calculated to be lowest in 
energy (27.7 kcal/mol). Reductive elimination would provide the desired product and 
regenerate the Pd0 catalyst. The selective preference for a methyl versus ethyl (compound 86) 
was also supported by DFT calculations: activating an ethyl C–H bond proved to be 5.5 
kcal/mol higher in energy than the corresponding methyl C–H bond. Although high-yielding, 
the transformation was restricted to the use of aryl bromides and the presence of an α-
quaternary centre.74  
Scheme 36. Fagnou’s intramolecular C(sp3)–H activation74 
 
The synthesis of benzocyclobutene 91 was disclosed by the group of Baudoin (Scheme 
37).75 Again, the major limitation was the absolute necessity for an α-quaternary centre, due to 
competing β-hydride elimination. A collaborative effort by Baudoin and Fagnou expanded the 
reaction scope of the intramolecular cyclization to aryl chlorides 90b, in the synthesis of 
benzocyclobutenes 91 and indanes 95.76 Interestingly, for the synthesis of indanes, α-tertiary 
centres were viable substrates in presence of the bulky tertiary cyclopentyl phosphine as the 
ligand.76 Furthermore, Ohno reported that α-tertiary centres can also be applied in the 
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carboxylate-assisted synthesis of various indolines 93, in presence of 
tricyclohexylphosphine.77  
Based on the experimental and computational evidence provided,75,76,78 a simplified 
general mechanism for the intramolecular C(sp3)–H functionalization with aryl halides is 
presented in Scheme 38. The first step is oxidative addition of Pd0 into the aryl halide bond to 
form 96. Then, exchange of the halide ligand on Pd by carbonate or pivalate is presumed to 
occur to give 97, followed by a concerted metalation-deprotonation step (transition state 98) to 
provide a six-membered palladacycle 99. Reductive elimination provides the desired product 
and regenerates the Pd catalyst. 
Scheme 37. Intramolecular C(sp3)-H functionalization with aryl halides 
 
  
 36 
Scheme 38. General mechanism for the intramolecular C(sp3)–H arylation 
 
 
1.3.2.2 Direct C-X bond formation 
The direct transformation of C(sp3)–H bonds into C-heteroatom bonds has high 
synthetic utility (Scheme 39). Pioneering work by Melanie Sanford in the palladium-catalyzed 
acetoxylation reaction79,14d has not only provided significant mechanistic understanding of the 
PdII/IV catalytic cycle, but also opened the door to the application of the reactivity to other 
systems. In addition to oxygenations, C–N bond formation has also been studied (Scheme 
39).80 Others have shown that C-halide bond synthesis was also possible.14d,35 More recently, 
C–F bond formation has become a hot topic in organic synthesis.81  
Scheme 39. Selected examples of C(sp3)–O and C-N bond formation (Sanford,79 Glorius80a) 
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1.3.3 Cyclopropyl C–H functionalization 
Cyclopropanes have unique physical, chemical and electronic properties as a result of 
ring strain.82 The bond angle in a cyclopropane is 60°, while the normal sp3 hybridized bond 
angle is 109.5°; thus, its carbon atoms display sp2-like properties, which makes them an 
attractive target for C–H bond functionalization processes.  
At the start of my PhD, there was little precedent in the literature on the direct 
functionalization of cyclopropyl C–H bonds. The few scattered examples that existed were 
from the Yu lab, and are summarized in Scheme 40. Diastereoselective iodination of a 
cyclopropane was possible via palladium catalysis on a substrate containing a cyclopropyl ring 
directly bound to an oxazoline (100), the oxazoline moiety acting as a directing group.83a The 
reaction was performed under mild conditions, at room temperature; however, it required four 
days for completion. Yu then showed that cyclopropane 102 can be directly coupled with alkyl 
boronic acids, under Pd catalysis to afford alkylated cyclopropanes 103 and 104 in 58% and 
72% yields, respectively.83b The use of 2,2,5,5-tetramethyltetrahydrofuran as solvent was key. 
It was believed that the bulky solvent prevented homocoupling of the boronic acid, as well as 
β-hydride elimination. A Pd-catalyzed olefination of sp3 C–H bonds was also disclosed by 
Yu,83c where an amide-directing group was employed, and after the olefination, compound 
106 underwent a 1,4-addition to provide the corresponding lactam 107. A plausible 
mechanism for the transformation would first involve an amide directed C–H insertion by PdII, 
followed by carbopalladation of the olefin, and a β-hydride elimination to provide 
intermediate 106. Pd0 would be reoxidized by AgI/CuII, while 106 would cyclize to provide to 
the final product. The main disadvantage of all the cyclopropane-containing substrates (100, 
102 and 105) was the need for a quaternary centre on the cyclopropane to prevent β-hydride 
elimination, or attenuate decomposition pathways of the cyclopropane. The presence of a 
quaternary centre also resulted in lengthy starting material syntheses.  
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Scheme 40. Yu’s contribution for cyclopropane functionalization up to 201083 
 
Later, in 2011, the group of Yu disclosed the first enantioselective C–H activation of 
cyclopropanes.84 Initially, the optimization of the racemic reaction was performed; usually, a 
mixture of mono and di-functionalized cyclopropanes was obtained (Scheme 41). Then, a 
thorough screen of amino acids and their derivatives led to the application of chiral ligand 113 
in the intermolecular arylation of cyclopropanes 108 (Scheme 42). Ph-BPin was the best 
nucleophile, while the employment of alkyl boronic esters led to generally low yields and 
enantioselectivities. The conditions were relatively mild, however the necessity for an α-
quaternary centre, the employment of an electron-poor amide auxiliary, the use of a double 
batch method and lack of applicability for large scale synthesis (reactions were ran on 0.1 
mmol only) are still major issues that require improvement. Yu followed the report one year 
later with a more thorough investigation of conditions for the activation of methylene C–H 
bonds with aryl iodides.85 After altering the auxiliary and employing a substituted quinoline 
ligand for Pd, the only cyclopropane example from the scope could be arylated in 86%. 
Notably, the need for an α-quaternary centre was obviated by the use of the quinoline ligand. 
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Scheme 41. Yu’s racemic intermolecular direct functionalization of cyclopropanes84 
 
Scheme 42. The first enantioselective C–H functionalization of cyclopropanes84 
 
Sanford and Kubota looked at the functionalization of cyclopropanes under oxidative 
conditions, employing directing groups such as oximes or pyridines (Scheme 43).86a Their 
attempted acetoxylation and iodination reactions mainly resulted in opening of the 
cyclopropane or low yields. A more successful example was the aerobic olefination with ethyl 
acrylate of 2-cyclopropylpyridine 118.86b  
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Scheme 43. Sanford’s efforts towards cyclopropane C–H activation86 
 
Rousseaux, Liegault and Fagnou reported the elegant formation of quinoline and 
tetrahydroquinoline derivatives via a C–H activation of cyclopropane.87 It was found that the 
resulting dihydroquinolines 121 were prone to decomposition, thus a one-pot aromatization 
protocol employing DDQ as the oxidant was developed to provide 122 (Scheme 44). 
Alternatively, a one-pot hydrogenation of intermediate 121 to the tetrahydroquinoline species 
123 was also a viable alternative. Both aryl bromides and chlorides were feasible substrates, 
however under slightly different conditions. In particular, the ligand tricyclohexylphosphine 
worked better with aryl chlorides. Mechanistic studies by the authors have demonstrated that 
C–H activation of the cyclopropyl bond via a pivalate-assisted concerted metalation-
deprotonation step C occured prior to the ring opening (step D) (Scheme 45). Then, 
deprotonation and reductive elimination (step E) would occur to give product 121. 
Alternatively, step F, the direct reductive elimination was shown not be possible.87   
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Scheme 44. Rousseaux and Fagnou’s synthesis of quinolones and tetrahydroquinolines87 
 
Scheme 45. Proposed reaction mechanism for the synthesis of dihydroquinolines 12187 
 
 Although some elegant advances in the direct C–H functionalization of cyclopropanes 
have been achieved, there is still plenty of room for exploration. In particular, the use of 
directing groups was limited to amides, and only one example of the use of aryl halides for the 
intermolecular arylation of cyclopropanes was available. Additionally, the full substrate scope 
of some of the functionalizations (i.e. formation of C–X bonds) has not been fully examined.  
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1.4 Homolytic aromatic substitution 
The introduction or replacement of substituents onto an aromatic ring represents a vital 
transformation in organic synthesis. Aromatic substitution can be divided into four basic 
mechanisms: 1) electrophilic, 2) nucleophilic, 3) radical, and 4) transition-metal catalyzed.88 
While the previous sections of the introduction looked mostly at numbers 4) and 1), the 
following section will deal with number 3), in terms of C–C bond forming reaction. 
Homolytic aromatic substitution (HAS) is defined as the addition of a radical onto an 
aromatic ring, with the replacement of a leaving group X (usually H).10 The general 
mechanism, pictured in Scheme 46, involves initial attack of the radical, followed by the 
formation of a radical σ-complex A, then loss of the leaving group to give the product C. In 
many cases, HAS may involve an oxidative step to obtain a cationic σ-complex B, and then 
loss of X+, which is not well understood in the literature. The most common ways of preparing 
radical R• involve the use of tributyltin hydride (Bu3SnH) in presence of 2,2-
azobisisobutyronitrile (AIBN) as the initiator; or, tris(trimethylsilyl)silane (TTMSS) with 
AIBN. In comparison to HAS, the mechanisms for electrophilic and nucleophilic aromatic 
substitution involve the formation of a cationic or anionic σ-complex, respectively.88  
Scheme 46. General HAS mechanism10  
 
According to studies by Bowman89 and Russell,90 the unimolecular radical nucleophilic 
substitution reaction (SRN1) on arenes or heteroarenes can be regarded as HAS.10 The SRN1 
reaction on aromatics was first investigated in 1970 by Bunnett and Kim.91 The proposed 
mechanism involved a radical chain reaction (Scheme 47). The distinctive feature was the 
initiation, which occurred via an electron transfer (ET) to an aryl halide bond, giving rise to a 
radical anion (step D); fast fragmentation of the species results in an aryl radical and X- (step 
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E). Attack of a nucleophile generated another radical anion (step F), which could transfer an 
electron to the substrate and propagate the cycle (step G).  
Scheme 47. General SRN1 mechanism 
 
  As mentioned above, the re-aromatization step of the cyclohexadienyl radical A 
(Scheme 46) is a highly debatable topic in HAS chemistry. In most cases, the leaving group X 
is hydrogen, requiring an H-abstraction step. In the synthesis of oxindole product 125, 
Bowman and Storey ruled out the involvement of HSnBu3 in this abstraction step by running 
control experiments with a deuterated tributyltin species.92 When employing deuterated 
DSnBu3 126 in the reaction with 124, no deuterium incorporation in the product or any HD 
gas by-product was observed in the reaction (Scheme 48). Additionally, no HD gas was 
produced when 127 was used as precursor, suggesting that HSnBu3 was also not capable of 
producing a radical anion for a presumed SRN1-like initial step. Turning to the role of the 
initiator, AIBN, only 0.3 equivalents of N2 gas were detected by GC analysis of the gaseous 
mixture. The fact implied that the rest of 0.9 equivalents of the initiator were consumed 
elsewhere in the reaction. It was postulated that the initiator acted as an oxidizing agent for the 
cyclohexadienyl radical by abstracting an H and forming a hydrazyl species, as previously 
suggested by Curran.93 To sum up the findings, and the AIBN/Bu3SnH mechanism, the 
reaction mechanism for the synthesis of oxindole 125 is shown in Scheme 48. In presence of 
heat, AIBN decomposes to produce nitrogen gas and a tertiary radical 128; the species 
abstracts H• from tributyltinhydride to provide the active Bu3Sn• radical 129, concluding the 
initiation step. The tin radical 129 abstracts bromide from aryl halide 124 to give aryl radical 
130 and BrSnBu3; a 1,5-H abstraction provides a stable cyclopropyl radical 131. Attack of the 
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cyclopropyl radical onto the arene provides cyclohexadienyl species 132, from which AIBN 
abstracts a hydrogen providing the product 125 (in a chain terminating event) and a hydrazyl 
radical 133. Radical 133 may undergo another oxidation step (i.e. abstract another H• from 
another species 132) or undergo disproportionation. Although hydrazyl 134 derived from 
AIBN was never isolated, due to its instability under the reaction conditions, other reduced 
AIBN derivatives have been isolated.94 The current mechanistic findings were mostly 
applicable to intramolecular reactions involving aryl bromides; in the case of aryl iodides, a 
single electron transfer from a radical anion intermediate can cause C–I bond homolysis and 
propagate the chain.95  
Scheme 48. Synthesis of oxindole 125 and proposed mechanism92 
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1.4.1 HAS: examples and reagents 
Fused pyrroles 136 were synthesized via HAS promoted by AIBN and Bu3SnH 
(Scheme 49).89b The acetyl substituent was necessary to lower the electron density of the 
electron rich pyrrole, thus enabling attack of the nucleophilic alkyl radical at the electrophilic 
C-2 position (also β-position with respect to the ketone). In the absence of the acetyl 
substituent, only reduced product 137 was obtained. Five-, six-, and seven-membered rings 
were produced, along with significant amounts of reduced starting material 137.  
Scheme 49. Synthesis of fused pyrroles via HAS89b 
 
Eight-membered ring 141 was synthesized via an ipso-substitution onto an aromatic 
ring starting from indanone 138 (Scheme 50).96 Generation of an aryl radical from the aryl 
iodide with the aid of AIBN/Bu3SnH, followed by a 5-exo-trig cyclization provides 
intermediate 139. Radical 139 undergoes a β-scission to produce a stable radical 140. Here, H-
abstraction from Bu3SnH gives rise to the final product 141, as a single diastereomer after 
recrystallization. It is worth noting that 141 is the core of the natural product series of 
steganes.97 In contrast, tetralone type compounds such as 142 led to a mixture of ipso- and 
ortho-substitution (143 and 144, Scheme 53).96  
An example that will be more relevant to the topic in Chapter 5 (vide infra) and 
represents a direct comparison to transition metal catalyzed C–H arylation is shown in 
Scheme 51.98 Harrowven and co-workers studied the intramolecular additions of aryl radicals 
onto benzyl ethers. Standard radical-forming conditions were employed (AIBN/Bu3SnH) for 
benzyl ether 145. After aryl radical 146 was formed, it underwent a 5-exo-trig ipso cyclization 
to provide 147. A number of competing pathways (H-abstraction, bond scission, addition) lead 
to the formation of three different products in quite low yields. The desired benzopyran 152 
was only formed in 18% yield. The radical approach could be compared, for example, with 
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Fagnou’s Pd-catalyzed intramolecular direct arylation strategy, where a similar benzopyran 
product was isolated in 96% yield (Scheme 3, vide supra). It was unclear how phenol product 
150 was produced in the reaction.98   
Scheme 50. Harrowven’s synthesis of eight-membered and nine-membered rings96 
 
Scheme 51. Radical cyclization of iodobenzyl ether 145 leads to mixture of products98 
O O O O
I
O
Bu3SnH, AIBN
PhMe, OH
21%
OMe O
18% 18%
145
146 147 148 149
150 151 152
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In general, the rise of transition metal-catalyzed cross-couplings and direct 
functionalizations has superseded the use of HAS in organic chemistry, due to the low yields, 
side-product formation and poor regioselectivity.10 In addition, there are concerns associated 
with the reagents: a. organotin hydrides are known to be highly toxic; b. removal of tin 
residues after the reaction is problematic, thus limiting its applicability in the pharmaceutical 
industry; c. AIBN may present an explosion risk.99 A greener alternative is represented by the 
use of (TMS)3SiH in presence of Et3B or O2 (Scheme 52).100 For the synthesis of biaryl 153, 
reduction product 154 was isolated in 10% yield in presence of HSnBu3, while use of 
(TMS)3SiH and oxygen as the chain carrier lead to 87% desired product and no 
dehalogenation product. In addition, the reaction was performed under much milder conditions 
(room temperature versus 80 °C). The chain carrier mechanism invokes the presence of 
peroxides (Scheme 53) and is proposed to occur in the folloing manner: (i) abstraction of the 
iodide by (TMS)3Si•, (ii) attack of the resulting aryl 155 onto benzene, (iii) oxidation of 
cyclohexadienyl species 156 by O2 to give the rearomatized product and a hydroperoxy 
radical, and  (iv) reaction of this hydroperoxy radical with TTMSS to regenerate the 
(TMS)3Si• radical.100  
Scheme 52. Comparison between Bu3SnH and (TMS)3SiH100 
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Scheme 53. Proposed mechanism for HAS mediated by (TMS)3SiH/O2100 
 
Photolysis of aryl or alkyl iodides has also been used to generate radicals; however, the 
reaction of aryl or alkyl bromides is sluggish.101 More recently, the groups of Kellogg, 
Stephenson, MacMillan and others have advanced the use of visible light in presence of a 
photoredox catalyst (e.g. [Ru(bpy)3]Cl2) to generate aryl or alkyl radical from the 
corresponding bromides.102 
1.4.2 The Minisci reaction 
The Minisci reaction is the addition of an alkyl radical onto a protonated heteroarene 
and is a popular HAS transformation.103 Substituents on the heteroarene play a significant role 
in determining reactivity and regioselectivity due to polar and steric effects. For example, 
addition of an alkyl radical onto quinoline provided a mixture of three products (Scheme 
54).104 However, when either the C-2 or C-4 positions are substituted, the reaction provides 
solely the C-4 or C-2 alkylated products.105 The general mechanism for the Minisci reaction is 
similar to HAS (Scheme 46), but employs a protonated heterocycle. Another difference is 
represented by the way the radical is generated in presence of silver salts and persulfate from 
an alkyl carboxylic acid (Scheme 54).104 The use of carboxylic acids as precursors is 
successful for a wide variety of linear and cyclic alkyls;106 however, the reaction fails with aryl 
carboxylic acids. Recently, Baran disclosed the Minisci reaction of electron deficient 
heterocyles with aryl boronic acids.107 
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Scheme 54. The Minisci reaction and generation of the radical 
 
1.5 Research goals 
The research undertaken during my PhD focused on developing novel methodologies 
for C–C bond formation, reaching from one end of the spectrum (homolytic aromatic 
substitution) to the other (C(sp3)–H activation). In designing model systems and reaction 
conditions, my work has always been guided by the green chemistry principles discussed at 
the beginning of the introduction. A ruthenium-catalyzed C–H arylation of imidazopyridines 
will be addressed in Chapter 2. The employment of ruthenium catalysis for C–H 
functionalizations has largely developed in the last 10-12 years, while imidazopyridines have 
plenty applications in medicinal chemistry and also as fluorescence materials.  Significant 
work also targeted the direct functionalization of cyclopropanes and these projects will be 
discussed in Chapters 3 and 4. Our group has a long-standing interest in both the synthesis and 
functionalization of cyclopropanes. Before 2011, there was no full account in the literature on 
direct C–H cyclopropyl activation; at the moment of writing the thesis, there are over ten such 
publications. Finally, strong base-promoted homolytic aromatic substitution which will be 
presented in Chapters 5 and 6 was unheard of in 2009, but became a “hot” and highly 
debatable topic a year later. 
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Figure 9. C-C bond formation achieved during the PhD 
  
 
 
 
Chapter 2. Ruthenium catalyzed direct C–H 
functionalization of imidazo[1,5-a]pyridines 
2.1 Introduction 
 Nitrogen-containing fused heterocyclic scaffolds represent a special class of 
biologically relevant compounds. The development of straightforward methodologies for their 
synthesis and functionalization has consequently gathered a lot of effort from the medicinal 
and academic organic chemistry community.108 Among nitrogen-containing pharmacophores, 
polyfunctionalized units containing a bridgehead “pyridine” nitrogen (as exemplified in 
Figure 10) are particularly challenging to prepare, mainly due to the commercial 
inaccessibility of the required starting materials.109  
 
Figure 10. Fused bridgehead nitrogen-containing heterocycles 
 As part of a general program aimed at the development of methodologies for pyridine 
functionalizations,110 our group has disclosed an elegant synthesis of pyrazolo[1,5-a]pyridines 
commencing from pyridinium ylide 161, via a direct functionalization/cyclization sequence 
(Scheme 55).111,64b The powerful Pd-catalyzed transformation tolerates a variety of vinyl 
bromides, iodides or alkynes as coupling partners. Furthermore, the N-iminopyridinium ylide 
161 is easily accessible from pyridine in two steps.112 In 2011, David Gareau, a summer 
student, investigated the functionalization of the C-1 position of pyrazolopyridine 162 by 
direct arylation, but it proved a difficult task.113  
Our group published a transition metal free, triflic anhydride mediated synthesis of 
imidazo[1,5-a]pyridines 164 under mild conditions (Scheme 55).114 These compounds could 
be derived in two steps starting from inexpensive materials (2-aminomethylpyridine and 
various acyl chlorides) via a Bishler-Napieralski-type cyclization.  
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Scheme 55. Our group’s approach for the synthesis of pyrazolo[1,5-a]pyridines and 
imidazo[1,5-a]pyridines111,114 
  
2.1.1 Importance of imidazo[1,5-a]pyridines  
Imidazo[1,5-a]pyridines have several noteworthy applications in medicinal chemistry 
and material sciences. Lately, an increasing number of compounds with anti-cancer, anti-
inflammatory and other medicinal properties containing the imidazo[1,5-a]pyridine scaffold 
have been studied (Figure 11).115 In 2003, the first natural product containing an imidazo[1,5-
a]quinolone scaffold was discovered by Petit and co-workers in the marine sponge 
Cribrochalina sp.116 The natural product, named Cribrostatin 6, shows promising anti-cancer 
and anti-inflammatory activity. Other applications of imidazo[1,5-a]pyridines include their use 
as precursors in the synthesis of N-heterocyclic carbenes.117 
 
Figure 11. Applications of imidazo[1,5-a]pyridines  
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Most interestingly, photophysical studies revealed that certain imidazo[1,5-a]azines 
exhibit high fluorescence efficiencies. Table 4 shows a few relevant examples along with their 
UV/Vis and fluorescence properties;118 special attention should be noted to the quantum yield 
(ΦF), as it is a direct measurement of the efficiency of the compound to emit light (ΦF is equal 
to the number of photons emitted divided by the number of photons absorbed).119 While most 
aryl substituted imidazo[1,5-a]pyridines (entries 1-4) possessed a quantum yield that was 
equal or less than 0.1, some of the more conjugated systems (structures 168-170) showed 
improved light absorbing/emitting properties (entries 5-7). In particular, electron donating 
groups (OMe, NMe2) influenced positively the quantum yield value. 
Table 4. UV/Vis and fluorescence properties of some imidazo[1,5-a]pyridines 
entry structure UV/vis fluorescence
λmax (nm) log ε λmax (nm) ΦF 
1 
 
317 4.25 461 0.07 
2 165, R = OMe 306 4.05 469 0.05 
3 166, R = CF3 340 4.12 459 0.04 
4 167, R = tBu N/D N/D N/D 0.04a 
5 
 
348 4.41 488 0.32 
6 
 
304 4.11 449 0.19 
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7 
 
303 4.31 479 0.22 
aThis result was provided by Léa Constantineau-Forget, a former MSc in our group. 
2.1.2 Direct functionalization of imidazo[1,5-a]pyridines  
Since aryl groups enhance the photophysical properties of imidazo[1,5-a]pyridines,118b 
there is an interest in developing new methodologies for the functionalization of fused N-
heterocycles.120 The arylation is usually performed via a two-step sequence: halogenation of 
the most nucleophilic position of the heterocycle, followed by cross-coupling with an 
organometallic reagent.115a,118b For example, in Scheme 56, compound 164 can be either 
iodinated or brominated at the C-1 position, then coupled to an aryl Grignard reagent or an 
aryl boronic acid to provide the corresponding products (171 and 172) in very good yields 
over two steps.118b If the C-1 position is blocked (heterocycle 173), then bromination occurrs 
at the C-3 position, and that position can then be functionalized via a Pd-catalyzed reaction to 
provide 174 (Scheme 56B).115a  
In 2010, the group of Murai disclosed the catalytic use of a cationic Pd-complex 
Pd(phen)2(PF6)2  in presence of two equivalents cesium carbonate as the base for the direct 
arylation of the C-1 position of 3-(pyridin-2-yl)imidazo[1,5-a]pyridine 175 (Scheme 57).121 
The reaction provided the corresponding product 176 in quantitative yield after stirring for 24 
h in DMA at 150 °C. Preliminary mechanistic studies suggested against C–H bond breaking as 
a rate-determining step, and an electrophilic or a radical pathway was proposed. 
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Scheme 56. Multistep functionalizations of imidazo[1,5-a]pyridines 
 
Scheme 57. Murai’s arylation of the C-1 position121 
 
  In back-to-back publications, the groups of Gevorgyan and Murai disclosed the first 
direct arylation of imidazo[1,5-a]pyridines at the C-3 position in 2011 (Scheme 58).122,123 
More precisely, Gevorgyan employed aryl bromides as coupling partners, palladium acetate as 
the catalyst, triphenylphosphine as the ligand and tetrabutylammonium acetate as the base.122 
Remarkably, no traces of arylation at the C-1 position were observed. A number of aryl 
bromides could be successfully coupled; however, electron withdrawing substituents provided 
better yields. Preliminary mechanistic studies were undertaken and indicated a kinetic isotope 
effect of 1.0 (calculated via an intermolecular competition reaction in the same flask), which 
would suggest against a C–H activation step being rate-limiting.  
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In parallel, Murai and co-workers employed their previously reported conditions121 to 
functionalize the C-3 position of 177 with aryl iodides (Scheme 58).123 Expectedy, some 
arylation at the C-1 position was detected, but could be suppressed by diluting the reaction 
mixture from 1.0 M to 0.5 M. Therefore, a second arylation at the C-1 site with a different aryl 
iodide was possible in a one-pot process (see formation of 178).  
Scheme 58. Direct arylation of imidazo[1,5-a]pyridines at the C-3 position 
 
Of late, Murai reported the oxidative coupling of imidazo[1,5-a]pyridines with alkynes 
(Scheme 59).124 The optimized conditions were Pd(OAc)2 as the catalyst, silver carbonate, 
acetic acid as the additive and a mixture of DMF/DMSO as the solvent. The combination of 
reagents allowed for selective alkynylation at the C-3 position. Furthermore, slow addition of 
the alkyne was necessary to prevent its homocoupling. There was no reaction when any of the 
silver carbonate or acetic acid were omitted, which lead the authors to suggest that a CMD-
type pathway is operative. It should be noted that the C-1 position could also be alkynylated, 
however a two-step sequence involving a bromination, then Sonogashira coupling was 
necessary.  
Scheme 59. Oxidative coupling of imidazo[1,5-a]pyridines and alkynes124 
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Recently, a couple of direct functionalization examples were also disclosed by the 
Charette group as part of our studies on the triflic anhydride-mediated synthesis of 
imidazopyridines (Scheme 60).114 For example, bromoimidazo[1,5-a]pyridine 179 could 
either undergo an intramolecular direct arylation cyclization in presence of a Pd0 source to 
give 180 or a Sonogashira coupling with phenylacetylene to provide product 181 in very good 
yields.  
Scheme 60. Direct arylation and Sonogashira coupling of imidazo[1,5-a]pyridine 179114 
 
 2.1.3 Research goals 
 Considering the potential of imidazo[1,5-a]azines in medicinal chemistry and their 
applications as fluorescent materials, as well as our continued interest in direct arylations, we 
sought to develop novel C–H functionalizations of the substrates. We also had in hand an 
easy, two-step sequence that would give imidazo[1,5-a]pyridines substituted at the C-3 
position in high yields.114 Prompted by the advances in ruthenium-catalyzed direct arylations 
(Section 1.2), we envisioned that the imidazo[1,5-a]pyridine functionality could act as a 
potential directing group for Ru catalysts. Whereas several nitrogen-containing five-membered 
heterocycles have been used as chelating groups (Figure 8, vide supra), fused nitrogen 
heterocycles of the type shown in Figure 10 have yet to be tested. Furthermore, the Ru-
catalyzed reaction would be complimentary to the Pd-arylation at the C-3 or C-1 positions 
developed by Murai and Gevorgyan (Scheme 61). 
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Scheme 61. Pd- versus Ru-catalyzed direct arylation of imidazo[1,5-a]pyridines 
 
 
2.2 Results and discussion 
2.2.1 Initial studies 
 We commenced our studies by adapting Ackermann’s previously established 
conditions for carboxylate-assisted ruthenation to a generic imidazo[1,5-a]pyridine template.48 
Imidazopyridine 182 containing a meta-OMe group provided monoaryl 183 as the main 
product, along with traces of 184 in about 70% (Scheme 62) when subjected to the reaction 
conditions.  
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Scheme 62. Preliminary results for the Ru-catalyzed arylation of 182 and 185 
 
A cyclopropane substituted imidazopyridine 185 was also tested (Scheme 62); 
unfortunately, only starting material was recovered in this case, suggesting that the present 
conditions were not suitable for cyclopropyl C–H activation. Nonetheless, a promising result 
with aryl C–H activation led us to pursue this study further.  
2.2.2 Reaction optimization 
 An intern from France (Valentin Poiret) helped with the initial optimization of the 
methodology. A few additives were screened for the reaction of 182 with 4-bromoanisole and 
the results are disclosed in Table 5. In absence of any carboxylate additive, there was no 
reaction (entry 1), while adding benzoic acid or 2,4,6-trimethylbenzoic acid (MesCO2H) with 
only 2.5 mol % [RuCl2(p-cymene)]2 as the catalyst resulted in incomplete conversions (entries 
2 and 3). Increasing the catalyst loading to 5 mol % led to complete conversion of the starting 
material to 183, and traces of 184. A higher yield was obtained with the more sterically 
hindered acid MesCO2H versus benzoic acid (compare entries 4 and 5). It should be noted that 
the reaction does not proceed at a lower temperature (≤100 °C). Separating traces of 184 from 
the product 183 proved to be quite challenging via column chromatography. In addition, using 
1H NMR yields for the optimization was also troublesome due to the overlap of the starting 
material and products peaks in the spectrum.  
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Table 5. Initial optimization with 4-bromoanisole and 182 
 
entry [Ru] catalyst additive commentsa 
1 2.5 mol % --- <2% 183 
2 2.5 mol % BzOH about a 1:1 mixture of 182:183 
3 2.5 mol % MesCO2H about a 1:1 mixture of 182:183 
4 5.0 mol % BzOH 57% 183 (traces of 184) 
5 5.0 mol % MesCO2H 66% 183 (traces of 184) 
aReactions were run on a 0.3 or 0.4 mmol scale; isolated or estimated yields.  
 In order to avoid complications due to analytical issues, the optimization of the 
additive was revisited employing 4’-bromoacetophenone as the coupling partner, as the two 
products 182a and 182b were easily separable by column chromatography (Table 6). Both 
BzOH and MesCO2H provided good yields of the products, with a similar 2:1 ratio of mono- 
to diaryl (entries 1 and 2). 1-Adamantyl carboxylic acid (AdCO2H) gave a lower yield (entry 
3), while pivalic acid resulted in 33% unreacted starting material (entry 4). Employing 
potassium acetate as the additive provided a 1:1 mixture of mono and diarylated products.  
Table 6. Screen of additives 
 
entry ArBr (x equiv) additive 
yielda (%) 
182 182a 182b 
1 1.5 BzOH 0 50 19 
2b 1.2 MesCO2H 0 51 22 
3b 1.5 AdCO2H 0 44 20 
4 1.5 PivOH 33 57 2 
5 1.2 KOAc 0 34 30 
a Reactions were run on a 0.2 mmol scale. Isolated yields. b Reaction was run on a 0.4 mmol scale. Isolated yield. 
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 We next looked at other Ru complexes as catalysts. Using 10 mol % of inexpensive 
RuCl3 hydrate (containing 48-50% Ru, about 5 mol % Ru in the reaction) resulted in no 
reaction (Table 7, entry 1). Other RuII sources could be successfully employed in the reaction, 
however incomplete conversions (entry 2) or lower yields (entry 3) were obtained. In the end, 
the initial [RuCl2(p-cymene)]2 was the optimal catalyst (entry 4). 
Table 7. Screen of Ru catalysts 
 
 
entry Ru (mol %) 
yielda (%) 
182 182a 182b 
1 RuCl3∙xH2O (10) 87 0 0 
2 [RuCl2(cod)]n (5) 42 17 7 
3 [RuCl2(benzene)]2 (5) 0 36 26 
4b [RuCl2(p-cymene)]2 (5) 0 51 22 
a 1H NMR yield using Ph3CH as internal standard. bIsolated yield on a 0.4 mmol scale. 
 Upon analysis of the reaction mixture by LC-MS, we also observed some higher 
molecular weight peaks corresponding to dimerization of either the starting material, or the 
product, or a mixture of both. The dimerization side-reaction is comparable to an oxidative 
homocoupling Ackermann and co-workers observed when employing ortho-substituted aryl 
halides as coupling partners.60a The side-reaction would explain why the product yield reached 
a plateau of 70-80%, despite observing no unreacted starting material by LC-MS.  
2.2.3 Scope of the imidazo[1,5-a]pyridine partner 
Various meta-substituted imidazo[1,5-a]pyridines were screened in presence of either 
1.2 or 0.5 equivalents of 4’-bromoacetophenone as the coupling partner (Scheme 63). When 
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the imidazo[1,5-a]pyridine was used as the limiting reagent, an electron donating group 
(OMe) on 182 led to the lowest selectivity for the monoarylated product 182a (2:1), while 
both methyl (186) and trifluoromethyl (187) substituents gave predominantly monoarylation 
(20:1 and 10:1 respectively). When the reaction was performed employing the aryl bromide as 
the limiting reagent (1.0 equiv ArBr to 2.0 equiv imidazo[1,5-a]pyridine), an almost 
quantitative conversion of the desired monoarylation products was isolatedNo diarylation was 
observed; instead, unreacted imidazo[1,5-a]pyridine was recovered (20%), along with some 
dimerization of the starting imidazo[1,5-a]pyridine.  
Scheme 63. Screen of meta-substituted imidazo[1,5-a]pyridines 
 
In order to investigate the dimerization further, Ackermann’s oxidative homocoupling 
work was revisited.60a In a recently published study, a reaction performed in presence of 2-
chlorotoluene as the coupling partner, furnished 67% isolated dimer as the sole product 
(Scheme 64). In the present case, imidazo[1,5-a]pyridine 186 was reacted with 2-
bromotoluene, and, under our optimized reaction conditions, 27% of direct arylation product 
186c was isolated, along with 46% dimer 188 (the structure of dimer 188 was determined via 
COSY NMR). Unlike Ackermann’s results, where dimerization is observed exclusively, we 
are able to obtain some direct arylation product with the sterically hindered 2-bromotoluene.  
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Scheme 64. Oxidative homocoupling with ortho-substituted aryl halides 
 
 Imidazo[1,5-a]pyridines containing a para-substituent were also tested under the 
reaction conditions with 1.2 equivalents aryl halides (Scheme 65). It was expected that the 
diarylation products would be more prominent versus the meta-series. Indeed, the ratio was 
roughly 2-2.5:1 for all substituents, similar to what Inoue and Oi had observed (Table 3, vide 
supra),54 while the best overall yield (92%) was obtained for the trifluoromethyl-substituted 
166. A bulky tert-butyl substituent did not improve the mono:di ratio significantly (2.5:1). A 
reaction between 4’-chloroacetophenone and imidazo[1,5-a]pyridine 165 was also set up; both 
the yields and ratios were higher than the corresponding bromide, consistent with the 
reactivity order ArCl>ArBr. 
Scheme 65. Screen of para-substituted imidazo[1,5-a]pyridines 
R = 4-tBu (167)
1.2 equiv ArBr 55% 22%
167a 167bR = 4-CF3 (166)
1.2 equiv ArBr 59% 30%
166a 166bR = 4-MeO (165)
1.2 equiv ArBr 32% 16%
165a 165b
NN X
[RuCl2(p-cymene)]2 (5 mol %)
MesCO2H (0.3 equiv)
K2CO3 (2 equiv)
PhMe, 130 C, 15 h
O
0.4 mmol
R
1.2 equiv ArCl 49% 20%
NN NN
compound a compound b
O O O
R R
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When the unsubstituted imidazo[1,5-a]pyridine 164 was submitted to the reaction 
conditions, a mixture of mono- and diarylation was obtained with all aryl halides tested 
(Scheme 66). Adding excess of the aryl bromide resulted in the formation of diaryl 164b 
solely. Therefore, by modulating the amount of the coupling partner, one can obtain either 
product as major. Again, the reactivity order for different halides was determined to be 
ArCl>ArBr>ArI. 
Scheme 66. Functionalization of unsubstituted imidazo[1,5-a]pyridine 164 
 
Finally, other substituted imidazo[1,5-a]pyridines were tested in the reaction (Table 8). 
ortho-Methyl 189 led to the formation of the monoaryl product in 63% yield (entry 1). 
Quinoline substrate 190 provided solely monoaryl 190a in 66% yield (entry 2); a second 
arylation did not occur presumably due to a restricted conformation imposed by π,π-stacking 
between the acetophenone and the quinoline ring. Lower yields were obtained with 2-naphthyl 
substrate 191 (entries 3-4), while 1-naphthyl 192 led to 57% of the expected monoaryl 192a 
(entry 5). Interestingly, the molecular weight of a potential diaryl substrate was observed by 
LC-MS analysis of the crude mixture, and 19% yield 192b was isolated. Upon 1D and 2D 
NMR analysis, it was determined that the second arylation occurred on the naphthyl ring at the 
C-9’ position (see structure 192b). 
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Table 8. Screen of other imidazo[1,5-a]azines 
 
entry imidazo[1,5-a]azine 4’-bromoacetophenone mono, yielda diaryl, yielda
1 189 1.5 equiv 189a, 63% 189b, 0 
2 190 1.2 equiv 190a, 66% 190b, 0 
3 191 1.2 equiv 191a, 32% 191b, 20% 
4 191 0.5 equiv 191a, 41% 191b, 0 
5 192 1.2 equiv 192a, 57% 192b,b 19% 
 aReaction conditions: imidazo[1,5-a]azine (0.4 mmol), 4’-bromoacetophenone (x equiv), [RuCl2(p-cymene)]2 (5 
mol %), K2CO3 (2 equiv), PhMe (2 mL), 130 °C, 15 h. Isolated yields. bSee structure of 192b.  
To sum up, the product distribution observed can be correlated to the sterics and 
electronic influence exerted by the C-3 aryl group of the starting imidazo[1,5-a]pyridine. As 
such, electron neutral and electron withdrawing groups on the C-3 phenyl ring provided better 
yields and mono- to diarylation ratios than the 3- or 4-MeO-substituted imidazo[1,5-
a]pyridines. Having the aryl halide as the limiting reagent was also ideal, leading to over 90% 
yields in almost all cases.   
2.2.4 Scope of the aryl halide 
 Following the latter study, we next considered the functional group tolerance of the 
aryl halide partner (Table 9). To have a better understanding of the steric influence versus 
electronics in the reaction, imidazo[1,5-a]pyridines substituted in the meta and para positions 
were evaluated. Heterocycles 186 and 187 tolerated a variety of aryl halides containing 
electron withdrawing (CF3, MeO2C, PhC(O), entries 1-3) or electron neutral groups (entries 6 
and 7). Notably, heterocycles such as 2-bromothiophene and 5-bromo-1-methyl-1H-indole 
performed well to provide the monoarylated products in excellent yields (entries 4-5). Most of 
the products were solely obtained as monoaryl, but in some cases traces of diarylation were 
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also observed (details in the Experimental section). tert-Butyl-substituted imidazopyridine 167 
also tolerated electron withdrawing (F, Et2NC(O), entries 8-9) or electron donating  groups (3-
OMe, entry 10). Lower yields were obtained in the case of imidazo[1,5-a]pyridine 165 (entries 
11-12) as significant dimerization of products 165c and 165e was observed by LC-MS. In 
addition, when 1-bromo-4(trifluoromethyl)benzene was employed as coupling partner, the 
corresponding arylated imidazo[1,5-a]pyridines had a higher propensity to decompose to 
unknown by-products, even when stored at -20 °C.125  
Table 9. Scope of the aryl halide 
 
entry imidazo[1,5-a]pyridine aryl halide mono, yield di, yield 
1 
 
 186d, 60% 186e, 0 
2 
 
186f, 47% 186g, <3% 
3  186h, 48% 186i, 0 
4 
 
 187c, 77% 187d, 6% 
5 
 
187e, 81% 187f, <3% 
6  187g, 89% 187h, 0 
7  187i, 77% 187j, 0 
N
Br
Br
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8 
 
 167c, 47% 167d, 21% 
9 
 
167e, 69% 167f, 9% 
10  
167g, 47% 
(98%)a 
167h, 18% 
11 
 
 
165c, 40% 165d, 16% 
12  165e, 22% 165f, 10% 
a0.5 equiv of aryl halide was used.  
In order to preferentially obtain diarylated products, the reactions of imidazo[1,5-
a]pyridine 164 with 3.0 equivalents aryl halides were investigated. In the case of 4’-
bromoacetophenone (Scheme 66, vide supra), the diarylation product was obtained 
exclusively; however, other aryl halides tested provided the diaryl compound only 
preferentially (Table 10, entries 1-3). The best partner was 4-bromobenzophenone which 
provided 164d in 83% (entry 1). 4-Chlorotoluene gave an overall yield of 72%, but an almost 
1:1 mixture of mono and di (entry 4). We reasoned that the bulky MesCO2- ligand (MesCO2H 
is deprotonated in situ by K2CO3) on the Ru centre might significantly encumber the second 
arylation, so we switched to KOAc as the additive, as the exchange of chloride with acetate 
easily takes place for [RuCl2(p-cymene)]2.126 Granted, the ratio was improved to 2:1 favouring 
diarylation, but the yield was not improved (entry 5).  
Table 10. Direct arylation with excess aryl halide 
 
NN
167
tBu
BrMeO
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entry aryl halide mono, yield di, yield 
1 
 
164c, 9% 164d, 83% 
2  164e, 16% 164f, 55% 
3 
 
164g, 10% 164h, 43% 
4 
5  
164i, 32% 
164i, 20%a 
164j, 40% 
164j, 43%a 
aKOAc (0.3 equiv) instead of MesCO2H. 
The reactivity of ortho-tolyl imidazo[1,5-a]pyridine 189 proved to be substrate 
dependant (Scheme 67). Whereas 4’-bromoacetophenone provided 63% product (Table 8, 
entry 1), other aryl halides screened gave very poor conversion; starting material was 
recovered, and no dimerization of 189 was observed by LC-MS.   
Scheme 67. Scope of ortho-substituted imidazo[1,5-a]pyridine (1H NMR yields using 
triphenylmethane as internal standard) 
 
 
NN Br
[RuCl2(p-cymene)]2 (5 mol %)
MesCO2H (0.3 equiv)
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NN
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Me Me
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 69 
2.2.5 Mechanistic investigations 
2.2.5.1 Deuteration experiments 
To study the reaction mechanism, control reactions were ran in presence of a 1:9 
mixture of D2O and toluene as the solvent, leading to 90% deuterium incorporation at the 
ortho positions of the 3-aryl-substituted imidazo[1,5-a]pyridines (Scheme 68), clearly 
demonstrating the reversibility of the C–H ruthenation step (Scheme 25, vide supra).59 
Furthermore, the C-1 position was also deuterated in variable amounts, thus implying that 
arylation at the position should also be possible; however, no C-1 arylation product was 
observed during the scope exploration. 
Scheme 68. Deuterium incorporation experiments 
 
An interesting comparison between the site selectivity of Ru versus Pd is shown in 
Scheme 69. Under the Ru deuteration conditions described above, imidazo[1,5-a]pyridine 164 
underwent exchange at the expected ortho-tolyl C–H and C-1 positions. In parallel, heating up 
the substrate with Pd(OAc)2 and AcOD, incorporated deuterium mainly at the C-1 position, 
with small traces at the ortho-tolyl position. 
Scheme 69. Deuterium incorporation for Pd versus Ru catalysis 
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2.2.5.2 Competition experiments 
A competition experiment performed between different electronics on the imidazo[1,5-
a]pyridines demonstrated a clear preference for arylation on the electron poor imidazo[1,5-
a]pyridine 166 (Scheme 70). The result was consistent with some of the poor yields associated 
with reactions involving electron rich imidazo[1,5-a]pyridines. Moreover, another competition 
experiment between an electron rich and an electron poor aryl bromide also led to a clear 
preference for the electron withdrawing acetophenone reactant (Scheme 72). The preferences 
were in accord with the previous work disclosed by Ackermann.59  
Scheme 70. Competition experiments 
 
2.2.5.3 Proposed mechanism 
Based on our preliminary mechanistic investigations, as well as on the previous studies 
with carboxylate-assisted Ru-catalyzed direct arylations (Section 1.2), a plausible mechanism 
is depicted in Scheme 71. It is generally accepted that the active catalytic species forms in situ 
upon reaction with the carboxylic acid additive (step A). Then, coordination of the RuII species 
to the nitrogen of the imidazo[1,5-a]pyridine (step B) is followed by a carboxylate-assisted 
reversible C–H ruthenation (step C), with loss of MesCO2K (which may form by reaction of 
1.5 equiv 1.5 equiv
Br
[RuCl2(p-cymene)]2 (5 mol %)
MesCO2H (0.3 equiv)
K2CO3 (2 equiv)
PhMe, 130 C, 15 h
NN
CF3
NN
OMe
NN
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p-Tol
NN
OMe
p-Tol
2.5 : 1
92%
(1.0 equiv)166 165
[RuCl2(p-cymene)]2 (5 mol %)
MesCO2H (0.3 equiv)
K2CO3 (2 equiv)
PhMe, 130 C, 15 h
Br
(1.5 equiv)
MeO
Br
O
(1.5 equiv)
91%
2 : 1 3 : 1
NN
164
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MesCO2H with K2CO3). The oxidative addition of the aryl halide (step D) gives rise to a RuIV 
species, followed by reductive elimination (step E) to provide the desired product and 
regenerate the active RuII catalyst. The second arylation would take place in a similar manner. 
Scheme 71. Proposed mechanism for Ru-catalyzed arylation of imidazo[1,5-a]azines 
 
However, the above mechanism does not explain how the dimerization of the starting 
material occurrs. In a report, Li and co-workers63 used sub-stoichiometric amounts of iron 
oxidant and hypothesized that oxygen in the air acted as an extra oxidant (to account for 
roughly 7% of product, Scheme 29). Ackermann proposed that ortho-substituted aryl halides 
acted as sacrificial oxidants.60a Indeed, we also observed oxidative homocoupling as the major 
product in case of 2-bromotoluene (Scheme 64). However, traces of dimerization were also 
observed when other aryl bromides were employed throughout the scope. Performing a control 
reaction with imidazo[1,5-a]pyridine 164 in absence of aryl bromide resulted in roughly 10% 
dimer (estimated by 1H NMR and LC-MS), along with unreacted 164 (Scheme 72), 
demonstrating that the Ru reagent reacts stoichiometrically in the dimerization. In order to test 
whether oxygen affects the homocoupling process, the reaction in Scheme 64 was performed 
under air. To our surprise, mostly unreacted starting material 186 was recovered at the end of 
the reaction, with only traces (<5%) of 186c and 188, suggesting against a potential re-
oxidation of Ru0 to RuII by O2.  
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Scheme 72. Control reaction in absence of aryl halide 
 
Based on our results, the following mechanism is proposed for the homocoupling 
(Scheme 73). A RuII species undergoes chelation-assisted oxidative addition into the C–H 
bond of imidazo[1,5-a]pyridine 186 (step F), followed by reductive elimination of HCl (step 
G). A subsequent oxidative addition followed by loss of another HCl molecule (steps H and 
I), leads to a RuII intermediate containing two imidazopyridines. Reductive elimination of the 
latter intermediate provides the homocoupled product 188 and a Ru0 species. In presence of an 
ortho-substituted aryl halide, Ru0 can oxidatively add into the aryl halide bond to regenerate a 
RuII species which can continue the catalytic cycle. The base, K2CO3, may be involved in 
quenching the HCl formed in the reaction; the role of the carboxylic acid MesCO2H remains 
under investigation. 
Scheme 73. Plausible mechanism for the formation of homocoupled product 188 
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2.3 Conclusion 
To sum up, we have established that imidazo[1,5-a]pyridines can act as directing 
groups in Ru-catalyzed direct arylations. Meta-substituted imidazo[1,5-a]pyridines gave the 
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best mono- to diarylated ratios, while electron withdrawing or electron neutral groups on the 
3-aryl substitutent proved to be ideal. A variety of aryl chlorides, bromides, and iodides were 
also tolerated under the reaction conditions. Excess of the aryl coupling partner led to 
diarylated imidazo[1,5-a]pyridines. Preliminary mechanistic studies established that the C–H 
ruthenation step was reversible; in addition, a plausible mechanism for the dimerization side 
reaction was proposed. Moreover, a distinctive site selectivity for C–H activation was 
determined for Ru versus Pd catalysts.  
 
 
 
Chapter 3: Intramolecular direct functionalization of 
cyclopropanes 
References: (a) Ladd, C. L.; Sustac Roman, D.; Charette, A. B. Org. Lett. 2013, 15, 1350. (b) 
Ladd, C. L.; Roman, D. S.; Charette, A. B. Tetrahedron 2013, 69, 4479.   
3.1 Introduction 
The cyclopropyl ring, a three-membered carbocycle, is a versatile building block in 
organic chemistry. It is widely found in natural products or current drug targets (Figure 12). 
The simplest of these natural products is 1-aminocyclopropane carboxylic acid (ACC), which 
is synthesized by an ACC synthase enzyme, and then converted to ethylene by an ACC 
oxidase enzyme.127 Cyclopropanes can also be part of trans-fatty acids, as exemplified by (±)-
grenadamide.128 Trans-chrysanthemic acid has applications as an insecticide,129 while 
bicyclohumulenone, a sesquiterpene, is used in the perfume industry.130 U-106305, a potent 
cholesteryl ester transfer protein inhibitor, contains a total of five cyclopropyl units and has 
been previously synthesized by our group.131A few examples of FDA-approved drugs 
containing a cyclopropane are also shown; perhaps the most relevant example here is 
Montelukast (SingulairTM), an anti-asthmatic and anti-allergic compound, developed at the 
former Merck facilities in Montréal.132 In a recent article, the cyclopropane ring placed in the 
10th spot in a Top 100 list of the most frequently used rings in the synthesis of small molecule 
drugs, thus highlighting its continual relevance in biologically active compounds.133  
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Figure 12. Examples of natural products (A) and drugs (B) that contain a cyclopropyl unit 
3.1.1 Synthesis and cross-coupling of cyclopropanes 
Given the predominance of cyclopropanes in medicinal chemistry and natural product 
synthesis, a plethora of methods are currently available for their synthesis and 
functionalization. Nature uses rearrangements (cationic, radical, and metal-catalyzed), redox 
or photochemical reactions for the biosynthesis of cyclopropanes,134 which have most 
certainly inspired current cyclopropane synthesis (Scheme 74). Three main synthetic 
strategies are depicted, all based on a [2+1] cyclization starting from a substituted alkene, 
either involving a metal carbene or carbenoid, or a Michael-initiated ring closing (MIRC). 
Two famous named reactions related to the transformations discovered over half a century ago 
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are Simmons-Smith135 and Corey-Chaykovsky.136 Our research group has also had a long-
standing interest in the asymmetric synthesis of cyclopropanes, developing an enantioselective 
methodology employing a dioxaborolane chiral auxiliary,137 based on the original Simmons-
Smith reaction. Furthermore, it contributed to the field of “metal carbene” cyclopropanations, 
looking both at the nature of the diazo and designing new chiral rhodium catalysts.138  
Scheme 74. Most common synthetic pathways to accessing cyclopropanes 
 
Cyclopropanes may also act as precursors en route towards accessing more chemical 
complexity, via involvement in a variety of reactions such as cycloadditions, ring openings or 
cross-couplings.82 Cyclopropanes can also be employed as “radical clocks” to test for radical 
intermediates in mechanistic studies (e.g. cyclopropylmethyl radical undergoes ring-opening 
with a rate constant of 1.2*108 s-1 at 37 °C).139 Indeed, the applications of the cyclopropane 
ring and its derivatives in organic synthesis are abundant, therefore, the following brief 
introduction will concentrate on mainly Pd-catalyzed transformations, as direct C–H 
functionalizations of cyclopropanes were covered in Section 1.3.3.   
There is ample literature precedence for the functionalization of cyclopropanes via 
cross-couplings.82 The cyclopropane can act as either the “nucleophile” (organometallic 
reagent) or “electrophile” (cyclopropyl halide). Both roles require a number of synthetic steps 
to achieve the pre-functionalized partners. For example, cyclopropylzinc 194 is derived via 
halogen-magnesium exchange from iodocyclopropane 193, followed by transmetalation with 
ZnBr2; subsequent addition of Pd catalyst, ligand and aryl halide provides the desired product 
195 in excellent yield (Scheme 75A).140 Stille-type cross-couplings are less refined; due to the 
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low nucleophilicity and bulkiness of the alkylstannane species, transmetalation to Pd is not 
very favourable, resulting in low yields (Scheme 75B).141 As a consequence, 
stannylcyclopropanes are instead employed as precursors to other cyclopropyl 
organometallics. Of late, our group disclosed a Hiyama-Denmark cross-coupling of 
cyclopropylsilanols, where the silanol moiety acts both as a directing group, and also mediates 
the transmetalation (Scheme 75C).142 It may be that the most popular cross-coupling reaction 
for cyclopropanes is the Suzuki-Miyaura coupling, due to the mild conditions, functional 
group tolerance, and, most notably, the ease of isolation and stability of cyclopropyl 
organoboron reagents, combined with straightforward transmetalation to Pd (Scheme 75D).143 
Cyclopropylboronic esters can be obtained from the corresponding alkenylboronic esters; and, 
in 2013, Hartwig published an elegant direct C–H borylation of cyclopropanes employing an 
iridium catalyst.144  
Scheme 75. Selected examples of cross-couplings where the cyclopropane acts as a 
“nucleophile” A. Negishi, B. Stille, C. Hiyama-Denmark, D. Suzuki-Miyaura 
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Cyclopropyl halides can also be employed directly in cross-coupling, however, 
examples are scarce. In comparison to the use of alkyl halides, the advantage of using the 
cyclopropane scaffold as an electrophile lies in avoiding β-hydride elimination, as it would 
create a strained cyclopropene species. Consequently, our group developed Suzuki-Miyaura 
cross-couplings of racemic iodocyclopropane 196 (Scheme 76).145 Recently, an example of a 
Sonogashira cross-coupling employing a cyclopropyl halide was disclosed by the group of 
Cossy.146  
Scheme 76. Suzuki-Miyaura coupling of iodocyclopropanes145a 
 
Cross-couplings involving cyclopropyl derivatives suffer from the same disadvantages 
as aryl cross-couplings, such as, lengthy syntheses of cyclopropyl organometallics or halides, 
low atom economy, waste generation, as well as toxic concerns with some of the reagents 
used.     
3.1.2 Palladium-catalyzed ring-opening of cyclopropanes 
The activation of cyclopropanes resulting in their ring-opening has a lot of synthetic 
potential in organic chemistry. The strategy can be matched with a subsequent nucleophilic 
attack, coupling or cycloaddition leading to novel substrates. Vinylcyclopropanes can form π-
allyl intermediates in presence of transition metals and undergo transformations similar to a 
Tsuji-Trost reaction. An early example comes from the group of Bäckvall, who, in 1985, 
studied the chloropalladation of (+)-2-carene (Scheme 77).147 It was speculated that an initial 
binding of Pd (used in stoichiometric amounts) to the olefin aided with the opening of the 
cyclopropane, followed by nucleophilic attack (methanol or other alcohol) to give complex 
198. Complex 198 was then reacted with sodium dimethyl malonate to provide product 199 as 
one isomer.  
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Scheme 77. Nucleophilic ring-opening of a vinylcyclopropane147 
 
Cyclopropane ring-opening can be used to generate a homoenolate, a species 
containing an anionic carbon β to a carbonyl group (Scheme 78A). The opening was routinely 
performed with a Lewis acid; however, in 1988, Nakamura and Kawajima reported the first 
catalytic generation of a Pd-homoenolate (Scheme 78B).148 Key to the success of the reaction 
was electron donation from a C–C σ-bond to an empty orbital onto the metal complex. 
Siloxycyclopropanes were ideal substrates, as their HOMO is higher in energy in comparison 
with cyclopropane or ethylene. Equally important was the generation of an electrophilic 
cationic Pd species, which was only possible when aryl triflates or diazonium salts were 
employed as the coupling partner (aryl halides were unreactive). Additionally, the use of an 
electron rich (p-methoxy-substituted) aryl triflate resulted in no reaction, also underlying the 
electrophilic nature of the metal. The proposed mechanism involved a Pd0/II catalytic cycle, 
while computational and experimental studies revealed that the C–C bond cleavage occurred 
through a “corner attack” from the electrophilic Pd species, thus forming a positive partial 
charge at the C-1 position (transition state 200 in Scheme 78C).149  The group of Nakamura 
extended the Pd-homoenolate methodology to the addition of acyl chlorides, several 
carbonylative couplings, and use of aryl iodonium salts.150 
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Scheme 78. Pd-catalyzed ring-opening of siloxycyclopropanes 
 
Later it was shown that hydroxycyclopropanes 201 can also undergo ring-opening 
(Scheme 79).151 The reaction was proposed to proceed through a Pd-enolate 203a, followed 
by opening of the C–C bond and β-hydride elimination to give α,β-unsaturated ketones 202; 
when the cyclopropane contained further substitution, the less substituted C–C bond would be 
cleaved preferentially. Inspired by the latter work, Rosa and Orellana demonstrated the intra- 
and intermolecular cross-coupling of cyclopropanols with aryl halides (Scheme 80).152 The 
reaction was viable in presence of an unprotected hydroxyl group (204); however, better yields 
were obtained if the alcohol was protected with a TMS group (205) and an in situ deprotection 
with TBAF was performed. The proposed mechanism involved oxidative addition of the Pd 
catalyst into the aryl bromide bond, followed by ligand exchange, Pd-homoenolate formation 
via a cyclopropyl rearrangement and reductive elimination (Scheme 80).  
Scheme 79. Pd-catalyzed ring-opening of hydroxycyclopropanes151 
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Scheme 80. Pd-catalyzed cross-coupling of cyclopropanols with aryl halides152 
 
He and Yudin explored the ring expansion of arylcyclopropanes bearing a heteroatom 
substitution in the ortho-position of the aryl ring (Scheme 81).153 The intramolecular Pd-
catalyzed process was amenable to amides, carboxylic acids and phenols in presence of 
oxidants such as copper chloride or benzoquinone. Although the mechanistic picture was not 
fully elucidated, plausible mechanisms based on NMR observations and deuterium scrambling 
were proposed. In case of amide 207, based on deuterium exchange experiments, π-allyl 210 
was proposed as an intermediate (Scheme 81A). A subsequent amide attack on the central 
carbon would provide 211, containing a four-membered palladacycle. Then, protonation of 
211 by either HX or DX would give 212 and 213, respectively. β-Hydride elimination of the 
latter intermediates would provide the major product 208. Formation of the minor product 209 
would occur via methylstyrene 214 and a subsequent Wacker-type oxidation (Scheme 81B). 
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Scheme 81. Yudin’s Pd-catalyzed oxidative opening of arylcyclopropanes A. Proposed 
mechanism for 208, B. Proposed mechanism for 209 
 
Shortly after Fagnou reported on the Pd-catalyzed opening of cyclopropanes (described 
in Section 1.3.3),87 another report surfaced in the literature. The work involved the preparation 
of different arylaminocyclopropanes (such as 215) via a Ugi-Smiles condensation (Scheme 
82).154 Then, the cyclopropyl substrates were submitted to microwave irradiation in presence 
of 5 mol % PdCl2(PPh3)2  and 1.5 equivalents Hunig’s base to obtain dihydropyridines in good 
yields (216, 86%). The reaction required no source of acetate and pivalate, and no 
experimental evidence was proposed to support a CMD pathway. Additionally, only aryl 
iodides could be used as substrates. Nonetheless, the work provided easy access to some 
biologically relevant cyclized enamines. 
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Scheme 82. Ugi-Smiles condensation followed by aminocyclopropane cyclization154 
 
3.1.3 Project origin and research goals 
Given the prevalence and significance of cyclopropanes in the various areas of 
biological chemistry, natural product synthesis and other applications, our group sought to 
develop methodologies for their direct functionalization. A former PhD student in the group, 
James Mousseau, briefly looked at developing an intramolecular C–H arylation of 
cyclopropanes employing an ester tether (Scheme 83).155 None of the desired six- or seven-
membered rings were obtained even after screening several reaction conditions. The only 
product isolated was coupling of the aryl bromide with the toluene solvent when the base 
employed was silver carbonate.40 In retrospect, perhaps the formation of a seven- or eight-
membered palladacyle intermediate would have been too difficult; or, the ester was not such a 
good chelator for Pd. However, the work was a great inspiration for the development of the 
current project.  
Scheme 83. James Mousseau’s attempt at intramolecular cyclopropane arylation 
 
An additional inspiration was also some of the more recent literature employing amides 
as directing groups for performing C(sp3)–H arylation.156 Along with an MSc student in the 
group, Carolyn Ladd, we embarked on the challenging task of developing conditions for an 
intramolecular arylation of cyclopropyl C–H bonds.  Indeed, it was discovered that 
biologically relevant cyclopropyl oxindoles could be synthesized starting from bromoanilides 
under Pd catalysis (Scheme 84). Moreover, the ring-opening of cyclopropyl amides was also 
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explored as a complementary reaction to our system. Mechanistic studies supporting direct 
activation of the C–H cyclopropyl bond by Pd will also be described.  
Scheme 84. Proposed direct arylation of cyclopropanes 
 
3.2 Palladium-catalyzed, silver-mediated intramolecular direct 
arylation of cyclopropanes 
3.2.1 Importance of cyclopropyl oxindoles 
A simple search in Reaxys for the 3,3’-cyclopropyl oxindole motif (allowing for all 
atom substitutions in the query) provided over 2000 compounds with bioactivity/ecotox data. 
Furthermore, even protection of the amide moiety with a methyl group still gave about 200 
compound results, strongly supporting the utility of the motif in medicinal chemistry, and also 
in other fields such as agriculture. A few examples of such compounds are depicted below 
(Figure 13).157   
 
Figure 13. 3,3’-Cyclopropyl oxindoles possessing bioactivity 
As described before (Section 3.1.2), ring-opening of cyclopropanes is also a useful 
reaction leading to novel compounds. For example, the group of Carreira disclosed an elegant 
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ring expansion of 3,3’-cyclopropyl oxindole 217 with aldimines in presence of the Lewis acid 
MgI2 (Scheme 85).158 The strategy was later exploited for the total syntheses of (±)-
strychnofoline,159 (±)-horsfiline,160 and (-)-spirotryprostatin B161 by the same group.  
Scheme 85. Carreira’s ring expansion strategy158 
 
3.2.2 Reaction optimization 
Cyclopropylbromoanilide 219 was chosen as the model substrate for the intramolecular 
cyclopropane arylation, due to its straightforward (two-step) synthesis from commercially 
available 2-bomoaniline and cyclopropanecarbonyl chloride. The optimization experiments 
were carried out by Carolyn Ladd and were described in her MSc thesis.162 Only a brief 
summary will be provided here.  
Initially, Fagnou-type conditions employing a pivalic acid additive were tested;45 
gratifyingly, the reaction proceeded well for aryl chlorides and bromides, but failed with aryl 
iodides (Scheme 86). As previously encountered in the literature, it was believed that 
accumulation of iodide anions in the reaction mixture had a detrimental effect on the activity 
of the Pd catalyst (known as catalyst poisoning). In such cases, some bases, and especially 
silver sources, can be employed to sequester iodide.163 For example, Fagnou and co-workers 
employed silver carbonate to sequester iodide.17 Moreover, in Fagnou’s case, silver sources 
were found to accelerate reaction times and lower the temperature. Upon adding silver 
carbonate to the model cyclization, improved yields were observed for aryl iodides and 
bromides, while the chloride failed to react (Scheme 89). 
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Scheme 86. Initial studies with PivOH and Ag2CO3a 
 
The optimization was further pursued utilizing an aryl bromide in presence of a silver 
salt, and some modifications to the reaction conditions in Scheme 86 are presented in Table 
11. Both Pd0 and PdII sources could be applied to the reaction and an acetate source was not 
required (not shown). A sterically demanding (PtBu3∙HBF4) or a bidentate phosphine (BINAP) 
gave poor conversions (entries 1 and 2). Triphenylphosphine provided the product in a modest 
62% yield (entry 3). K2CO3 and Cs2CO3 gave the best conversions, and inexpensive K2CO3 
was chosen as the optimal base (entry 4). NaOtBu, a much stronger base resulted in 
decomposition (entry 6), while another weaker base, K3PO4, provided a lower yield (entry 5). 
Silver acetate gave a low 30% yield (entry 7), while other silver sources such as Ag3PO4 and 
AgNO3 were effective in promoting the reaction (entries 8 and 9). It was important that only 
one equivalent of cationic silver was employed, as increasing or decreasing that amount 
significantly inhibited the reaction.162 Finally, the amount of base could be reduced to 1.5 
equivalents, and reaction was complete in 3 h at 130 °C (entry 10). It should be noted that the 
reaction could also be performed at 110 °C with minimum loss of yield (85%). A series of 
control reactions were also performed by omitting each reaction component; it was found that 
the silver source, the base, the catalyst and the ligand were all necessary for the reaction to 
occur. 
Table 11. Summary of the reaction optimization 
Br
N
Me
O
219b
Pd(OAc)2 (10 mol %)
ligand (10 mol %)
base (2 equiv)
Ag source (1 equiv)
PhMe (0.5 M), 130 °C, 16 h
N
O
Me
220  
entry ligand base Ag source yield 220a
1 rac-BINAP K2CO3 Ag2CO3 25% 
X
N
Me
O
Pd(OAc)2 (5 mol %)
PCy3 (10 mol %)
219a-c
Cs2CO3 (1.5 equiv)
PivOH (30 mol %)
PhMe, 130 °C, 16 h
N
O
Me
220
X = Cl 78%
Br 81%
I 0%
X
N
Me
O
Pd(OAc)2 (5 mol %)
PCy3 (10 mol %)
K2CO3 (1.5 equiv)
Ag2CO3 (50 mol %)
PhMe, 130 °C, 16 h
N
O
Me
220
X = Cl 0%
Br 90%
I 48%
a 1H NMR yields employing trimethoxybenzene as internal standard.
219a-c
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3 PtBu3∙HBF4 K2CO3 Ag2CO3 trace 
3 PPh3 K2CO3 Ag2CO3 62% 
4 PCy3 Cs2CO3 Ag2CO3 89% 
5 PCy3 K3PO4 Ag2CO3 61% 
6 PCy3 NaOtBu Ag2CO3 25% 
7 PCy3 K2CO3 AgOAc 30% 
8 PCy3 K2CO3 Ag3PO4 90% 
9 PCy3 K2CO3 AgNO3 89% 
10b PCy3 K2CO3 Ag3PO4 90% 
a 1H NMR yield using trimethoxybenzene as internal standard. b Optimal conditions: Pd(OAc)2 (5 mol %), PCy3 
(5 mol %), K2CO3 (1.5 equiv), Ag3PO4 (0.33 equiv), PhMe (0.5 M), 130 °C, 3 h. 
Carolyn Ladd explored several amide protecting groups (Scheme 87). In absence of 
any protecting group, the substrate decomposed, while anilides protected with a Boc 221 or 
Cbz 222 produced only traces of product. A benzyl protecting group was found to be 
compatible (223), providing 55% of the desired product 226. It is necessary to note that no 
cyclization onto the phenyl group was detected, thus highlighting the fact that the conditions 
are selective for C(sp3)–H functionalization. 
Scheme 87. Screen of anilide protecting groups 
 
3.2.3 Reaction scope 
The scope was pursued by exploring substitution on the aryl moiety. The substrates 
were synthesized by Carolyn Ladd using various synthetic operations and submitted to the 
optimized conditions (Scheme 88). Pleasingly, a variety of functional groups were tolerated, 
including methoxy (228, 229), trifluoromethyl (230), nitrile (231), ester (232), and ketone 
(233). Also, a chloro substituent was viable (234), thus allowing for further functionalizations.  
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Scheme 88. Probing substitution on the aryl moietya 
 
Next, the scope with respect to substitution on the cyclopropane was explored (Scheme 
89). A multitude of trans, racemic, aryl-substituted cyclopropanes were synthesized via a 
Corey-Chaykovsky/amide formation/methylation sequence and then tested under the reaction 
conditions. A mixture of two diastereomers was produced, which were separable in some 
cases. The structure of the diastereomers was determined via X-ray crystallography (Scheme 
90). Initially, the reactions were performed for 15 h at 130 °C to afford good to excellent 
yields, but modest diastereoselectivities. It was later found by Carolyn Ladd that the yields and 
diastereoselectivities could be improved when the reaction was performed the reaction for 
only 3 h. The reaction could tolerate ortho, meta and para substitution (236-238), as well as 
many functional groups including methoxy (239), fluoro (240), trifluoromethyl (241), and 
chloro (242) in the para position. In addition, heterocycles such as thiophene (243) and furan 
(244) gave good yields and diastereoselectivities (>8:1). In general, the reaction was not found 
to be highly sensitive to either sterics or electronics; however, better dr’s were obtained in 
case of electron donating substituents.  
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Scheme 89. Effect of arylcyclopropane substitutiona 
 
Scheme 90. X-Ray structures of diastereomers 
 
N
O
15 h: 90%, 6:1 dr
N
O
15 h: 91%, 6:1 dr
3 h: 92%, 8:1 dr
N
O
15 h: 89%, 6:1 dr
3 h: 93%, 8:1 dr
N
O
15 h: 99%, 7:1 dr
3 h: 99%, 8:1 dr
N
O
15 h: 90%, 4:1 dr
3 h: 85%, 5:1 dr
N
O
15 h: 88%, 5:1 dr
3 h: 95%, 5:1 dr
N
O
15 h: 98%, 7:1 dr
3 h: 98%, 11:1 dr
N
O
15 h: 80%, 7:1 dr
3 h: 94%, 14:1 dr
N
O
15 h: 67%, 10:1 dr
3 h: 95%, 8:1 dr
N
O
15 h: 40%, >10 :1 dr
3 h: 79%, 9:1 dr
N N
O
R
Pd(OAc)2 (5 mol %)
PCy3 (5 mol %)
K2CO3 (1.5 equiv)
Ag3PO4 (0.33 equiv)
PhMe (0.5 M), 130 °C, 3 or 15 h
N
O
R
major minor
Me Me
Me MeO
F F3C Cl
S O
235 236 237 238 239
240 241 242 243 244
Br
O
R
trans, racemic
aReactions were perfomed on a 0.5 mmol sclae. Isolated yields. For compounds 240, 241 and 242 the diastereomers were separable.
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It should be noted that for all the substrates above, only the five-membered 
spirooxindole ring was isolated; no trace of the six-membered ring was observed. We 
attempted to form a six-membered ring by cyclizing amide 245, which contained a longer 
tether (Scheme 91). Unfortunately, none of the desired product was observed, and only 
unreacted starting material and traces of the aryl bromide coupling with the toluene solvent 
was detected. The results were reminiscent of James Mousseau’s initial attempt at 
intramolecular arylation of cyclopropanes (Scheme 83, vide supra), implying that a potential 
seven-membered palladacycle is not feasible. Additionally, changing the amide tether to an 
ether or methyl-protected amine was also unsuccessful, resulting in unreacted starting material 
or dehalogenation (Scheme 91). 
Scheme 91. Attempts at forming other spiro products 
 
3.2.4 Mechanistic studies 
We wanted to probe whether the reaction was occurring through a CMD-type pathway 
or enolate arylation. Hartwig and co-workers had previously investigated α-arylation of 
amides on bromoanilide substrates in presence of the strong base NaOtBu (Scheme 92).164 In 
2001, the same group disclosed improved conditions for the arylation: use of the less sterically 
demanding PCy3 allowed for lower temperatures (even room temperature in some cases) and 
the employment of aryl chlorides at 70 °C (Scheme 92).165 It was argued that the steric 
demand of the bromoamide starting material accounted for the need to use PCy3, that is, a 
smaller [Pd0] species would be able to insert faster into the Ar-X bond.  
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Scheme 92. Hartwig’s α-arylation of amides164-165 
 
Mechanistic studies on the relative rates of each step determined that oxidative addition 
was the rate-determining step, while deprotonation of the amide occurred rapidly. The 
proposed mechanism is shown in Scheme 93: rate-limiting oxidative addition (step A); 
deprotonation and formation of an arylpalladium intermediate (step B); and finally, reductive 
elimination (step C) to provide the oxindole product 248 and a [Pd0] species.   
Scheme 93. Proposed mechanism for α-arylation of amides  
 
In contrast with Hartwig’s system, our optimized reaction conditions employed mild 
K2CO3 and Ag3PO4 as bases, while use of NaOtBu resulted in decomposition of the starting 
material. Nonetheless, the preceding observations are not enough evidence to discount the 
enolate pathway. As we were also intrigued by the fact that different diastereoselectivities 
were obtained for different reaction times, we decided to pursue other studies that would shed 
light on the behaviour. 
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3.2.4.1 Isomerization and epimerization studies 
Initially, the behaviour of a racemic trans versus cis substituted arylcyclopropane 250 
or 251 was investigated (Scheme 94). When submitting 250 to the optimized reaction 
conditions for 15 h, a 6:1 mixture of diastereomers was recovered, while repeating the same 
experiment with 251, a 1.7:1 mixture was recovered. The major diastereomer was 235a in 
both cases. Upon taking the 1.7:1 mixture obtained above and resubmitting to the same 
reaction conditions, a mixture of 3.6:1 favouring 235a was obtained. Additionally, a control 
reaction in toluene demonstrated some isomerization also occurred. Thus, the minor 
diastereomer 235b slowly isomerizes to the major 235a over time.  
Scheme 94. Studies on the isomerization of arylcyclopropanes 
 
In order to determine if a potential enolate was forming during the reaction, the 
epimerization of the arylcyclopropane was investigated. Two enantiopure starting materials 
250 and 251 (95% and 91% ee) were prepared using the standard Simmons-Smith 
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methodology developed in our group.166 After three hours the reaction was complete and little 
erosion in enantioselectivities for both substrates was observed (Scheme 95). The observation 
is not consistent with an enolate mechanism, where complete epimerization of the product is 
expected at the end of the reaction. However, the enantioselectivity does erode over time, but 
as a result of the isomerization of the product.  
Scheme 95. Epimerization studies of enantiopure cyclopropyl starting materials 
 
3.2.4.2 Kinetic isotope effect 
Scheme 96. Kinetic isotope effect study 
 
A deuterated cyclopropane 252 was prepared and the kinetic isotope effect of the 
cyclization was measured. Two parallel reactions were set up and the relative rates of 
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conversion were analysed via NMR spectroscopy (details in the experimental section).20 The 
KIE was calculated to be 3.9, which indicated C–H cleavage to be rate-limiting (Scheme 96).  
3.2.4.3 Proposed mechanism 
At the end of the mechanistic investigations, an enolate pathway was rejected based on the 
following arguments: 
• In contrast to Hartwig’s system where a strong base NaOtBu was employed, we could 
use a mild base K2CO3, while NaOtBu gave mainly decomposition; 
• Little erosion of enantioselectivity was observed when the reaction was complete, thus 
suggesting against an enolate mechanism; 
• C–H cleavage was determined to be rate-determining, while Hartwig determined the 
oxidative addition to be rate-limiting for the α-arylation of amides. 
A direct functionalization pathway was deemed plausible, based on the KIE observed. In 
addition, the role of the reactants in the concerted metalation-deprotonation step was carefully 
examined and the following could be concluded: 
• Catalytic acetate was not necessary for the reaction, as PdBr2 was also an effective 
catalyst; 
• Either carbonate or phosphate could be the base involved in the CMD step; 
• The silver salt could sequester halide, but it is also well known that AgI can abstract 
halide from a Pd intermediate to provide a cationic Pd species.167 
Based on all the observations, the mechanism shown in Scheme 97A was proposed. An 
initial oxidative addition step D is followed by bromide abstraction by Ag+ to give a cationic 
Pd species (step E), which can undergo the concerted metalation-deprotonation mediated by 
carbonate (or phosphate, F and G). The six-membered palladacycle then undergoes reductive 
elimination (step H) to give the product and regenerate the Pd0 catalyst.  
It is known in the literature that cyclopropanes rearrange via homolytic cleavage of the 
most substituted bond, followed by bond rotation and then re-bonding (Scheme 97B).168 It is 
possible that the pathway is also viable in our case, and is responsible for the thermal cis/trans 
isomerization observed. Opening of the cyclopropane would also explain why the 
enantioselectivity drops so significantly over time, especially for the cis substrate. However, 
besides the loss of enantioselectivity, there is currently no other experimental evidence in its 
support.   
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Scheme 97. Proposed reaction mechanism 
 
3.2.5 Related work 
During our manuscript preparation, two related examples appeared in the literature that 
are worthwhile mentioning here. Namely, the group of Cramer first disclosed an 
enantioselective, intramolecular cyclopropyl C–H arylation to form tetrahydroquinolines of 
type 256 (Scheme 98).169 In a Pd-catalyzed, pivalic acid-promoted cyclization, aryl bromides 
containing a triflyl protected amine tether could be cyclized in excellent yields and 
enantioselectivities. The chiral ligand 254 was TADDOL-derived. Of note is the use of an 
alkyl (or aryl) substituent on the cyclopropane to induce a seven-membered palladacycle; in its 
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absence, a six-membered palladacycle would be formed which would reductively eliminate to 
give spiroindoline 257 in 95% yield (Scheme 99).170 Interestingly, improved conversions were 
observed when PCy3 was used as a ligand, while the overall conditions were somewhat 
reminiscent of Fagnou’s previous work on direct arylation.47  
Scheme 98. Cramer’s enantioselective, intramolecular arylation of cyclopropanes169 
 
Scheme 99. Cramer’s synthesis of spiroindolines170 
 
3.3 Palladium-catalyzed ring-opening of cyclopropyl benzamides 
While the project discussed above was still ongoing in our lab, we pursued a 
complementary reaction. Our goal was to induce C–H activation of cyclopropane, followed by 
ring-opening. We hypothesized that a neighbouring nitrogen lone pair could facilitate the 
opening. Indeed, upon submitting amide 258 to our previously optimized conditions, we 
observed full conversion of the starting material and detected about 46% product resulting 
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from cyclopropane opening, under the form of two isomers 259 and 260 (Scheme 100). The 
rest of the material consisted of five-membered and six-membered spirooxindoles 261 and 
262. The reaction also represented the first instance we were able to produce a six-membered 
ring 261 with an intact cyclopropane.  
Scheme 100. Initial studies on amide 258 
 
The seven-membered aza-heterocycles formed are formally referred to as 
benzo[c]azepine-1-ones and are compounds of significant bioactivity, used in a range of 
medicinal chemistry applications (Figure 14).171 Additionally, compounds of type 259 or 260 
could be used as precursors for more complex aza-heterocycle-containing molecules.171d-e  
 
Figure 14. Benzazepine type compounds in medicinal chemistry 
3.3.1 Reaction optimization 
The reaction optimization was commenced by a phosphine ligand screen (Table 12). A 
significant ligand effect was observed; bulky PtBu3∙HBF4 provided exclusively the 
benzazepinone products 259 and 260 (entry 2), while phosphines such as PPh3, DavePhos or 
JohnPhos also provided the desired products, albeit in low yields (entries 3-5). Thus, 
PtBu3∙HBF4 appeared to have the optimal steric (Tolman cone angle 182° versus PCy3 
170°)172 and electronic properties for the C–H activation and cyclopropane opening. 
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Table 12. Ligand screen  
 
  yielda (%)
entry ligand 258 259 260 261 262 Total product 
1 PCy3b 0 24 22 39 15 100 
2 PtBu3∙HBF4 0 66 26 0 0 92 
3 PPh3 27 18 15 0 trace 33 
4 DavePhos 21 43 9 0 trace 52 
5 JohnPhos 10 37 12 12 19 80 
a 1H NMR yields using trimethoxybenzene as internal standard. b Isolated yield with 10 mol % PCy3. 
Next, the role of the silver salt in the reaction was investigated. Silver salts such as 
carbonate, acetate or bromide provided complete conversion, but lower yields of the desired 
products (Table 13, entries 1-3). Silver triflate provided complete decomposition of the 
starting material (entry 4). Furthermore, my colleague Carolyn Ladd screened the 
stoichiometry of silver phosphate in the reaction and discovered that, similarly to the previous 
section, exactly one equivalent of cationic silver was required; increasing the amount of Ag 
resulted in lower yields.162 
Table 13. Screen of silver salts 
 
  yielda (%) 
entry “Ag” source 259 260 Total product 
1 Ag2CO3 58 11 69 
2 AgOAc 44 9 53 
3 AgBr 31 41 72 
4 AgOTf 0 0 0 
a1H NMR yields using trimethoxybenzene as internal standard. 
A number of control reactions were also performed to determine the necessity for each 
reaction component (Table 14). In absence of the Pd catalyst, there was no reaction (entry 1). 
Omitting the ligand or the base did result in some product formation (entries 2-3). Omitting 
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the silver source provided only traces of product (entry 4). Replacing K2CO3 by the weaker 
base K3PO4 provided the products in a total yield of 6% (entry 5). The ideal temperature for 
the reaction was 125 °C, and lowering it to 100 °C resulted in significant loss of yield (entry 
6). It should be noted for all the reactions, the rest of the mass balance was recovered starting 
material 258.    
Table 14. Control reactions 
 
  yielda (%) 
entry variation from standard conditions 259 260 Total product  
1 no Pd 0 0 0 
2 no PtBu3∙HBF4 17 3 20 
3 no K2CO3 27 18 45 
4 no Ag3PO4 trace trace trace 
5 no Ag3PO4, K3PO4 instead of K2CO3 5 1 6 
6 at 100 °C 34 8 42 
a 1H NMR yields using trimethoxybenzene as internal standard. 
3.3.2 Reaction scope  
 The scope of the reaction was mainly explored by Carolyn Ladd, who synthesized all 
starting materials and submitted them to the cyclization, except for Scheme 103.162  
Scheme 101. Protecting group screen 
 
Upon changing the amide protecting group, it was discovered that benzyl 263 was also 
suitable (Scheme 101). In the cyclization of 263, a total product yield of 96% was obtained, 
and the cyclization was specific for C(sp3)–H bonds; none of the aryl cyclization was 
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observed. A carbamate protected substrate 264 was highly labile and underwent deprotection 
during the reaction to provide 267 in 53% yield along with a mixture of unknown alkenes.  
The scope was further investigated with substrates bearing a substitution on the 
aromatic ring (Scheme 102). Aryl iodides were also reactive (77% overall yield), but aryl 
chlorides gave no conversion (not shown). Furthermore, methyl, dimethyl, fluoro and difluoro 
substituents all provided the desired products in excellent yields; importantly, a methyl group 
ortho to the bromide did not seem to hinder the reaction, benzazepinones 272 and 273 being 
isolated in 94% yield. Additionally, a methoxy substituent was also tolerated, as 280 and 281 
were obtained in a total yield of 94%, in about a 1:1 ratio. Unfortunately, the reaction was 
sensitive to a very electron rich substrate bearing three methoxy substituents (27% overall 
yield) and unreacted and dehalogenated starting material were also isolated. 
A substrate bearing aryl substitution was also tested under the ring-opening conditions 
(Scheme 103). Compound 284 bearing a p-tolyl substituent was quite unreactive and even 
after 72 h of heating at 120 °C only 44% yield of the desired products (the exact structure was 
not assigned) were obtained, along with other unidentified alkenyl products. It was concluded 
that a substituted cyclopropane was not suitable for the transformation, perhaps as a result of 
steric interaction with the bulky PtBu3∙HBF4. 
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Scheme 102. Scope with respect to the aryl halide 
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Scheme 103. Ring-opening of a substrate bearing an aryl-substituted cyclopropane 
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As an application, it was demonstrated that the mixture of products can be easily 
hydrogenated to give one product 285 in 93% yield (Scheme 104), thus providing easy access 
to a benzolactam product.  
Scheme 104. Hydrogenation of benzazepinones 
 
3.3.3 Mechanistic investigations 
To gain an understanding into the formation of each product, each alkene isomer was 
separately re-submitted to the reaction conditions (Scheme 105A). The major benzoazepinone 
product 259 remained unchanged, while minor 260 provided a 3:1 mixture of 259:260. What 
is more, when the reaction was tested after only 30 min, formation of minor 260 was 
predominant (30% versus 17%), while at the end of the 16 h reaction time, 259 was formed in 
majority, with about a 2.5:1 ratio to 260 (Scheme 105B). The results suggest that 260 was the 
kinetic product and 259 was the thermodynamic product.162 
Scheme 105. Isomerization studies of A. 259-260 and B. 258 
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Next, we wished to investigate whether the cyclopropyl C–H activation occurred prior 
to the cyclopropane opening. Benzamide 258 was submitted to the reaction conditions 
previously disclosed by Fagnou et al,87 and under both conditions dihydroisoquinoline 261 
was the major product (47% or 50% yield), along with spirooxindole 262 (Scheme 106). 
Benzoazepinone products were also isolated, albeit in much lower yields. Products 261 and 
262 are believed to form via a pivalate-mediated CMD transition state to give either a six- or 
seven-membered palladacycle, followed by reductive elimination. It was hypothesized that 
perhaps 261 was prone to ring-opening during the reaction, and led to the formation of 259 
and 260; however, 261 was fully recovered at the end of 16 hours (Scheme 107).   
Scheme 106. Screen of pivalate conditions 
 
Scheme 107. Control reaction with 261 
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For the cyclopropane arylation presented in Section 3.2, it was found that both PdII and 
Pd0 sources were reactive, and that catalytic acetate was not necessary for the CMD step. For 
the ring-opening transformation, when Pd2(dba)3 was evaluated as catalyst, a low conversion 
was observed; upon adding acetate in the reaction (1.1 equiv KOAc instead of K2CO3), most 
of the reactivity was restored (Table 15). The result suggested the necessity of acetate during 
the CMD step.  
Table 15. Influence of acetate on the reaction outcome 
 
   yielda (%) 
entry “Pd” base 259 260 Total product 
1 Pd2(dba)3 (2.5 mol %) K2CO3 8 6 14 
2 Pd2(dba)3 (2.5 mol %) KOAc 52 11 63 
a 1H NMR yield using trimethoxybenzene as internal standard. 
A short summary of all mechanistic investigations and observations is presented below: 
• C–H activation of cyclopropane does not require the presence of pivalate (compare the 
formation of dihydroisoquinoline 261 in Scheme 100 and Scheme 106); 
• Dihydroisoquinoline 261 does not undergo ring-opening under the reaction conditions; 
• Acetate is responsible for proton abstraction during the CMD step (Table 15); 
• Exactly one equivalent of Ag+ was found necessary for the cyclization;  
• It is speculated that the silver source may be involved in halide abstraction and 
formation of a cationic Pd species; 
• A sterically hindered ligand was important for formation of the ring-opened products. 
Based on the observations, the following plausible catalytic cycle was proposed (Scheme 
108). Initial oxidative addition forms complex 286, followed by halide abstraction by the 
cationic silver to produce cationic Pd intermediate 287. A seven-membered palladacycle 289 
forms via an acetate-mediated CMD transition state 288. When PCy3 is employed as ligand, 
reductive elimination gives rise to dihydroisoquinoline 261, which was shown to not undergo 
any ring-opening. In presence of sterically hindered PtBu3 ring-opening occurs, aided by both 
Pd and the nitrogen lone pair to give 290 which may undergo deprotonation and then reductive 
elimination to provide either product.  
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Scheme 108. Plausible catalytic cycle 
 
A plausible mechanism for the alkene isomerization is shown in Scheme 109. It is well 
known that double bond migration can be promoted by a variety of transition metals, including 
Ru, Rh, Pd, Fe etc.173 Coordination of Pd to the alkene is followed by a π-allyl formation via a 
1,3-H shift to give 291, then reductive elimination to produce the more stable enamide-type 
structure.   
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Scheme 109. Possible isomerization mechanism 
 
 
3.4 Conclusion 
 In summary, two novel intramolecular C–H functionalizations of cyclopropanes were 
developed. In the first project, cyclopropyl spirooxindoles were synthesized starting from 
easily available bromoanilides. It was demonstrated that the reaction mechanism followed a 
CMD-type pathway, and not enolate arylation, through epimerization experiments and 
determination of the KIE. In the second project, benzoazepinone-type products were 
synthesized starting from benzamides. It was demonstrated that a bulky ligand such as PtBu3 
resulted in cyclopropane opening, while a less hindered ligand such as PCy3 provided mainly 
cyclization of the intact cyclopropane. Mechanistic studies and comparison to the Fagnou 
conditions led us to conclude that C–H activation of the cyclopropyl bond via a CMD pathway 
occurred previous to ring-opening. 
 The projects added to the few known examples in the literature of direct cyclopropane 
functionalization, demonstrated the use of Ag in generating a reactive cationic species and 
opened the door to the development of other activation cyclopropanes methodologies. 
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Chapter 4: Auxiliary-enabled, Pd-catalyzed, 
intermolecular arylation of cyclopropanes 
Reference: Sustac Roman, D.; Charette, A. B. Org. Lett. 2013, 15, 4394. 
The introductory chapter provided an overview of monodentate directing groups used 
in transition metal catalysis. The current chapter will present a brief overview of amide-based 
bidentate groups for Pd catalysis, and applications to the functionalization of cyclopropanes. 
In comparison to monodentate coordination, bidentate groups maintain a higher degree of 
stereochemical control around the metal centre, which enables the formation of more rigid 
cyclometalated species.  
4.1 N,N-Bidentate directing groups 
The concept of bidentate coordination being able to promote sp2 or sp3 C–H activation 
has been well known in the literature, with most of the early work employing stoichiometric 
transition metal.174 A breakthrough in the field came in 2005, when Daugulis et al introduced 
the picolinamide and aminoquinolinamide auxiliaries for Pd-catalyzed direct arylation of 
C(sp2)–H and C(sp3)–H centers with aryl iodides (Scheme 110).175a The reaction took place in 
presence of Pd(OAc)2 (5 mol %), AgOAc (1.1 to 4.1 equiv), in absence of any solvent 
between 130-150 °C. The authors followed up the initial communication with a full paper in 
which the scope and mechanism were fully investigated.175b Key to a successful bidentate 
auxiliary was the presence of an acidic NH group, as well as a nitrogen or sulfur (derived from 
2-methylthioaniline) coordinating group; it was suggested that the bidentate coordination 
mode would retard β-hydride elimination (Scheme 110). Either β-arylation of carboxylic acids 
or γ-arylation of amines could be performed, depending on the type of auxiliary used. 
Additionally, alkylation with alkyl iodides or benzyl bromides could also be achieved.  The 
reactions conditions could also be modified to avoid the use of stoichiometric silver, using 
instead K2CO3 as the base and a mixture of t-amylOH and H2O as the solvent (Scheme 110). 
The bidentate auxiliary derived from 8-aminoquinoline could be removed in refluxing sulfuric 
acid. 
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Scheme 110. Daugulis’ auxiliaries for C(sp3)–H arylation175 
 
In terms of mechanistic studies, several complexes related to reaction intermediates 
have been isolated and characterized by Shabashov and Daugulis (Scheme 111).175b Upon 
stirring aminoquinolinamide 292 in acetonitrile with stoichiometric Pd(OAc)2 the 
corresponding cyclometalated complex 293 was formed. The complex underwent replacement 
of the labile nitrile solvent with tBuCN to form 294. At – 78 °C, complex 294 oxidatively 
added bromine to provide PdIV complex 295, which was characterized by NMR and X-ray 
crystallography. It also represented one of the first examples of alkyl-PdIV complexes isolated. 
Attempts at replacing the bromine with other substituents were unsuccessful.  
Scheme 111. Isolation of reaction intermediates175b 
 
Based on all the experimental evidence, a generalized mechanism for bidentate-
directed C–H functionalization was proposed (Scheme 112).175b Initial formation of a 
palladium amide species 296 is followed by a fast concerted metalation-deprotonation to give 
complex 297, containing a five-membered kinetically favoured palladacycle. Complex 297 
undergoes oxidative addition to provide a PdIV complex 298. At which point, the authors could 
not discount the formation of a bimetallic PdIII species.37 Reductive elimination, followed by 
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ligand exchange provides the desired product 301 and regenerates the Pd catalyst. The silver 
salt’s role is in sequestering the iodide produced as an insoluble salt.  
Scheme 112. Daugulis’ proposed mechanism175 
 
The reports by Daugulis were followed by many other publications, all employing 
either the picolinamide or aminoquinolamide auxiliaries to perform various C–H 
functionalizations.176 Selected examples using Pd catalysis are shown in Scheme 113. The 
group of Chen disclosed an intramolecular arylation using the aminoquinoline auxiliary.177 An 
extensive screen of aliphatic and aryl carboxylic acids revealed o-phenyl benzoic acid as the 
best ligand for Pd to promote the reaction, obtaining 303 in 88% yield. The same group 
achieved the monoarylation of cyclohexane (not shown) and exo-norbornane 304.178 The 
methodology was also applied to alkylation reactions of 306 employing primary alkyl 
iodides.179 Catalytic amounts of an organic phosphate, acting as a solid-to-solution phase-
transfer catalyst, were found necessary to control the concentration of Ag+ cations in solution.  
Furthermore, C–heteroatom bond formation was also possible (Scheme 114). 
Intramolecular picolinamide-directed C–H amination to provide azetidine 309 was achieved in 
presence of the oxidant iodosobenzene diacetate.180 Other N-heterocycles such as pyrrolidine 
or indoline could also be synthesized. An acetoxylation by-product was observed during the 
cyclization, which the Chen group explored in a subsequent publication to form ether products 
of type 311 in good yields.181 The proposed mechanism implicated oxidation of palladacycle 
312 by PhI(OAc)2. Subsequently, PdIV complex 313 can undergo reductive elimination to 
provide either C–N or C–O bond formation. However, it was hypothesized that the OAc 
 110 
ligand may dissociate and be replaced by other nucleophiles, such as an alcohol to give 
complex 314 which reductively eliminates to give the desired ether product. 
Scheme 113. Selected examples of C–C bond formation using an N,N-bidentate auxiliary 
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Scheme 114. Selected examples of C-heteroatom bond formation using an N,N-bidentate 
auxiliary
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Corey first demonstrated in 2006 that unnatural amino acids can be accessed via 
aminoquinolinamide-directed Pd-catalyzed acetoxylation (Scheme 115).182  
Scheme 115. Corey’s synthesis of unnatural amino acids182 
 
The reaction conditions and choice of auxiliary were later improved by several groups 
and employed to access unnatural amino acids or lactams via alkylation, oxidation, or 
amidation reactions (Figure 15).183 Besides Pd-catalyzed reactions, Chatani, Daugulis, 
Nakamura and others have shown that other transition metals such as Ru, Ni, Cu or Fe can 
form bidentate metalacycles and give rise to C–C (aryl, alkenyl, alkynyl or alkyl) or C–
heteroatom (O, N, F, S) bonds.184,185,186,187 From the brief introduction, it can be concluded 
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that N,N-bidentate auxiliaries are reliable directing groups for C–H transformations with a 
variety of metals, as well as electrophiles and nucleophiles.  
 
Figure 15. Examples of other related auxiliaries 
4.1.1 Project goal 
 An efficient and practical methodology for the intermolecular functionalization of 
cyclopropanes was the goal of our project. Cognizant of the previous work from the Yu group 
(Section 1.3), where an expensive, tetrafluorobenzonitrile amide auxiliary was employed as 
directing group, we embarked upon finding other reaction conditions and systems to achieve 
cyclopropane C–H arylation. Use of a bidentate system consisting of an amide moiety and 
another coordinating atom appeared attractive, given the plethora of transformations utilizing 
picolinamide or aminoquinoline-based auxiliaries described above. It was hypothesized that 
the proximity effect induced by a bidentate auxiliary could be exploited for activation of a 
cyclopropyl C–H bond, mediated by a Pd catalyst (Scheme 116). Then, oxidative addition of 
an aryl halide followed by reductive elimination could produce a disubstituted cyclopropane. 
Furthermore, in order to achieve a successful transformation, the auxiliary should be 
inexpensive and easily cleavable. The resulting cis-cyclopropyl amines (after cleavage of the 
picolinamide auxiliary) or carboxylic acids (after cleavage of the aminoquinoline auxiliary) 
possess interesting pharmacological properties.188  
Scheme 116. Desired C–H functionalization of cyclopropanes 
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4.2 Reaction optimization 
4.2.1 Initial studies 
The picolinamide auxiliary was chosen as a model substrate (Scheme 117). 
Picolinamide 315 was synthesized in two steps starting from cyclopropanecarbonitrile and 2-
picolinic acid. Gratifyingly, when substrate 315 was submitted to Daugulis-type conditions,175 
46% of the desired product 316 (one diastereomer) was observed, along with 28% unreacted 
starting material. In addition, submitting 315 to the conditions previously developed in 
Chapter 3 for the intramolecular arylation of cyclopropanes, 68% arylated product 316 was 
observed, along with 21% unreacted 315. Traces of a diarylated product were also observed by 
LC-MS. Employing other conditions for cyclopropane arylation with pivalic acid and cesium 
carbonate, no desired product was isolated. It was decided to continue the optimization with 
the picolinamide auxiliary in presence of a silver salt. Interestingly, a sterically hindered 
phosphine ligand was tolerated in the reaction; its role would be investigated later on.  
Scheme 117. Initial studies with a picolinamide auxiliary 
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4.2.2 Optimization of reaction conditions using a silver salt 
As the conditions employing Ag3PO4/K2CO3/PtBu3∙HBF4 provided the best yield in the 
initial screen (Scheme 117), they were considered a good starting point for further optimizing 
the reaction. Firstly, other carbonate bases were screened (Table 16). Sodium carbonate (entry 
2) gave a better yield than the corresponding potassium base (entry 1), while cesium 
carbonate, although more soluble in the toluene solvent, was less reactive (entry 3). Significant 
amounts of the diaryl 317 were also observed. Compound 317 was found to have mainly a 
trans configuration, although in some cases traces of cis were also observed. 
Table 16. Base screen for the intermolecular arylation of cyclopropanes 
 
  yielda (%) 
entry base 315 316 317 
1 K2CO3 13 59 10 
2 Na2CO3 15 75 <5 
3 Cs2CO3 71 17 <1 
a 1H NMR yield using trimethoxybenzene as internal standard. 
Secondly, the silver source was investigated (Table 17). Silver phosphate (either 0.4 or 
0.5 equivalents) provided the best yield of the monoarylated product 316 (entries 1 and 2), 
while silver bromide the worst (entry 5). Silver carbonate also gave complete conversion and 
77% overall yield (entry 3), while silver acetate only provided 45% yield desired product 316 
(entry 4). 
Table 17. Silver source screen for the intermolecular arylation of cyclopropanes 
N
H
N
O
315
Pd(OAc)2 (10 mol %)
PtBu3 HBF4 (10 mol %)
4-iodoanisole (1.5 equiv)
Ag salt (x equiv)
Na2CO3 (2 equiv)
PhMe, 130 °C, 15 h
N
H
N
O
316 OMe
N
H
N
O
317 OMe
OMe
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  yielda (%) 
entry Ag salt (x equiv) 315 316 317 
1 Ag3PO4 (0.5 equiv) <2 71 5 
2 Ag3PO4 (0.4 equiv) <2 65 14 
3 Ag2CO3 (0.75 equiv) <1 61 16 
4 AgOAc (1.5 equiv) <2 45 11 
5 AgBr (1.5 equiv) 57 12 0 
a 1H NMR yield using trimethoxybenzene as internal standard. 
Thirdly, control reactions were run in order to determine the requirement for each 
reaction component (Table 18). The Pd loading could be decreased to 5 mol % (entry 1). In 
absence of the silver salt, only 5% yield product 316 was observed (entry 2), while omitting 
the base gave about 20% yield desired monoaryl 316 (entry 3). Removing the Pd catalyst 
resulted in no reaction (entry 4). Omitting the ligand had no impact on the transformation 
(entry 5). The result suggested that the sterically hindered ligand was probably not present on 
the metal centre during the course of the reaction; the picolinamide moiety acts as both 
substrate and ligand for the reaction.175 Consequently, developing an enantioselective version 
of the reaction with a phosphine ligand would not be viable. 
Table 18. Control reactions for the intermolecular arylation of cyclopropanes 
 
  yielda (%) 
entry variation 315 316 317 
1 5 mol % Pd <2 67 22 
2 no Ag3PO4 94 5 0 
3 no Na2CO3 54 20 <2 
4 no Pd(OAc)2 94 0 0 
5 no PtBu3∙HBF4 6 68 16 
a 1H NMR yield using trimethoxybenzene as internal standard. 
Lastly, the stoichiometry of base was investigated in the reaction, in the absence of the 
ligand (Table 19). It was shown that good yields could be obtained even when using 
substoichiometric amounts of carbonate base (entries 1-4), while increasing the base loading 
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slightly decreased the yields (entries 6-7). For ease of manipulation, 0.3 equivalents of dry 
Na2CO3 were chosen as ideal.  
Table 19. Base loading screen for the intermolecular arylation of cyclopropanes 
 
  yielda (%) 
entry Na2CO3 equiv. 315 316 317 
1 0.1 25 65 10 
2 0.2 9 75 15 
3 0.3 5 71 22 
4 0.5 5 73 10 
5 1.0 6 70 10 
6 1.5 7 64 9 
7 2.0 6 68 16 
a 1H NMR yield using trimethoxybenzene as internal standard. 
Additionally, lowering the temperature to 110 °C significantly decreased the yield to 
50%. The reactions were run for 15 h, as there were still traces of unreacted starting material 
after that time.  
4.2.3 Optimization of the reaction conditions using pivalic acid 
During the initial studies, no conversion was observed when pivalic acid was employed 
as an additive in the reaction in presence of cesium carbonate (Scheme 117). However, when 
the same reaction was now performed using K2CO3 as base and in absence of any ligand, 75% 
desired product 316 was observed, along with traces of diarylation and unreacted starting 
material (Table 20, entry 1). It is not surprising, as the group of Daugulis also reported 
conditions for the C(sp3)–H arylation employing employing a bidentate auxiliary 
trimethylacetic acid.175b Changing the base to Na2CO3 led to only traces of product (entry 2), 
highlighting the importance of the carbonate counter ion. In the absence of pivalic acid, there 
was little product formation (entry 3), while increasing the amount of pivalic acid dramatically 
affected the conversion (entry 4). 
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Table 20. Reaction optimization using pivalic acid 
 
  yielda (%) 
entry variation 315 316 317 
1b none 6 75 15 
2 Na2CO3 instead of K2CO3 82 <1 <1 
3 no PivOH 78 <5 <1 
4 PivOH (0.5 equiv) 74 20 <1 
 a 1H NMR yield using trimethoxybenzene as internal standard. b Isolated yield on 0.5 mmol. 
 4.2.4 Screen of other auxiliaries 
With two different reaction conditions in hand, other auxiliaries were investigated 
(Scheme 118). Protecting the amide with a methyl group (compound 318) resulted in no 
reaction, highlighting the importance of the secondary amide moiety for coordination to the 
metal centre. A substrate 319 containing the amide moiety next to the cyclopropane resulted in 
low yields and decomposition of the starting material. Replacing the amide entirely by an ester 
(320) did not provide any desired product. The auxiliary derived from 8-aminoquinoline, 321, 
provided only traces of product under both conditions.  
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Scheme 118. Screen of other auxiliariesa 
 
a 1H NMR yield using trimethoxybenzene as internal standard. 
4.2.5 Auxiliary cleavage 
The picolinamide auxiliary was removed in two steps: 1) protection of the amide with a 
Boc group, followed by 2) oxidative cleavage under basic conditions (Scheme 119). Other 
attempts at reducing the amide to the corresponding amine with NaBH4 or Tf2O/Et3SiH 
resulted in unreacted starting material, while LiAlH4 provided some desired product, along 
with decomposition.   
Scheme 119. Two-step auxiliary removal 
 
4.3 Reaction scope 
Aryl iodides were found reactive under reaction conditions A and B (Scheme 120); 
aryl bromides or chlorides failed to react under either conditions (not shown). It is 
hypothesized that oxidative addition onto a PdII complex to provide a PdIV complex is much 
more difficult for Ar-Br and Ar-Cl. Thus, the scope was explored employing aryl iodides 
(Scheme 120). A variety of substituents were tolerated at the para position, including electron 
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donating (methoxy), electron neutral (H, methyl) and electron withdrawing (trifluoromethyl, 
ester, ketone) groups. Bromo (326) and chloro (329) provided the desired products in 79% and 
77%, respectively, under conditions A. The Br and Cl groups allow for further 
functionalizations via other cross-couplings. Heterocycles were also viable coupling partners, 
the corresponding cyclopropanes being obtained in 83% (indole, 331) and 60% (thiophene, 
332) yields under the silver conditions, while the pivalic acid conditions provided much lower 
yields and selectivities (83% versus 48% for indole 331, 5:1 versus 1.4:1 mono:di selectivity). 
The reaction was found to be sensitive to sterics, as 1-iodonaphthalene only gave 44% total 
yield of 333 (conditions A) or 19% 333a (conditions B).  In all cases, the monoarylated 
product was exclusively the cis diastereomer, thus providing a robust method for the synthesis 
of aryl and heteroaryl cis-substituted cyclopropanes. The diarylated product had mainly a 
trans configuration for compounds 317, 331b and 333b, probably due to sterics for the latter 
two; a cis/trans mixture for 317, 327b and 328b, and a cis configuration for the rest.  
To prove the practicality and robustness of the methodology, the reaction was scaled 
up on 5 mmol in presence of 2 mol % Pd(OAc)2 to provide the desired product 316 in 74% 
yield, along with 6% diarylation 317 (Scheme 121).  
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Scheme 120. Scope of aryl iodidesa 
 
a Isolated yield on 0.5 mmol. b The reaction was run for 45 h. c 0.4 equiv Ag3PO4. d Reported as 1H NMR yield 
using trimethoxybenzene as an internal standard. e 10 mol % Pd(OAc)2. 
Scheme 121. Scale up of the reaction 
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To further prove the applicability of the transformation, a diastereoselective arylation 
of cyclopropanes was also achieved (Table 21). A picolinamide derivative, 334, substituted in 
the α-position by a methyl group and synthesized via a four-step sequence starting from 
Ellman’s auxiliary,189 was arylated under conditions A in good yield and diastereoselectivities 
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(entries 1 and 2). Traces of diarylation were also observed. Lower yields were obtained under 
condition B (entry 3), while replacing the methyl with a bulky isopropyl group shut down the 
reaction (entry 4), demonstrating the sensitivity of the reaction to steric hindrance.  
Table 21. Diastereoselective arylation of cyclopropanes 
 
entry R R’ condition total yielda (selectivity) 
1 Me, 334 4-OMe A 81% (7:1) 
2 Me, 334 4-CF3 A 69% (8:1) 
3 Me, 334 4-OMe B 45% (N/D)b 
4 iPr, 335 4-OMe A <1% 
a Isolated yields on 0.2 mmol. b Reported as 1H NMR yield using trimethoxybenzene as an internal standard. 
Since in some cases significant diarylation product was isolated, it was envisioned that 
a second arylation with a different aryl iodide could lead to synthetically useful trisubstituted 
cyclopropanes. Unfortunately, neither disubstituted cyclopropane 316 or 325a bearing an 
electron donating or electron withdrawing group, respectively, were very reactive under the 
reaction conditions (Scheme 122). Interestingly, the yields obtained (10% and 23%) roughly 
coincide with the amounts of diarylation observed in Scheme 120. The cis configuration of the 
starting disubstituted cyclopropane may sterically prevent the oxidative addition of another 
aryl iodide. Perhaps the conversion can be improved if the starting cyclopropane were trans. 
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Scheme 122. Attempts at cyclopropane diarylationa 
 
a 1H NMR yield using trimethoxybenzene as internal standard. 
4.4 Mechanistic studies 
In order to elucidate the role of the acetate ligand in the reaction mechanism, several 
control experiments were run in presence of Pd0 or PdII sources (Table 22). Pd2(dba)3 
provided 43% desired product 316 in absence of an acetate source (entry 2), while upon 
addition of 10 mol % KOAc the reactivity was re-established (entry 3). Another Pd0 source, 
Pd(PPh3)4, was ineffective either in the presence or absence of catalytic acetate (entries 4-5). 
The difference between the two Pd0 sources can be explained through the easier dissociation 
of the dibenzylideneacetone versus triphenylphosphine ligand. A PdII source, PdBr2, provided 
monoaryl 316 in 28% (entry 6), while addition of catalytic acetate restored the activity (entry 
7). Pd(TFA)2 was also tested, and the reaction was completely inhibited (entry 8). Again, 
reactivity was restored in presence of 10 mol % KOAc (51%, entry 9). The results support the 
direct involvement of the acetate ligand in a concerted metalation-deprotonation step.40,190 
Trifluoroacetic acid (pKa 0.5 versus 4.8 for AcOH) was a less effective proton shuttle. It is 
hypothesized that the carbonate or phosphate bases may be involved in regulating the pH of 
the reaction, by trapping the equivalent of “H+” generated.40 
Table 22. Screen of Pd sources and additives under conditions A 
 
N
H
N
O
315
"Pd" (x mol %)
KOAc
4-iodoanisole (1.5 equiv)
Ag3PO4 (0.5 equiv)
Na2CO3 (0.3 equiv)
PhMe, 130 °C, 15 h
N
H
N
O
316 OMe
N
H
N
O
317 OMe
OMe
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   yielda (%) 
entry Pd (x mol %) KOAc 315 316 317 
1 Pd(OAc)2 (5) --- 8 78 5 
2 Pd2(dba)3 (2.5) --- 53 43 <1 
3 Pd2(dba)3 (2.5) 10 mol % 8 76 14 
4 Pd(PPh3)4 (5) --- 95 <1 0 
5 Pd(PPh3)4 (5) 10 mol % >90 <1 0 
6 PdBr2 (5) --- 56 28 <1 
7 PdBr2 (5) 10 mol % 5 63 3 
8 Pd(TFA)2 (5) --- 98 <1 0 
9 Pd(TFA)2 (5) 10 mol % 25 51 5 
a 1H NMR yield using trimethoxybenzene as internal standard. 
Additionally, Pd0 and PdII sources were also tested under conditions B (Table 23). 
Some reactivity was observed in presence of Pd2(dba)3 (29%, entry 2), while the yield 
increased to 51% when catalytic acetate was added (entry 3). Both acetate and pivalate have 
previously been shown to be effective proton transfer agents.45 PdBr2 gave similar reactivity to 
Pd(OAc)2 (entries 1 and 4).  
Table 23. Screen of Pd sources and additives under conditions B 
 
   yielda (%) 
entry Pd (x mol %) KOAc 315 316 317 
1 Pd(OAc)2 (5) --- 6 75 15 
2 Pd2(dba)3 (2.5) --- 66 29 <1 
3 Pd2(dba)3 (2.5) 10 mol % 46 51 <1 
4 PdBr2 (5) --- 18 72 10 
a 1H NMR yield using trimethoxybenzene as internal standard. 
Perhaps the surprising result in Tables 22 and 23 was the fact that the reaction worked 
in presence of a Pd0 source. All previous examples of activation employing auxiliaries 
discussed at the beginning of Section 4 involved the use of a PdII source (Section 4.1). To gain 
more understanding into the reaction mechanism, cylopropyl picolinamide 315 was submitted 
to a deuterium exchange experiment (Scheme 123). In presence of 10 mol % Pd(OAc)2 and 10 
equivalents AcOD, 75% D/H exchange was observed on the cyclopropyl moiety. When the 
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catalyst was exchanged for Pd2(dba)3, no deuteration was observed. Upon addition of 0.5 
equivalents of Ag3PO4 to the experiment, 60% D incorporation was detected. Based on the 
results, the following can be concluded: 1) C–H activation of the cyclopropane bond in 
presence of Pd(OAc)2 occurs prior to oxidative addition, 2) Pd0 alone is not able to perform the 
C–H activation step, and 3) Ag3PO4 may be involved in oxidizing Pd0 to PdII. Additionally, 
oxidative addition of aryl iodide may occur before the C–H insertion step in case of Pd0, 
which could explain the results in absence of a silver source (Table 23, entries 2 and 3). 
Scheme 123. Deuterium incorporation experiments 
 
Moreover, a competition experiment between an electron donating and electron 
withdrawing para-substituted aryl iodide showed no significant preference for either product 
316 or 325b (Scheme 124).  
Scheme 124. Competition experiment for the arylation of picolinamide 315 
 
Based on all the experimental results, as well previous mechanistic work from 
Daugulis175 and Chen,178 the following PdII/IV mechanism was proposed for conditions A 
(Scheme 125). Coordination of Pd(OAc)2 to the picolinamide 315  to give complex A occurs 
with loss of one acetate molecule. Then, the acetate-mediated concerted metalation-
deprotonation provides complex B. Oxidative addition of the aryl iodide gives rise to a highly 
unstable PdIV complex C, which undergoes reductive elimination to provide complex D. Loss 
Condition A or B
MeO I
HN
OMe
HN
CF3F3C I
0.75 equiv
0.75 equiv A, 1 : 1.1
B, 1 : 1.2
PA PAHNPA
315 316 325b
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of iodide mediated by Ag3PO4 or Na2CO3, product dissociation and coordination of PdII to 
another picolinamide molecule closes the catalytic cycle. A PdII/III pathway cannot be 
excluded.37 A similar mechanism can be envisioned for condition B, except with pivalate 
instead of acetate, and K2CO3 as the base. Additionally, the silver salt may act as a base, 
halide sequester, oxidant (in case of Pd0 sources), or form a bimetallic species with Pd.191 
Scheme 125. Plausible mechanism 
 
4.5 Further functionalizations 
We sought to extend the current methodology to the formation of C-heteroatom bonds, 
as well as a direct oxidative coupling, as many of these reactions employing a cyclopropane 
are unreported or scarce in the literature (Scheme 126).83  
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Scheme 126. Proposed cyclopropane functionalizations 
 
4.5.1 Formation of C–heteroatom bonds 
C–H bond oxidation is an attractive area of research.192 In particular, the development 
of general methods for the oxidation of C(sp3)–H bonds has been the target in recent years.14 
Challenges associated with the type of transformation include regioselectivity and high 
potential for over-oxidation. Chen already established an oxidation protocol for a 
picolinamide-directed C(sp3)–H bond oxidation using PhI(OAc)2 as the oxidant (Scheme 
114).181 Under certain conditions, an oxidation followed by an intramolecular C–N bond 
formation also occurred. Earlier work from the Sanford group exploring the functionalization 
of cyclopropanes under oxidative conditions resulted in low yields, decomposition and lack of 
desired reactivity.86a 
Inspired by Chen181 and Sanford’s86a work, the oxidation of cyclopropyl substrate 315 
was pursued (Scheme 127). Unfortunately, extending the oxidation methodology to 
cyclopropanes proved challenging. No desired acetoxylation product was observed using 
PhI(OAc)2 as the oxidant. Other oxidants (oxone, benzoquinone, potassium persulfate, 
Selectfluor) provided only unreacted starting material, while cerium ammonium nitrate gave 
mainly decomposition. Interestingly, when monoarylated cyclopropane 316 was submitted to 
the same oxidation conditions, mono and di-acetoxylation of the aryl ring were observed as 
the only products (Scheme 127). Moreover, attempts at acetoxylation of aminoquinoline 321 
yielded a mixture of mono- and diacetoxylation of the quinoline ring in about 30%. The results 
clearly demonstrate how much more facile sp2 versus sp3 oxidation is.  
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Scheme 127. Attempts at acetoxylation of cyclopropane 315 
 
Furthermore, a recent publication by the group of Rao explored oxidations of similar 
picolinamide substrates employing cyclic hypervalent iodide reagents.193 Although the 
reaction was robust for alkyl or cyclic alkyl substrates, employment of a cyclopropane resulted 
in ring-opening to provide 341 in 30% yield (Scheme 128).   
Scheme 128. Oxidation of cyclopropane resulting in ring-opening 
 
4.5.2 Cross-dehydrogenative coupling  
From the point of view of atom economy, one drawback of the above methodology 
was the use of an aryl halide (a pre-functionalized coupling partner). The direct oxidative 
coupling between a cyclopropane C–H bond and an aryl C–H bond would be ideal. Such a 
reaction has been long established for the formation of aryl-aryl bonds,8 but has yet to be 
reported for cyclopropanes. The use of the bidentate auxiliary in presence of a transition metal 
should facilitate the process through chelation to the metal centre and thus stabilization of 
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cyclometalation intermediates. Moreover, the directing group should dictate the 
regioselectivity of the reaction; the reaction site is often problematic in the absence of a pre-
functionalized coupling partner.  
In 2013, Miura disclosed aminoquinolinamide 342 and picolinamide 344 directed 
cross-dehydrogenative coupling employing aryl C–H bonds only (Scheme 129).194 The 
reactions employed copper acetate as the excess oxidant at high temperatures. The scope 
included azole-type heterocycles, due to the presence of an acidic hydrogen, thus avoiding 
regioselectivity issues.  
Scheme 129. Miura’s CDC using the aminoquinolamide auxiliary194 
 
Attempting the reaction with the cyclopropyl substrates 315 and 321 under a variety of 
reaction conditions: various copper salts (Cu(OAc)2, Cu(OTf)2), additives (PivOH), catalysts 
(Pd(OAc)2) never led to any desired product formation, even when heating to 150 °C for 
extended periods of time (Scheme 130). The only product detected was the benzoxazole dimer 
348. Additionally, no coupling with the toluene solvent was observed by LC-MS.  
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Scheme 130. Attempts at CDC on cyclopropanes 
 
Overall, the oxidation of cyclopropyl C–H bonds has proven a more ambitious project 
than initially anticipated. Cyclopropanes did not behave as their alkyl or aryl counterparts 
under similar reaction conditions, thus underlying the difficulty of developing conditions for 
cyclopropane functionalizations. 
4.5.3 Related work 
During the preparation of our manuscript, a similar publication appeared in Organic 
Letters. The group of Babu showed that the aminoquinoline auxiliary 321 could be employed 
for C–H activation of cyclopropanes with excess aryl iodide under palladium catalysis 
(Scheme 131).195 Later, the group of Shuto demonstrated that quaternary centers could be 
synthesized in good yields in presence of the bidentate aminoquinoline auxiliary 349 (Scheme 
131).196 
Scheme 131. Babu and Shuto’s intermolecular direct arylation of cyclopropanes 
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4.6 Conclusion 
In summary, a methodology for the intermolecular arylation of cyclopropanes was 
established. Two reaction conditions were developed, involving either Ag3PO4 and Na2CO3 or 
PivOH and K2CO3 in presence of catalytic Pd(OAc)2. Key to the reactivity was the 
employment of a N,N-bidentate auxiliary which formed a kinetically-favoured five-membered 
cyclometalated complex able to activate the cyclopropane bond via  concerted-metalation 
deprotonation. The deuteration studies suggested that the C–H activation step occurred prior to 
oxidative addition of the aryl halide for PdII sources. Pd0 sources with easily dissociative 
ligands could also be employed as catalysts; it was hypothesized that either the silver salt 
acted as an oxidant for Pd, or oxidative addition occurred initially. The reaction was 
compatible with a variety of aryl and heteroaryl iodides. Moreover, extension of the oxidative 
conditions for sp3 centers to cyclopropanes was not successful, demonstrating the requirement 
for novel approaches for cyclopropane C–H functionalization. 
 
 
 
 
Chapter 5: Potassium tert-butoxide mediated 
intramolecular homolytic aromatic substitution 
Reference: Sustac Roman, D.; Takahashi, Y.; Charette, A. B. Org. Lett. 2011, 13, 3242. 
5.1 Introduction 
5.1.1 Fe-catalyzed direct arylation 
In an effort to develop more eco-friendly methodologies for direct functionalizations, 
the Charette group disclosed an iron-catalyzed intermolecular biaryl formation.197 Iron is the 
most abundant element in the Earth’s crust, is inexpensive and possesses low toxicity.198 
While iron catalysis in cross-couplings is well-established,199 its use in direct transformations 
is relatively unexplored.187 Thus, in the presence of 5 mol % Fe(OAc)2, 10 mol % 
bathophenanthroline (PhPhen) and two equivalents KOtBu at 80 °C, aryl iodides could be 
coupled with a variety of arenes in good to excellent yields (Scheme 132). If the arene was 
unsymmetrical, a mixture of ortho, meta, and para biaryls 357 were isolated, with ortho 
substitution being the major product. 
Scheme 132. Selected scope of Fe-catalyzed arylation197 
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The intermolecular KIE of the reaction was determined to be 1.04, suggestive of a 
radical pathway.197 The addition of radical scavengers such as TEMPO or galvinoxyl shut 
down the reaction. Control reactions determined no conversion in the absence of the iron 
catalyst (Table 24, entry 2). Additionally, replacing the catalyst with the known radical 
initiator AIBN (20 mol %) gave an almost stoichiometric amount of product, relative to AIBN 
(entry 3). In absence of the base, but presence of iron salt and AIBN, there was no reaction 
(entry 4), highlighting the necessity of the base for radical generation and propagation. 
Table 24. Control reactions197 
 
entry catalyst PhPhen (x) KOtBu (y) yield 358 (GC-MS) 
1 Fe(OAc)2 10 2 91% 
2 none 10 2 <1% 
3 AIBN none 2 17% 
4 Fe(OAc)2 + AIBN 10 none <1% 
Scheme 133. Plausible mechanism for Fe-catalyzed biaryl formation197 
 
  Based on all the observations, the above mechanism was proposed for the reaction 
(Scheme 133).197 A one-electron oxidation from the metal centre activates the aryl halide to 
form a radical arene, presumably associated to an FeIII species (step A). Then, the radical 
attacks the unactivated arene (step B). Rearomatization occurs by proximal proton abstraction 
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of the iodine (step C), releasing HI, which may be quenched by the base (step D), and 
regeneration of the iron catalyst. However, a different role for the butoxide base could not be 
ruled out. 
Shortly after, a similar publication appeared from the group of Lei.200 In their case, aryl 
iodides, bromides and even chlorides could be coupled with excess unactivated arenes in 
presence of 15 mol % FeCl3, 30 mol % DMEDA (dimethylenediamine) and two equivalents 
LiHMDS as the base at 80 °C (Scheme 134). The authors ruled out a benzyne pathway based 
on the regiochemistry of the reaction. A KIE of 1.7 was calculated for the transformation. 
Scheme 134. Lei’s Fe-catalyzed arylation of aryl bromides200 
 
Prior to our investigation of the current project, there was one other intriguing report in 
the literature which employed a strong base for biaryl synthesis. In 2008, the group of Itami 
disclosed KOtBu-mediated coupling of aryl halides with excess electron-deficient 
heteroarenes under microwave conditions (Scheme 135).201 The authors hypothesized a 
radical mechanism, HAS or SRN1 (discussed in Section 1.4), as performing the reaction in the 
presence of well-known radical scavengers provided no product.  
Scheme 135. Itami’s KOtBu-mediated arylation of heteroarenes201 
 
5.1.2 Research goal 
Several arylation strategies have already been presented in this thesis, all employing 
rather expensive Pd or Ru catalysts (Chapters 2-4). In order to develop a more sustainable 
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process, a transformation employing a more available and less costly catalyst was investigated. 
After the development of the Fe-catalyzed biaryl formation by former group members Frédéric 
Vallée and James Mousseau,197 an intramolecular version of the reaction was pursued 
(Scheme 136). The reaction would be complimentary to some of Fagnou’s Pd-catalyzed work 
(Scheme 3, vide supra).  Another goal was to elucidate the role of the iron catalyst and the 
tert-butoxide base.  
Scheme 136. Development of an intramolecular arylation reaction 
 
Additionally, the resulting cyclized products (benzopyran, phenanthrene, 
phenanthridine, phenanthridinone) have many applications in medicinal chemistry and 
materials synthesis. In particular, phenanthridine and phenanthridinone motifs are part of the 
core of many alkaloid natural products, including nitidine and fagaronine (anti-cancer 
properties), parnafungin A (anti-fungal properties), or as the core of current medicinal 
chemistry targets (Figure 16).202  
 
Figure 16. Bioactive phenanthridines and phenanthridones202 
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5.1.3 Concomitant work 
Before launching into the results and discussion of the project, it is necessary to 
describe some of the related work that appeared in the literature concomitant with our own 
studies. Undoubtedly, the results presented below have greatly influenced the direction of the 
current project. 
After disclosing the Fe-catalyzed biaryl formation (Scheme 134), the group of Lei 
described a similar transition metal-free transformation occurring in the presence of 20 mol % 
DMEDA and three equivalents KOtBu as the base at 80 °C (Scheme 137).203 The authors 
referred to the transformation as “organocatalysis” and “a striking breakthrough to the frame 
of traditional cross-coupling/C–H functionalizations.”203 Hayashi and Shirakawa also 
disclosed biaryl formation in the presence of two equivalents NaOtBu and 10 mol % 
bathophenanthroline at high temperatures (155 °C).204 The group of Shi revealed biaryl 
synthesis in presence of 0.4 equivalents phenanthroline and three equivalents KOtBu at 100 
°C.205 The latter authors also described the reaction in terms of organocatalysis. Compared to 
the earlier conditions developed by our group,197 each of these transition metal-free reactions 
employed either higher temperatures or larger loadings of the base/organocatalyst. 
Scheme 137. Transition metal-free arylations203-205 
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A summary of the catalyst and base screen from the three reports above is given in 
Table 25. The strong base KOtBu (pKa of conjugate acid 17) was highly reactive in all three 
cases, although NaOtBu was chosen by Hayashi and Shirakawa.204 Interestingly, Lei’s work 
reports no reaction with NaOtBu,203 while Shi’s paper does not report a base screen.205 Weaker 
bases (such as Na2CO3, or KOAc) and even other stronger bases (LiOtBu, LiHMDS, NaH, 
NaOH, KOH) were found unreactive, implying a special role for the tert-butoxide anion and 
K+ or Na+ as counterions. In terms of organocatalysts, N-based, bidentate ligands worked best. 
Lei reports that pyridine or pyrazine did not work, while both Lei and Hayashi found 
bipyridine and TMEDA (tetramethylethylenediamine) unreactive.203,204 Shi’s group reports no 
reactivity with DMEDA and aryl bromides,205 while DMEDA was the catalyst of choice for 
Lei’s work with aryl iodides.203 Hayashi and Shirakawa screened phenanthroline derivatives 
having nitrogens at the 1,7 or 4,7-positions, but these were found ineffective.204  
Table 25. Summary of catalyst and base screen for transition metal-free arylations203-205 
 
Group Organocatalyst (+)a Organocatalyst (-)a Base (+)a Base (-)a
Lei203 
DMEDA 
L-proline 
ethylene diamine 
ethanolamine 
cis-cyclohexane-1,2-diol 
bipyridine 
TMEDA 
pyridine 
pyrazine 
KOtBu 
NaOtBu 
LiOtBu 
LiHMDS 
NaH, KOH 
Na2CO3 
Hayashi & 
Shirakawa204 
PhPhen 
Phen 
Me-Phen 
bipyridine 
TMEDA 
1,7-Phen 
4,7-Phen 
Ph-Phen’ 
NaOtBu 
KOtBu 
LiOtBu 
NaOH 
Na2CO3 
Bu3N 
Shi205 
Phen 
PhPhen 
neocuproine 
DMEDA 
NO2-Phen KOtBu N/A 
a (+): >30% yield, (-): <30% yield (or unreactive) 
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Furthermore, running the reaction in presence of radical scavengers provided no 
product in all three cases. Hayashi determined a KIE of 1.07,204 and Shi of 1.1.205 In cases 
where a mixture of biaryl isomers was possible, the major isomer was ortho. All of the 
observations led the authors to suggest a radical mechanism for the transformation. A 
plausible mechanism for the reaction via a homolytic aromatic substitution pathway was 
proposed by Hayashi and Shirakawa (Scheme 138).204 Interaction between the base and 
catalyst was thought to provide complex 362, responsible for a single-electron transfer to the 
aryl iodide, giving rise to a radical anion 363 and a radical cation 364. After loss of iodide, 
aryl radical 155 added to benzene, to give cyclohexadienyl radical 156. A single-electron 
oxidation of radical 156 by the radical cation 364 produced aryl cation 366. Intermediate 366 
was deprotonated by tert-butoxide to give the product, 157, and tert-butanol. Complex 362 
was regenerated through reaction of 365 (or free PhPhen) with NaOtBu.204 An interaction 
between the base, phenanthroline catalyst and benzene substrate was also suggested by Shi 
and co-workers; π-π or K+-π interactions were proposed to promote the reaction.205  
Scheme 138. Hayashi and Shirakawa’s proposed HAS mechanism for transition metal-free 
arylation204 
 
Studer and Curran discussed the findings in a subsequent essay.12 The authors 
suggested that instead of referring to the transformations as “organocatalysis,” a better 
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explanation was “base-promoted homolytic aromatic substitution” via a chain mechanism 
(Scheme 139). The propagation mechanism involves attack of an aryl radical 155 onto an 
arene to give cyclohexadienyl radical 156 (step 1), which gets deprotonated by KOtBu to give 
a radical anion 367, a powerful reducing agent (step 2). Radical anion 367 is able to transfer 
an electron to another aryl iodide to provide the biaryl product 157, aryl radical 155 and KI 
(step 3). The electron-transfer step takes place via an outer-sphere (dissociative) pathway, 
meaning the aryl radical is short-lived. The main differences between the mechanism proposed 
by Hayashi and Shirakawa204 and the current one are that the former is not a chain mechanism 
and the order of the electron-transfer/proton-transfer steps.  
Scheme 139. Base-promoted HAS: chain mechanism proposed by Studer and Curran12 
 
5.2 Results and discussion 
5.2.1 Reaction optimization 
Initially, iodobenzylether 145 was cyclized under the Fe catalysis conditions 
previously established by our group (Scheme 140).197 Employing either benzene or dioxane as 
the solvent at 80 °C, benzopyran 152 was observed in about 50% yield, along with traces of 
dehalogenation 368.  
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Scheme 140. Initial studies for Fe-catalyzed intramolecular arylation 
 
The optimization of the reaction was pursued on iodobenzylether 145 with a ligand 
screen (Table 26). PhPhen provided the best yield (45%, entry 1), while Phen provided 38% 
desired product 152 (entry 3). Another Phen-type ligand (4-MeO-PhPhen) containing two 
EDG substituents afforded an improved yield (53%, entry 4). Other ligands such as bipyridine, 
ethylenediamine, cis-cyclohexane-1,2-diol, ethanolamine provided the product in much lower 
yields (entries 5-8). DMEDA, Lei’s catalyst of choice, resulted in only 6% yield of 152 (entry 
9), while TMEDA gave almost no conversion (entry 10). One phosphine, dppf, was also 
unreactive under the reaction conditions (entry 11). Although 4-MeO-PhPhen gave the best 
yield, the optimization was continued with PhPhen (or Phen) as these are commercially 
available.  
Table 26. Ligand screen for Fe-catalyzed intramolecular arylation 
 
  yielda (%) 
entry ligand 145 152 368 
1 PhPhen 34 45 2 
2b PhPhen 70 19 1 
3 Phen 61 35 2 
4 4-MeO-PhPhen 35 53 3 
5 bipyridine 77 9 <2 
6 ethylenediamine 75 14 2 
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7 cis-cyclohexane-1,2-diol 60 28 <2 
8 ethanolamine 56 27 4 
9 DMEDA 85 6 0 
10 TMEDA >95 <5 0 
11 dppf >95 <5 0 
a 1H NMR yield using trimethoxybenzene as internal standard. b KOtBu (3 equiv) 
Next, the solvent and other parameters were screened (Table 27). Dioxane provided 
the product in only 21% yield (entry 1) versus benzene in 45% yield (entry 2). Increasing the 
amount of ligand to 30 mol % in the reaction resulted in improved conversion and provided 
benzopyran 152 in 64% yield (entry 3). The breakthrough came when pyridine was employed 
as solvent. Iodoarene 145 was completely consumed in the reaction to provide 152 in 80%, 
along with 9% debrominated ether 368 (entry 4). To our surprise, similar yields were observed 
in the absence of the iron catalyst (entry 5).  
Table 27. Screen of reaction parameters for the intramolecular cyclization 
 
  yielda (%) 
entry solvent 145 152  368 
1 dioxane 67 21 2 
2 PhH 34 45 2 
3b PhH 18 64 8 
4 pyridine <1 80 9 
5c pyridine 12 79 4 
a 1H NMR yield using trimethoxybenzene as internal standard. b PhPhen 30 mol %. c No Fe(OAc)2. 
Having confirmed that the intramolecular cyclization of iodobenzyl ether 145 occurred 
in the absence of an iron catalyst, the optimization of the transition metal-free transformation 
was continued. In order to improve the reaction conditions, the optimization was pursued 
under microwave irradiation.206 Use of a microwave enabled the reaction time to be shortened 
to 10 min, at a temperature of 160 °C. Moreover, the PhPhen ligand could be replaced by the 
less expensive phenanthroline (Table 28, entry 1). Under the new conditions, the reaction 
even occurred in the absence of any ligand/organocatalyst (entry 2)! However, the yield 
dropped to 50%. In the absence of both base and phenanthroline, there was no reaction (entry 
3). Other tert-butoxide bases tested under the ligand-free conditions provided only unreacted 
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145 (entries 4-5). The HMDS bases gave complete conversion, but mostly dehalogenated 
material 368 (entries 6-7), with the exception of KHMDS, which provided 25% product (entry 
8). A weak base, K2CO3, was completely unreactive (entry 9). It should also be noted that the 
reaction was performed with KOtBu that was purified via sublimation, and no difference in 
the yield was observed to the unsublimed version. Both sublimed and unsublimed KOtBu 
were checked for metal contaminants via ICP-AES analysis, but no metal contaminants were 
discovered. 
Table 28. Optimization of the Fe-free arylation under microwave conditionsa 
 
   yielda (%) 
entry organocatalyst base 145 152 368 
1 Phen KOtBu <1 77 4 
2 --- KOtBu 20 50 18 
3 --- --- >95 0 0 
4 --- LiOtBu >95 0 0 
5 --- NaOtBu >95 0 0 
6 --- LiHMDS <1 0 81 
7 --- NaHMDS <1 0 64 
8 --- KHMDS <1 25 60 
9 --- K2CO3 >95 0 0 
a 1H NMR yield using trimethoxybenzene as internal standard. 
5.2.2 Reaction scope 
The scope of the reaction was explored with the help of a postdoc in the group, Dr. 
Yoko Takahashi, who was involved in synthesizing some starting materials, as well as 
performing some of the cyclizations and helping with the mechanism determination. All the 
reactions were performed with freshly sublimed KOtBu.  
The ring size of the cyclization was evaluated under the metal-free, ligand-free 
conditions (Scheme 141). Unfortunately, no five-membered or seven-membered products 371 
or 372 were formed. Instead, iodoarene 369 underwent coupling with pyridine as the major 
product (dehalogenation was also observed), while iodoarene 370 decomposed to 2-
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iodophenol. In contrast, similar five-membered or seven-membered rings are accessible via 
Pd-catalysis.16,17 
Scheme 141. Evaluation of ring size for the intramolecular cyclization 
 
To continue the scope, both iodide and bromide analogues of 145 underwent 
cyclization to provide 152 in good yields in presence of 10 mol % Phen (Scheme 142). Other 
classes of substrates besides ethers were also tested. An all-carbon tether provided the desired 
product 373 in 89% yield starting from the iodide, in the absence of Phen. The corresponding 
bromide could also be cyclized in 71% yield in presence of catalytic Phen (the reaction works 
in absence of Phen, but in a diminished yield). Incorporation of a nitrogen atom in the tether 
allowed for the isolation of the corresponding phenanthridine 375 in 82% yield, in the 
absence of Phen, while the corresponding bromide resulted in 64% yield, with 10 mol % 
Phen. A benzyl protected iodoaniline also worked in the cyclization, providing 374 in 62% 
isolated yield, in presence of Phen. Other protecting groups tested, Piv and Cbz, resulted in 
decomposition in the presence of the strong base KOtBu. Substitution on the aryl halide ring 
was also possible, a Me group being well tolerated in 64% of 376, while CF3 gave a poor 
yield, 31% of 377. In general, aryl iodides cyclized well in the absence of phenanthroline, 
with the exception of ether substrates, while the corresponding bromides provided better 
yields in presence of 10 mol % phen.  
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Scheme 142. Scope evaluation of the KOtBu-promoted cyclization 
 
Furthermore, substitution on the benzyl moiety of the aryl system was also explored 
(Table 29). In most cases, a mixture of regioisomeric products was observed (structures were 
confirmed via 1D nOe). p-tert-Butyl-substituted aryl ether 378 cyclized to give a 5:1 mixture 
of two regioisomers, 379a and 379b in 88% yield (entry 1). An analogous N-methyl aniline 
380 exhibited the same trend, with an even better regioisomeric ratio (10:1, entry 2). p-Methyl 
and p-methoxy-substituted aniline derivatives 382 and 384 also provided the corresponding 
phenanthridines 383a/b and 385a/b in good yields and ratios (entries 3 and 4). Substitution in 
the meta position gave rise to major isomer 387a in 67% yield, along with traces of an 
unidentified minor isomer (entry 5). Di-methoxy-substituted aniline 388 yielded a 7:1 mixture 
of products in 62% yield (entry 6). The reaction was sensitive to sterics, as the ortho-
susbtituted aniline 390 cyclized in only 25% yield (entry 7). Lastly, p-Me-substituted carbon 
analogue 392 reacted in 92% yield to give a 2.3:1 mixture of isomers (entry 8). Interestingly, 
the major isomer was opposite to what was observed with the other para-substituted 
substrates. 
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Table 29. Scope of the benzyl ether 
 
entry arene products yielda (ratio a:b) 
1 
 
88% (5:1)b 
2 
 
86% (10:1) 
3 
 
82% (>15:1) 
4 
 
83% (10:1) 
5 
 
67% 
6 
 
 
62% (7:1) 
N
I
Me
tBu380
N
Me
OMe
N
Me
OMe
385a 385b
N
Me
OMe
387a
 145 
7 
 
25% 
8 
 
92% (1:2.3) 
a Isolated yields on 0.5 mmol. In certain cases, traces of the reduced arene were observed. b With 10 mol % Phen. 
The reaction was found sensitive to substitution by electron withdrawing groups (CF3) 
or heterocycles (pyridine, furan), as these resulted in decomposition and some reduced arene 
(20% in case of 396) (Scheme 143). para-Chloride 395 provided some decomposition, but 
also a low yielding (<25%) mixture of product, reduced arene and replacement of the chloride 
by pyridine in the cyclized product (mass observed by LC-MS). 
Scheme 143. Substrates that resulted in decomposition/reduced arene 
 
Phenanthridone 399 can also be cyclized from the corresponding amide 398, albeit in a 
low yield (43%,Scheme 144). An alternative, better yielding, two-step procedure to aceess 
phenanthridones is the cyclization of aniline 400, followed by oxidation with barium 
manganate (67% over two steps). 
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Scheme 144. Access to phenanthridone 399 via two routes 
 
5.2.3 Mechanistic studies 
 The most surprising discovery during the scope evaluation was the isolation of 
regioisomeric products when substitution was present on the benzyl moiety (Table 29). In 
their intramolecular C–H arylation studies on similar starting materials, the group of Fagnou 
isolated only one product, 402 (Scheme 145).17 Furthermore, benzopyran 402 corresponded to 
the minor product isolated in our work, 379b. In addition to the aforementioned observation, 
the absence of a transition metal in our optimized reaction conditions, along with use of a 
strong base at elevated temperatures, led us to reject a C–H activation pathway.  
Scheme 145. Comparison of Fagnou’s cyclization with the KOtBu-promoted intramolecular 
arylation 
 
The formation of regioisomeric products in presence of a strong base was perhaps 
more reminiscent of a benzyne pathway.207 Bajracharya and Daugulis reported the KOtBu-
mediated intramolecular arylation of phenols and proposed a benzyne pathway for the 
transformation (Scheme 146).208 Employing aryl bromides, a 3.2:1 mixture of regioisomeric 
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products 404a and 404b was isolated. It was speculated that the reaction proceeded through 
the initial formation of a benzyne intermediate 405 in presence of the strong base at 140 °C. 
Cyclization of intermediate 405 occured either via ortho or para attack with respect to the 
potassium phenolate. Subsequent protonation by tBuOH and aromatization lead to the 
formation of products 404a and 404b. When deuterated tBuOD was added to the reaction, D 
was incorporated at the C-10 position in both products 404, thus confirming the benzyne 
pathway. Moreover, a control reaction employing methyl ether 406 did not produce any 
cyclization product, only trapping of benzyne by an external nucleophile (tBuO-) to provide a 
3.7:1 mixture of 407a:407b (Scheme 146C).  
Scheme 146. Daugulis’ work A. Intramolecular arylation of phenols B. Proposed mechanism 
C. Control reaction with methyl ether208 
 
To test if cyclization via a benzyne pathway was occurring in our reaction system, 
benzyl ether 403 was cyclized under the optimized microwave conditions (Scheme 147). Only 
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one isomer,“ortho” 404a was isolated in 19%, along with 45% unreacted 403, compared to 
96% yield reported by Daugulis for the two isomers.208 Alone, the experiment neither proves 
nor disproves the existence of a benzyne pathway in our reaction. However, a methoxy-
substituted arene 406 did not undergo the cyclization under Daugulis’ benzyne conditions 
(Scheme 146C),208 while several methoxy-substituted arenes were shown to be viable 
substrates in our case, even in the meta-position (Table 29). The regioisomeric ratios obtained 
by Daugulis ranged between 1.1:1 to 5.5:1, while most of the ratios we observed were >5:1. 
The observations inclined us to believe that the intermediacy of benzyne as a main reaction 
pathway was less likely in our transformation; however, we cannot discount the involvement 
of a benzyne activation as initiation in a radical mechanism.209 
Scheme 147. Control experiment for a benzyne mechanism 
 
Next, a radical mechanism was considered for our system. Recent publications from 
the group of Rossi reported the synthesis of phenanthridine via irradiation (photochemical 
reactor with two 400 W Hg lamps) of iodobenzylamine 408 in presence of KOtBu (Scheme 
148).210 No reaction occurred in the dark. An SRN1 mechanism was suggested for the reaction 
(Scheme 148). After deprotonation of the aniline by KOtBu to give anion 411, initiation is 
proposed to occur via a photoinduced one electron transfer (ET) to give radical anion 412. 
Loss of iodide would give rise to another radical anion 413, capable of intramolecular attack 
of the other aryl ring to provide conjugated radical 414. The reaction cycle is propagated by 
electron transfer from intermediate 414 to anion 411, which also releases 415. Under the basic 
reaction conditions, intermediate 415 is deprotonated to provide 416. During the acidic work 
up of the reaction, 416 is protonated and oxidized under air to the desired phenanthridine 409. 
Regioisomeric products were never observed when the aniline was substituted, the only by-
product isolated being the reduced starting material 410.210 
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Scheme 148. Photoinduced phenanthridine synthesis and mechanism210 
 
Additionally, iodobenzylether 145 had been previously submitted to refluxing 
AIBN/Bu3SnH in toluene and the desired benzopyran was obtained in 18% yield, along with 
other rearranged products from β-scission (Scheme 51, vide supra). Moreover, when 
substituents were present in the meta-position, a regioisomeric mixture of 422 and 425 was 
observed by the group of Bowman (Scheme 149).211 The reaction followed a general HAS 
mechanism, with initiation mediated by AIBN/Bu3SnH and generation of an aryl radical 418, 
which underwent a 5-exo-trig cyclization to produce spiro radical 419. Then, radical 419 was 
able to undergo a neophyl (1,2-phenyl) rearrangement and ring expansion in two distinct ways 
to produce isomers 421 and 424, which upon rearomatization211 provided the final products 
422 and 425 in 20% yield each. β-Scission of radical 419 also occurred to produce alcohol 426 
in 25% yield. 
  
 150 
Scheme 149. Generation of regioisomeric products via HAS 
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Back to our microwave reaction, experiments performed in presence of known radical 
scavengers such as TEMPO or galvinoxyl shut down the reaction (Scheme 150), an indication 
towards a radical pathway. The regioisomeric distributions obtained in our intramolecular 
cyclization can also be explained through an HAS mechanism, involving 5-exo or 6-exo/endo-
trig, followed by neophyl rearrangement (Scheme 151, vide infra). 
Scheme 150. Radical inhibition studies 
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Then, the question arises, what is responsible for the initial single electron transfer? In 
the examples above, electron transfer occurred from an initiator (e.g. AIBN) or was 
photoinduced. However, none of the circumstances are valid for our system. Nonetheless, 
KOtBu is known to function as a single or two-electron donor to certain functional groups.212 
Phenanthroline, and other conjugated derivatives, have a low lying LUMO and can act as an 
SET acceptor, delocalizing an electron around the ring.204 The LUMO of Phen would explain 
why it is suitable for the reaction, while bipyridine, a non-conjugated system, is not. But the 
majority of the scope for the present transformation was performed in absence of Phen, in the 
sole presence of two equivalents KOtBu and pyridine as the solvent. Thus, the exact 
mechanism of the SET to the aryl iodide bond is yet to be fully understood. 
Based on our radical scavenging studies, the formation of regioisomeric products and 
the similarities between HAS and the current transformation, the following mechanism was 
suggested for a para-substituted arene (Scheme 151). At high temperature, a favourable 
interaction between KOtBu and Phen or pyridine is responsible for the initial generation of 
radical A (most likely through generation of a radical anion first, then loss of iodide). A 
kinetically favoured 5-exo-trig ipso attack gives rise to spiro radical B, which can form a fused 
cyclic species C via 3-exo closure. Radical C can undergo a neophyl rearrangement to give D, 
followed by rearomatization mediated by the base to give rise to the minor product E. The 
major product G is produced via a ring expansion of intermediate B, followed by loss of a 
proton and an electron. Alternatively, the minor isomer E can arise from a 6-endo/exo ring 
cyclization. β-Scission is also a viable alternative for Sn-mediated radical reactions, especially 
in presence of a heteroatom which can stabilize alkyl radical H with its lone pair. No ether 
product derived from radical H was isolated in our system, due to the absence of a quenching 
H source (such as Bu3SnH in Scheme 51). Thus, alkyl radical H is proposed to attack the aryl 
ring in an ortho fashion and provide cyclohexadienyl intermediate F. Alternatively, a 
concerted ring enlargement from B to F is less likely. The β-scission pathway accounts for the 
formation of the major product for para-, meta- and ortho-substituted derivatives. In case of 
iodoarene 392 with an all-carbon tether, the reverse selectivity can be explained by lack of 
stabilization of the primary alkyl radical in the β-scission step (Table 29, entry 8). The 
rearomatization step may occur as previously described by Studer and Curran12 (Scheme 139, 
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vide supra): (i) proton transfer by KOtBu to give rise to a powerful reducing agent I which can 
(ii) transfer an electron to another aryl iodide to provide the product G and regenerate aryl 
radical A (Scheme 152). 
Scheme 151. Plausible reaction mechanism 
 
Scheme 152. Plausible rearomatization step for the base-promoted HAS 
 
5.2.4 Related work 
The impact of the transition metal free, KOtBu-mediated reactions is tremenduous. 
Shortly after our disclosure of the project in 2011, reports appeared on the KOtBu-mediated 
intermolecular and intramolecular alkenylation reactions from the groups of Hayashi, Shi and 
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Rueping (Scheme 153).213 In addition, other research groups expanded the scope of the 
“ligands” or “organocatalysts” for the TM-free arylation to alcohols,214 diols,215 proline,216 
porphyrin,217 a pyridinium carboxylate,218 a macrocyclic aromatic pyridine,219 a MOF (metal-
organic framework)220 or, in some cases, no organocatalyst at all.221  
Scheme 153. KOtBu-mediated alkenylation213 
 
During the preparation of the current thesis, two interesting reports related to the origin 
of the radical formation appeared in the literature. The first report, from Murphy’s group, 
argued that organic electron donors derived from phenanthroline 427 or pyridine 428 are 
formed in situ by deprotonation from the base and can trigger the reaction (Scheme 154).209 In 
absence of nitrogen-based additives, a benzyne-pathway was proposed to give rise to an 
electron-donor species.209 The second report, from Wilden’s group, clearly showed that no 
additives were necessary for the intermolecular arylation of aryl iodides with unactivated 
arenes at 160 °C, overall disagreeing with Murphy’s electron donor hypothesis.222 The paper 
by Wilden et al argues that the alkoxide (tert-butoxide) can supply electrons to an organic 
substrate when it is highly dissociated from the cation, thus the degree of dissociation is 
important (Scheme 155).222 KOtBu is superior to NaOtBu or LiOtBu, due to a longer K–O 
bond (2.46 Å versus 1.70-2.05 for Li and Na).223 The publications show that KOtBu-mediated 
transformations are still a “hot” topic in organic chemistry and the initiation step of the 
reaction is highly debatable. 
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Scheme 154. Murphy’s hypothesis: "super electron-donors" from Phen (427) and pyr (428) 
 
Scheme 155. Wilden’s hypothesis: alkoxide dissociation leads to electron transfer 
 
5.3 Conclusion 
In summary, a transition metal-free intramolecular cyclization of aryl ethers, amides 
and anilines was developed. The reaction occurred in the sole presence of two equivalents 
potassium tert-butoxide as the base and pyridine as the solvent under microwave conditions, 
when anilines were used as substrates, or with 10 mol % Phen additive for ethers and amides. 
The reaction was proved to proceed through homolytic aromatic substitution, where a 5-exo-
trig ipso cyclization was favoured, followed by ring expansion to provide the major product. 
The resulting phenanthridine and phenanthridinone products are part of many alkaloid natural 
products. Base-promoted HAS has provided not only a novel way of looking at “C–H 
functionalization,” but also a more environmentally-friendly way to think about radical 
chemistry.   
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Chapter 6: Nickel-catalyzed intramolecular arylation of 
unactivated alkyl iodides 
Reference: Beaulieu, L.-P. B.; Sustac Roman, D.; Vallée, F. ; Charette, A. B. Chem. Commun. 
2012, 48, 8249. 
6.1 Introduction 
Nickel complexes are versatile catalysts for cross-coupling or direct functionalization 
reactions.224 In 1972, Kumada et al employed nickel complexes as catalysts for the coupling of 
aryl or alkenyl halides with Grignard reagents.225 In 1977, Negishi et al reported the cross-
coupling of organozinc compounds with aryl halides in presence of Ni0 complexes as 
catalysts.226 Later, transformations of organometallic compounds via Ni catalysis were 
extensively studied by the Knochel227 and Fu228 groups. In contrast with Pd-catalyzed 
reactions, many transformations involving Ni catalysts are proposed to occur through a radical 
pathway.229 For example, Vicic and co-workers disclosed a NiI-terpyridine-alkyl complex 429 
involved in alkyl-alkyl Negishi cross-coupling (Scheme 156).230 Extensive studies revealed 
that complex 429 does not undergo the traditional oxidative addition, transmetalation and 
reductive elimination pathway to afford the final product. Instead, the best representation for 
the ground-state of complex 429 is a NiII-methyl cation and a reduced ligand containing an 
unpaired electron (Scheme 156A).230b The electron can then be transferred to an alkyl halide 
430 to provide an alkyl radical 432 and complex 431 (Scheme 156B). Due to the proximity of 
alkyl radical 432 and complex 431, an oxidative radical addition occurs next, to provide NiIII 
complex 433, followed by a fast reductive elimination to provide complex 435 and the desired 
product 434.230b  
Later, Cárdenas et al disclosed a Ni-catalyzed intramolecular cyclization of alkyl 
halides with olefins, followed by coupling with organozinc reagents (Scheme 157).231 It was 
found that a pybox-type ligand 438 and [Ni(pyr)4Cl2] as the catalyst provided the best yields. 
Based on their experimental studies, the proposed mechanism involved the following: (i) 
generation of complex 440, (ii) capable of SET to the aryl iodide 436 to give alkyl radical 441; 
then, (iii) radical 441 undergoes a fast 5-exo-trig cyclization to provide radical 443, (iv) which 
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in presence of NiII complex 442 does an oxidative radical addition to provide complex 444. 
Finally, (v) reductive elimination of complex 444 releases the desired product 439 and a NiI 
complex, which reacts with organozinc 437 to regenerate catalyst 440. Both cis and trans 
diastereomers of 436 provided the same yield and stereochemistry of the product 439, 
indicating a common reaction intermediate for both pathways (presumably 441).231 
Scheme 156. A. Representations of complex 429. B. Plausible radical mechanism230 
 
Scheme 157. Ni catalyzed cyclization and coupling with organozinc reagents, and proposed 
mechanism231 
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Pd-catalyzed direct alkylation was discussed in Section 1.3.1. In contrast with the use 
of Pd, examples of direct C–H transformations involving Ni complexes are scarcer in the 
literature. The direct addition of unactivated alkyl halides to sp centers (Sonogashira-type) in 
presence of Ni catalysts was first reported by the Hu group.232 The functionalization of 
aromatic heterocycles possessing an acidic proton (such as benzoazoles or benzothiazoles, 
with pKa 24-28, comparable to terminal alkynes) with non-activated alkyl halides has recently 
been demonstrated by several groups. For example, Miura’s group described in 2010 two 
examples of coupling of benzothiazole with alkyl bromides in presence of NiBr2∙diglyme as 
the catalyst and terpyridine as the ligand (Scheme 158).233 The groups of Hu234 and 
Ackermann235 disclosed the effective alkylation of benzoazoles in presence of Ni complexes 
(447 or NiBr2∙diglyme) and CuI as catalysts (Scheme 158). Although the reaction could occur 
in the sole presence of the Ni catalyst, improved yields were obtained with the addition of 7.5 
mol % CuI.  
Scheme 158. Coupling of heterocycles with unactivated alkyl halides via Ni catalysis 
 
The working mechanistic hypothesis of Ackermann’s reaction involves Cu as a 
transmetalation mediator from the anionic azole to Ni (Scheme 159, step A).235 The next steps 
are similar to the previous work by Vicic:230 (B) formation of a an alkyl radical, (C) oxidative 
 158 
addition of this radical to the NiII complex and (D) reductive elimination to provide the 
coupled product.235 
Scheme 159. Working mechanistic hypothesis235 
 
6.1.1 Research goal 
We wished to extend the intermolecular and intramolecular direct arylations previously 
reported by our group (Chapter 5) to an alkyl system. Direct alkylation, as explained in 
Section 1.3.1, faces two main obstacles: (1) difficult oxidative addition compared to aryl 
halides, due to the alkyl halides being more electron rich, and (2) high tendency for β-hydride 
elimination. It was hypothesized that an intramolecular alkyl system, with the β-position 
blocked, would be ideal for the study (Scheme 160). A goal of the work was also to avoid the 
use of an expensive transition metal, such as Pd or Ru, and instead develop a methodology 
employing Fe, Ni, Cu or no transition metal. Furthermore, we wished to gain more 
understanding into the mechanism of the reaction, especially the role of the transition metal. 
Scheme 160. Project goal 
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6.2 Results and discussion 
6.2.1 Optimization 
Initial attempts at an intermolecular system were performed by a former MSc student, 
Frédéric Vallée, and a former PhD student, Dr. Louis-Philippe Bonhomme-Beaulieu.236 It was 
found that primary alkyl iodides, such as iodohexane or neopentyl iodide, only provided the 
desired product in 11% and 25% yields respectively (Scheme 161). A secondary alkyl iodide, 
iodocyclohexane resulted in complete conversion, although only 28% yield of the desired 
product, along with 24% elimination. Attempts at further optimization of the system were not 
successful. Perhaps the elimination result is not surprising, in presence of a strong base and at 
80 °C for 20 h. 
Scheme 161. Initial studies for intermolecular direct alkylation 
 
Dr. Beaulieu then focused his efforts on designing an intramolecular system with a 
quaternary centre in the β-position, thus avoiding any E2 elimination issues. Thioarene 450 
containing a gem-dimethyl group was chosen as the model substrate for the optimization, due 
to its straightforward synthesis (Table 30). Using our previously published conditions with 
Fe(OAc)2 (10 mol %), PhPhen (20 mol %) and KOtBu (2 equiv) in PhH at 80 °C,197 the 
cyclized product 451 was obtained in 37% yield (entry 1). Changing the base to NaHMDS 
resulted in no product formation (entry 2). After testing more bases and catalysts (entries 3-5), 
it was determined that the combination of a Ni0 catalyst, Ni(PPh3)4, and NaHMDS in the 
absence of a Phen-type ligand provided 73% yield of product 451 (entry 6). Small amounts of 
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a starting material dimer, 452, were also observed in the reaction. The catalyst loading could 
be reduced to 5 mol %, without a major loss of yield (entry 7). Other bases tested in presence 
of Ni0, resulted in low yields (LiHMDS, entry 8, KOtBu, entry 10), while KHMDS 
decomposed the starting material (entry 9). The quantity of NaHMDS could be reduced to 1.5 
equivalents, to provide product 451 in 75% yield, with only 4% dimer 452. Control reactions 
in the absence of the catalyst demonstrated no reactivity at 80 °C or 120 °C (entries 12 and 
13). Finally, running the reaction with 5 or 20 mol % catalyst, in the absence of any base, led 
to only traces of thioarene 451 by GC-MS analysis (entries 14 and 15).  
Table 30. Optimization of the intramolecular system 
 
    yielda (%) 
entry catalyst (x) ligand (y) base (z) 450 451 452 
1 Fe(OAc)2 (10) PhPhen (20) KOtBu (2) 18 37 0 
2 Fe(OAc)2 (10) PhPhen (20) NaHMDS (2) 72 0 0 
3 NiCl2 (10) PhPhen (20) NaHMDS (2) 37 25 0 
4 Ni(cod)2 (10) PhPhen (20) NaHMDS (2) 0 47 10 
5 Ni(PPh3)4 (10) PhPhen (20) NaHMDS (2) 0 55 13 
6 Ni(PPh3)4 (10) --- NaHMDS (2) 0 73 8 
7 Ni(PPh3)4 (5) --- NaHMDS (2) 0 68 4 
8 Ni(PPh3)4 (5) --- LiHMDS (2) 51 25 5 
9 Ni(PPh3)4 (5) --- KHMDS (2) 0 0 0 
10 Ni(PPh3)4 (5) --- KOtBu (2) 59 27 0 
11 Ni(PPh3)4 (5) --- NaHMDS (1.5) 5 75 4 
12 --- --- NaHMDS (1.5) 100 0 0 
13b --- --- NaHMDS (1.5) 82 0 0 
14 Ni(PPh3)4 (5) --- --- >95 <5 0 
15 Ni(PPh3)4 (20) --- --- >95 <5 0 
a 1H NMR yield using trimethoxybenzene as internal standard. b Reaction at 120 °C. 
6.2.2 Reaction scope 
The scope of the transformation was evaluated in collaboration with Dr. Beaulieu 
(Table 31). Substitution on the aryl ring of the thioarene was well tolerated, product 454 being 
obtained in 88% yield, along with 8% dimer (entry 2). An all-carbon tether could be 
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successfully employed in the reaction (entry 3). The rest of the scope was further evaluated 
using the carbon tether. Electron donating (methoxy) or electron neutral (methyl, t-butyl) at 
the para position provided the desired products 458, 460, and 462 in 88%, 85%, and 86% 
yield, respectively (entries 4-6). A chloride-containing arene 463 could also be cyclized in 
74% yield, thus allowing for potential further transformations of 464 via cross-coupling (entry 
7).237 A tertiary amide was also tolerated in the reaction and product 466 was isolated in 70% 
yield (entry 8). When the starting material contained a meta-substitution, a 3:1 mixture of 
isomers was obtained for both m-OMe and m-Me (85% and 81% total yield, respectively, 
entries 9-10). The structures of the regioisomers were determined by 1D nOe experiments. 
Interestingly, for the major products, 468a and 470a, cyclization occurred ortho to the 
substituent, a typical trend observed in HAS.  An ortho-substituted arene, 471, gave 71% of 
the desired product 472a (entry 11). Upon careful analysis of the 1H NMR spectrum of the 
product, traces of a regioisomer 472b were observed, and its structure was confirmed by 1D 
nOe. The gem-dimethyl group could be successfully replaced by a cyclohexane, which 
provided arene 474 in an excellent 94% yield (entry 12). Removing the substituents in the β-
position led to traces of the desired product 476, and mostly elimination product (entry 13). 
No dimerization was observed in case of the all-carbon tether substrates. 
Table 31. Scope of the Ni-catalyzed intramolecular alkylation 
 
entry starting arene product(s) yielda (ratio a:b) 
1b 
 
70% 
2c 
 
88% 
3 
 
74% 
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4 
 
88% 
5 
 
85% 
6 
 
86% 
7 
 
74% 
8 
 
70% 
9 
 
85% (3:1) 
10 
 
81% (3:1) 
11 
 
71% (10:1) 
12 
 
94% 
13d 
 
<5% 
a Isolated yields on 0.5 mmol. b 8% dimer 452 also isolated. c 7% corresponding dimer also isolated. d The E2 
elimination product isolated in 47%. 
Next, the ring size of the cyclization was considered (Scheme 162). Formation of a 
five-membered ring 477 was possible in a lower yield (44%), while synthesis of a seven-
membered ring 478 led to traces of product and degradation.    
Me
Me
470a 470b
Me Me
472a 472b
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Scheme 162. Evaluation of the ring size of the cyclization 
 
6.2.3 Mechanistic studies 
At the onset of the studies, two mechanisms were considered: a Friedel-Crafts pathway 
or a radical pathway. The control reactions performed in the absence of the base (Table 30, 
entries 14 and 15) led to virtually complete recovery of the starting material, therefore 
suggesting against the role of the Ni catalyst as a Lewis acid in a potential Friedel-Crafts 
pathway. As presented in the introductory section of the current chapter, Ni complexes may 
react via a radical mechanism, and the pathway was further investigated. 
6.2.3.1 Radical scavenging experiments 
The addition of radical scavengers such as TEMPO or galvinoxyl effectively shut 
down the reaction (Scheme 163). In addition, the TEMPO adduct of the starting arene 455 
was isolated in 33% yield (Table 32, entry 1). In absence of the base, only 5% yield product 
479 was isolated, an amount equal to the quantity of catalyst present in the reaction medium 
(entry 2). The latter result suggests that Ni(PPh3)4 may act as a radical initiator, while the 
former result demonstrates the necessity of the base to regenerate the Ni catalyst. In absence of 
the catalyst, no product 479 was produced, with nearly complete recovery of the starting 
material (entry 3). Finally, in the absence of both the base and catalyst, only starting material 
was recovered (entry 4). 
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Scheme 163. Radical scavenging experiments 
 
Table 32. TEMPO scavenging experiments 
 
   yielda (%) 
entry catalyst (x) base (y) 455 479 
1 Ni(PPh3)4 (5) NaHMDS (1.5) 63 33 
2 Ni(PPh3)4 (5) --- 93 5 
3 --- NaHMDS (1.5) 93 0 
4 --- --- 96 0 
a Isolated yields. 
6.2.3.2 NMR experiments 
To obtain more information on the nickel species present the reaction, equimolar 
amounts of NaHMDS and Ni(PPh3)4 were dissolved in C6D6 in an NMR tube. The 1H NMR 
spectrum showed the following signals: triphenylphosphine aromatic signals, HMDS signal at 
0.1 ppm, and one singlet at 0.48 ppm (Figure 17). The same signals were observed at room 
temperature and at 70 °C. It was hypothesized that the unknown singlet may correspond to a 
possible adduct formation between the Ni catalyst and the base.  
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Figure 17. 1H NMR study in presence of NaHMDS (top), Ni(PPh3)4 (middle), and equimolar 
amounts of Ni(PPh3)4 and NaHMDS (0.05 mmol each, bottom) at 70 °C in 0.75 mL C6D6 
To further investigate the formation of the presumed adduct, a Diffusion Ordered 
Spectroscopy (DOSY) experiment was performed with the help of Dr. Cédric Malveau (NMR 
Department, Université de Montréal). DOSY is a 2D NMR technique measuring the diffusion 
coefficients (D) of molecules in a solution, which are reported on one axis, while the typical 
chemical shift information is presented on the other.238 The diffusion coefficient D depends on 
the molecular weight, size, shape, and charge of the molecule, as well as other parameters 
such as temperature or aggregation state. D is determined according to the Stokes-Einstein 
equation (1), where kB is Boltzmann’s constant, T the temperature, η the viscosity, and r the 
hydrodynamic radius of the molecule. In a more simple way, DOSY is able to separate the 
species in a mixture of compounds spectroscopically; the technique is somewhat reminiscent 
of a chromatography experiment. The experiment has been previously used to distinguish 
between mononuclear and dinuclear Pd complexes.239 
D = (kBT)/6πηr                                           (1) 
Upon submitting a 1:1 mixture of Ni(PPh3)4 and NaHMDS to a DOSY experiment, the 
spectrum in Figure 18 was obtained. The signal at 0.48 ppm has a similar diffusion coefficient 
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to Ni(PPh3)4, and is larger than the NaHMDS signal at 0.1 ppm. The experiment confirms the 
existence of a new species in the solution. 
 
Figure 18. DOSY NMR study in presence of equimolar amounts of Ni(PPh3)4 and NaHMDS 
(0.05 mmol each) at room temperature in 0.75 mL C6D6 with a gradient of 48.2 Gcm-1 (the 
peak around 7.2 ppm corresponds to C6D6) 
A more detailed experiment was carried out with Ni(PPh3)4, 455 and NaHMDS (in a 
stoichiometric ratio of 1:2:3, respectively) in C6D6 (Figure 19). The 1H NMR spectrum led to 
the observation of an additional set of signals shifted slightly downfield from those of 455 in 
addition to the signals for 455, 456 and for the free and two bound states of NaHMDS.  
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Figure 19. Comparison among the aliphatic region of the 1H NMR spectra of NaHMDS, 
NaHMDS : Ni(PPh3)4 (3:1), 455, 456, and Ni(PPh3)4 : 455 : NaHMDS (1:2:3) in C6D6  at 25 
°C 
A DOSY NMR of the latter mixture was also performed. According to the relative 
integration values of the singlet at 0.62 ppm (HC) compared to the shifted signals of 455 (HD, 
HE, and HF), NaHMDS and 455 would associate to Ni(PPh3)n in a stoichiometric ratio of 1:1:1 
(Figure 20).  Due to the complexity of the DOSY spectrum, the values for the diffusion 
coefficients of the protons are presented in Table 33, with the values for the new 
Ni(PPh3)n/NaHMDS/455 adduct 481 highlighted in red (all around 6 units). Moreover, 
filtration of the mixture over silica and rinsing with hexanes, followed by concentration of the 
filtrate and analysis by 1H NMR, led to the disappearance of the peaks corresponding to 481, 
thus supporting the formation of an adduct, and not a reaction by-product. 
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Figure 20. Zoom-in of the aliphatic region of the 1H NMR spectrum of a Ni(PPh3)4 : 455 : 
NaHMDS (1:2:3) mixture in C6D6  at 25 °C, with integration and labelling of the protons 
according to the legend 
Table 33.The diffusion coefficients obtained from a DOSY NMR experiment of a Ni(PPh3)4 : 
455 : NaHMDS (1:2:3) mixture in C6D6  at 25 °C with a gradient of 52.1 Gcm-1 
Entry Proton Label Chemical Shift 
(ppm) 
Diffusion Constant 
(E-10 m2s-1) 
1  7.65-7.54 5.7 
2  7.42-7.33 8.9 
3  7.20-7.17 10.3 
4  7.17-7.14 16.1 
5  7.11-7.02 8.2 
6  7.02-6.97 6.5 
7 HJ 2.82-2.75 11.0 
8 HN 2.67-2.62 12.9 
9 HF 2.48-2.41 6.3 
10 HM 2.40-2.36 12.6 
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11 HI 2.32-2.21 11.0 
12 HE 1.61-1.55 6.2 
13 HH 1.48-1.41 10.8 
14 HL 1.39-1.34 11.0 
15 HD 1.19-1.13 6.0 
16 HK 0.87-0.85 12.5 
17 HG 0.84-0.78 10.9 
18 HC 0.65-0.57 5.9 
19 HB 0.33-0.15 6.0 
20 HA 0.14-0.05 13.1 
Additionally, 31P NMR analysis of the Ni(PPh3)n/NaHMDS/455 mixture revealed the 
presence of free PPh3, suggesting the dissociation of one or more phosphine ligands from the 
Ni catalyst to allow for the formation of the adduct. 31P DOSY analysis of the latter mixture 
revealed two other signals with similar diffusion coefficients, probably corresponding to 
adducts 480 and 481 (Table 34). The 31P NMR signal for Ni(PPh3)4 was not observed, 
suggesting the complete consumption of the Ni complex in the formation of the adducts. 
Table 34. DOSY 31P NMR experiment involving a Ni(PPh3)4 : 455 : NaHMDS (1:2:3) 
mixture in 0.75 mL of C6D6, performed at 25 °C with a gradient of 49.8 Gcm-1 
 
Entry Phosphorus 
Label 
Chemical Shift 
(ppm) 
Diffusion Constant 
(E-10 m2s-1) 
1 PB or PC 33.78-32.72 6.2 
2 PB or PC 30.93-29.91 5.9 
3 PA -4.60- -5.80 8.6 
Taken together, all the NMR experiments suggest the formation of an interaction 
between the catalyst, the starting material and the base, with the dissociation of PPh3 ligands. 
Until more evidence about the nature of the species is gathered, we have referred to it with a 
more general term, adduct (addition of three different molecules to form a single species, in 
such a way that there is a change in connectivity but no loss of atoms from any 
components).240,241 It is also hypothesized that adduct 481 is responsible for single electron 
transfer during the catalytic cycle.  
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6.2.3.3 Proposed mechanism 
Based on the radical scavenging experiments, as well as the discovery of adduct 481 
via DOSY NMR, a plausible cyclization mechanism is shown in Scheme 164. Initially, adduct 
481 forms among the Ni0 catalyst, NaHMDS and 450. The adduct is then responsible for a 
single electron transfer to form alkyl radical 482 and NiI species 483. A similar free radical 
formation was also proposed by Cárdenas and co-workers.231 Alkyl radical 482 cyclizes in a 6-
endo/exo-trig fashion to give cyclohexadienyl radical 485. NiI species 483 can also form NiI 
484 and NaI. Rearomatization of radical 485 regenerates the catalytically active Ni species.  
Scheme 164. Plausible catalytic cycle 
 
 
The 6-endo/exo-trig pathway can also explain the formation of cyclized products in 
case of the all-carbon tether. For meta-substituted alkyl iodides 467 and 469, the major 
products 468a and 470a, result from cyclization of the ortho-position of the substituent, a 
typical trend observed in radical transformations.119 In case of ortho-substituted compound 
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471, the major product 472a can also be formed via the same cyclization. However, minor 
product 472b cannot arise via the same mechanism. A spiro cyclization, followed by ring 
expansion can be invoked to account for the generation of 472b (Scheme 165). After the 
formation of alkyl radical 486a via SET from the Ni adduct, a 5-endo-trig spiro cyclization 
leads to formation of cyclohexadienyl intermediate 487. Homolytic cleavage of either the blue 
or red bond of 487 leads to radicals 486b and 486a, respectively. Then, cyclization of alkyl 
radicals 486b and 486a in an ortho fashion results in the formation of cyclohexadienyl 
intermediates 488 and 489, which, upon rearomatization, form 472b and 472a, respectively. 
The cleavage of the red bond is favoured, as it results in the formation of a stable neopentyl 
radical 486a, stabilized through hyperconjugation and inductive effects. As mentioned above, 
6-endo/exo-trig leading to cyclohexadienyl radical 489 can only form major product 472a. 
Scheme 165. Spiro pathway for the cyclization of ortho-substituted alkyl iodide 471 
 
The ipso pathway is less likely in case of thioether substrates (Scheme 166). No thiol 
490 or disulfide product 491 were ever observed in the reaction, only dimer 452 (structure 
determined by HMBC). The preferred ortho pathway for thioethers may be explained through 
the longer C–S (around 180 pm) versus C–C bond (around 154 pm).  
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Scheme 166. Possible ipso pathway for thioethers 
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To further investigate the ipso cyclization in presence of a heteroatom, ether substrate 
492 was submitted to the cyclization conditions (Scheme 167). No desired cyclized product 
493 was isolated. Instead, fragments of the translocated compounds 494 were observed by 
GC-MS analysis of the reaction mixture. The result implies formation of a spiro intermediate, 
followed by β-fission. The pathway is well established for AIBN/Bu3SnH promoted radical 
reactions for ethers or protected amines.242 In a typical example, alcohol 496 was obtained in 
24% via ipso substitution, along with 61% dehalogenated product 497 (Scheme 168).242a The 
tendency of alkyl ethers to undergo ipso substitution, can also be explained by the shorter C–O 
bond length (around 143 pm). 
Scheme 167. Attempts at cyclization of ether 491 
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Scheme 168. Aryl translocation: oxygen to carbon 
 
6.2.3.4 Rearomatization step 
As discussed in Section 1.4, the rearomatization or oxidation step of the 
cyclohexadienyl radical is highly debatable in HAS chemistry. The step involves the loss of an 
electron and a proton, possible in either order. Curran and Studer suggested that in presence of 
a strong base, formation of a cyclohexadienyl cation is unlikely; in contrast, loss of a proton to 
a strong base such as KOtBu gives rise to a radical anion capable of electron transfer to 
another aryl halide, therefore propagating the chain.12 The latter rearomatization mechanism 
was also suggested for our work in Chapter 5 (Scheme 152, vide supra). For the current alkyl 
cyclization, we can also rule out the formation of a cyclohexadienyl cation, due to the 
presence of the strong base NaHMDS (Scheme 170, vide infra). The pathway proposed by 
Curran and Studer is an attractive alternative. In 1974, Bunnett and Creary disclosed the 
replacement of two halogens in dihalobenzenes without the intermediacy of monosubstituted 
products.243 In other words, formation of a radical anion on an aromatic ring where another 
halogen is present, would lead to loss of the halogen, and disubstitution. When m-
chloroiodobenzene was irradiated in presence of thiophenoxide anion, the resulting radical 
anion 498 provided radical 500 via loss of chloride (Scheme 169). Radical 500 reacted with 
another thiophenoxide anion to provide 501, which could transfer an electron to another aryl 
iodide and propagate the chain. Disubstituted 502 was obtained in 91% yield, along with 
traces of 499. Later, Lei observed diarylation as the major product when dihalobenzenes were 
employed in his study and suggested the intermediacy of a radical anion in the reaction.203  
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Scheme 169. Bunnett and Creary’s probe for radical anion formation 
 
However, in our case, chloride-substituted compound 463 underwent the cyclization to 
give 464 in 74% yield, with the chloride surviving the reaction (Table 31). No coupling with 
the benzene solvent 506 was observed (Scheme 170). The intramolecular fragmentation of the 
substrate via loss of chloride should be favoured over intermolecular transfer of an electron to 
another alkyl iodide in a radical chain propagation. In Chapter 5, when a chloride-substituted 
substrate 395 was submitted to the KOtBu-mediated reaction, traces of coupling of the product 
with the pyridine solvent via loss of chloride were observed by LC-MS (Scheme 143, vide 
supra). Therefore, a radical propagation process as proposed by Curran and Studer12 for the 
KOtBu reactions may be ruled out. 
Scheme 170. Possible rearomatization pathways in the reaction 
 
The more likely pathway is the direct involvement of a Ni species in the 
rearomatization step. Two different possibilities arise here: (a) the direct abstraction of H atom 
from 485 by Ni-amide complex 484 or (b) electron transfer from a possible radical anion 505 
directly to NiI. The hydrogen atom abstraction (a) would parallel Curran, Bowman and 
Storey’s proposed H-atom abstraction by AIBN (Scheme 48, vide supra).  Additionally, it 
regenerates the Ni0 catalyst and leads to the formation of HMDS as by-product (Scheme 171). 
NiIII-imide complexes or CuII-amide complexes have been previously shown to perform 
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hydrogen atom abstraction from an sp3 C–H bond in various amination reactions.244 The latter 
possibility (b) cannot be ruled out; moreover, the involvement of traces of oxygen in the 
reaction for rearomatization also cannot be dismissed. 
Scheme 171. Proposed hydrogen atom abstraction by complex 484 
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6.3 Conclusion 
In summary, the intramolecular cyclization of alkyl iodides was reported in presence of 
Ni(PPh3)4 as the catalyst and NaHMDS as the base. The reaction tolerated a variety of 
functional groups, but required blocking of the β-position to avoid elimination reactions. The 
TEMPO adduct of the starting material was isolated, thus clearly demonstrating the 
involvement of radical species in the process. DOSY NMR studies revealed the existence of 
an adduct between the catalyst, the base and the starting material. The adduct is presumed to 
facilitate electron transfer between the Ni0 catalyst and the alkyl iodide. Then, the cyclization 
proceeded through either ortho or ipso attack, depending on the nature of the tether (carbon vs. 
thioether).  
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Chapter 7: Conclusion and perspectives 
The functionalization of C–H bonds as a means of achieving C–C bond formation was 
the main theme of my PhD research. On the one hand, part of the work involved the use of 
transition metal catalysis for accomplishing activation of sp2 and sp3 centers. In particular, the 
direct functionalization of cyclopropanes is a topic of great significance in our group, and the 
results presented in the thesis have added to the few other examples in the literature. On the 
other hand, base-promoted homolytic aromatic substitution is a topic introduced recently in 
the literature, and the work that we and many others have disclosed has lead to a 
“renaissance”245 of radical chemistry in organic synthesis.  
7.1 Direct functionalizations of cyclopropanes 
Throughout the work, three distinct direct functionalizations of cyclopropanes were 
described. In an intramolecular system, the formation of 3,3’-cyclopropyloxindoles was found 
possible via a Pd-catalyzed, Ag-mediated cyclization of 2-bromoanilides. Through 
epimerization studies, a possible enolate arylation mechanism was ruled out. The calculated 
kinetic isotope effect suggested C–H bond breaking as the rate-limiting step. A concerted 
metalation-deprotonation mechanism mediated by either carbonate or phosphate was proposed 
for the reaction. In addition, a complimentary ring-opening of cyclopropanes was pursued. It 
was demonstrated that synthetically useful benzazepinone products can be synthesized via 
activation of a cyclopropane with a Pd catalyst, followed by nitrogen-assisted ring-opening. 
Key to the reaction was the use of a bulky ligand, PtBu3, which also aided in the ring-opening. 
Finally, an intermolecular arylation of cyclopropanes was achieved using an N,N-bidentate 
auxiliary. The mechanism proposed involved a PdII/IV catalytic cycle, where the acetate moiety 
acted as proton shuttle. 
Certainly, one extension to the work would be the pursuit of an enantioselective 
cyclopropane arylation. Judicious screen of ligands for an intramolecular system could be a 
start point. For an intermolecular system, unfortunately, use of a tight binding auxiliary such 
as the picolinamide or aminoquinolinamide prevents the use of an additional ligand for 
palladium, as was demonstrated during our work. Since acetate or pivalate were proven 
 177 
necessary in the reaction, one possibility is the use of a chiral acid. Yu’s group designed novel 
chiral amino acids to achieve enantioselectivity.84 An initial screen of a few basic amino acids 
unfortunately led to no enantioselectivity in our picolinamide system. Nonetheless, the screen 
could be extended to other classes of acids, such as phosphoric acids. An alternate possibility 
would be the use of a monodentate chelating group that allows for a chiral ligand at the Pd 
centre.  
Finally, the development of methodologies for the synthesis of cyclopropyl C-
heteroatom bonds is attractive (Scheme 172). Although initial screenings for the acetoxylation 
reaction have not been fruitful, there remain many things to be investigated. In addition, 
transition metal-catalyzed direct fluorination of cyclopropanes with an electrophilic source of 
fluorine, which can also act as an oxidant, is worth pursuing.  
Scheme 172. Proposed route to cyclopropyl C-heteroatom bond synthesis 
 
7.2 Base-promoted homolytic aromatic substitution 
A transition metal-free intramolecular system for the cyclization of aryl ethers, amines 
and amides was developed. The reaction occurred in the presence of KOtBu as the base and 
pyridine as the solvent, under microwave conditions. The formation of regioisomers when 
substitution was present on one of the aryl groups, along with radical scavenging experiments, 
led us to propose a homolytic aromatic substitution pathway for the transformation. Moreover, 
the interaction of a Ni0 catalyst and NaHMDS promoted the cyclization of unactivated alkyl 
iodides at mild temperatures. The latter transformation was also proposed to occur via an 
HAS-like pathway. DOSY NMR studies determined the formation of an intereaction between 
the catalyst, base and starting material, presumably responsible for an electron transfer.  
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An extension of the work, based on our interest in cyclopropane functionalization, may 
involve addition of a cyclopropyl radical onto an arene in an HAS fashion (Scheme 173). 
Moreover, the design of domino radical cyclizations is also an alluring topic. 
Scheme 173. HAS with a cyclopropyl radical 
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7.3 Direct functionalization of imidazo[1,5-a]azines 
Prompted by easy access to a variety of imidazo[1,5-a]azines through a Tf2O-promoted 
cyclization, we investigated the functionalization of the substrates through Ru-catalyzed 
arylation. Indeed, the fused nitrogen-heterocyle proved to be a good directing group for Ru. A 
thorough investigation of the influence of the sterics and electronics of the reaction 
demonstrated a clear preference for electron-withdrawing groups on the starting imidazo[1,5-
a]pyridine. The proposed mechanism involved formation of a ruthenacycle prior to the 
oxidative addition step. An extension to the work would be to further arylate the imidazo[1,5-
a]pyridines at the C-1 position via Pd catalysis, and explore the Ru- and Pd-catalyzed 
reactions in a one-pot procedure. 
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Experimental Part 
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All non-aqueous reactions were run under argon atmosphere with flame-dried 
glassware using standard techniques for manipulating air-sensitive compounds.246 Anhydrous 
solvents were obtained by filtration through drying columns or by distillation over sodium or 
calcium hydride. Commercial reagents were used as supplied or purified by standard 
techniques where necessary. The reported yields represent the yields of products isolated 
following recrystallization or flash chromatography. 
Flash column chromatography was performed using 230-400 mesh silica or performed 
on an automatic purification system using the indicated solvent system (Teledyne Isco 
Combiflash® Rf or Sq16x). Pre-packed normal phase silica gel columns were used for 
separation of products using Teledyne Isco RediSep® Rf High Performance Gold or Silicycle 
SiliaSepTM High Performance columns (12g or 24g). Analytical thin-layer chromatography 
(TLC) was performed on pre-coated, glass-backed silica gel plates (Merck 60 F254) and 
visualized by UV absorbance (254 nm), and/or ceric ammonium molybdate (CAM), and 
potassium permanganate (KMnO4). Analytical supercritical fluid chromatography was 
performed with a Berger SFC fashioned with a UV diode detector. SFC results are reported as 
follows: column type, eluent, retention time (tr).  
Nuclear magnetic resonance spectra were recorded on an Avance AV400 MHz, 
Avance AV300 MHZ, DRX400 MHz, AV500 MHZ, or AV700 MHZ (1H, 13C, 19F, 1D 
NOESY) spectrometer. Chemical shifts for 1H NMR spectra are recorded in parts per million 
(ppm) from tetramethylsilane (TMS) with the solvent resonance as the internal standard 
(CHCl3, δ = 7.26 ppm). The data was reported as follows: chemical shift, multiplicity (s = 
singlet, s (br) = broad singlet, d = doublet, dd = doublet of doublets, dt = doublet of triplets, td 
= triplet of doublets, ddd = doublet of doublets of doublets, t = triplet, q = quadruplet, m = 
multiplet), integration and coupling constant in Hz. Chemical shifts for 13C NMR spectra were 
recorded in parts per million from tetramethylsilane using the central peak of CDCl3 (77.16 
ppm) as the internal standard. All 13C NMR spectra were obtained with complete proton 
decoupling.    
Infrared spectra were taken on a Bruker Vertex Series FTIR (neat) with the important 
vibrations reported in reciprocal centimeters (cm–1). Melting points were obtained using a 
Thomas Hoover melting point apparatus and are uncorrected. 
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High-resolution mass spectra were performed by the Centre régional de spectroscopie 
de masse de l’Université de Montréal using either ESI, or APPI ionization modes. X-ray 
structures were obtained though Laboratoire de diffraction des rayons-X de l’Université de 
Montréal using an Enraf-Nonius CAD-3 or CAD-4 apparatus.  
Experimental section of Chapter 2 
Synthesis of amides 
Procedure A: To a cooled (ice/water bath) solution of 2-picolylamine (10 mmol, 1.0 equiv) in 
DCM (0.2 M) was added the corresponding acyl chloride (11 mmol, 1.1 equiv) and 
triethylamine (12 mmol, 1.2 equiv) dropwise. The reaction was allowed to warm to room 
temperature and stirred under an atmosphere of argon until complete (followed by TLC). The 
reaction was quenched by the addition of saturated aqueous NaHCO3 (20 mL) and extracted 
with DCM (3x25 mL). The combined organic layers were dried (Na2SO4), filtered and 
concentrated. The residue was purified either by flash chromatography (Hex/EtOAc) or hot 
filtration (EtOAc).  
Procedure B: The corresponding carboxylic acid (10.5 mmol, 1.05 equiv) was dissolved in 
DCM (0.2 M) in a 100 mL round-bottomed flask. DMF (2-3 drops) was added to the solution, 
and the reaction was thoroughly purged with argon. Oxalyl chloride (11 mmol, 1.1 equiv) was 
added dropwise over 30 min. The reaction was stirred for an additional 1-2 h at ambient 
temperature (or until complete by TLC). The reaction was then concentrated to remove excess 
oxalyl chloride. The residue was dissolved in DCM (0.2 M) and cooled in an ice/water bath. 2-
Picolylamine (10 mmol, 1.0 equiv) and triethylamine (12 mmol, 1.2 equiv) were added 
dropwise. The reaction was allowed to warm up to room temperature and stirred overnight (or 
until complete by TLC). The reaction was quenched by the addition of saturated aqueous 
NaHCO3 (20 mL) and extracted with DCM (3x25 mL). The combined organic layers were 
dried (Na2SO4), filtered and concentrated. The residue was purified either by flash 
chromatography (Hex/EtOAc) or hot filtration (EtOAc).  
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N-(pyridin-2-ylmethyl)-3-(trifluoromethyl)benzamide (A1): Synthesized according to 
Procedure B, on a 10 mmol scale. After work-up, the residue was flashed in 50-100% 
EtOAc/Hex to give 2.54 g (9.06 mmol, 91% yield) of a yellow oil. 1H NMR (300 MHz, 
CDCl3): δ 8.50 (dd, 1H, J = 4.9, 0.6 Hz), 8.17-8.08 (m, 2H), 8.02 (d, 1H, J = 7.8 Hz), 7.73-
7.60 (m, 2H), 7.50 (t, 1H, J = 7.8 Hz), 7.30 (d, 1H, J = 7.9 Hz), 7.22-7.14 (m, 1H), 4.72 (d, 
2H, J = 5.0 Hz) ppm. 19F NMR (376 MHz, CDCl3): δ -62.7 ppm.13C NMR (75 MHz, CDCl3): 
δ 166.1, 156.1, 149.0, 137.0, 135.2, 131.3 (q, JC-F = 32.8 Hz), 130.4 (m), 129.2, 128.1(q, JC-F = 
3.8 Hz), 125.6 (q, JC-F = 272.3 Hz), 124.4 (q, JC-F = 3.8 Hz), 122.6, 122.3, 44.9 ppm. FTIR 
(cm-1) (neat): 3323, 3069, 1753, 1477, 1330, 1119. HRMS (ESI, Pos): calcd for C14H12F3N2O 
[M+H]+: 281.0896, found 281.0896 m/z. 
 
N-(pyridin-2-ylmethyl)-1-naphthamide (A2): Synthesized according to Procedure B, on a 
10 mmol scale. After work-up, the resulting solid was purified by hot filtration from EtOAc. A 
brown solid was obtained (1.34 g, 5.11 mmol, 51%). mp: 105-106 °C. 1H NMR (400 MHz, 
CDCl3): δ 8.54 (dd, 1H, J = 4.8, 0.7 Hz), 8.44-8.36 (m, 1H), 7.93 (d, 1H, J = 8.2 Hz), 7.91-
7.84 (m, 1H), 7.76-7.68 (m, 2H), 7.59-7.45 (m, 3H), 7.39 (d, 1H, J = 7.9 Hz), 7.34 (br, s, 1H), 
7.25-7.20 (m, 1H), 4.88 (d, 2H, J = 5.0 Hz) ppm. 13C NMR (125 MHz, CDCl3): δ 169.7, 
156.2, 149.2, 140.0, 134.4, 133.8, 130.8, 130.4, 128.4, 127.2, 126.5, 125.7, 125.4, 124.9, 
122.6, 122.3, 45.0 ppm. FTIR (cm-1) (neat): 3244, 3057, 1632, 1545, 1315, 776, 755. HRMS 
(ESI, Pos): calcd for C17H15N2O [M+H]+: 263.1179, found 263.1186 m/z. 
 
N-(pyridin-2-ylmethyl)-4-(trifluoromethyl)benzamide (A3): Synthesized according to 
Procedure A, on a 5 mmol scale. After work-up, the residue was flashed in 50-100% 
EtOAc/Hex to give 1.29 g (4.6 mmol, 92% yield) of a white solid. mp: 102-104 °C. 1H NMR 
(400 MHz, CDCl3): δ 8.57 (dd, 1H, J = 4.9, 0.9 Hz), 7.99 (dd, 1H, J = 8.1, 0.6 Hz), 7.79 (br. 
s), 7.76-7.67 (m, 3H), 7.37-7.30 (m, 1H), 7.29-7.20 (m, 1H), 4.77 (d, 2H, J = 4.5 Hz) ppm. 19F 
NMR (282 MHz, CDCl3): δ -62.9 ppm. 13C NMR (100 MHz, CDCl3): δ 166.2, 155.8, 149.1, 
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137.8, 137.1, 133.5 (q, JC-F = 32.1 Hz), 127.1, 125.7 (q, JC-F = 3.8 Hz), 125.2 (q, JC-F = 272.1 
Hz), 122.7, 122.4, 44.8 ppm. FTIR (cm-1) (neat): 3325, 1642, 1550, 1324, 1306, 1109, 1069. 
HRMS (ESI, Pos): calcd for C14H12F3N2O [M+H]+: 281.0896, found 281.0883 m/z. 
Synthesis of imidazo[1,5-a]pyridines 
Procedure C: Adapted from a literature procedure,114 in a flame-dried 20 mL microwave vial, 
the starting amide (3 mmol, 1.0 equiv) was dissolved in 6 mL dry DCM under Ar and the vial 
was crimped. To this, 2-methoxypyridine (3.3 mmol, 1.1 equiv) was added, and the reaction 
was cooled in an ice/water bath. Triflic anhydride (freshly distilled over P2O5) (4.5 mmol, 1.5 
equiv) was added dropwise (reaction turned dark red). After the addition was complete, the 
reaction was stirred at room temperature for 5 min, then at 35 °C o/n. The reaction was cooled 
to room temperature and quenched by the slow addition of saturated aqueous NaHCO3 (8 
mL), followed by stirring for 5 min. Then, the two layers were separated and the aqueous 
layer was extracted with DCM (2x15 mL). The combined organic layers were washed with 
brine (10 mL), dried (Na2SO4), filtered and concentrated. 
Some of the imidazo[1,5-a]azines have been previously reported in the literature.114,122  
 
3-(m-tolyl)imidazo[1,5-a]pyridine (186): Synthesized according to Procedure C on a 2.69 
mmol scale. After work-up, the residue was flashed in 15-20% EtOAc/Hex to give 469 mg 
(2.25 mmol, 84%) of a red oil. 1H NMR (300 MHz, CDCl3): δ 8.26 (dq, 1H, J = 7.3, 1.0 Hz), 
7.63 (ddd, 1H, J = 1.5, 1.1, 0.9 Hz), 7.61-7.56 (m, 1H), 7.55 (d, 1H, J = 0.9 Hz), 7.48 (dt, 1H, 
J = 9.2, 1.2 Hz), 7.40 (t, 1H, J = 7.6 Hz), 7.28-7.22 (m, 1H), 6.72 (ddd, 1H, J = 9.2, 6.4, 0.9 
Hz), 6.56 (ddd, 1H, J = 7.4, 6.3, 1.2 Hz), 2.44 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3): δ 
139.0, 138.4, 131.6, 130.1, 129.7, 129.0, 128.9, 124.9, 121.7, 120.3, 119.0, 118.9, 113.2, 21.6 
ppm. FTIR (cm-1) (neat): 2966, 2921, 1633, 1506, 1351, 1033. HRMS (ESI, Pos): calcd for 
C14H13N2 [M+H]+: 209.1073, found 209.1083 m/z. 
 184 
 
3-(3-(trifluoromethyl)phenyl)imidazo[1,5-a]pyridine (187): Synthesized according to 
Procedure C on a 3 mmol scale. After work-up, the residue was flashed in 15-20% EtOAc/Hex 
to give 540 mg (2.06 mmol, 69%) of a dark orange solid. mp: <50 °C. 1H NMR (300 MHz, 
CDCl3): δ 8.23 (dd, 1H, J = 7.2, 0.8 Hz), 8.09 (s, 1H), 8.00 (d, 1H, J = 7.4 Hz), 7.71-7.61 (m, 
2H), 7.59 (s, 1H), 7.52 (d, 1H, J = 9.2 Hz), 6.79 (ddd, 1H, J = 9.2, 6.4, 0.6 Hz), 6.64 (dd, 1H, J 
= 7.4, 6.2, 1.2 Hz) ppm. 19F NMR (282 MHz, CDCl3): δ -64.2 ppm. 13C NMR (75 MHz, 
CDCl3): δ 136.7, 132.2, 131.9 (q, JC-F = 32.5 Hz), 131.3, 130.9 (m), 129.7, 125.8 (q, JC-F = 
272.5 Hz), 125.2 (q, JC-F = 3.7 Hz), 124.8 (q, JC-F = 3.9 Hz), 121.2, 121.1, 119.4, 119.1, 114.0 
ppm. FTIR (cm-1) (neat): 3066, 2936, 1320, 1308, 1164, 1107. HRMS (ESI, Pos): calcd for 
C14H10F3N2 [M+H]+: 263.0791, found 263.0790 m/z. 
 
3-(naphthalen-1-yl)imidazo[1,5-a]pyridine (192): Synthesized according to Procedure C on 
a 3 mmol scale. After work-up, the residue was flashed in 15-20% EtOAc/Hex to give 622 mg 
(2.55 mmol, 85%) of a brown solid. mp: 121-123 °C. 1H NMR (300 MHz, CDCl3): δ 7.99 (d, 
1H, J = 8.2 Hz), 7.94 (d, 1H, J = 8.1 Hz), 7.78-7.64 (m, 4H), 7.60 (t, 1H, J = 7.7 Hz), 7.57-
7.49 (m, 1H), 6.75 (dd, 1H, J = 9.1, 6.4 Hz), 6.47 (t, 1H, J = 6.8 Hz) ppm. 13C NMR (75 MHz, 
CDCl3): δ 137.0, 134.1, 132.0, 131.2, 129.9, 128.7, 127.4, 127.1, 126.4, 125.7, 125.4, 121.9, 
120.3, 119.0, 118.7, 112.8 ppm. FTIR (cm-1) (neat): 2922, 2865, 1353, 1055, 1033, 902. 
HRMS (ESI, Pos): calcd for C14H12N2 [M+H]+: 245.1073, found 245.1065 m/z. 
Ruthenium-catalyzed direct arylation 
Procedure D: To a microwave vial (previously kept in an oven and cooled under argon) fit 
with a stir bar, the corresponding imidazo[1,5-a]azine (if solid, 0.4 mmol, 1.0 equiv), 2,4,6-
trimethylbenzoic acid (0.12 mmol, 0.3 equiv) and the aryl bromide (0.48 mmol, 1.2 equiv), if 
solid, were added. The vial was then placed in a glove box where dichloro(p-
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cymene)ruthenium dimer (0.02 mmol, 0.05 equiv) and potassium carbonate (0.8 mmol, 2.0 
equiv) were added. The vial was crimped and taken out of the glove box. The aryl bromide 
(0.48 mmol, 1.2 equiv), if liquid, was added via syringe, followed by dry toluene (2 mL); or, if 
the imidazo[1,5-a]azine was an oil, it was added at this point as a solution in 2 mL toluene 
(0.2 M solution). The reaction was stirred at 130 °C for 15 h. Then, the reaction was allowed 
to cool to rt, and filtered over a pad of silica and celite, rinsing with EtOAc (15-20 mL). The 
organic layer was washed with a solution of saturated aqueous K2CO3 (15 mL), water (15 
mL). The aqueous layer was extracted with EtOAc (2x10 mL). The combined organic layers 
were washed with brine (10 mL), dried (Na2SO4) and concentrated in vacuo. The resulting 
residue was purified by flash chromatography.  
Procedure E: To a microwave vial (previously kept in an oven and cooled under argon) fit 
with a stir bar, the corresponding imidazo[1,5-a]azine (if solid, 0.4 mmol, 2.0 equiv), 2,4,6-
trimethylbenzoic acid (0.06 mmol, 0.3 equiv) and the aryl bromide (0.2 mmol, 1.0 equiv), if 
solid, were added. The vial was then placed in a glove box where dichloro(p-
cymene)ruthenium dimer (0.01 mmol, 0.05 equiv) and potassium carbonate (0.4 mmol, 2.0 
equiv) were added. The vial was crimped and taken out of the glove box. The aryl bromide 
(0.2 mmol, 1.0 equiv), if liquid, was added via syringe, followed by dry toluene (2 mL); or, if 
the imidazo[1,5-a]azine was an oil, it was added at this point as a solution in 2 mL toluene 
(0.2 M solution). The reaction was stirred at 130 °C for 15 h. Then, the reaction was allowed 
to cool to rt, and filtered over a pad of silica and celite, rinsing with EtOAc (15-20 mL). The 
organic layer was washed with a solution of saturated aqueous K2CO3 (15 mL), water (15 
mL). The aqueous layer was extracted with EtOAc (2x10 mL). The combined organic layers 
were washed with brine (10 mL), dried (Na2SO4) and concentrated in vacuo. The resulting 
residue was purified by flash chromatography.  
 
1-(2'-(imidazo[1,5-a]pyridin-3-yl)-4'-methoxy-[1,1'-biphenyl]-4-yl)ethanone (182a) and 
1,1'-(2'-(imidazo[1,5-a]pyridin-3-yl)-4'-methoxy-[1,1':3',1''-terphenyl]-4,4''-
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diyl)diethanone (182b): Synthesized according to Procedure D, employing 4’-
bromoacetophenone as the coupling partner. After work-up, the residue was purified via flash 
chromatography (25-80% EtOAc/Hex) to give 182a (70 mg, 0.204 mmol, 51%) as a yellow 
oil and 182b (40 mg, 0.087 mmol, 22%) as a dark oil.  
Synthesized according to Procedure E, employing 4’-bromoacetophenone as the coupling 
partner. After work-up, the residue was purified via flash chromatography (15-80% 
EtOAc/Hex) to give 182a (63.5 mg, 0.186 mmol, 93%) and unreacted 182 (19 mg, 0.0847 
mmol, 21%).  
182a: 1H NMR (300 MHz, CDCl3): δ δ 7.72-7.64 (m, 2H), 7.54-7.45 (m, 2H), 7.37-7.31 (m, 
1H), 7.23 (d, 1H, J = 2.8 Hz), 7.19 (dd, 1H, J = 7.2, 0.9 Hz), 7.13 (dd, 1H, J =8.6, 2.8 Hz), 
7.12-7.06 (m, 2H), 6.52 (ddd, 1H, J = 9.1, 6.4, 0.7 Hz), 6.15 (td, 1H, J = 6.8, 1.1 Hz), 3.89 (s, 
3H), 2.48 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3): δ 197.8, 159.9, 145.2, 137.4, 135.3, 
132.9, 131.5, 130.8, 130.0, 128.5, 128.1, 120.9, 120.2, 118.8, 118.2, 116.7, 116.6, 112.4, 55.7, 
26.7 ppm. FTIR (cm-1) (neat): 2938, 2865, 1678, 1602, 1264, 1177, 1051. HRMS (ESI, Pos): 
calcd for C22H19N2O2 [M+H]+: 343.1441, found 343.1424 m/z. 
182b: 1H NMR (400 MHz, CDCl3): δ 7.71-7.63 (m, 4H), 7.56 (d, 1H, J = 8.6 Hz), 7.28-7.15 
(m, 4H), 7.06 (d, 2H, J = 8.3 Hz), 6.47 (dd, 1H, J = 9.0, 6.4 Hz), 6.22 (t, 1H, J = 6.4 Hz), 3.83 
(s, 3H), 2.48 (d, 6H) ppm. 13C NMR (125 MHz, CDCl3): δ 198.0, 197.9, 156.9, 145.2, 141.2, 
135.5, 135.4, 135.3, 134.9, 132.5, 131.0, 130.1, 129.5, 129.4, 128.5, 128.2, 127.6, 120.3, 
119.8, 118.3, 118.2, 112.8, 112.6, 56.2, 26.7 (2) ppm. FTIR (cm-1) (neat): 2938, 2865, 1677, 
1355, 1264, 1056, 1006. HRMS (ESI, Pos): calcd for C30H25N2O3 [M+H]+: 461.1860, found 
461.1861 m/z. 
 
1-(2'-(imidazo[1,5-a]pyridin-3-yl)-4'-methyl-[1,1'-biphenyl]-4-yl)ethanone (186a) and 
1,1'-(2'-(imidazo[1,5-a]pyridin-3-yl)-4'-methyl-[1,1':3',1''-terphenyl]-4,4''-
diyl)diethanone (186b): Synthesized according to Procedure D, employing 4’-
bromoacetophenone as the coupling partner. After work-up, the residue was purified via flash 
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chromatography (25-80% EtOAc/Hex) to give 186a (113 mg, 0.356 mmol, 87%) as a thick 
yellow oil and 186b (8 mg, 0.017 mmol, 4%) as a thick yellow oil. 
Synthesized according to Procedure E, employing 4’-bromoacetophenone as the coupling 
partner. After work-up, the residue was purified via flash chromatography (15-80% 
EtOAc/Hex) to give 186a (64 mg, 0.196 mmol, 98%) and unreacted 186 (21 mg, 0.10 mmol, 
25%). The dimer 188 was also isolated (14 mg, 0.0338 mmol, 17%). 
186a: 1H NMR (300 MHz, CDCl3): δ 7.68 (d, 2H, J = 8.5 Hz), 7.56-7.48 (m, 2H), 7.48-7.43 
(m, 1H), 7.41-7.36 (m, 1H), 7.32 (d, 1H, J = 9.2 Hz), 7.18 (dd, 1H, J = 7.2, 1.0 Hz), 7.12 (d, 
2H, J = 8.4 Hz), 6.50 (ddd, 1H, J = 9.1, 6.4, 0.8 Hz), 6.13 (td, 1H, J = 6.8, 1.1 Hz), 2.47 (s, 
3H), 2.45 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3): δ 197.7, 145.4, 138.8, 137.6 (2), 135.4, 
133.0, 130.7, 130.6, 130.1, 128.5, 128.4, 128.2, 120.8, 120.1, 118.6, 118.1, 112.2, 26.6, 21.1 
ppm. FTIR (cm-1) (neat): 2972, 2865, 1678, 1603, 1354, 1265, 1055, 1014. HRMS (ESI, Pos): 
calcd for C22H19N2O [M+H]+: 327.1492, found 327.1507 m/z. 
186b: 1H NMR (300 MHz, CDCl3): δ 7.90 (d, 2H, J = 8.5 Hz), 7.60-7.54 (m, 2H), 7.52 (d, 1H, 
J = 7.9 Hz), 7.46-7.39 (m, 3H), 7.28-7.23 (m, 2H), 7.05 (d, 2H, J = 8.5 Hz), 6.89 (d, 1H, J = 
1.7 Hz), 6.62 (dd, 1H, J = 8.9, 6.4 Hz), 6.24 (t, 1H, J = 6.7 Hz), 2.62 (s, 3H), 2.47 (s, 3H), 1.99 
(s, 3H) ppm. 13C NMR (125 MHz, CDCl3): δ 203.0, 197.9, 145.6, 143.4, 140.0, 139.0, 138.0, 
137.8, 137.3, 136.3, 133.1, 131.0, 130.1, 130.0, 129.0, 128.8, 128.6, 127.7, 121.1, 120.3, 
118.8, 118.2, 112.3, 30.3, 27.0, 21.1 ppm. FTIR (cm-1) (neat): 2972, 1682, 1346, 1056, 1032, 
1013. HRMS (ESI, Pos): calcd for C30H25N2O2 [M+H]+: 445.1910, found 445.1904 m/z. 
 
1-(2'-(imidazo[1,5-a]pyridin-3-yl)-4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)ethanone 
(187a): Synthesized according to Procedure D, employing 4’-bromoacetophenone as the 
coupling partner. After work-up, the residue was purified in flash chromatography (10-80% 
EtOAc/Hex) to give 187a (108 mg, 0.284 mmol, 71%) and a mixture of 187b, 187a and 
MesCO2H (13 mg).  
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Synthesized according to Procedure E, employing 4’-bromoacetophenone as the coupling 
partner. After work-up, the residue was purified via flash chromatography (15-80% 
EtOAc/Hex) to give 187a (74 mg, 0.195 mmol, 98%) and unreacted 187 (18 mg, 0.069 mmol, 
17%).  
187a: 1H NMR (300 MHz, CDCl3): δ 8.01 (d, 1H, J = 1.2 Hz), 7.83 (dd, 1H, J = 8.2, 1.3 Hz), 
7.77-7.65 (m, 3H), 7.54 (s, 1H), 7.37 (d, 1H, J = 9.2 Hz), 7.20-7.12 (m, 3H), 6.57 (ddd, 1H, J 
= 9.1, 6.4, 0.6 Hz), 6.25-6.17 (m, 1H), 2.49 (s, 3H) ppm. 19F NMR (282 MHz, CDCl3): δ -
64.04 ppm. 13C NMR (125 MHz, CDCl3): δ 197.6, 143.9, 143.8 (m), 136.3, 135.8, 133.2 (q, 
JC-F  = 33.0 Hz), 131.0, 130.8, 129.6, 129.5 (q, JC-F  = 3.8 Hz), 128.7, 128.3, 126.6 (q, JC-F = 3.6 
Hz), 125.7 (q, JC-F = 272.6 Hz), 120.7, 120.5, 119.2, 118.4, 112.9, 26.7 ppm. FTIR (cm-1) 
(neat): 2972, 2865, 1681, 1321, 1261, 1056, 1005. HRMS (ESI, Pos): calcd for C22H16F3N2O 
[M+H]+: 381.1209, found 381.1208 m/z. 
 
1-(2'-(imidazo[1,5-a]pyridin-3-yl)-5'-methoxy-[1,1'-biphenyl]-4-yl)ethanone (165a) and 
1,1'-(2'-(imidazo[1,5-a]pyridin-3-yl)-5'-methoxy-[1,1':3',1''-terphenyl]-4,4''-
diyl)diethanone (165b): Synthesized according to Procedure D, employing 4’-
chloroacetophenone as the coupling partner. After work-up, the residue was purified by flash 
chromatography (20-80% EtOAc/Hex) to give 165a (67 mg, 0.196 mmol, 49%) as a yellow 
solid and 165b (36 mg, 0.078 mmol, 20%) as an off-white solid. 
165a: mp = 122-126 °C. 1H NMR (500 MHz, acetone-d6): δ 7.73 (d, 2H, J = 8.5 Hz), 7.61-
7.54 (m, 1H), 7.45-7.39 (m, 2H), 7.37 (dd, 1H, J = 7.2, 0.9 Hz), 7.23 (d, 2H, J = 8.5 Hz), 7.19-
7.14 (m, 2H), 6.57 (ddd, 1H, J = 9.1, 6.3, 0.8 Hz), 6.31-6.24 (m, 1H), 3.95 (s, 3H), 2.47 (s, 
3H) ppm. 13C NMR (125 MHz, acetone-d6): δ 197.5, 161.8, 146.2, 143.2, 138.1, 136.8, 134.5, 
131.5, 129.3, 129.0, 122.4, 122.0, 120.7, 119.3, 118.9, 116.3, 115.0, 112.9, 56.1, 26.7 ppm. 
FTIR (cm-1) (neat): 2950, 2865, 1678, 1600, 1356, 1056, 1013. HRMS (ESI, Pos): calcd for 
C22H19N2O2 [M+H]+: 343.1441, found 343.1454 m/z. 
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165b: mp = 229-231 °C. 1H NMR (500 MHz, CDCl3): δ 7.69 (d, 4H, J = 8.4 Hz), 7.26 (d, 1H, 
J = 0.6 Hz), 7.24-7.17 (m, 2H), 7.14-7.10 (m, 4H), 7.10 (s, 2H), 6.48 (ddd, 1H, J = 9.1, 6.4, 
0.7 Hz), 6.21 (td, 1H, J = 7.3, 1.1 Hz), 3.95 (s, 3H), 2.49 (s, 6H) ppm. 13C NMR (125 MHz, 
CDCl3): δ 197.8, 160.6, 145.4, 145.1, 135.8, 135.0, 129.7, 128.6, 128.1, 120.2, 119.8, 119.7, 
118.3, 118.2, 115.4, 112.6, 55.8, 26.7 ppm. FTIR (cm-1) (neat): 2939, 2865, 1670, 1594, 1345, 
1266, 1209, 1055, 1013. HRMS (ESI, Pos): calcd for C30H25N2O3 [M+H]+: 461.1860, found 
461.1865 m/z. 
 
1-(2'-(imidazo[1,5-a]pyridin-3-yl)-5'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)ethanone 
(166a) and 1,1'-(2'-(imidazo[1,5-a]pyridin-3-yl)-5'-(trifluoromethyl)-[1,1':3',1''-
terphenyl]-4,4''-diyl)diethanone (166b): Synthesized according to Procedure D, employing 
4’-bromoacetophenone as the coupling partner. After work-up, the residue was purified by 
flash chromatography (15-50% EtOAc/Hex) to give 166a (92 mg, 0.242 mmol, 60%) as a 
thick yellow oil and 166b (63 mg, 0.126 mmol, 32%) as a brown solid. 
166a: 1H NMR (300 MHz, CDCl3): δ 7.90-7.68 (m, 5H), 7.55 (d, 1H, J = 0.7 Hz), 7.37 (d, 1H, 
J = 9.2 Hz), 7.22-7.12 (m, 3H), 6.58 (ddd, 1H, J = 9.2, 6.4, 0.7 Hz), 6.25-6.15 (m, 1H), 2.50 
(s, 3H) ppm. 19F NMR (282 MHz, CDCl3): δ -62.6 ppm. 13C NMR (75 MHz, CDCl3): δ 197.6, 
144.0, 141.0, 136.2, 135.9, 133.0, 132.4, 132.1 (q, JC-F = 32.7 Hz), 131.2, 128.7, 128.3, 127.2 
(m), 125.7 (q, JC-F = 272.6 Hz), 125.4 (m), 120.9, 120.6, 119.2, 118.4, 112.9, 26.7 ppm. FTIR 
(cm-1) (neat): 2950, 2844, 1681, 1332, 1122, 1056, 1013. HRMS (ESI, Pos): calcd for 
C22H16F3N2O [M+H]+: 381.1209, found 381.1223 m/z. 
166b: mp = 229-231 °C. 1H NMR (300 MHz, CDCl3): δ 7.84 (d, 2H, J = 0.4 Hz), 7.76-7.70 
(m, 4H), 7.33-7.25 (m, 2H), 7.18 (dd, 1H, J = 7.2, 1.0 Hz), 7.15-7.09 (m, 4H), 6.54 (ddd, 1H, J 
= 9.1, 6.4, 0.7 Hz), 6.27 (td, 1H, J = 7.4, 1.1 Hz), 2.51 (s, 6H) ppm. 19F NMR (282 MHz, 
CDCl3): δ -62.7 ppm. 13C NMR (125 MHz, CDCl3): δ 197.6, 144.5, 144.0, 136.2, 133.6, 132.6 
(q, JC-F = 33.0 Hz), 130.9, 130.1, 128.6, 128.4, 126.7 (m), 124.8 (q, JC-F = 273.1 Hz), 120.5, 
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119.9, 118.9, 118.4, 113.3, 26.7 ppm. FTIR (cm-1) (neat): 1938, 2823, 1682, 1357, 1263, 1055, 
1014. HRMS (ESI, Pos): calcd for C30H22F3N2O2 [M+H]+: 499.1628, found 499.1609 m/z. 
 
1-(5'-(tert-butyl)-2'-(imidazo[1,5-a]pyridin-3-yl)-[1,1'-biphenyl]-4-yl)ethanone (167a) and 
1,1'-(5'-(tert-butyl)-2'-(imidazo[1,5-a]pyridin-3-yl)-[1,1':3',1''-terphenyl]-4,4''-
diyl)diethanone (167b): Synthesized according to Procedure D, employing 4’-
bromoacetophenone as the coupling partner. After work-up, the residue was purified by flash 
chromatography (20-80% EtOAc/Hex) to give 167a (81 mg, 0.220 mmol, 55%) as a thick 
brown oil and 167b (42 mg, 0.086 mmol, 22%) as an off-white solid. 
167a: 1H NMR (400 MHz, CDCl3): δ 7.72 (d, 2H, J = 8.2 Hz), 7.66-7.63 (m, 1H), 7.60-7.52 
(m, 2H), 7.49 (s, 1H), 7.32 (d, 1H, J = 9.2 Hz), 7.28-7.23 (m, 1H), 7.16 (d, 2H, J = 8.2 Hz), 
6.51 (dd, 1H, J = 9.1, 6.4 Hz), 6.15 (t, 1H, J = 6.8 Hz), 2.49 (s, 3H), 1.41 (s, 9H) ppm. 13C 
NMR (75 MHz, CDCl3): δ 197.8, 153.2, 146.1, 140.2, 137.5, 135.6, 132.0, 130.6, 128.4 (2), 
127.2, 125.9, 125.8, 121.0, 120.0, 118.6, 118.2, 112.2, 35.1, 31.4, 26.7 ppm. FTIR (cm-1) 
(neat): 2922, 2844, 1680, 1603, 1455, 1355, 1056, 1014. HRMS (ESI, Pos): calcd for 
C25H25N2O [M+H]+: 369.1961, found 369.1959 m/z. 
167b: mp = 212-214 °C. 1H NMR (500 MHz, CDCl3): δ 7.71 (d, 4H, J = 8.7 Hz), 7.57 (s, 2H), 
7.28 (d, 1H, J = 0.7 Hz), 7.26-7.20 (m, 2H), 7.15-7.09 (m, 4H), 6.51-6.46 (m, 1H), 6.20 (ddd, 
1H, J = 7.3, 6.4, 0.9 Hz), 2.50 (s, 6H), 1.45 (s, 9H) ppm. 13C NMR (125 MHz, CDCl3): δ 
197.9, 153.6, 146.1, 143.2, 135.6, 135.3, 129.7, 128.7, 128.2, 127.3, 124.5, 120.4, 120.0, 
118.4, 118.2, 112.6, 35.2, 31.4, 26.7 ppm. FTIR (cm-1) (neat): 2939, 2865, 1678, 1454, 1266, 
1055, 1014. HRMS (ESI, Pos): calcd for C33H31N2O2 [M+H]+: 487.2380, found 487.2390 m/z. 
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1-(2'-(imidazo[1,5-a]pyridin-3-yl)-[1,1'-biphenyl]-4-yl)ethanone (164a) and 1,1'-(2'-
(imidazo[1,5-a]pyridin-3-yl)-[1,1':3',1''-terphenyl]-4,4''-diyl)diethanone (164b): 
Synthesized according to Procedure D, employing the corresponding 4-haloacetophenone as 
the coupling partner. After work-up, the residue was purified by flash chromatography (20-
100% EtOAc/Hex, RediSep Gold column 12 g) to give 164a as a thick yellow oil and 164b as 
a brown solid. 
4’-bromoacetophenone: 164a (51 mg, 0.163 mmol, 41%) and 164b (39 mg, 0.091 mmol, 
23%); 4’-chloroacetophenone: 164a (62 mg, 0.199 mmol, 50%) and 164b (46 mg, 0.107 
mmol, 27%); 4’-iodoacetophenone: 164a (39 mg, 0.125 mmol, 31%) and 164b (34 mg, 0.079 
mmol, 20%); 4’-bromoacetophenone (3 equiv): 164a (133 mg, 0.309 mmol, 77%) and 164b 
(none observed) 
164a: 1H NMR (400 MHz, CDCl3): δ 7.75-7.66 (m, 3H), 7.63-7.52 (m, 2H), 7.51 (s, 1H), 7.34 
(d, 1H, J = 9.2 Hz), 7.22 (dd, 1H, J = 7.2, 0.9 Hz), 7.18-7.10 (m, 2H), 6.53 (ddd, 1H, J = 9.1, 
6.4, 0.7 Hz), 6.17 (td, 1H, J = 8.8, 1.1 Hz), 2.49 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3): δ 
197.8, 145.4, 140.6, 137.4, 135.7, 132.4, 130.7, 130.2, 130.0, 128.8 (2), 128.5, 128.3, 120.8, 
118.7, 118.2, 112.4, 26.7 ppm. FTIR (cm-1) (neat): 2922, 2844, 1679, 1356, 1265, 1055, 1006.  
HRMS (ESI, Pos): calcd for C21H17N2O [M+H]+: 313.1335, found 313.1340 m/z. 
164b: mp = 92-94 °C. 1H NMR (400 MHz, CDCl3): δ 7.74-7.66 (m, 5H), 7.61-7.56 (m, 2H), 
7.29 (s, 1H), 7.27-7.23 (m, 1H), 7.19 (dd, 1H, J = 7.1, 0.8 Hz), 7.11-7.09 (m, 4H), 6.50 (ddd, 
1H, J = 9.2, 6.4, 0.6 Hz), 6.22 (td, 1H, J = 7.3, 1.2 Hz), 2.50 (s, 6H) ppm. 13C NMR (75 MHz, 
CDCl3): δ 197.8, 145.4, 143.6, 135.7, 135.1, 130.4, 130.1, 129.8, 128.6, 128.2, 127.3, 120.2, 
120.0, 118.5, 118.3, 112.8, 26.7 ppm. FTIR (cm-1) (neat): 2949, 2844, 1674, 1356, 1265, 1055, 
1014. HRMS (ESI, Pos): calcd for C29H23N2O2 [M+H]+: 431.1754, found 431.1772 m/z. 
 
1-(2'-(imidazo[1,5-a]pyridin-3-yl)-3'-methyl-[1,1'-biphenyl]-4-yl)ethanone (189a): 
Synthesized according to Procedure D, employing 4’-bromoacetophenone (1.5 equiv) as the 
coupling partner. After work-up, the residue was purified by flash chromatography (20-50% 
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Et2O/Hex) to give 189a (82 mg, 0.251 mmol, 63%) as a brown solid and unreacted 189 (3 mg, 
<4%). mp = 119-122 °C. 1H NMR (500 MHz, CDCl3): δ 7.65 (d, 2H, J = 8.6 Hz), 7.51-7.45 
(m, 2H), 7.42-7.37 (m, 1H), 7.37-7.30 (m, 2H), 7.15 (dd, 1H, J = 7.2, 1.0 Hz), 7.10 (d, 2H, J = 
8.5 Hz), 6.54 (ddd, 1H, J = 9.1, 6.3, 0.8 Hz), 6.25 (ddd, 1H, J = 7.2, 6.3, 1.1 Hz), 2.46 (s, 3H), 
2.17 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): 197.0, 145.8, 142.5, 140.6, 136.0, 135.4, 
130.4, 130.0 (2), 128.5, 128.1, 127.6, 125.6, 120.7, 119.7, 118.4, 118.3, 112.5, 26.7, 20.1 ppm.  
FTIR (cm-1) (neat): 2939, 2826, 1679, 1604, 1355, 1266, 1055, 1014. HRMS (ESI, Pos): calcd 
for C22H19N2O [M+H]+: 327.1492, found 327.1505 m/z. 
 
1-(2'-(imidazo[1,5-a]quinolin-1-yl)-[1,1'-biphenyl]-4-yl)ethanone (190a): Synthesized 
according to Procedure D, employing 4’-bromoacetophenone as the coupling partner. After 
work-up, the residue was purified in flash chromatography (20-80% EtOAc/Hex) to give 190a 
(96 mg, 0.264 mmol, 66%) as a brown solid. mp = 156-158 °C. 1H NMR (300 MHz, CDCl3): 
δ 7.72 (d, 1H, J = 7.4 Hz), 7.67 (td, 1H, J = 7.5, 1.2 Hz), 7.64-7.57 (m, 1H), 7.56-7.51 (m, 
3H), 7.50 (s, 1H), 7.44 (d, 1H, J = 7.5 Hz), 7.27-7.17 (m, 3H), 7.14-7.06 (m, 1H), 6.98 (d, 2H, 
J = 8.3 Hz), 6.85 (d, 1H, J = 9.4 Hz), 2.41 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3): δ 197.8, 
144.9, 141.5, 140.7, 135.4, 132.5, 131.9, 131.4, 130.4, 130.2, 130.0, 128.9 (2), 128.5, 127.8, 
127.5, 125.3, 125.2, 121.7, 121.5, 116.9, 116.5, 26.6 ppm. FTIR (cm-1) (neat): 2972, 2865, 
1681, 1605, 1372, 1266, 1055, 1013. HRMS (ESI, Pos): calcd for C25H19N2O [M+H]+: 
363.1492, found 363.1458 m/z. 
 
1,1'-(2'-(imidazo[1,5-a]pyridin-3-yl)-4'-(trifluoromethyl)-[1,1':3',1''-terphenyl]-4,4''-
diyl)diethanone (191a) and 1,1'-((2-(imidazo[1,5-a]pyridin-3-yl)naphthalene-1,3-
diyl)bis(4,1-phenylene))diethanone (191b): Synthesized according to Procedure D, 
 193 
employing 4’-bromoacetophenone as the coupling partner. After work-up, the residue was 
purified via flash chromatography (20-80% EtOAc/Hex) to give 191a (46 mg, 0.127 mmol, 
32%) as a thick brown oil and 191b (38 mg, 0.079 mmol, 20%) as a thick brown oil.  
Synthesized according to Procedure E, employing 4’-bromoacetophenone as the coupling 
partner. After work-up, the residue was purified via flash chromatography (15-80% 
EtOAc/Hex) to give 191a (30 mg, 0.083 mmol, 41%) and unreacted 191 (10 mg, 0.041 mmol, 
10%).  
191a: 1H NMR (300 MHz, CDCl3): δ 8.20 (s, 1H), 8.01 (s, 1H), 7.92 (t, 2H, J = 8.3 Hz), 7.71 
(d, 2H, J = 8.0 Hz), 7.61-7.49 (m, 3H), 7.33 (d, 1H, J = 9.2 Hz), 7.29-7.18 (m, 3H), 6.52 (dd, 
1H, J = 8.1, 7.2 Hz), 6.16 (t, 1H, J = 6.5 Hz), 2.48 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3): 
δ 197.8, 145.4, 138.0, 135.7, 133.8, 132.9, 132.4, 129.7, 128.5 (2), 128.3, 128.2, 127.6, 127.3, 
126.7, 120.8, 120.2, 118.8, 118.3, 112.5, 26.7 ppm. FTIR (cm-1) (neat): 2938, 2865, 1677, 
1603, 1403, 1264, 1055, 1010. HRMS (ESI, Pos): calcd for C25H19N2O [M+H]+: 363.1492, 
found 363.1509 m/z. 
191b: 1H NMR (300 MHz, CDCl3): δ 8.10 (s, 1H), 8.05 (d, 1H, J = 8.0 Hz), 7.90 (d, 1H, J = 
8.0 Hz), 7.77-7.70 (m, 3H), 7.70-7.60 (m, 2H), 7.59-7.47 (m, 2H), 7.32-7.17 (m, 5H), 7.08 (d, 
1H, J = 7.7 Hz), 6.51 (t, 1H, J = 7.5 Hz), 6.32-6.21 (m, 1H), 2.57 (s, 3H), 2.52 (s, 3H) ppm.  
13C NMR (125 MHz, CDCl3): δ 197.9 (2), 145.3, 143.2, 142.6, 139.5, 136.0, 135.7, 135.2, 
134.1, 131.7, 131.4, 129.6, 129.5, 129.1, 128.8, 128.6, 128.1, 127.8, 127.6, 127.4, 126.7, 
120.2, 119.7, 118.4, 118.3, 112.7, 26.7 (2) ppm. FTIR (cm-1) (neat): 2938, 2843, 1681, 1604, 
1455, 1357, 1266, 1055, 1014. HRMS (ESI, Pos): calcd for C33H25N2O2 [M+H]+: 481.1910, 
found 481.1933 m/z. 
 
1-(4-(1-(imidazo[1,5-a]pyridin-3-yl)naphthalen-2-yl)phenyl)ethanone (192a) and 1-(4-(1-
(1-(4-acetylphenyl)imidazo[1,5-a]pyridin-3-yl)naphthalen-2-yl)phenyl)ethanone (192b): 
Synthesized according to Procedure D, employing 4’-bromoacetophenone as the coupling 
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partner. After work-up, the residue was purified via flash chromatography (20-80% 
EtOAc/Hex) to give 192a (83 mg, 0.228 mmol, 57%) as a green solid and 192b (36 mg, 0.075 
mmol, 19%) as a thick brown oil. Structure of 192b was confirmed by HMBC, COSY and 
NOESY experiments on a 700 MHz spectrometer. 
192a: mp = 171-174 °C. 1H NMR (400 MHz, CDCl3): δ 8.09 (d, 1H, J = 8.4 Hz), 7.96 (d, 1H, 
J = 7.9 Hz), 7.71 (d, 2H, J = 8.2 Hz), 7.67 (d, 1H, J = 8.6 Hz), 7.64 (s, 1H), 7.61 (d, 1H, J = 
8.4 Hz), 7.55 (t, 1H, J = 7.4 Hz), 7.46 (t, 1H, J = 7.4 Hz), 7.40 (d, 1H, J = 9.2 Hz), 7.21 (d, 
2H, J = 8.2 Hz), 7.12 (d, 1H, J = 7.1 Hz), 6.57 (dd, 1H, J = 9.0, 6.4 Hz), 6.20 (t, 1H, J = 6.8 
Hz), 2.49 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ 197.8, 145.7, 139.9, 135.6, 135.0, 
133.7, 133.4, 130.6, 130.4, 128.8, 128.2 (2), 127.6, 127.4, 126.9, 126.3, 125.4, 120.9, 120.2, 
118.7, 118.3, 112.5, 26.7 ppm. FTIR (cm-1) (neat): 2972, 2865, 1678, 1601, 1357, 1261, 1054, 
1013. HRMS (ESI, Pos): calcd for C25H19N2O [M+H]+: 363.1492, found 363.1496 m/z. 
192b: 1H NMR (700 MHz, CDCl3): δ 8.16 (d, 1H, J = 8.5 Hz), 8.02 (dd, 1H, J = 8.2, 1.2 Hz), 
7.65-7.61 (m, 3H), 7.58 (dd, 1H, J = 8.1, 7.2 Hz), 7.55 (dd, 1H, J = 8.0, 1.9 Hz), 7.32 (dd, 1H, 
J = 7.0, 1.2 Hz), 7.12 (dd, 1H, J = 8.0, 1.7 Hz), 7.08 (dd, 1H, J = 8.0, 1.9 Hz), 7.03 (dd, 1H, J 
= 7.0, 1.0 Hz), 6.95 (d, 2H, J = 8.3 Hz), 6.93-6.91 (m, 2H), 6.71 (dd, 1H, J = 8.0, 1.8 Hz), 6.45 
(dd, 1H, J = 9.1, 6.3 Hz), 6.34-6.28 (m, 1H) 2.46 (s, 3H), 2.40 (s, 3H) ppm. 13C NMR (175 
MHz, CDCl3): δ 197.8, 197.7, 146.1, 145.9, 142.9, 139.5, 135.3, 135.2, 134.6, 134.1, 131.7, 
131.5, 131.3, 129.5, 129.1 (2), 128.5, 127.9 (2), 126.8, 126.1, 126.0, 125.5, 124.7, 120.5, 
120.0, 118.3, 117.8, 112.8, 26.7, 26.6 ppm. FTIR (cm-1) (neat): 2922, 2865, 1675, 1601, 1356, 
1264, 1056, 1014. HRMS (ESI, Pos): calcd for C33H25N2O2 [M+H]+: 481.1910 m/z, found 
481.1916 m/z. 
 
3-(4-methyl-4'-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)imidazo[1,5-a]pyridine (186d): 
Synthesized according to Procedure D, employing 4-trifluoromethylbromebenzene as the 
coupling partner. After work-up, the residue was purified via flash chromatography (10-80% 
EtOAc/Hex) to give 186d (84 mg, 0.238 mmol, 60%) as an off-white solid. Traces of a dimer 
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188 were observed by LC-MS analysis. mp = 120-122 °C. 1H NMR (300 MHz, CDCl3): δ 
7.54 (dd, 1H, J = 1.2, 0.6 Hz), 7.51 (d, 1H, J = 0.8 Hz), 7.47-7.43 (m, 1H), 7.42-7.38 (m, 1H), 
7.38-7.31 (m, 3H), 7.18 (dq, 1H, J = 7.2, 1.0 Hz), 7.14 (d, 2H, J 8.0 Hz), 6.53 (ddd, 1H, J = 
9.2, 6.4, 0.9 Hz), 6.16 (ddd, 1H, J = 7.3, 6.3, 1.2 Hz), 2.46 (s, 3H) ppm. 19F NMR (282 MHz, 
CDCl3): δ -62.6 ppm. 13C NMR (75 MHz, CDCl3): δ 144.2, 138.9, 137.5, 137.4, 133.0, 130.8, 
130.7, 130.2, 129.2 (q, JC-F = 32.5 Hz), 128.6, 128.4, 125.3 (q, JC-F = 3.6 Hz), 123.1 (q, JC-F = 
272.0 Hz), 120.8, 120.2, 118.6, 118.2, 112.3, 21.1 ppm. FTIR (cm-1) (neat): 2939, 2865, 1323, 
1164, 1121, 1056, 1015, 851. HRMS (ESI, Pos): calcd for C21H16F3N2 [M+H]+: 353.1261, 
found 353.1269 m/z. 
 
(2'-(imidazo[1,5-a]pyridin-3-yl)-4'-methyl-[1,1'-biphenyl]-4-yl)(phenyl)methanone (186f): 
Synthesized according to Procedure D, employing 4’-bromobenzophenone as the coupling 
partner. After work-up, the residue was purified via flash chromatography (10-80% 
EtOAc/Hex) to give 186f (57.5 mg, 0.148 mmol, 37%) as a brown oil, a mixture of 186f and 
186g (23 mg, 4:1, 10% 186f) and 188 (15 mg, 18%). 1H NMR (400 MHz, CDCl3): δ 7.66-7.59 
(m, 2H), 7.59-7.48 (m, 6H), 7.42 (d, 3H, J = 6.3 Hz), 7.36 (d, 1H, J = 8.9 Hz), 7.19 (d, 1H, J = 
6.8 Hz), 7.13 (d, 2H, J = 8.3 Hz), 6.55 (t, 1H, J = 8.1 Hz), 6.16 (t, 1H, J = 7.1 Hz), 2.47 (s, 
3H) ppm. 13C NMR (75 MHz, CDCl3): δ 196.4, 144.7, 138.9, 137.7, 137.6, 135.8, 133.0, 
132.4, 130.8, 130.7, 130.2, 130.0, 128.6, 128.3, 127.9, 121.0, 120.2, 118.6, 118.2, 112.2, 21.2 
ppm. FTIR (cm-1) (neat): 2972, 1654, 1602, 1276, 1056, 1014. HRMS (ESI, Pos): calcd for 
C27H12N2O [M+H]+: 389.1648, found 389.1657 m/z. 
N N
Me
CO2Et
 
ethyl 2'-(imidazo[1,5-a]pyridin-3-yl)-4'-methyl-[1,1'-biphenyl]-3-carboxylate (186h): 
Synthesized according to Procedure D, employing ethyl-3-bromobenzoate as the coupling 
partner. After work-up, the residue was purified via flash chromatography (15-80% 
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EtOAc/Hex) to give 186h (68 mg, 0.191 mmol, 48%, containing traces of MesCO2H) as a 
thick yellow oil and dimer 188 (17 mg, 0.041 mmol, 20%). Compound 186h was further 
washed with saturated aqueous K2CO3 to remove traces of MesCO2H. 1H NMR (300 MHz, 
CDCl3): δ 7.89 (d, 1H, J = 1.6 Hz), 7.76 (dt, 1H, J = 7.1, 1.6 Hz), 7.56-7.45 (m, 3H), 7.38 (d, 
1H, 7.9 Hz), 7.30 (d, 1H, J = 9.1 Hz), 7.15 (d, 1H, J = 7.1 Hz), 7.11-7.01 (m, 2H), 6.48 (dd, 
1H, J = 9.1, 6.3 Hz), 6.11 (td, 1H, J = 7.2, 1.0 Hz), 4.29 (q, 2H, J = 7.1 Hz), 2.44 (s, 3H), 1.33 
(t, 3H, J = 7.1 Hz) ppm. 13C NMR (125 MHz, CDCl3): δ 166.4, 140.7, 138.4, 137.7 (2), 133.0, 
132.3, 130.8 (2), 130.6, 130.1, 129.1, 128.5, 128.3, 128.2, 121.0, 120.1, 118.5, 118.1, 112.2, 
61.0, 21.1, 14.4 ppm. FTIR (cm-1) (neat): 2938, 2844, 1714, 1354, 1233, 1055, 1014, 730. 
HRMS (ESI, Pos): calcd for C23H21N2O2 [M+H]+: 357.1598, found 357.1609 m/z. 
 
3-(2-(thiophen-2-yl)-5-(trifluoromethyl)phenyl)imidazo[1,5-a]pyridine (187c): 
Synthesized according to Procedure D, employing 2-bromothiophene as the coupling partner. 
After work-up, the residue was purified via flash chromatography (10-80% EtOAc/Hex) to 
give 187c (76 mg, 0.221 mmol, 55%) as a thick yellow oil and a mixture of 187c and 187d (40 
mg, containing 22% 187c and 6% 187d). However, compound 187d could not be separated 
and thus not characterized. 1H NMR (300 MHz, CDCl3): δ 7.94 (s, 1H), 7.84-7.72 (m, 2H), 
7.62 (s, 1H), 7.44 (d, 1H, J = 9.2 Hz), 7.21 (dd, 1H, J = 7.2, 0.7 Hz), 7.16 (dd, 1H, J = 5.1, 1.1 
Hz), 6.79 (dd, 1H, J = 5.1, 3.7 Hz), 6.69-6.58 (m, 2H), 6.29 (td, 1H, J = 7.5, 1.0 Hz) ppm. 19F 
NMR (282 MHz, CDCl3): δ -64.02 ppm. 13C NMR (75 MHz, CDCl3): δ 140.1, 138.0 (m), 
137.7, 131.2, 130.3 (q, JC-F = 33.0 Hz), 130.2, 130.0 (q, JC-F = 3.8 Hz), 128.8, 127.8, 127.6, 
126.9, 126.6 (q, JC-F = 3.6 Hz), 125.7 (q, JC-F = 272.4 Hz), 120.9, 120.5, 119.2, 118.3, 112.9 
ppm. FTIR (cm-1) (neat): 2972, 2865, 1321, 1119, 1056, 1004, 696. HRMS (ESI, Pos): calcd 
for C18H12 F3N2S [M+H]+: 345.0668, found 345.0668 m/z. 
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3-(2-(1-methyl-1H-indol-5-yl)-5-(trifluoromethyl)phenyl)imidazo[1,5-a]pyridine (187e): 
Synthesized according to Procedure D, employing 5-bromo-1-methyl-1H-indole as the 
coupling partner. After work-up, the residue was purified via flash chromatography (10-80% 
EtOAc/Hex) to give 187e (127 mg, 0.324 mmol, 81%) as an off-white solid. Traces of the 
corresponding diarylated imidazopyridine 187f were also observed by LC-MS. mp = 142-144 
°C. 1H NMR (400 MHz, CDCl3): δ 8.00 (s, 1H), 7.79 (dd, 1H, J = 8.2, 1.3 Hz), 7.73 (d, 1H, J 
= 8.1 Hz), 7.57 (s, 1H), 7.50 (d, 1H, J = 1.0 Hz), 7.30 (dd, 1H, J = 9.1, 1.0 Hz), 7.15 (dd, 1H, J 
= 7.2, 0.9 Hz), 7.01 (d, 1H, J = 8.6 Hz), 6.97 (d, 1H, J = 3.1 Hz), 6.82 (dd, 1H, J = 8.6, 1.6 
Hz), 6.44 (ddd, 1H, J = 9.1, 6.4, 0.8 Hz), 6.37 (dd, 1H, J = 3.1, 0.7 Hz), 6.03 (td, 1H, J = 6.8, 
1.0 Hz), 3.66 (s, 3H) ppm. 19F NMR (376 MHz, CDCl3): δ -62.3 ppm. 13C NMR (100 MHz, 
CDCl3): δ 146.2, 137.2, 136.3, 131.3, 130.8, 130.4, 129.7 (q, JC-F = 3.8 Hz), 129.6, 129.5, 
129.4 (q, JC-F = 33.0 Hz), 128.8, 126.2 (q, JC-F = 3.2 Hz), 125.6 (q, JC-F = 272.3 Hz), 121.6, 
121.1, 120.7, 120.4, 118.7, 117.9, 112.1, 109.4, 101.5, 32.9 ppm. FTIR (cm-1) (neat): 2967, 
2865, 1321, 1168, 1056, 1006. HRMS (ESI, Pos): calcd for C23H16F3N3 [M+H]+: 392.1369, 
found 392.1383 m/z. 
 
3-(4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)imidazo[1,5-a]pyridine (187g): Synthesized 
according to Procedure D, employing bromobenzene as the coupling partner. After work-up, 
the residue was purified via flash chromatography (10-50% EtOAc/Hex) to give 187g (120 
mg, 0.355 mmol, 89%) as a thick brown oil. The corresponding diarylated imidazopyridine 
187h was not observed. 1H NMR (400 MHz, CDCl3): δ 8.01 (s, 1H), 7.80 (d, 1H, J = 8.1 Hz), 
7.67 (d, 1H, J = 8.1 Hz), 7.55 (s, 1H), 7.33 (d, 1H, J = 9.1 Hz), 7.18-6.98 (m, 6H), 6.53 (dd, 
1H, J = 8.3, 7.2 Hz), 6.19-6.05 (m, 1H) ppm. 19F NMR (376 MHz, CDCl3): δ -62.4 ppm. 13C 
NMR (100 MHz, CDCl3): δ 144.8, 139.1, 136.4, 130.9, 130.8, 130.4 (q, JC-F = 32.9 Hz), 129.6, 
129.5 (q, JC-F = 3.8 Hz), 128.7, 128.1, 127.9, 126.4 (q, JC-F = 3.8 Hz), 125.4 (q, JC-F = 272.1 
Hz), 120.8, 120.6, 118.8, 118.0, 112.3 ppm. FTIR (cm-1) (neat): 2972, 2865, 1356, 1121, 1055, 
1005, 729. HRMS (ESI, Pos): calcd for C20H14 F3N2 [M+H]+: 339.1104, found 339.1096 m/z. 
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3-(3'-methyl-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)imidazo[1,5-a]pyridine (187i): 
Synthesized according to Procedure D, employing 3-chlorotoluene as the coupling partner. 
After work-up, the residue was purified via flash chromatography (10-50% EtOAc/Hex) to 
give 187i (108 mg, 0.306 mmol, 77%) as a thick brown oil. The corresponding diarylated 
imidazopyridine was not observed, but traces of an imidazopyridine dimer were observed by 
LC-MS. 1H NMR (400 MHz, CDCl3): δ 8.01 (s, 1H), 7.79 (d, 1H, J = 9.1 Hz), 7.67 (d, 1H, J = 
8.2 Hz), 7.55 (s, 1H), 7.34 (d, 1H, J = 9.2 Hz), 7.16 (d, 1H, J = 7.2 Hz), 7.13-7.07 (m, 2H), 
7.05-6.92 (m, 2H), 6.54 (dd, 1H, J = 8.8, 6.7 Hz), 6.14 (t, 1H, J = 6.8 Hz), 2.14 (s, 3H) ppm. 
19F NMR (376 MHz, CDCl3): δ -40.4 ppm. 13C NMR (100 MHz, CDCl3): δ 144.9, 139.0, 
138.4, 136.6, 130.9, 130.7, 130.2 (q, JC-F = 33.1 Hz), 129.6, 129.5 (q, JC-F = 3.8 Hz), 128.8, 
128.6, 128.5, 126.3 (q, JC-F = 3.9 Hz), 125.4 (q, JC-F = 272.4 Hz), 125.0, 120.9, 120.5, 118.8, 
118.0, 112.2, 21.3 ppm. FTIR (cm-1) (neat): 2972, 2865, 1321, 1121, 1056, 1005. HRMS (ESI, 
Pos): calcd for C21H15 F3N2 [M+H]+: 353.1260, found 353.1274 m/z. 
 
3-(5-(tert-butyl)-4'-fluoro-[1,1'-biphenyl]-2-yl)imidazo[1,5-a]pyridine (167c) and 3-(5'-
(tert-butyl)-4,4''-difluoro-[1,1':3',1''-terphenyl]-2'-yl)imidazo[1,5-a]pyridine (167d): 
Synthesized according to Procedure D, employing 4-bromofluorobenzene as the coupling 
partner. After work-up, the residue was purified by flash chromatography (20-80% 
EtOAc/Hex) to give 167c (65 mg, 0.189 mmol, 47%) as an off-white solid and 167d (37 mg, 
0.0844 mmol, 21%) as a green solid. 
167c: mp = 194-197 °C. 1H NMR (500 MHz, CDCl3): δ 7.61 (d, 1H, J = 8.0 Hz), 7.55-7.49 
(m, 3H), 7.36-7.31 (m, 1H), 7.21 (dd, 1H, J = 7.2, 1.0 Hz), 7.06-7.00 (m, 2H), 6.85-6.78 (m, 
2H), 6.53 (ddd, 1H, J = 9.2, 6.4, 0.7 Hz), 6.16 (td, 1H, J = 6.8, 1.1 Hz), 1.41 (s, 9H) ppm. 19F 
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NMR (376 MHz, CDCl3): δ -115.4 (m) ppm. 13C NMR (125 MHz, CDCl3): δ 163.1 (d, JC-F = 
246.6 Hz), 153.1, 140.3, 137.9, 137.2 (d, JC-F = 3.3 Hz), 132.0, 130.5, 129.8 (d, JC-F = 8.3 Hz), 
127.2, 125.9, 125.2, 121.2, 120.1, 118.5, 118.1, 115.4 (d, JC-F = 21.4 Hz), 112.0, 35.0, 31.4 
ppm. FTIR (cm-1) (neat): 2951, 2865, 1438, 1159, 1055, 838. HRMS (ESI, Pos): calcd for 
C23H22FN2 [M+H]+: 345.1716, found 345.1760 m/z.  
167d: Mp = 156-158 °C. 1H NMR (500 MHz, CDCl3): δ 7.50 (s, 2H), 7.33-7.31 (m, 1H), 
7.28-7.23 (m, 1H), 7.21 (dd, 1H, J = 7.2, 1.0 Hz), 7.03-6.96 (m, 4H), 6.83-6.75 (m, 4H), 6.55-
6.49 (m, 1H), 6.26-6.20 (m, 1H), 1.44 (s, 9H) ppm. 19F NMR (376 MHz, CDCl3): δ -115.7- -
115.6 (m) ppm. 13C NMR (125 MHz, CDCl3): δ 163.1 (d, JC-F = 246.5 Hz), 153.5, 143.2, 
137.1 (d, JC-F = 3.0 Hz), 135.7, 130.1 (d, JC-F = 8.0 Hz), 129.5, 126.8, 124.1, 120.6, 119.2, 
118.5, 118.2, 115.2 (d, JC-F = 21.3 Hz), 112.6, 35.2, 31.5 ppm. FTIR (cm-1) (neat): 2965, 2843, 
1505, 1222, 1055, 836. HRMS (ESI, Pos): calcd for C29H25F2N2 [M+H]+: 439.1980, found 
439.1998 m/z. 
 
5'-(tert-butyl)-N,N-diethyl-2'-(imidazo[1,5-a]pyridin-3-yl)-[1,1'-biphenyl]-4-carboxamide 
(167e) and 5'-(tert-butyl)-N4,N4,N4'',N4''-tetraethyl-2'-(imidazo[1,5-a]pyridin-3-yl)-
[1,1':3',1''-terphenyl]-4,4''-dicarboxamide (167f): Synthesized according to Procedure D, 
employing 4-bromo-N,N-diethylbenzamide as the coupling partner. After work-up, the residue 
was purified in flash chromatography (25-80% EtOAc/Hex) to give 167e (117 mg, 0.275 
mmol, 69%) as an off-white solid and 167f (22 mg, 0.0367 mmol, 9%) as an off-white solid. 
167e: mp = 144-146 °C. 1H NMR (500 MHz, CDCl3): δ 7.67-7.61 (m, 1H), 7.55 (dq, 2H, J = 
4.3, 2.1 Hz), 7.51 (s, 1H), 7.31 (dt, 1H, J = 9.2, 1.1 Hz), 7.16 (dq, 1H, J = 7.2, 1.0 Hz), 7.13-
7.05 (m, 4H), 6.47 (ddd, 1H, J = 9.1, 6.3, 0.8 Hz), 6.10 (td, 1H, J = 6.8, 1.1 Hz), 3.46 (br. s, 
2H), 2.99 (br. s, 2H), 1.41 (s, 9H), 1.17 (br. s, 3H), 0.97 (br. s, 3H) ppm. 13C NMR (125 MHz, 
CDCl3): δ 171.0, 153.1, 142.0, 140.4, 137.9, 135.9, 132.0, 130.5, 128.1, 127.0, 126.4, 125.9, 
125.5, 121.4, 120.1, 118.2, 118.1, 111.7, 43.2, 39.3, 35.0, 31.4, 14.2, 13.0 ppm. FTIR (cm-1) 
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(neat): 2938, 2866, 1628, 1357, 1056, 1014, 751. HRMS (ESI, Pos): calcd for C28H32N3O 
[M+H]+: 426.254, found 426.2554 m/z. 
167f: mp = 80-84 °C. 1H NMR (500 MHz, CDCl3): δ 7.55 (s, 2H), 7.27-7.24 (m, 1H), 7.24-
7.18 (m, 2H), 7.13-7.02 (m, 8H), 6.44 (dd, 1H, J = 9.7, 6.4 Hz), 6.21-6.12 (m, 1H), 3.44 (br. s, 
4H), 3.05 (br. s, 4H), 1.45 (s, 9H), 1.18 (br. s, 6H), 0.99 (br. s, 6H) ppm. 13C NMR (125 MHz, 
CDCl3): δ 171.2, 153.4, 143.5, 142.1, 135.8, 135.7, 129.5, 128.5, 126.8, 126.0, 124.4, 120.8, 
119.6, 118.0 (2), 112.0, 43.2, 39.4, 35.2, 31.5, 14.3, 13.0 ppm. FTIR (cm-1) (neat) 2938, 2866, 
1624, 1426, 1056, 1014, 749. HRMS (ESI, Pos): calcd for C39H45N4O2 [M+H]+: 601.3537, 
found 601.3533 m/z. 
 
3-(5-(tert-butyl)-3'-methoxy-[1,1'-biphenyl]-2-yl)imidazo[1,5-a]pyridine (167g) and 3-(5'-
(tert-butyl)-3,3''-dimethoxy-[1,1':3',1''-terphenyl]-2'-yl)imidazo[1,5-a]pyridine (167h): 
Synthesized according to Procedure D, employing 3-bromoanisole as the coupling partner. 
After work-up, the residue was purified by flash chromatography (20-80% EtOAc/Hex) to 
give a mix of 167g and 167h (101 mg) consisting of 167g (0.190 mmol, 47%) and 167h 
(0.0722 mmol, 18%). 167h could not be separated from 167g and could not be characterized. 
Synthesized according to Procedure E, employing 3-bromoanisole (0.206 mmol) as the 
coupling partner. After work-up, the residue was purified via flash chromatography (15-80% 
EtOAc/Hex) to give 167g (71 mg, 0.199 mmol, 97%) and unreacted 167 (25 mg, 0.0501 
mmol, 25%). Traces of the imidazopyridine dimer were also observed by LC-MS.  
167g: 1H NMR (500 MHz, CDCl3): δ 7.63 (d, 1H, J = 8.1 Hz), 7.60-7.51 (m, 3H), 7.32 (d, 1H, 
J = 9.2 Hz), 7.21 (d, 1H, J = 7.2 Hz), 7.08 (t, 1H, J = 8.0 Hz), 6.78 (d, 1H, J = 7.5 Hz), 6.66 
(dd, 1H, J = 8.3, 2.5 Hz), 6.56-6.47 (m, 2H), 6.12 (t, 1H, J = 6.7 Hz), 3.49 (s, 3H), 1.42 (s, 9H) 
ppm. 13C NMR (125 MHz, CDCl3): δ 159.4, 153.0, 142.5, 141.0, 138.2, 132.0, 130.5, 129.5, 
127.1, 125.9, 125.2, 121.4, 120.6, 119.8, 118.5, 117.9, 113.7, 112.8, 111.8, 55.2, 35.0, 31.4 
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ppm. FTIR (cm-1) (neat): 2966, 2844, 1356, 1179, 1054, 730. HRMS (ESI, Pos): calcd for 
C24H25N2O [M+H]+: 357.1961, found 357.1969 m/z. 
 
3-(3',5'-difluoro-5-methoxy-[1,1'-biphenyl]-2-yl)imidazo[1,5-a]pyridine (165c) and 3-
(3,3'',5,5''-tetrafluoro-5'-methoxy-[1,1':3',1''-terphenyl]-2'-yl)imidazo[1,5-a]pyridine 
(165d): Synthesized according to Procedure D, employing 1-bromo-3,5-difluorobenzene as 
the coupling partner. After work-up, the residue was purified in flash chromatography (5-80% 
EtOAc/Hex) to give 165c (22 mg, 0.025 mmol, 16%) as a yellow oil and 165d (72 mg, 0.161 
mmol, 40%) as a white solid. 
165c: 1H NMR (500 MHz, CDCl3): δ 7.60 (d, 1H, J = 8.5 Hz), 7.50 (d, 1H, J = 0.7 Hz), 7.36 
(dt, 1H, J = 9.2, 1.1 Hz), 7.25-7.21 (m, 1H), 7.08 (dd, 1H, J = 8.5, 2.7 Hz), 7.04 (d, 1H, J = 2.6 
Hz), 6.61-6.53 (m, 4H), 6.25 (ddd, 1H, J = 7.3, 6.3, 1.2 Hz), 3.92 (s, 3H) ppm. 19F NMR (470 
MHz, CDCl3): δ -109.7 (d). 13C NMR (125 MHz, CDCl3): δ 163.7 (d, JC-F = 13.0 Hz), 161.7 
(d, JC-F = 13.0 Hz), 160.8, 143.7 (t, JC-F = 9.8 Hz), 141.0 (d, JC-F = 2.4 Hz), 136.8, 133.8, 
130.6, 121.1, 120.8, 120.1, 118.5, 118.4, 112.4, 111.2 (d, JC-F = 26.1 Hz), 111.1 (d, JC-F = 13.5 
Hz), 102.9 (t, JC-F = 25.2 Hz), 55.7 ppm. FTIR (cm-1) (neat): 2922, 1748, 1622, 1592, 1433, 
1356, 1056. HRMS (ESI, Pos): calcd for C20H15F2N2O [M+H]+: 337.1147, found 337.1150 
m/z. 
165d: mp = 203-204 °C. 1H NMR (400 MHz, acetone-d6): δ 7.49-7.37 (m, 2H), 7.32 (d, 1H, J 
= 0.7 Hz), 7.25 (s, 2H), 6.85-6.70 (m, 6H), 6.61 (ddd, 1H, J = 9.1, 6.4, 0.8 Hz), 6.47-6.36 (m, 
1H), 4.04 (s, 3H) ppm. 19F NMR (282 MHz, acetone-d6): δ 65.7 (m) ppm. 13C NMR (75 MHz, 
CDCl3): δ 164.7 (d, JC-F = 13.4 Hz), 161.6 (d, JC-F = 13.2 Hz), 161.4, 144.9 (t, JC-F = 10.0 Hz), 
144.7 (t, JC-F = 2.3 Hz), 135.1, 131.0, 121.6, 120.5, 120.2, 119.4, 118.7, 116.4, 113.4, 112.7 
(d, JC-F = 25.8 Hz), 112.6 (d, JC-F = 9.3 Hz), 103.2 (t, JC-F = 25.8 Hz), 56.2 ppm. FTIR (cm-1) 
(neat): 2939, 1618, 1455, 1116, 1055, 1032, 1013. HRMS (ESI, Pos): calcd for C26H17F4N2O 
[M+H]+: 449.1272, found 449.1284 m/z. 
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3-(4-methoxy-2-(thiophen-2-yl)phenyl)imidazo[1,5-a]pyridine (165e) and 3-(4-methoxy-
2,6-di(thiophen-2-yl)phenyl)imidazo[1,5-a]pyridine (165f): Synthesized according to 
Procedure D, employing 2-bromothiophene as the coupling partner. After work-up, the 
residue was purified in flash chromatography (20-100% EtOAc/Hex, RediSep Gold column 12 
g) to give 165e (12 mg, 0.039 mmol, 10%) as a yellow oil and 165f (34 mg, 0.084 mmol, 
22%) as a green solid. 
165e: 1H NMR (300 MHz, CDCl3): δ 7.59-7.51 (m, 2H), 7.40 (dt, 1H, J = 9.2, 1.1 Hz), 7.28-
7.23 (m, 1H), 7.20 (d, 1H, J = 5.3 Hz), 7.10 (dd, 1H, J = 5.1, 1.2 Hz), 7.01 (dd, 1H, J = 8.5, 
2.7 Hz), 6.76 (dd, 1H, J = 5.1, 3.6 Hz), 6.63-6.53 (m, 2H), 6.23 (td, 1H, J = 6.8, 1.2 Hz), 3.92 
(s, 3H) ppm. 13C NMR (75 MHz, CDCl3): δ 160.7, 141.7, 137.2, 136.1, 134.1, 130.7, 127.5, 
126.3, 125.9, 121.3, 120.8, 119.8, 118.6, 118.2, 115.0, 113.8, 112.2, 55.7 ppm. FTIR (cm-1) 
(neat): 2922, 2844, 1456, 1346, 1055, 1013. HRMS (ESI, Pos): calcd for C18H15N2OS 
[M+H]+: 307.0900, found 307.0910 m/z. 
165f: mp = 171-172 °C. 1H NMR (300 MHz, CDCl3): δ 7.51 (s, 1H), 7.39 (d, 1H, J = 9.2 Hz), 
7.28-7.23 (m, 1H), 7.07 (dd, 2H, J = 5.1, 0.6 Hz), 6.77 (dd, 2H, J = 4.9, 3.8 Hz), 6.65 (dd, 2H, 
J = 3.6, 0.6 Hz), 659 (dd, 1H, J = 9.1, 6.4 Hz), 6.34-6.24 (m, 1H), 3.95 (s, 3H) ppm. 13C NMR 
(75 MHz, CDCl3): δ 160.5, 141.6, 139.0, 134.6, 130.4, 127.1, 126.4 (2), 121.0, 119.8, 118.8, 
118.6, 118.2, 114.9, 112.5, 55.7 ppm. FTIR (cm-1) (neat): 2938, 2865, 1455, 1347, 1055, 1014. 
HRMS (ESI, Pos): calcd for C22H16N2OS2 [M+H]+: 389.0777, found 389.0769 m/z. 
 
(2'-(imidazo[1,5-a]pyridin-3-yl)-[1,1'-biphenyl]-4-yl)(phenyl)methanone (164c) and (2'-
(imidazo[1,5-a]pyridin-3-yl)-[1,1':3',1''-terphenyl]-4,4''-diyl)bis(phenylmethanone) 
(164d): Synthesized according to Procedure D, employing 4-bromobenzophenone (3 equiv) 
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as the coupling partner. After work-up, the residue was purified by flash chromatography (15-
100% EtOAc/Hex) to give 164d (148 mg) as a thick brown oil, 164c (10 mg) as a thick dark 
oil and a mix of 164c and 164d (40 mg, 1:6), to a total of 164c (0.0374 mmol, 9%) and 164d 
(0.332 mmol, 83%). 
164c: 1H NMR (400 MHz, CDCl3): δ 7.75 (d, 1H, J = 7.0 Hz), 7.68-7.61 (m, 4 H), 7.61-7.53 
(m, 4H), 7.47-7.35 (m, 3H), 7.29-7.25 (m, 1H), 7.22 (d, 1H, J = 6.4 Hz), 7.16 (d, 2H, J = 8.1 
Hz), 6.57 (dd, 1H, J = 9.1, 6.3 Hz), 6.19 (t, 1H, J = 6.4 Hz) ppm. 13C NMR (175 MHz, 
CDCl3): δ 196.4, 144.7, 140.6, 137.7, 137.5, 136.1, 132.5 (2), 130.7, 130.3, 130.2, 130.1, 
130.0, 129.0, 128.8, 128.4, 128.0, 121.0, 120.4, 118.6, 118.2, 112.3 ppm. FTIR (cm-1) (neat): 
2865, 2844, 1656, 1602, 1277, 1055, 1013, 739, 701. HRMS (ESI, Pos): calcd for C26H16N2O 
[M+H]+: 375.1492, found 375.1481 m/z. 
164d: 1H NMR (400 MHz, CDCl3): δ 7.74-7.69 (m, 1H), 7.68-7.62 (m, 6H), 7.59-7.50 (m, 
6H), 7.47-7.38 (m, 4H), 7.33 (s, 1H), 7.28 (d, 1H, J = 9.3 Hz), 7.23 (d, 1H, J = 7.2 Hz), 7.13 
(d, 4H, J = 8.2 Hz), 6.52 (dd, 1H, J = 8.8, 6.4 Hz), 6.24 (td, 1H, J = 7.2, 0.9 Hz) ppm. 13C 
NMR (125 MHz, CDCl3): δ 196.3, 144.8, 143.6, 137.7, 136.0, 135.1, 132.4, 130.4, 130.0 (2), 
129.9, 129.8, 128.3 (2), 127.4, 120.3, 120.1, 118.4, 118.2, 112.6 ppm. FTIR (cm-1) (neat): 
2938, 2844, 1652, 1600, 1273, 1056, 696. HRMS (ESI, Pos): calcd for C39H27N2O2 [M+H]+: 
555.2067, found 555.2063 m/z. 
 
3-(4'-fluoro-[1,1'-biphenyl]-2-yl)imidazo[1,5-a]pyridine (164e) and 3-(4,4''-difluoro-
[1,1':3',1''-terphenyl]-2'-yl)imidazo[1,5-a]pyridine (164f): Synthesized according to 
Procedure D, employing 4-bromofluorobenzene (3 equiv) as the coupling partner. After 
work-up, the residue was purified by flash chromatography (20-80% EtOAc/Hex) to give 164e 
(19 mg, 0.0659 mmol, 16%) as a thick brown oil and 164f (85 mg, 0.220 mmol, 55%) as an 
off-white solid. 
164e: 1H NMR (500 MHz, CDCl3): δ 7.69 (dd, 1H, J = 7.5, 1.0 Hz), 7.60-7.48 (m, 4H), 7.35 
(dt, 1H, J = 9.2, 1.1 Hz), 7.18 (dd, 1H, J = 7.2, 1.0 Hz), 7.06-7.00 (m, 2H), 6.84-6.76 (m, 2H), 
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6.55 (ddd, 1H, J = 9.1, 6.4, 0.9 Hz), 6.17 (ddd, 1H, J = 7.3, 6.3, 1.2 Hz) ppm. 19F NMR (470 
MHz, CDCl3): δ – 115.1 (m) ppm. 13C NMR (125 MHz, CDCl3): δ 163.2, 161.2, 140.7, 137.7, 
136.5 (d, JC-F = 3.2 Hz), 132.4, 130.6, 130.2, 129.9, 129.8 (d, JC-F = 8.1 Hz), 128.8, 128.1, 
121.0, 118.6, 118.2, 115.4 (d, JC-F = 21.4 Hz), 112.2 ppm. FTIR (cm-1) (neat): 2938, 2865, 
1506, 1357, 1223, 1055, 1013, 762. HRMS (ESI, Pos): calcd for C19H14FN2 [M+H]+: 
289.1136, found 289.1129 m/z. 
164f: Mp = 171-172 °C. 1H NMR (300 MHz, CDCl3): δ 7.67-7.57 (m, 1H), 7.52  (s, 1H), 7.49 
(d, 1H, J = 1.0 Hz),  7.31 (s, 1H), 7.28-7.21 (m, 1H), 7.16 (dd, 1H, J = 7.2, 0.9 Hz), 7.03-6.92 
(m, 4H), 6.83-6.72 (m, 4H), 6.50 (ddd, 1H, J = 9.1, 6.4, 0.8 Hz), 6.21 (td, 1H, J = 7.3, 1.1 Hz) 
ppm. 19F NMR (282 MHz, CDCl3): δ – 115.4 (m) ppm. 13C NMR (125 MHz, CDCl3): δ 163.7, 
143.6, 136.6 (d, JC-F = 3.3 Hz), 135.6, 130.1, 130.0 (d, JC-F = 7.9 Hz), 129.6 (2), 127.4, 120.3, 
119.8, 118.3, 118.2, 115.0 (d, JC-F = 21.4 Hz), 112.4 ppm. FTIR (cm-1) (neat): 2938, 
28651346, 1223, 1055, 1013, 739. HRMS (ESI, Pos): calcd for C25H17F2N2 [M+H]+: 
383.1354, found: 383.1350 m/z. 
 
N,N-diethyl-2'-(imidazo[1,5-a]pyridin-3-yl)-[1,1'-biphenyl]-4-carboxamide (164g) and 
N4,N4,N4'',N4''-tetraethyl-2'-(imidazo[1,5-a]pyridin-3-yl)-[1,1':3',1''-terphenyl]-4,4''-
dicarboxamide (164h): Synthesized according to Procedure D, employing 4-bromo-N,N-
diethylbenzamide (3 equiv) as the coupling partner. After work-up, the residue was purified by 
flash chromatography (15-100% EtOAc/Hex) to give 164g (15 mg, 0.041 mmol, 10%) as a 
thick brown oil and 164h (93 mg, 0.171 mmol, 43%) as a thick green-brown oil. 
164g: 1H NMR (400 MHz, CDCl3): δ 7.73 (d, 1H, J = 7.0 Hz), 7.60-7.51 (m, 4H), 7.33 (d, 1H, 
J = 9.2 Hz), 7.17-7.04 (m, 5H), 6.49 (dd, 1H, J = 9.1, 6.3 Hz), 6.15-6.07 (m, 1H), 3.47 (br s, 
2H), 2.98 (br s, 2H), 1.18 (br s, 3H), 0.94 (br s, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ 
171.0, 141.4, 140.9, 137.8, 136.1, 132.4, 130.6, 130.0 (2), 128.9, 128.4, 128.1, 126.4, 121.2, 
120.3, 118.4, 118.1, 111.8, 43.2, 39.3, 14.2, 13.0 ppm. FTIR (cm-1) (neat): 2937, 2866, 1627, 
 205 
1427, 1055, 1012. HRMS (ESI, Pos): calcd for C24H23N3NaO [M+Na]+: 392.1733, found 
392.1749 m/z. 
164h: 1H NMR (400 MHz, CDCl3): δ 7.69-7.62 (m, 1H), 7.59-7.50 (m, 2H), 7.23-7.14 (m, 
1H), 7.12-7.06 (m, 4H), 7.06-7.00 (m, 4H), 6.46-6.42 (m, 1H), 6.22-6.14 (m, 1H), 3.46 (br s, 
4H), 3.01 (br 2, 4H), 1.17 (br s, 6H), 0.96 (br s, 6H) ppm. 13C NMR (75 MHz, CDCl3): δ 
171.0, 143.8, 141.4, 135.8, 135.5, 130.2, 129.6, 129.5, 128.4, 127.3, 126.0, 120.6, 119.7, 118.0 
(2), 112.1, 43.2, 39.4, 14.2, 13.0 ppm. FTIR (cm-1) (neat): 2938, 2844, 1620, 1425, 1287, 
1055, 1016. HRMS (ESI, Pos): calcd for C35H36N4NaO2 [M+Na]+: 567.2730, found 567.2727 
m/z. 
 
3-(4'-methyl-[1,1'-biphenyl]-2-yl)imidazo[1,5-a]pyridine (164i) and 3-(4,4''-dimethyl-
[1,1':3',1''-terphenyl]-2'-yl)imidazo[1,5-a]pyridine (164j): Synthesized according to 
Procedure D, employing 4-chlorotoluene (3 equiv) as the coupling partner. After work-up, 
the residue was purified by flash chromatography (10-60% EtOAc/Hex) to give 164i (36 mg, 
0.127 mmol, 32%) as a thick yellow oil and 164j (60 mg, 0.160 mmol, 40%) as an off-white 
solid. 
164i: 1H NMR (500 MHz, CDCl3): δ 7.67 (dt, 1H, J = 7.5, 1.0 Hz), 7.57-7.53 (m, 2H), 7.52 (d, 
1H, J = 0.7 Hz), 7.51-7.43 (m, 1H), 7.33 (dt, 1H, J = 9.1, 1.1 Hz), 7.22-7.12 (m, 1H), 6.97-
6.89 (m, 4H), 6.52 (ddd, 1H, J = 9.1, 6.3, 0.9 Hz), 6.41 (ddd, 1H, J =7.3, 6.3, 1.2 Hz), 2.21 (s, 
3H) ppm. 13C NMR (125 MHz, CDCl3): δ 141.7, 138.2, 137.6, 137.0, 132.4, 130.6, 130.2, 
129.8, 129.2, 128.7, 127.9, 127.7, 121.3, 120.0, 118.4, 118.0, 111.9, 21.1 ppm. FTIR (cm-1) 
(neat): 2949, 2844, 1507, 1356, 1055, 1009, 724. HRMS (ESI, Pos): calcd for C20H17N2 
[M+H]+: 285.1386, found 285.1400 m/z. 
164j: p = 158-159 °C. 1H NMR (300 MHz, CDCl3): δ 7.64-7.56 (m, 1H), 7.52 (s, 1H), 7.49 (d, 
1H, J = 1.3 Hz), 7.32 (s, 1H), 7.27-7.18 (m, 2H), 6.91 (s, 8H), 6.52-6.42 (m, 1H), 6.19 (td, 1H, 
J = 7.0, 1.1 Hz), 2.21 (s, 6H) ppm. 13C NMR (75 MHz, CDCl3): δ 144.5, 137.9, 136.6, 136.3, 
129.9, 129.4, 129.3, 128.7, 128.2, 127.1, 120.8, 119.5, 118.0, 117.9, 112.0, 21.1 ppm. FTIR 
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(cm-1) (neat): 2949, 2844, 1356, 1056, 1014, 792, 740. HRMS (ESI, Pos): calcd for C27H23N2 
[M+H]+: 375.1856, found 375.1868 m/z. 
 
N N
Me Me
N N
NN
 
3-(2',4-dimethyl-[1,1'-biphenyl]-2-yl)imidazo[1,5-a]pyridine (186c) and 3,3'-(4,4'-
dimethyl-[1,1'-biphenyl]-2,2'-diyl)diimidazo[1,5-a]pyridine (188): Synthesized according 
to Procedure D, employing 2-bromotoluene (1.24 equiv) as the coupling partner, except on a 
0.2 mmol scale. After work-up, the residue was purified by flash chromatography (15-100% 
EtOAc/Hex) to give 186c (16 mg, 0.054 mmol, 27%) as a dark oil and 188 (19 mg, 0.046 
mmol, 46%) as an off-white solid. 
186c: 1H NMR (500 MHz, CDCl3): δ 7.52 (dd, 1H, J = 1.2, 0.6 Hz), 7.43 (d, 1H, J = 0.8 Hz), 
7.37-7.33 (m, 2H), 7.33-7.30 (m, 1H), 7.28 (dt, 1H, J = 9.1, 1.2 Hz), 7.04-6.99 (m, 2H), 6.99-
6.90 (m, 2H), 6.52 (ddd, 1H, J = 9.1, 6.4, 0.9 Hz), 6.18 (ddd, 1H, J = 7.3, 6.3, 1.2 Hz), 2.46 (s, 
3H), 2.05 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3): δ 140.1, 138.9, 138.2, 137.6, 135.6, 
132.4, 131.1, 130.5, 130.3, 130.0, 129.9, 129.7, 127.3, 125.5, 121.4, 120.0, 118.3, 118.1, 
111.6, 21.2, 20.2 ppm. FTIR (cm-1) (neat): 2922, 2865, 1352, 1055, 1013, 725, 698. HRMS 
(ESI, Pos): calcd for C21H18N2 [M+H]+: 299.1543, found 299.1544 m/z. 
188: mp = 230-233 °C. 1H NMR (500 MHz, CDCl3): δ 7.86-7.76 (m, 1H), 7.29 (s, 1H), 7.28-
7.24 (m, 2H), 7.10-7.03 (m, 1H), 6.99 (d, 1H, J = 7.7 Hz), 6.55 (dd, 1H, J = 8.9, 6.4 Hz), 6.23 
(t, 1H, J = 6.6 Hz), 2.32 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3): δ 138.3, 137.6, 137.1, 
131.2, 131.0, 130.6, 130.0, 128.6, 122.0, 120.1, 118.5, 118.0, 112.0, 21.1 ppm. FTIR (cm-1) 
(neat): 2939, 2865, 1354, 1055, 1032, 1012, 748. HRMS (ESI, Pos): calcd for C28H22N4Na 
[M+Na]+: 437.1737, found 437.1758 m/z. 
Deuterium exchange experiments 
To a microwave vial (previously kept in an oven and cooled under argon) fit with a stir bar, 
the corresponding imidazopyridine (if solid, 0.2 mmol, 1.0 equiv) and 2,4,6-trimethylbenzoic 
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acid (0.06 mmol, 0.3 equiv) were added. The vial was then placed in a glove box where 
dichloro(p-cymene)ruthenium dimer (0.01 mmol, 0.05 equiv) and potassium carbonate (0.4 
mmol, 2.0 equiv) were added. The vial was crimped and taken out of the glove box. Toluene 
(dry, 0.9 mL) and deuterium oxide (0.1 mL) were added via syringe. The reaction was stirred 
at 130 °C for 15 h. Then, the reaction was allowed to cool to rt, and filtered over a pad of silica 
and celite, rinsing with EtOAc (15-20 mL). The reaction was flashed in 20% EtOAc/Hex on a 
small column. The product was analyzed by 1H NMR. The results are summarized in Schemes 
68 and 69 (Chapter 2). 
Competition experiments 
 
To a microwave vial (previously kept in an oven and cooled under argon) fit with a stir bar, 
the corresponding imidazopyridines, 3-(4-methoxyphenyl)imidazo[1,5-a]pyridine 165 and 3-
(4-(trifluoromethyl)phenyl)imidazo[1,5-a]pyridine 166 (0.2 mmol, 1.0 equiv each), and 2,4,6-
trimethylbenzoic acid (0.06 mmol, 0.3 equiv) were added. The vial was then placed in a glove 
box where dichloro(p-cymene)ruthenium dimer (0.01 mmol, 0.05 equiv) and potassium 
carbonate (0.4 mmol, 2.0 equiv) were added. The vial was crimped and taken out of the glove 
box. 4-Bromotoluene (0.2 mmol, 1.0 equiv), was added via syringe, followed by dry toluene 
(1 mL). The reaction was stirred at 130 °C for 15 h. Then, the reaction was allowed to cool to 
rt, and filtered over a pad of silica and celite, rinsing with EtOAc (15-20 mL). The organic 
layer was washed with a solution of saturated aqueous K2CO3 (15 mL), water (15 mL). The 
aqueous layer was extracted with EtOAc (2* 10 mL). The combined organic layers were 
washed with brine (10 mL), dried (Na2SO4) and concentrated in vacuo. The resulting residue 
was purified by flash chromatography in 15-100% EtOAc/Hex to provide 51 mg of a mixture 
of 166 and 166c (0.14:1) and 40 mg of a mixture of 165 and 165g (2:1). The estimated yields 
based on 1H NMR ratios of product versus starting material were: 166c 66% and 165g 26%.  
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To a microwave vial (previously kept in an oven and cooled under argon) fit with a stir bar, 3-
phenylimidazo[1,5-a]pyridine 164 (0.4 mmol, 1.0 equiv), 4-bromoacetophenone (0.6 mmol, 
1.5 equiv), and 2,4,6-trimethylbenzoic acid (0.12 mmol, 0.3 equiv) were added. The vial was 
then placed in a glove box where dichloro(p-cymene)ruthenium dimer (0.02 mmol, 0.05 
equiv) and potassium carbonate (0.8 mmol, 2.0 equiv) were added. The vial was crimped and 
taken out of the glove box. 4-Bromoanisole (0.6 mmol, 1.5 equiv), was added via syringe, 
followed by dry toluene (2 mL). The reaction was stirred at 130 °C for 15 h. Then, the reaction 
was allowed to cool to rt, and filtered over a pad of silica and celite, rinsing with EtOAc (15-
20 mL). The organic layer was washed with a solution of saturated aqueous K2CO3 (15 mL), 
water (15 mL). The aqueous layer was extracted with EtOAc (2*10 mL). The combined 
organic layers were washed with brine (10 mL), dried (Na2SO4) and concentrated in vacuo. 
The resulting residue was purified by flash chromatography in 15-100% EtOAc/Hex to 
provide a mixture of mono- and diarylated products. The estimated yields based on 1H NMR 
ratios are shown in the equation above.   
Experimental section of Chapter 3 
Part 1 
Synthesis of 2-bromoanilines 
The following 2-bromoanilines were obtained via bromination from their corresponding 
anilines according to literature procedure: 2-bromo-4-methylaniline,247 4-amino-3-
bromobenzaldehyde,247 2-bromo-4-(trifluoromethyl)aniline,248 4-amino-3-
bromobenzonitrile,248 2-bromo-4-chloroaniline,249 ethyl 4-amino-3-bromobenzoate,249 2-
bromo-3,4-dimethoxyaniline,250 and 2-bromo-4-methoxyaniline.250 
Synthesis of 2-bromoanilides 
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Procedure F: To a 0.1 M solution of the corresponding 2-bromoaniline (1.0 equiv) in THF, 
was added cyclopropanecarbonyl chloride (1.1 equiv) dropwise, forming a cloudy off-white 
solution. The mixture was stirred overnight (16 h) at ambient temperature. EtOAc (40 mL) 
was added and the solution was washed with saturated aqueous NaHCO3 (3x40 mL), and 
brine (2x40 mL). The combined organics were then dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo to give a white solid, which was used crude in the subsequent 
methylation step.  
The crude intermediate was dissolved in THF (0.1 M), cooled to 0 °C, where NaH (1.5 equiv) 
was added, forming a grey solution. After 15 minutes, MeI (7.0 equiv) was added dropwise. 
The reaction was allowed to warm up to rt and stirred overnight (16 h). The reaction was 
quenched with water (40 mL), and EtOAc (40 mL) was added. The layers were separated, and 
the aqueous layer was extracted with EtOAc (3x50 mL). The combined organics were washed 
with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give 
the desired product. The crude was then purified via column chromatography in the given 
solvent. 
 
N-(2-bromophenyl)-N-methylcyclopropanecarboxamide (219b): Synthesized according to 
Procedure F on a 14.4 mmol scale. The product was obtained as a brown oil in 90% yield 
(3.3 g, 13.0 mmol). The observed characterization data was consistent with that previously 
reported in the literature.251   
 
N-(2-bromo-4-methylphenyl)-N-methylcyclopropanecarboxamide (B1): Synthesized 
according to Procedure F on a 7.07 mmol scale and then purified via column chromatography 
(5% EtOAc/Hex) to give a brown oil in 65% yield (1.23 g, 4.60 mmol). 1H NMR (CDCl3, 400 
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MHz): δ 7.53 (s, 1H), 7.27 (d, 1H, J = 7.9 Hz), 7.23-7.21 (m, 1H), 3.20 (s, 3H), 2.40 (s, 3H), 
1.27-1.19 (m, 1H), 1.05-0.96 (m, 2H), 0.65-0.56 (m, 2H) ppm. 13C NMR (CDCl3, 75 MHz): δ 
173.1, 139.8, 139.6, 133.7, 129.3, 123.0, 35.6, 20.5, 11.8, 8.1, 7.6 ppm. FTIR (cm-1) (neat): 
3011, 1655, 1493, 1390, 1283, 1058, 823, 577. HRMS (ESI, Pos) calcd for C12H14BrNNaO  
[M+Na]+: 290.0151, found 290.0144 m/z. 
 
N-(2-bromo-4-methoxyphenyl)-N-methylcyclopropanecarboxamide (B2): Synthesized 
according to Procedure F on a 7.46 mmol scale and then purified via column chromatography 
(5% EtOAc/Hex) to give a dark purple oil in 70% yield (1.49 g, 5.25 mmol). 1H NMR (CDCl3, 
400 MHz): δ 7.282-7.279 (m, 1H), 7.23 (d, 1H, J = 2.8 Hz), 6.92 (dd, 1H, J = 8.7, 2.8 Hz), 
3.85 (s, 3H), 3.20 (s, 3H), 1.24-1.18 (m, 1H), 1.08-0.95 (m, 2H), 0.69-0.55 (m, 2H) ppm. 13C 
NMR (CDCl3, 75 MHz): δ 173.7, 159.4, 135.5, 130.3, 124.0, 118.5, 114.5, 55.7, 36.1, 12.0, 
8.4, 7.9 ppm. FTIR (cm-1) (neat): 3009, 1653, 1493, 1390, 1031, 890, 605. HRMS (APPI, Pos) 
calcd for C12H15BrNO2 [M+H]+: 284.0281, found 284.0272 m/z. 
 
N-(2-bromo-4,5-dimethoxyphenyl)-N-methylcyclopropanecarboxamide (B3): Synthesized 
according to Procedure F on a 3.13 mmol scale and then purified via column chromatography 
(5% EtOAc/Hex) to give a dark purple solid in 80% yield (0.782 g, 2.49 mmol). mp: 75-78 °C. 
1H NMR (CDCl3, 400 MHz): δ 7.06 (s, 1H), 6.81 (s, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 3.14 (s, 
3H), 1.22-1.14 (m, 1H), 1.00-0.89 (m, 2H), 0.62-0.52 (m, 2H) ppm. 13C NMR (CDCl3, 100 
MHz): δ 173.7, 149.2, 149.1, 135.2, 115.3, 113.6, 112.2, 56.23, 56.19, 35.9, 12.0, 8.4, 7.9 
ppm. FTIR (cm-1) (neat): 2937, 1648, 1525, 1382, 1070, 898, 875, 637; HRMS (ESI, Pos) 
calcd for C13H16BrNNaO3 [M+Na]+: 336.0206, found 336.0207 m/z. 
Br
N
O
Me
O
 
N-(4-acetyl-2-bromophenyl)-N-methylcyclopropanecarboxamide (B4): Synthesized 
according to Procedure F on a 5.18 mmol scale and then purified via column chromatography 
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(5% EtOAc/Hex) to give an orange oil in 65% yield (1.04 g, 3.39 mmol). 1H NMR (CDCl3, 
300 MHz): δ 8.27 (d, 1H, J = 1.9 Hz), 7.97 (dd, 1H, J = 8.1, 1.9 Hz), 7.47 (d, 1H, J = 8.1 Hz), 
3.22 (s, 3H), 2.63 (s, 3H), 1.13-0.98 (m, 3H), 0.68-0.58 (m, 2H) ppm. 13C NMR (CDCl3, 100 
MHz): δ 195.6, 173.0, 146.9, 137.9, 133.8, 130.4, 128.7, 124.4, 35.9, 26.7, 12.6, 8.8, 8.4 ppm. 
FTIR (cm-1) (neat): 3010, 1768, 1687, 1655, 1424, 1264, 1127, 1085, 604. HRMS (ESI, Pos) 
calcd for C13H14BrNNaO2 [M+Na]+: 318.0100, found 318.0099 m/z. 
 
Ethyl 3-bromo-4-(N-methylcyclopropanecarboxamido)benzoate (B4): Synthesized 
according to Procedure F on a 4.07 mmol scale and then purified via column chromatography 
over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give a light yellow solid in 
66% yield (0.88 g, 2.70 mmol). mp: 68-72°C. 1H NMR (CDCl3, 400 MHz): δ  8.29 (d, 1H, J = 
1.9 Hz), 8.00 (dd, 1H, J = 8.1, 1.9 Hz), 7.39 (d, 1H, J = 8.1 Hz), 4.34 (q, 2H, J = 7.1 Hz), 3.15 
(s, 3H), 1.34 (dd, 3H, J = 9.2, 5.1 Hz), 1.06-0.89 (m, 3H), 0.61-0.50 (m, 2H) ppm. 13C NMR 
(CDCl3, 100 MHz): δ 172.0, 163.4, 145.7, 133.9, 130.7, 129.11, 128.97, 122.9, 60.6, 34.9, 
13.3, 11.5, 7.7, 7.3 ppm. FTIR (cm-1) (neat): 3013, 1715, 1649, 1592, 1471, 1280, 1121, 753. 
HRMS (ESI, Pos) calcd for C14H16BrNNaO3 [M+Na]+: 348.0206, found 348.0206 m/z. 
 
N-(2-bromo-4-cyanophenyl)-N-methylcyclopropanecarboxamide (B5): Synthesized 
according to Procedure F on a 4.10 mmol scale and then purified via column chromatography 
over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give an orange solid in 84% 
yield (0.949 g, 3.40 mmol). mp: 210-213°C. 1H NMR (CDCl3, 400 MHz): δ  7.99 (s, 1H), 7.69 
(dd, 1H, J = 8.1, 1.6 Hz), 7.48 (d, 1H, J = 8.1 Hz), 3.18 (s, 3H), 1.07-0.93 (m, 3H), 0.70-0.56 
(m, 2H) ppm. 13C NMR (CDCl3, 100 MHz): δ 172.9, 147.3, 137.3, 132.6, 131.1, 124.8, 116.6, 
113.6, 36.0, 12.7, 9.0, 8.6 ppm. FTIR (cm-1) (neat): 2927, 2229, 1660, 1481, 1425, 1143, 610. 
HRMS (ESI, Pos) calcd for C12H11BrN2NaO [M+Na]+: 300.9950, found 300.9944 m/z. 
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N-(2-bromo-4-(trifluoromethyl)phenyl)-N-methylcyclopropanecarboxamide (B6): 
Synthesized according to Procedure F on a 0.92 mmol scale and then purified via column 
chromatography over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give a 
white solid in 72% yield (0.214 g, 0.663 mmol). mp: 49-52°C. 1H NMR (CDCl3, 400 MHz): δ  
7.95 (s, 1H), 7.66-7.64 (m, 2H), 7.49 (d, 1H, J = 8.0 Hz), 3.19 (s, 3H), 1.08-0.96 (m, 3H), 
0.67-0.57 (m, 2H) ppm. 13C NMR (CDCl3, 75 MHz): δ 173.1, 146.3, 131.7 (q, JC-F = 33.5 Hz), 
131.1 (q, JC-F = 3.9 Hz), 130.7, 126.0 (q, JC-F = 3.5 Hz), 122.8 (q, JC-F = 273 Hz), 35.9, 12.6, 
8.9, 8.4 ppm. 19F NMR (282 MHz, CDCl3): δ - 62.7. FTIR (cm-1) (neat): 2935, 1783, 1657, 
1428, 1157, 935, 680, 648. HRMS (ESI, Pos) calcd for C12H11BrF3NNaO [M+Na]+: 343.9868, 
found 343.9868 m/z. 
 
N-(2-bromo-4-chlorophenyl)-N-methylcyclopropanecarboxamide (B7): Synthesized 
according to Procedure F on a 6.55 mmol scale and then purified via column chromatography 
over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAC/Hex to give a light pink solid in 
63% yield (1.18 g, 4.08 mmol). mp: 61-63°C. 1H NMR (CDCl3, 300 MHz): δ  7.70 (d, 1H, J = 
2.3 Hz), 7.37 (dd, 1H, J = 8.4, 2.3 Hz), 7.30 (d, 1H, J = 8.4 Hz), 3.18 (s, 3H), 1.15-0.95 (m, 
3H), 0.68-0.57 (m, 2H) ppm. 13C NMR (CDCl3, 75 MHz): δ 173.5, 141.8, 134.8, 133.6, 131.0, 
129.3, 124.6, 36.1, 12.5, 8.9, 8.4 ppm. FTIR (cm-1) (neat): 2932, 1655, 1556, 1285, 1034, 894, 
579. HRMS (APPI, Pos) calcd for C11H12BrClNO [M+H]+: 287.9785, found 287.9776 m/z. 
Synthesis of trans-rac-N-(2-bromophenyl)-N-methyl-2-phenylcyclopropanecarboxamide  
(250) 
 
To a solution of 2-bromoaniline (11.6 mmol, 1 equiv) in THF (25 mL) was added cinnamyl 
chloride (11.9 mmol, 1.1 equiv) under Ar. The reaction was stirred at room temperature for 16 
h. Then, EtOAc (50 mL) was added and the organic phase was washed with saturated aqueous 
NaHCO3 solution (2x30 mL) and brine (15 mL). The organic phase was dried over anhydrous 
Na2SO4, filtered and concentrated in vacuo. The resulting solid was dried on a vacuum pump, 
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then dissolved in 25 mL of THF, purged with argon, and cooled down in an ice bath. NaH 
(15.9 mmol, 1.37 equiv) was added to the solution portionwise over a few minutes. The 
reaction was stirred for an additional 10 min at 0 °C, then MeI (17.4 mmol, 1.5 equiv) was 
added to the reaction. The reaction was allowed to warm up to room temperature, and stirred 
overnight. The reaction was quenched with water (15 mL), and extracted with EtOAc (3x25 
mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The residue was flashed in 5-30% EtOAc/Hex to give 77% 
(2.8 g) of N-(2-bromophenyl)-N-methylcinnamamide as an off-white solid to be used in the 
subsequent step. 
To a solution of trimethylsulfoxonium iodide (2 equiv) in DMSO (100 mL) was added 
NaH (2 equiv) portionwise over 15 min. The reaction was allowed to stir for 30 min at room 
temperature, then a solution of N-(2-bromophenyl)-N-methylcinnamamide in 5 mL of DMSO 
was added dropwise. The reaction was allowed to stir for 16 h. Then, the reaction was 
neutralized with 2.0 M HCl, and extracted with EtOAc (2x25 mL). The combined organic 
layer was washed with brine (2x30 mL), dried over anhydrous Na2SO4 and concentrated in 
vacuo. The residue was purified by flash chromatography in 5-10% EtOAc/Hex, affording the 
title compound as a clear oil in 75% yield and as the trans-racemic product.  
250: reported as a 1:1 mixture of rotamers. 1H NMR (CDCl3, 400 MHz): δ 7.69-7.57 (br d, 
1H), 7.39-7.36 (m, 1H), 7.28-7.25 (m, 1H), 7.19-7.11 (m, 4H), 6.97 (d, 1H, J = 7.7 Hz), 6.90 
(d, 1H, J = 7.7 Hz), 3.25 (s, 3H), 2.62-2.49 (m, 1H), 1.70-1.57 (m, 1H), 1.43-1.37 (m, 1H), 
1.14-1.02 (m, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ 172.3, 172.2, 142.7, 142.6, 140.8, 
140.7, 134.0, 133.9, 130.4, 130.2, 129.8 (2C), 129.0 (2C), 128.4, 128.3, 126.9, 126.4, 126.2, 
124.0, 123.7, 36.3, 36.2, 26.6, 26.2, 23.8, 23.3, 17.4, 16.4 ppm. FTIR (cm–1) (neat): 3002, 
1647, 1583, 1457, 1423, 1358, 1312, 749, 728, 697. HRMS (ESI, Pos) calcd for 
C17H16BrNNaO [M+Na]+: 352.0307, found 352.0304 m/z. 
Synthesis of cis-rac-N-(2-bromophenyl)-N-methyl-2-phenylcyclopropanecarboxamide 
(251) 
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To a 250-mL round-bottom flask (flame-dried and cooled under Ar) was added [Rh(OAc)2]2 
(70 mg, 0.324 mmol, 0.5 mol %) and DCM (100 mL). Styrene (11.0 mL, 97 mmol, 3 equiv) 
was added via syringe, and the reaction was cooled to 0 ºC. Ethyl diazoacetate (3.7 g, 32.4 
mmol, 1.0 equiv) was then added over 60 min via a syringe pump. The reaction was stirred for 
another 3 h, then filtered through a silica-cotton plug and concentrated in vacuo. The racemic 
mixture was then flashed in 5-10% EtOAc/Hex and the cis-product isolated in 28 % yield (1.7 
g, 8.9 mmol). 
1.7 g (8.9 mmol) of the cis-racemic cyclopropane ester was then placed in a 100-mL round-
bottom flask containing 15 mL of THF and 10 mL of MeOH. 2.0 M NaOH (19 mL, 37.4 
mmol, 5.0 equiv) was then added and the mixture was heated to 55 ºC for 5 hours. The 
reaction was then cooled to ambient temperature, acidified with 30 mL of 10% HCl. This was 
transferred to a 250-mL separatory funnel and extracted with benzene (3x25 mL). The 
combined organics were then washed with brine, dried over anhydrous Na2SO4 and 
concentrated in vacuo to give the desired cis-rac-cyclopropanecarboxylic acid. 
251 was then synthesized according to Procedure H (vide infra) on a 1.9 mmol scale. The 
residue was purified by flash chromatography (5-20% EtOAc/Hex), affording the cis-racemic 
product 251 as a clear oil in 79% yield (494 mg, 1.50 mmol). Reported as a 3:1 mixture of 
rotamers. 1H NMR (CDCl3, 400 MHz): δ 7.72-7.67 (two d, 1H, J = 8.0, 1.3 Hz), 7.41-7.15 (m, 
7H), 6.87 (dd, 1H, J = 7.8, 1.6 Hz), 3.07 & 3.01 (s, 3H), 2.30 & 2.06 (q, 1H, J =8.4 Hz), 1.90-
1.86 & 1.81-1.77 (m, 1H), 1.73-1.66 (m, 1H), 1.21-1.14 (m, 1H) ppm. 13C NMR (CDCl3, 100 
MHz): δ 169.5, 168.4, 143.0, 142.4, 137.2, 136.6, 133.8, 133.6, 130.6, 130.2, 129.7, 129.6, 
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129.5, 128.8, 128.6, 128.2, 127.8, 127.4, 126.2, 126.1, 123.7, 123.2, 35.9, 35.8, 26.5, 25.5, 
24.4, 21.0, 12.2, 11.2 ppm. FTIR (cm–1) (neat): 3059, 3008, 1655, 1497, 1476, 1458, 1329, 
1068, 1026, 728, 696, 664. HRMS (ESI, Pos) calcd for C17H16BrNNaO [M+Na]+: 352.0308, 
found 352.0305 m/z. 
Synthesis of trans-rac-2-arylcyclopropanecarboxylic acids 
O
P CO2Et
OEtO
EtO
NaH, THF
rt, 1 h
O
OEt Me3SOI, NaH
DMSO, rt, 16 h
acidic work up
O
OH
R R R
 
The ethyl-(E)-3-arylacrylates were synthesized according to the literature procedure.252 The 
Corey-Chaykovsky cyclopropanation was performed as outlined in the literature,253 except an 
acidic work up was added to isolate the carboxylic acid. All the intermediates have been 
previously synthesized and match reported literature data.  
Synthesis of 2-bromoanilides using trans-rac-2-arylcyclopropanecarboxylic acids 
 
Procedure G: To a THF (0.3 M) solution of the corresponding cyclopropanecarboxylic acid 
(1.0 equiv) under Ar, was added catalytic DMF (2-3 drops). Oxalyl chloride (1.1 equiv) was 
then added dropwise over 30 min. The reaction was stirred for an additional 30 min at ambient 
temperature (or until complete by TLC) and then concentrated in vacuo to remove excess 
oxalyl chloride. The residue was re-dissolved in THF (10 mL). 2-Bromoaniline (0.95 equiv), 
then Et3N (1.0 equiv) were both added dropwise. The reaction was stirred at ambient 
temperature for a further 16 h. It was then quenched with water (10 mL), and the aqueous 
layer was extracted with EtOAc (2x25 mL). The combined organic layers were washed with 
saturated aqueous NaHCO3 solution (20 mL), brine (10 mL), dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The crude was then dissolved in THF (10 mL) in a 25-mL 
round-bottomed flask under argon and cooled in an ice bath. NaH (1.1 equiv) was added 
portionwise. The reaction was stirred for an additional 10 min, then MeI (1.5 equiv) was 
O
OH
1. i) (COCl)2 (1.1 equiv)
DMF (drops), THF, rt, 1 h
ii) concentrate
iii) THF, Et3N (1 equiv)
rt, o/n Br
NH2
Br
NH
O
NaH (1.1 equiv)
MeI (1.5 equiv)
THF, 0 °C to rt, 16 h
R
R
Br
N
O
RMe
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added. The reaction was allowed to warm up to ambient temperature and stirred for 16 h. 
Then, the reaction was quenched with water (10 mL) and extracted with EtOAc (3x20 mL). 
The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The residue was purified by flash chromatography. As 
indicated, the desired products were trans-racemic. 
 
Procedure H: To a THF (0.3 M) solution of the corresponding cyclopropanecarboxylic acid 
(1.0 equiv) under Ar, was added catalytic DMF (2-3 drops). Oxalyl chloride (1.1 equiv) was 
then added dropwise over 30 min. The reaction was stirred for an additional 30 min at ambient 
temperature (or until complete by TLC). The reaction was then concentrated in vacuo to 
remove excess oxalyl chloride, and the residue was re-dissolved in THF (10 mL). 2-bromo-N-
methylaniline254 (0.95 equiv), then Et3N (1.0 equiv) were both added dropwise. The reaction 
was stirred at ambient temperature for a further 16 h. It was then quenched with water (10 
mL), and the aqueous layer was extracted with EtOAc (2x25 mL). The combined organic 
layers were washed with saturated aqueous NaHCO3 solution (20 mL) and brine (10 mL), and 
dried over anhydrous Na2SO4. After filtration and concentrating in vacuo, the residue was 
purified by flash chromatography or re-crystallization to give trans-racemic products.  
 
trans-rac-N-(2-bromophenyl)-N-methyl-2-(p-tolyl)cyclopropanecarboxamide (B8): 
Synthesized according to Procedure H on a 2.85 mmol scale. The residue was purified by 
flash chromatography (5-20% EtOAc/Hex), to give an off-white solid in 77% yield (769 mg, 
2.30 mmol). Reported as a 1:1 mixture of rotamers. mp: 98-99 °C. 1H NMR (CDCl3, 400 
MHz): δ 7.69-7.59 (two d, 1H), 7.38-7.36 (m, 1H), 7.28-7.26 (m, 1H), 7.22-7.17 (m, 1H), 
7.00-6.97 (m, 2H), 6.89 (dd, 1H, J = 8.0, 1.5 Hz), 6.80 (dd, 1H, J = 8.0, 1.5 Hz), 3.25 (s, 3H), 
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2.60-2.47 (m, 1H), 2.26 (s, 3H), 1.67-1.54 (m, 1H), 1.41-1.34 (m, 1H), 1.11-0.99 (m, 1H) 
ppm. 13C NMR (CDCl3, 100 MHz): δ 172.4, 172.2, 142.7, 142.6, 137.6 (2), 135.7 (2), 133.9 
(2), 130.4, 130.1, 129.8, 129.7, 129.0 (2), 128.9, 126.8 (2C, 126.3, 124.0, 123.7, 36.2 (2), 26.2, 
25.9, 23.5, 23.0, 21.1 (2), 17.2, 16.3 ppm. FTIR (cm–1) (neat): 3082, 3024, 1644, 1581, 1475, 
1423, 963, 871, 671. HRMS (ESI, Pos) calcd for C18H19BrNO [M+H]+: 344.0646, found 
344.0649 m/z. 
 
trans-rac-N-(2-bromophenyl)-N-methyl-2-(m-tolyl)cyclopropanecarboxamide (B9): 
Synthesized according to Procedure G on a 3.0 mmol scale. The residue was purified by flash 
chromatography (5-20% EtOAc/Hex), to give an off-white solid in 74% yield (764 mg, 2.22 
mmol). Reported as a 1:1 mixture of rotamers. mp: 87-88 °C. 1H NMR (CDCl3, 400 MHz): δ 
7.72-7.62 (two br d, 1H, J = 7.3 Hz), 7.41-7.40 (m, 1H), 7.32-7.27 (m, 1H), 7.24-7.21 (m, 1H), 
7.10-7.07 (m, 1H),  6.97-6.96 (d, 1H, J = 7.2 Hz), 6.86-6.71 (m, 2H),  3.28 (s, 3H), 2.63-2.50 
(m, 1H), 2.27 (s, 3H), 1.72-1.59 (m, 1H), 1.47-1.41 (m, 1H), 1.15-1.04 (m, 1H) ppm. 13C 
NMR (CDCl3, 100 MHz): δ 172.2, 172.1, 142.7, 142.6, 140.6, 140.5, 137.8, 137.7, 133.9 (2), 
130.4, 130.1, 129.7 (2), 129.0, 128.9, 128.2, 128.1, 127.9, 127.3, 126.9, 124.0, 123.8, 123.7, 
123.3, 36.2, 36.1, 26.4, 26.1, 23.6, 23.0, 21.4, 17.2, 16.2 ppm. FTIR (cm–1) (neat): 2922, 1650, 
1607, 1427, 1363, 1252, 1031, 930, 730, 697, 673. HRMS (ESI, Pos) calcd for C18H19BrNO 
[M+H]+: 344.0644, found 344.0647 m/z.  
 
trans-rac-N-(2-bromophenyl)-N-methyl-2-(o-tolyl)cyclopropanecarboxamide (B10): 
Synthesized according to Procedure H on a 1.9 mmol scale, then purified by flash 
chromatography (5-20% EtOAc/Hex), to give a clear oil in 94% yield (618 mg, 1.80 mmol). 
Reported as a 1:1 mixture of rotamers. mp: 91-93 °C. 1H NMR (CDCl3, 400 MHz): δ 7.71-
7.66 (m, 1H), 7.40-7.37 (m, 2H), 7.27-7.21 (m, 1H), 7.12-7.06 (m, 2H), 7.02-6.97 (m, 1H), 
6.74-6.66 (m, 1H), 3.29 (s, 3H), 2.70-2.56 (m, 1H), 2.39 (d, 3H, J = 9.0 Hz), 1.69-1.53 (m 
1H), 1.46-1.41 (m, 1H), 1.12-0.99 (m, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ 172.5, 172.4, 
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142.7, 142.6, 138.4 (2C), 138.3, 137.9, 134.0 (2), 130.3, 130.1, 129.8, 129.7, 129.0 (2), 126.4, 
126.1, 126.0, 125.5, 123.9, 36.2, 36.1, 24.5, 24.4, 21.4, 19.8, 19.7, 16.3, 15.8 ppm. FTIR (cm–
1) (neat): 2939, 1644, 1580, 1477, 1358, 1270, 1059, 1029, 767, 752, 723. HRMS (ESI, Pos) 
calcd for C18H19BrNO [M+H]+: 344.0644, found 344.0644 m/z.  
 
trans-rac-N-(2-bromophenyl)-2-(4-methoxyphenyl)-N-methylcyclopropanecarboxamide 
(B11): Synthesized according to Procedure G on a 2.37 mmol scale. The residue was purified 
by flash chromatography (5-20% EtOAc/Hex), to give a clear oil in 74% yield (632 mg, 1.75 
mmol). Reported as a 1:1 mixture of rotamers. 1H NMR (CDCl3, 400 MHz): δ 7.71-7.61 (two 
br d, 1H), 7.42-7.37 (m, 1H), 7.31-7.27 (m, 1H), 7.23-7.19 (m, 1H), 6.94 (d, 1H, J = 8.4 Hz), 
6.86 (d, 1H, J = 8.5 Hz), 6.73 (dd, 2H, J = 8.8, 2.5 Hz), 3.75 (s, 3H), 3.27 (s, 3H), 2.60-2.47 
(m, 1H), 1.68-1.55 (m, 1H), 1.39-1.32 (m, 1H), 1.10-0.99 (m, 1H) ppm. 13C NMR (CDCl3, 
100 MHz): δ 172.4, 172.3, 158.1 (2C), 142.7, 142.6, 133.9 (2), 132.7, 132.6, 130.4, 130.2, 
129.8, 129.7, 129.0, 128.9, 128.0, 127.5 (2), 124.0, 123.7, 113.8, 55.3 (2), 36.2, 36.1, 25.9, 
25.6, 23.5, 23.0, 17.0, 16.1 ppm. FTIR (cm–1) (neat): 28344, 1651, 1611, 1583, 1514, 1475, 
1245, 1119, 1034, 823, 671. HRMS (ESI, Pos) calcd for C18H18BrNNaO2 [M+Na]+: 382.0413, 
found 382.0407 m/z. 
 
trans-rac-N-(2-bromophenyl)-2-(4-fluorophenyl)-N-methylcyclopropanecarboxamide 
(B12): Synthesized according to Procedure H on a 3.5 mmol scale. The residue was purified 
by re-crystallization from EtOAc/Hex, to give a white solid in 78% yield (931 mg, 2.68 
mmol). Reported as a 1:1 mixture of rotamers. mp: 99-100 °C. 1H NMR (CDCl3, 400 MHz): δ 
7.67-7.55 (two br d, 1H), 7.37-7.36 (m, 1H), 7.26-7.25 (m, 1H), 7.19-7.15 (m, 1H), 6.93-6.89 
(m, 1H), 6.84-6.80 (m 3H), 3.23 (s, 3H), 2.57-2.45 (m, 1H), 1.68-1.57 (m 1H), 1.38-1.32 (m, 
1H), 1.07-0.97 (m, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ 171.8, 171.7, 162.4, 160.0, 
142.4 (2), 136.2 (d, JC-F = 3 Hz), 136.1 (d, JC-F = 3 Hz), 133.8, 133.7, 130.1, 130.0, 129.7 (2), 
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128.9, 128.8, 128.1, 128.0, 127.6, 127.7, 123.8, 123.5, 115.1, 115.0, 114.9, 114.8, 36.0 (2), 
25.6, 25.2, 23.6, 23.1, 16.9, 16.0 ppm. 19F NMR (CDCl3, 282 MHz): δ -116.6 (m) ppm.  FTIR 
(cm–1) (neat): 2966, 1650, 1528, 1510, 1475, 1419, 1320, 1211, 1083, 864, 746, 671, 572. 
HRMS (ESI, Pos) calcd for C17H16BrFNO [M+H]+: 348.0394, found 348.0392 m/z.  
 
 
trans-rac-N-(2-bromophenyl)-2-(4-chlorophenyl)-N-methylcyclopropanecarboxamide 
(B13): Synthesized according to Procedure H on a 1.9 mmol scale. The residue was purified 
by flash chromatography (5-20% EtOAc/Hex), to give a white solid in 77% yield (533 mg, 
1.46 mmol). Reported as a 1:1 mixture of rotamers. mp: 80-82 °C. 1H NMR (CDCl3, 400 
MHz): δ 7.69-7.57 (two br d, 1H, J = 8.3 Hz), 7.41-7.37 (m, 1H), 7.27-7.25 (m, 1H), 7.13-7.11 
(m, 2H), 6.98 (d, 1H, J = 8.1 Hz), 6.82 (d, 1H, J = 8.1 Hz),  3.25 (s, 3H), 2.56-2.46 (m, 1H), 
1.72-1.61 (m, 1H), 1.40-1.33 (m, 1H), 1.11-1.00 (m, 1H) ppm. 13C NMR (CDCl3, 100 MHz): 
δ 171.8, 171.7, 142.5, 142.4, 139.2 (2), 133.9, 133.8, 131.8 (2), 130.2, 130.0, 129.8 (2), 129.0, 
128.9, 128.4 (2), 128.3, 128.0, 127.7, 123.9, 123.6, 36.2, 36.14, 25.8, 25.4, 23.9, 23.5, 17.2, 
16.3 ppm. FTIR (cm–1) (neat): 2922, 2866, 1657, 1492, 1477, 1358, 1056, 1012. HRMS (ESI, 
Pos) calcd for C17H16BrClNO [M+H]+: 364.0098, found 364.0097 m/z.  
 
trans-rac-N-(2-bromophenyl)-N-methyl-2-(4-
(trifluoromethyl)phenyl)cyclopropanecarboxamide (B14): Synthesized according to 
Procedure H on a 1.36 mmol scale. The residue was purified by flash chromatography (5-
20% EtOAc/Hex), to give a yellow solid in 66% yield (356 mg, 0.894 mmol). Reported as a 
1:1 mixture of rotamers. mp: 74-75 °C. 1H NMR (CDCl3, 400 MHz): δ 7.71-7.57 (two br d, 
1H), 7.43-7.39 (m, 3H), 7.27-7.26 (m, 1H), 7.23-7.19 (m, 1H), 7.09 (d, 1H, J = 7.9 Hz), 6.99 
(d, 1H, J = 7.9 Hz),  3.26 (s, 3H), 2.69-2.59 (m, 1H), 1.77-1.66 (m 1H), 1.49-1.42 (m, 1H), 
1.18-1.06 (m, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ 171.6, 171.5, 145.0 (2), 142.5, 142.4, 
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134.0 (2), 130.2, 130.1, 129.9 (2), 129.1, 129.0, 126.8, 126.4, 125.3-125.2 (m), 123.9, 123.7, 
36.2 (2), 26.1, 25.7, 24.3, 23.8, 17.6, 16.6 ppm. 19F NMR (CDCl3, 282 MHz): δ -62.3 (d, J = 
9.7 Hz) ppm. FTIR (cm–1) (neat): 2931, 1655, 1618, 1476, 1423, 1323, 162, 1116, 1067, 826, 
727, 711. HRMS (ESI, Pos) calcd for C18H16BrF3NO [M+H]+: 398.0362, found 398.0355 m/z.  
 
trans-rac-N-(2-bromophenyl)-2-(furan-2-yl)-N-methylcyclopropanecarboxamide (B15): 
Synthesized according to Procedure H on a 2.85 mmol scale. The residue was purified by 
flash chromatography (5-20% EtOAc/Hex), to give a yellow oil in 77% yield (707 mg, 2.21 
mmol). Reported as a 1:1 mixture of rotamers. 1H NMR (CDCl3, 400 MHz): δ 7.66-7.59 (two 
br d, 1H, J = 8.0 Hz), 7.39-7.29 (m, 2H), 7.21-7.16 (m, 1H), 7.10-7.08 (m, 1H), 6.15-6.13 (m, 
1H), 5.96-5.82 (br d, 1H, J = 12.7, 2.6 Hz), 3.21 (s, 3H), 2.54-2.44 (m, 1H), 1.59-1.46 (m, 
2H), 1.16-1.06 (m, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ 171.5, 171.4, 154.0 (3), 142.4, 
142.3, 140.8, 140.7, 133.8, 130.2, 130.0, 129.7 (2), 128.9 (2), 123.9, 123.5, 110.2, 105.0, 
104.8, 36.1 (2), 32.2, 21.4, 19.5, 19.1, 15.0, 14.4 ppm. FTIR (cm–1) (neat): 3008, 2923, 1650, 
1583, 1507, 1422, 1315, 1131, 1119, 1013, 764, 727. HRMS (ESI, Pos) calcd for 
C15H14BrNNaO2 [M+Na]+: 342.0100, found 342.0099 m/z.  
 
trans-rac-N-(2-bromophenyl)-N-methyl-2-(thiophen-2-yl)cyclopropanecarboxamide 
(B16): Synthesized according to Procedure G on a 2.76 mmol scale. The residue was purified 
by flash chromatography (5-20% EtOAc/Hex), to give an off-white solid in 67% yield (622 
mg, 1.85 mmol). Reported as a 1:1 mixture of rotamers. mp: 119-121 °C. 1H NMR (CDCl3, 
400 MHz): δ 7.69-7.64 (m, 1H), 7.41-7.31 (m, 2H), 7.24-7.20 (m, 1H), 7.00 (t, 1H, J = 4.5 
Hz), 6.81-6.79 (m, 1H),  6.66-6.59 (two d, 1H, J = 3.2 Hz), 3.25 (s, 3H), 2.72-2.53 (m, 1H), 
1.73-1.62 (m 1H), 1.48-1.43 (m, 1H), 1.15-1.04 (m, 1H) ppm. 13C NMR (CDCl3, 100 MHz): 
δ171.6, 171.5, 144.9, 144.8, 142.6, 142.5, 134.0 (2), 130.4, 130.1, 129.9, 129.8, 129.1, 129.0, 
126.7, 126.6, 124.2, 124.1, 123.7, 123.6, 123.3, 123.1, 36.2 (2), 24.4, 24.0, 21.5, 21.3, 17.9, 
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17.1 ppm. FTIR (cm–1) (neat): 2923, 1643, 1582, 1476, 1426, 1203, 1056, 923, 761, 700. 
HRMS (ESI, Pos) calcd for C15H15BrNO [M+H]+: 336.0052, found 336.0050 m/z.  
Synthesis of spiro 3,3’-cyclopropyl oxindoles 
Procedure I: To a 5 mL microwave vial in a glovebox was added in the following order: 
Pd(OAc)2 (5.6 mg, 0.025 mmol), PCy3 (7.0 mg, 0.025 mmol), K2CO3 (104 mg, 0.75 mmol) 
and Ag3PO4 (0.17 mmol, 69.1 mg). The vial was crimped shut. The corresponding 2-
bromoanilide (0.50 mmol) was weighed into a vial, dissolved in 0.4 mL of toluene and added 
to the reaction vial. The vial containing 2-bromoanilide was rinsed with 3x0.2 mL of toluene 
for a total volume of 1.0 mL. The yellowish-orange solution was then heated to 130 °C in an 
oil bath for 3 h as indicated by TLC. The reaction turned black within five minutes. The 
reaction was cooled to ambient temperature, filtered over a cotton-Celite® plug, rinsing with 
15 mL EtOAc, and concentrated in vacuo to give the crude product. The crude was purified 
via column chromatography over silica gel using the given solvent gradient. 
 
1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (220): Synthesized according to 
Procedure I on a 0.464 mmol scale to give an orange solid in 90% yield (72. 4 mg, 0.418 
mmol). The observed characterization data was consistent with that previously reported in the 
literature.92 
 
1',5'-dimethylspiro[cyclopropane-1,3'-indolin]-2'-one (227): Synthesized according to 
Procedure I on a 0.508 mmol scale and then purified via column chromatography over silica 
gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give a light pink solid in 81% yield 
(77.2 mg, 0.412 mmol). mp: 75-78°C. 1H NMR (CDCl3, 400 MHz): δ 7.06-7.04 (m, 1H), 
6.81-6.78 (m, 1H), 6.66 (dd, 1H, J = 1.0, 0.4 Hz), 3.28 (s, 3H), 2.35 (s, 3H), 1.74-1.69 (m, 
2H), 1.50-1.46 (m, 2H) ppm. 13C NMR (CDCl3, 75 MHz): δ 177.2, 141.3, 131.6, 131.0, 130.3, 
127.1, 119.2, 107.8, 27.1, 26.7, 21.2, 19.1 ppm. FTIR (cm-1) (neat): 2918, 1691, 1493, 1392, 
 222 
1230, 890, 700, 554. HRMS (ESI, Pos) calcd for C12H13NNaO [M+Na]+: 210.0889, found  
210.0881 m/z. 
N
O
MeO
 
5'-methoxy-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (228): Synthesized according 
to Procedure I on a 0.506 mmol scale and then purified via column chromatography over 
silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give a cream-coloured solid in 
67% yield (69.4 mg, 0.342 mmol). mp: 72-75°C. 1H NMR (CDCl3, 400 MHz):  δ 6.80 (d, 2H, 
J = 2.1 Hz), 6.47 (t, 1H, J = 0.9 Hz), 3.80 (s, 3H), 3.29 (s, 3H), 1.75 (m, 2H), 1.49 (m, 2H) 
ppm. 13C NMR (CDCl3, 75 MHz): δ 176.8, 155.9, 137.3, 132.4, 111.0, 108.3, 106.1, 56.0, 
27.5, 26.7, 19.3 ppm. FTIR (cm-1) (neat): 2930, 1694, 1370, 1210, 793. HRMS (APPI, Pos) 
calcd for C12H14NO2 [M+H]+: 204.1019, found 204.1027 m/z. 
 
5',6'-dimethoxy-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (229): Synthesized 
according to Procedure I on a 0.5 mmol scale and then purified via column chromatography 
over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give a cream-coloured solid 
in 74% yield (86.3 mg, 0.37 mmol). mp: 148-150°C. 1H NMR (CDCl3, 400 MHz): δ 6.55 (s, 
1H), 6.45 (s, 1H), 3.92 (s, 3H), 3.85  (s, 3H), 3.27 (s, 3H), 1.69-1.66 (m, 2H), 1.45-1.42 (m, 
2H) ppm. 13C NMR (CDCl3, 75 MHz):  δ 177.5, 148.9, 145.1, 137.3, 121.6, 104.3, 94.8, 57.1, 
56.7, 27.3, 26.7, 18.7 ppm. FTIR (cm-1) (neat): 2932, 1687, 1508, 1285, 1150, 901, 777. 
HRMS (ESI, Pos) calcd for C13H15NNaO3 [M+Na]+: 256.0944, found 256.0942 m/z. 
 
1'-methyl-5'-(trifluoromethyl)spiro[cyclopropane-1,3'-indolin]-2'-one (230): Synthesized 
according to Procedure I on a 0.485 mmol scale and then purified via column 
chromatography over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give an 
orange solid in 85% yield (99.4 mg, 0.412 mmol). mp: 132-134°C. 1H NMR (CDCl3, 400 
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MHz): δ 7.53 (d, 1H, J = 8.2 Hz), 7.05 (dd, 1H, J = 1.2, 0.5 Hz), 6.96 (d, 1H, J = 8.2 Hz), 3.32 
(s, 3H), 1.82-1.79 (m, 2H), 1.59-1.61 (m, 2H) ppm. 13C NMR (CDCl3, 75 MHz): 177.1, 146.5, 
131.6, 124.6 (q, JC-F = 271 Hz), 124.6 (q, JC-F = 4.1 Hz), 124.5 (q, JC-F = 32.7 Hz), 119.2, 
115.5 (q, JC-F = 3.6 Hz), 114.4, 27.2, 26.9, 19.8 ppm. 19F NMR (CDCl3, 282 MHz): -61.3 ppm. 
FTIR (cm-1) (neat): 2925, 1708, 1624, 1460, 1163, 954, 520; HRMS (ESI, Pos) calcd for 
C12H10F3NNaO [M+Na]+: 264.0606, found 264.0603 m/z. 
 
1'-methyl-2'-oxospiro[cyclopropane-1,3'-indoline]-5'-carbonitrile (231): Synthesized 
according to Procedure I on a 0.524 mmol scale and then purified via column 
chromatography over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give an 
orange solid in 78% yield (80.9 mg, 0.409 mmol). mp: 124-127°C. 1H NMR (CDCl3, 400 
MHz): δ  7.58 (dd, 1H, J = 8.1, 1.5 Hz), 7.07 (d, 1H, J = 1.3 Hz), 6.95 (d, 1H, J = 8.1 Hz), 
3.32 (s, 3H), 1.82 (m, 2H), 1.60 (m, 2H) ppm. 13C NMR (CDCl3, 75 MHz):  δ 176.8, 147.4, 
132.16, 132.12, 121.7, 119.5, 108.4, 105.2, 27.0, 26.9, 20.2 ppm. FTIR (cm-1) (neat): 3053, 
2919, 2220, 1711, 1618, 1591, 1253, 829. HRMS (ESI, Pos) calcd for C12H10N2NaO 
[M+Na]+: 221.0685, found 221.0681 m/z. 
 
Ethyl 1'-methyl-2'-oxospiro[cyclopropane-1,3'-indoline]-5'-carboxylate (232): Synthesized 
according to Procedure I on a 0.432 mmol scale and then purified via column 
chromatography over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give an 
orange solid in 99% yield (105 mg, 0.426 mmol). mp: 124-126°C. 1H NMR (CDCl3, 400 
MHz): δ 8.00 (d, 1H, J = 8.1 Hz), 7.50 (s, 1H), 6.91 (d, 1H, J = 8.1 Hz), 4.35 (q, 2H, J = 7.0 
Hz), 3.32 (s, 3H), 1.77 (m, 2H), 1.61-1.60 (m, 2H), 1.38 (t, 3H, J = 7.0 Hz) ppm. 13C NMR 
(CDCl3, 75 MHz):  δ 177.4, 166.6, 147.6, 130.9, 129.5, 124.4, 119.6, 107.5, 61.0, 27.1, 26.9, 
19.6, 14.5 ppm. FTIR (cm-1) (neat): 2961, 1701, 1615, 1298, 1104, 1025, 772. HRMS (ESI, 
Pos) calcd for C14H15NNaO3 [M+Na]+: 268.0944, found 268.0940 m/z. 
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5'-acetyl-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (233): Synthesized according to 
Procedure I on a 0.412 mmol scale and then purified via column chromatography over silica 
gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give a cream-coloured solid in 62% 
yield (54.9 mg, 0.255 mmol). mp: 165-167 °C. 1H NMR (CDCl3, 400 MHz): δ 7.93-7.90 (m, 
1H), 7.49 (d, 1H, J = 1.3 Hz), 6.93 (dd, 1H, J = 8.1, 3.3 Hz), 3.33 (s, 3H), 2.58 (s, 3H), 1.80-
1.76 (m, 2H), 1.63-1.61 (m, 2H) ppm. 13C NMR (CDCl3, 75 MHz): δ 197.1, 177.5, 147.9, 
131.8, 131.3, 129.0, 118.2, 107.3, 27.1, 26.9, 26.5, 19.8 ppm. FTIR (cm-1) (neat): 2920, 2851, 
1711, 1659, 1616, 1424, 1259, 826, 618, 535. HRMS (ESI, Pos) calcd for C13H13NNaO2 
[M+Na]+: 238.0838, found 238.0833 m/z. 
 
5'-chloro-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (234): Synthesized according to 
Procedure I on a 0.491 mmol scale and then purified via column chromatography over silica 
gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give a pink-colored solid in 89% yield 
(90.4 mg, 0.437 mmol). mp: 130-132°C. 1H NMR (CDCl3, 400 MHz): δ  7.23 (d,  1H, J = 8.3 
Hz), 6.83-6.81 (m, 2H), 3.29 (s, 3H), 1.78-1.77 (m, 2H), 1.54 (m, 2H) ppm. 13C NMR (CDCl3, 
75 MHz): δ 176.6, 142.2, 132.8, 127.5, 126.7, 118.9, 108.9, 27.3, 26.8, 19.6 ppm. FTIR (cm-1) 
(neat): 3058, 2924, 1697, 1612, 1587, 1388, 1085, 802, 666, 545, 458. HRMS (APPI, Pos) 
calcd for C11H11ClNO [M+H]+: 208.0525, found 208.0524 m/z. 
 
(1S,2R)-1'-methyl-2-phenylspiro[cyclopropane-1,3'-indolin]-2'-one (235a) and (1R,2R)-
1'-methyl-2-phenylspiro[cyclopropane-1,3'-indolin]-2'-one (235b): Synthesized according 
to Procedure I, except the reaction was run for 15 h, from trans-racemic 235 on a 0.5 mmol 
scale and then purified via column chromatography over silica gel in 5-20% EtOAc/Hex to 
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give a yellow oil in 90% yield (112 mg, 0.449 mmol) as an inseparable mixture of major and 
minor diastereomers (6:1 dr). From cis-racemic 235 on a 0.4 mmol scale: 93% yield, (93 mg, 
0.37 mmol) in 1:5 dr. Diastereomeric ratios were determined via 1H NMR. 1H NMR (CDCl3, 
400 MHz): Major 235a: δ 7.33-7.26 (m, 4H), 7.21-7.14 (m, 3H), 6.99 (d, 1H, J = 7.9 Hz), 6.70 
(t, 1H, J = 7.5 Hz), 5.98 (d, 1H, J = 7.6 Hz), 3.34 (s, 3H), 3.38-3.34 (m, 1H), 2.20 (dd, 1H, J = 
9.1, 4.5 Hz), 2.0 (dd, 1H, J = 8.0, 4.4 Hz), Minor 235b: δ 7.35-6.87 (m, 9H), 3.16 (s, 3H), 
3.18-3.15 (m, 1H), 2.41 (dd, J = 8.6, 4.9 Hz), 2.07 (dd, 1H, J = 8.9, 4.6 Hz) ppm. 13C NMR 
(CDCl3, 100 MHz): mixture: δ 176.5 (2), 143.9, 135.2, 134.4, 130.9, 130.0, 129.3, 128.7, 
128.0, 127.6, 127.4, 127.3, 126.9, 126.6, 125.8, 121.9, 121.5, 120.7, 118.1, 107.9, 107.8, 38.2, 
35.9, 33.9, 33.4, 26.7, 26.5, 22.6, 22.5 ppm. FTIR (cm–1) (neat): 3056, 3028, 1699, 1614, 
1468, 1345, 1128, 747, 696. HRMS (ESI, Pos): calcd for C17H16NO [M+H]+: 250.1226, found 
250.1224 m/z. 
N
O
Me
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(1S,2R)-1'-methyl-2-(p-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-one (236a) and (1R,2R)-
1'-methyl-2-(p-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-one (236b): Synthesized according 
to Procedure I on a 0.496 mmol scale and then purified via column chromatography over 
silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give a yellow oil in 93% yield 
(121 mg, 0.459 mmol) as an inseparable mixture of major and minor diastereomers (8:1 dr). 
Reaction was also run for 15 h to give 89% yield (118 mg, 6:1 dr). Diastereomeric ratios were 
determined via 1H NMR. 1H NMR (CDCl3, 400 MHz): Major 236a: δ 7.34-7.07 (m, 5H), 
6.90-6.86 (m, 1H), 6.72 (t, 1H, J = 7.5 Hz), 6.03 (d, 1H, J = 7.5 Hz), 3.33 (s, 3H), 3.36-3.32 
(m, 1H), 2.34 (s, 3H), 2.18 (dd, 1H, J = 8.9, 4.5 Hz), 1.99 (dd, 1H, J = 7.8, 4.5 Hz), Minor 
236b: δ 7.37-6.86 (m, 8H), 3.19 (s, 3H), 3.16-3.13 (m, 1H), 2.42-2.38 (m, 1H), 2.34 (s, 3H), 
2.06 (dd, 1H, J = 9.0, 4.7 Hz) ppm. 13C NMR (CDCl3, 100 MHz): Major 236a: δ 176.6, 143.8, 
137.0, 132.1, 129.8, 129.1, 127.7, 126.5, 121.5, 120.8, 107.8, 35.7, 33.4, 26.7, 22.6, 21.2, 
Minor 236b: δ 176.6, 149.3, 136.8, 131.3, 129.4, 126.8, 125.8, 121.9, 118.7, 118.1, 107.8, 
36.1, 33.9, 26.5, 22.6, 21.3 ppm. FTIR (cm–1) (neat): 3001, 2922, 1701, 1614, 1517, 1378, 
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1215, 1158, 748, 585. HRMS (ESI, Pos) calcd for C18H17NNaO [M+Na]+: 286.1202, found 
286.1199 m/z.  
 
(1S,2R)-1'-methyl-2-(m-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-one (237a) and (1R,2R)-
1'-methyl-2-(m-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-one (237b): Synthesized 
according to Procedure I on a 0.485 mmol scale and then purified via column 
chromatography over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give a 
yellow oil in 98% yield (126 mg, 0.477 mmol) as an inseparable mixture of major and minor 
diastereomers (11:1 dr). Reaction was also run for 15 h to give 98% (129 mg, 7:1 dr). 
Diastereomeric ratios were determined via 1H NMR. 1H NMR (CDCl3, 400 MHz): Major 
237a: δ 7.18-7.14 (m, 2H), 7.08-7.06 (m, 1H), 7.03 (br s, 1H), 6.98 (d, 1H, J = 7.6 Hz), 6.88 
(d, 1H, J = 7.8 Hz), 6.71 (td, 1H, J = 7.6, 1.0 Hz), 6.03 (dt, 1H, J = 7.5, 0.5 Hz), 3.34 (s, 3H), 
3.35-3.30 (m, 1H), 2.31 (s, 3H), 2.18 (dd, 1H, J = 9.1, 4.5 Hz), 2.00 (dd, 1H, J = 8.0, 4.5 Hz) 
ppm. 13C NMR (CDCl3, 100 MHz): mixture: δ 176.5, 143.9, 138.1, 137.4, 135.1, 134.3, 131.0, 
130.7, 130.2, 128.2 (2C), 128.1, 127.8, 127.7, 126.9, 126.8, 126.6, 126.3, 121.9, 121.5, 120.8, 
118.1, 107.8 (2C), 38.2, 35.9, 33.9, 33.4, 26.7, 26.5, 22.6, 21.5, 21.4 ppm. FTIR (cm-1) (neat): 
2922, 1702, 1650, 1613, 1492, 1346, 1128, 730, 672. HRMS (ESI, Pos) calcd for C18H18NO 
[M+H]+: 264.1383, found 264.1380 m/z.  
 
(1S,2R)-1'-methyl-2-(o-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-one (238a) and (1R,2R)-
1'-methyl-2-(o-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-one  (238b): Synthesized 
according to Procedure I on a 0.471 mmol scale and then purified via column 
chromatography over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give a 
yellow oil in 94% yield (90.4 mg, 0.437 mmol) as an inseparable mixture of major and minor 
 227 
diastereomers (14:1 dr). Reaction was also run for 15 h to give 80% yield (108 mg, 7:1 dr). 
Diastereomeric ratios were determined via 1H NMR. 1H NMR (CDCl3, 400 MHz): Major 
238a: δ 7.40 (d, 1H, J = 7.4 Hz), 7.28-7.15 (m, 3H), 7.06-7.05 (m, 1H), 6.89 (d, 1H, J = 7.8 
Hz), 6.69-6.65 (m, 1H), 5.88 (d, 1H, J = 7.5 Hz), 3.37 (s, 3H), 3.39-3.31 (m, 1H), 2.27 (dd, 
1H, J = 9.0, 4.5 Hz), 2.06 (dd, 1H, J = 8.0, 4.5 Hz), 1.78 (s, 3H) ppm. 13C NMR (CDCl3, 100 
MHz): mixture: δ 176.6, 173.9, 143.7, 143.5, 139.3, 138.0, 133.7, 130.7, 130.1, 130.0, 129.7, 
129.1, 128.7, 127.7, 127.6, 127.5, 126.7, 125.9, 125.7, 122.0, 121.6, 119.9, 118.2, 107.9, 
107.8, 36.8, 35.1, 33.3, 33.1, 26.8, 26.6, 22.6, 22.5, 19.5, 19.2 ppm. FTIR (cm–1) (neat): 2938, 
1701, 1646, 1493, 1380, 1344, 1133, 748, 728. HRMS (ESI, Pos): calcd for C18H18NO 
[M+H]+: 264.1382, found 264.1379 m/z.  
 
(1S,2R)-2-(4-methoxyphenyl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (239a) 
and (1R,2R)-2-(4-methoxyphenyl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one 
(239b): Synthesized according to Procedure I on a 0.496 mmol scale and then purified via 
column chromatography over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to 
give an off-white in 92% yield (127 mg, 0.456 mmol) as an inseparable mixture of major and 
minor diastereomers (10:1 dr). Reaction was also run for 15 h to give 91% (127 mg, 6:1 dr). 
Diastereomeric ratios were determined via 1H NMR. mp: 76-74°C. 1H NMR (CDCl3, 400 
MHz): Major 239a: δ 7.16 (td, 1H, J = 7.8, 1.1 Hz), 7.10 (d, 2H, J = 8.3 Hz), 6.88-6.81 (m, 
3H), 6.71 (td, 1H, J = 7.7, 0.6 Hz), 6.00 (dd, 1H, J = 7.5, 0.6 Hz), 3.79 (s, 3H), 3.32 (s, 3H), 
3.32-3.29 (m, 1H), 2.17 (dd, 1H, J = 9.2, 4.5 Hz), 1.95 (dd, 1H, J = 7.9, 4.5 Hz), Minor 239b: 
δ 7.37-6.80 (m, 8H), 3.78 (s, 3H), 3.18 (s, 3H), 3.15-3.12 (m, 1H), 2.37 (dd, 1H, J = 8.6, 4.8 
Hz), 2.05 (dd, 1H, J = 8.6, 4.8 Hz) ppm. 13C NMR (CDCl3, 100 MHz): Major 239a: δ 176.5, 
158.8, 143.8, 131.0, 127.7, 127.2, 126.5, 121.5, 120.8, 113.8, 107.8, 55.3, 35.3, 33.4, 26.6, 
22.8, Minor 239b: δ 174.0, 158.7, 143.4, 130.3, 128.3, 127.0, 126.7, 122.6, 121.9, 118.0, 
113.4, 55.2, 37.8, 33.9, 26.5, 22.7 ppm. FTIR (cm–1) (neat): 2933, 1704, 1613, 1515, 1494, 
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1346, 1249, 974, 696. HRMS (ESI, Pos) calcd for C18H17NNaO2 [M+Na]+: 302.1152, found 
302.1147 m/z.  
N
O
F
N
O
F
 
(1S,2R)-2-(4-fluorophenyl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (240a) and 
(1R,2R)-2-(4-fluorophenyl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (240b): 
Synthesized according to Procedure I on a 0.498 mmol scale and then purified via column 
chromatography over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give a 
white solid in 99% yield (132 mg, 0.494 mmol) as a separable mixture of major and minor 
diastereomers (8:1 dr). Diastereomeric ratios were determined via 1H NMR. Reaction was also 
run for 15 h to give 87% (116 mg) of a white solid 240a and 12% (16 mg) of a white solid 
240b. Major 240a: mp: 69-70 °C. 1H NMR (CDCl3, 400 MHz): δ 7.19-7.13 (m, 3H), 7.01-
6.96 (m, 2H), 6.89-6.87 (m, 1H), 6.72 (td, 1H, J = 7.6, 1.0 Hz), 5.94 (d, 1H, J = 7.8 Hz), 3.33 
(s, 3H), 3.32-3.29 (m, 1H), 2.19 (dd, 1H, J = 9.2, 4.6 Hz), 1.93 (dd, 1H, J = 7.9, 4.3 Hz) ppm. 
13C NMR (CDCl3, 100 MHz): δ 176.3, 162.0 9 (d, JC-F = 245.0 Hz), 143.9, 131.5 (d, JC-F = 8.0 
Hz), 130.6 (d, JC-F = 3.2 Hz), 127.3, 126.8, 121.6, 120.7, 115.3 (d, JC-F = 22.0 Hz), 107.9, 
34.9, 33.2, 26.7, 22.7 ppm. 19F NMR (CDCl3, 282 MHz): δ -114.6 (m) ppm. FTIR (cm–1) 
(neat): 2938, 2844, 1696, 1612, 1510, 1379, 1245, 1090, 1015, 841, 750. HRMS (ESI, Pos) 
calcd for C17H15FNO [M+H]+: 268.1132, found 268.1128 m/z.  
Minor 240b: mp: 111-114 °C. 1H NMR (CDCl3, 400 MHz): δ 7.31-7.27 (m, 3H), 7.08 (td, 1H, 
J = 7.5, 0.9 Hz), 7.01-6.96 (m, 3H), 6.90 (d, 1H, J = 7.8 Hz), 3.19 (s, 3H), 3.15-3.12 (m, 1H), 
2.36 (dd, 1H, J = 8.6, 5.0 Hz), 2.07 (dd, 1H, J = 9.1, 5.0 Hz) ppm. 13C NMR (CDCl3, 75 
MHz): δ 173.9, 162.0 (d, JC-F = 245 Hz), 143.6, 130.9 (d, JC-F = 8.1 Hz), 130.7, 130.1 (d, JC-F 
= 3.1 Hz), 127.0, 122.1, 118.2, 114.9 (d, JC-F = 21.5 Hz), 108.0, 37.3, 33.9, 26.6, 22.8 ppm. 19F 
NMR (CDCl3, 282 MHz): δ -115.2 (m) ppm. FTIR (cm–1) (neat): 2922, 1704, 1615, 1512, 
1469, 1315, 1252, 1230, 1196, 1131, 1102, 908, 730. HRMS (ESI, Pos) calcd for C17H15FNO 
[M+H]+: 268.1132, found 268.1130 m/z.  
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(1S,2R)-1'-methyl-2-(4-(trifluoromethyl)phenyl)spiro[cyclopropane-1,3'-indolin]-2'-one 
(241a) and (1R,2R)-1'-methyl-2-(4-(trifluoromethyl)phenyl)spiro[cyclopropane-1,3'-
indolin]-2'-one (241b): Synthesized according to Procedure I on a 0.30 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) in 10-50% 
EtOAc/Hex to give an orange solid in 85% yield (80.7 mg, 0.254 mmol) as a separable 
mixture of major and minor diastereomers (5:1 dr). Diastereomeric ratios were determined via 
1H NMR. Reaction was also run for 15 h to give 71% (113 mg) of an orange solid 241a and 
19% (31 mg) of an off-white solid 241b. 
Major 241a: mp: 123-125 °C. 1H NMR (CDCl3, 400 MHz): δ 7.55 (d, 2H, J = 8.2 Hz), 7.31 
(d, 2H, J = 8.2 Hz), 7.18 (td, 1H, J = 7.7, 0.9 Hz), 6.89 (d, 1H, J = 7.9 Hz), 6.72 (td, 1H, J = 
7.6, 0.9 Hz), 5.95 (d, 1H, J = 7.3 Hz), 3.34 (s, 3H), 3.35-3.31 (m, 1H), 2.13 (dd, 1H, J = 9.1, 
4.7 Hz), 2.00 (dd, 1H, J = 8.0, 4.7 Hz) ppm. 13C NMR (CDCl3, 100 MHz): δ 176.0, 143.9 
139.4, 130.3, 130.0 (q, JC-F = 32.0 Hz), 128.2-120.0 (q, JC-F = 272.0 Hz), 127.0, 126.8, 125.3 
(q, JC-F = 3.9 Hz), 121.7, 120.5, 108.0, 35.1, 32.3, 26.7, 22.2 ppm. 19F NMR (CDCl3, 282 
MHz): δ -62.4 (s) ppm. FTIR (cm–1) (neat): 2934, 1695, 1615, 1496, 1322, 1160, 1112, 1066, 
977, 852, 751. HRMS (ESI, Pos) calcd for C18H15F3NO [M+H]+: 318.1100, found 318.1097 
m/z.  
Minor 241b: mp: 138-139 °C. 1H NMR (CDCl3, 400 MHz): δ 7.56 (d, 2H, J = 8.2 Hz), 7.44 
(d, 2H, J = 8.2 Hz), 7.31 (td, 1H, J = 7.6, 1.2 Hz), 7.10 (td, 1H, J = 7.5, 0.9 Hz), 6.99 (dd, 1H, 
J = 7.5, 0.9), 6.91 (d, 1H, J = 7.8 Hz), 3.19 (s, 3H), 3.20-3.16 (m, 1H), 2.41(dd, 1H, J = 8.5, 
5.0 Hz), 2.12 (dd, 1H, J = 9.0, 5.0 Hz) ppm. 13C NMR (CDCl3, 75 MHz): δ 173.7, 143.7, 
138.5, 130.4, 129.7, 129.5 (q, JC-F = 32.0 Hz), 124.4 (q, JC-F = 272.0 Hz), 127.5, 125.0 (q, JC-F 
= 3.8 Hz), 122.2, 118.3, 108.2, 37.3, 34.2, 26.6, 22.6 ppm. 19F NMR (CDCl3, 282 MHz): δ -
62.4 (s) ppm. FTIR (cm–1) (neat): 2930, 1699, 1615, 1493, 1379, 12544, 1193, 1121, 1069, 
744. HRMS (ESI, Pos) calcd for C18H15F3NO [M+H]+: 318.1100, found 318.1097 m/z. 
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(1S,2R)-2-(4-chlorophenyl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (242a) and 
(1R,2R)-2-(4-chlorophenyl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (242b): 
Synthesized according to Procedure I on a 0.348 mmol scale and then purified via column 
chromatography over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give an 
orange solid in 95% yield (93.8 mg, 0.331 mmol) as a separable mixture of major and minor 
diastereomers (5:1 dr). Diastereomeric ratios were determined via 1H NMR. Reaction was also 
run for 15 h to give 73% (103 mg) of an orange solid 242a and 15% (21 mg) of an off-white 
solid 242b. 
Major 242a: mp: 126-128 °C. 1H NMR (CDCl3, 400 MHz): δ 7.28-7.25 (m, 2H), 7.19 (td, 1H, 
J = 7.7, 1.1 Hz), 7.12 (d, 2H, J = 8.7 Hz), 6.89 (d, 1H, J = 8.0 Hz), 6.75 (td, 1H, J = 7.7, 0.9 
Hz) 5.98 (d, 1H, J = 7.5 Hz), 3.34 (s, 3H), 3.31-3.27 (m, 1H), 2.19 (dd, 1H, J = 9.0, 4.5 Hz), 
1.94 (dd, 1H, J = 7.9, 4.5 Hz) ppm. 13C NMR (CDCl3, 100 MHz): δ 176.2, 143.9, 133.8, 
133.2, 131.3, 128.6, 127.1, 126.4, 121.7, 120.7, 108.0, 35.0, 33.2, 26.7, 22.4 ppm. FTIR (cm–1) 
(neat): 2927, 1686, 1610, 1491, 1465, 1292, 1085, 1016, 785, 548. HRMS (ESI, Pos) calcd for 
C17H15ClNO [M+H]+: 284.0837, found 284.0834 m/z.  
Minor 242b: mp: 110-111 °C. 1H NMR (CDCl3, 400 MHz): δ 7.56 (td, 1H, J = 7.8, 1.2 Hz), 
7.27-7.24 (m, 4H), 7.08 (td, 1H, J = 7.5, 0.9 Hz), 6.97 (dd, 1H, J = 7.5, 0.9 Hz), 6.90 (d, 1H, J 
= 7.8, 0.9 Hz), 3.19 (s, 3H), 3.14-3.10 (m, 1H), 2.35 (dd, 1H, J = 8.6, 5.0 Hz), 2.07 (dd, 1H, J 
= 8.8, 4.9 Hz) ppm. 13C NMR (CDCl3, 75 MHz): δ 173.8, 143.6, 133.1, 133.0, 130.7, 130.6, 
128.2, 127.1, 122.1, 118.2, 108.0, 37.3, 34.0, 26.6, 22.6 ppm.  FTIR (cm–1) (neat): 2923, 1697, 
1614, 1492, 1469, 1345, 1315, 1195, 1109, 975, 746, 530. HRMS (ESI, Pos) calcd for 
C17H15ClNO [M+H]+: 284.0837, found 284.0837 m/z.  
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(1S,2S)-1'-methyl-2-(thiophen-2-yl)spiro[cyclopropane-1,3'-indolin]-2'-one (243a) and 
(1R,2S)-1'-methyl-2-(thiophen-2-yl)spiro[cyclopropane-1,3'-indolin]-2'-one (243b): 
Synthesized according to Procedure I on a 0.496 mmol scale and then purified via column 
chromatography over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give a 
yellow oil in 92% yield (127 mg, 0.456 mmol) as an inseparable mixture of major and minor 
diastereomers (10:1 dr). Reaction was also run for 15 h to give 67% (86 mg, 10:1 dr).  
Diastereomeric ratios were determined via 1H NMR. 1H NMR (CDCl3, 400 MHz): Major 
243a: δ 7.22-7.18 (m, 2H), 6.97-6.96 (m, 1H), 6.91-6.87 (m, 2H), 6.78 t(d, 1H, J = 7.6, 0.8 
Hz), 6.24 (d, 1H, J = 7.5 Hz), 3.32 (s, 3H), 3.32-3.28 (m, 1H), 2.25 (dd, 1H, J = 9.0, 4.5 Hz), 
2.02 (dd, 1H, J = 7.6, 4.5 Hz); Minor 243b: δ 7.41-6.85 (m, 7H), 3.21 (s, 3H), 3.20-3.18 (m, 
1H), 2.35 (dd, 1H, J = 8.5, 5.0 Hz), 2.14 (dd, 1H, J = 8.9, 4.6 Hz) ppm. 13C NMR (CDCl3, 100 
MHz): Major 243a: δ 175.9, 143.9, 139.1, 127.5, 127.0, 126.8, 125.4, 121.8, 120.4, 108.0, 
34.2, 30.1, 28.6, 26.7, 23.8; Minor 243b: δ 176.1, 143.5, 137.9, 127.1, 126.9, 126.7, 125.9, 
124.7, 122.0, 118.2, 34.3, 32.7, 26.5, 24.0 ppm. FTIR (cm–1 ) (neat): 2937, 1699, 1649, 1613, 
1493, 1423, 1380, 1028, 749, 696. HRMS (ESI, Pos): calcd for C15H14NOS [M+H]+: 
256.0791, found 256.0787 m/z.  
 
 (1S,2S)-2-(furan-2-yl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (244a) and 
(1R,2S)-2-(furan-2-yl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (244b): 
Synthesized according to Procedure I on a 0.494 mmol scale and then purified via column 
chromatography over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to give a 
yellow oil in 79% yield (92.2 mg, 0.388 mmol) as an inseparable mixture of major and minor 
diastereomers (9:1 dr). Reaction was also run for 15 h to give 40% (37 mg, >10:1 dr).  
Diastereomeric ratios were determined via 1H NMR. Major 244a: 1H NMR (CDCl3, 400 
MHz): δ 7.32-7.31 (m, 1H), 7.20 (t, 1H, J = 7.7 Hz), 6.87 (d, 1H, J = 7.7 Hz), 6.83 (t, 1H, J = 
7.6 Hz), 6.48 (d, 1H, J = 7.4 Hz), 3.31 (s, 3H), 3.14-3.11 (m, 1H), 2.18 (dd, 1H, J = 9.2, 4.5 
Hz), 2.12 (dd, 1H, J = 7.5, 4.5 Hz) ppm. 13C NMR (CDCl3, 100 MHz): δ 175.7, 150.4, 144.0, 
142.2, 127.3, 127.1, 122.0, 120.2, 110.7, 109.4, 108.1, 33.9, 28.7, 26.7, 21.3 ppm. FTIR (cm–1) 
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(neat): 2937, 1699, 1613, 1494, 1421, 1375, 1342, 1329, 1128, 1011, 735, 547. HRMS (ESI, 
Pos) calcd for C15H14NO2 [M+H]+: 240.1019, found 240.1016 m/z.  
Synthesis of d-labeled trans-rac-N-(2-bromophenyl)-N-methyl-2-
phenylcyclopropanecarboxamide 252 
 
Deuterated ethyl diazoacetate was synthesized according to the literature procedure255 and 
then used in the Rh-catalyzed cyclopropanation of styrene as described in the synthesis of cis-
250. 
The resulting trans-cyclopropane (410 mg, 2.15 mmol) was dissolved in 6 mL of THF and 
transferred to a 25 mL round-bottom flask. To this was added NaOD (2.0 M, 3.2 mL, 6.45 
mmol, 3.0 equiv) and the reaction was heated to 55 ºC for 3 days. It was then acidified with 10 
mL of 2.0 M HCl and extracted with EtOAc (3x10 mL). The combined organic layers were 
dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give a yellow solid in 
quantitative yield which was used crude in the amide synthesis by Procedure H. The 
deuterated trans-racemic product was obtained as a white solid in 70% yield (500 mg, 1.51 
mmol) and confirmed by 1H NMR. 
Kinetic Isotope Effect Studies 
Two parallel reactions using trans-rac-N-(2-bromophenyl)-N-methyl-2-
phenylcyclopropanecarboxamide 250 and d-labeled trans-rac-N-(2-bromophenyl)-N-methyl-
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2-phenylcyclopropanecarboxamide 252 were performed on a 0.5 mmol scale in accordance 
with Procedure I.  A known amount of internal standard (1,3,6-trimethoxybenzene) was 
added to each reaction and the formation of the major product was monitored over time using 
1H NMR.  The product concentration for the major product was then plotted vs. time to 
determine the rate of reaction (kH and kD) for both reactions.  
entry [P] deuterated [P] non-deuterated time (min) 
1 0.028 0.056 30 
2 0.033 0.0714 45 
3 0.039 0.11 60 
4 0.053 0.1792 90 
5 0.07 0.21 120 
 
Linear equation for d-labeled substrate: y = 4.6897E-04x + 1.2241E-02 
Linear equation for normal substrate (1sa): y = 1.8363E-03x - 1.3862E-03 
kH/kD = 3.9 
Isomerization studies 
The studies were performed according to Procedure I and as stated in Scheme 94, and the 
results were analyzed by 1H NMR only, employing trimethoxybenzene as internal standard.  
Preparation of enantioenriched 250 
 
 
 
Preparation of enantioenriched 251 
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Enantioenriched samples of both trans- and cis- N-(2-bromophenyl)-N-methyl-2-
phenylcyclopropanecarboxamide  250 and 251 were synthesized as shown above, starting 
from either trans- or cis- cinnamyl alcohol via an asymmetric Simmons-Smith 
cyclopropanation according to the literature procedure.256 The enantioenriched trans- or cis- 
cyclopropanes were then oxidized to the corresponding carboxylic acid257 and then converted 
to their amide analogues via Procedure H.  The enantiomeric excess for both substrates were 
determined by SFC analysis on a chiral stationary phase. Enantioenriched 251 could not be 
separated by SFC; % ee was determined using the cis-carboxylic acid. For 250: (Ad-H 25 cm, 
5% MeOH, 5mL/min, 35ºC, 150 bar, 254 nm, tr (major) 4.3 min, tr (minor) 6.6 min). SFC 
trace:  
 
 
 235 
 
For 251: (Ad-H 25 cm, 5% MeOH, 5mL/min, 35ºC, 150 bar, 254 nm, tr (major) 5.49 min, tr 
(minor) 3.98 min). SFC trace: 
 
 
 
Epimerization Studies 
Two sets of reactions were set up and carried out in parallel using Procedure I on a 0.4 mmol 
scale (with enantioenriched 250 and 251). Samples were taken out of the reactions after 3 h 
and 21 h and analyzed by 1H NMR (diastereomeric ratio) and SFC. The SFC traces at 3 h are 
presented below.   
For 235a from 250: (Ad-H 25 cm, 5% MeOH, 5mL/min, 35ºC, 150 bar, 254 nm, tr (major) 
14.6, 11.3 min, tr (minor) 7.32, 8.22, 9.23 min). 
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For 235b from 251:(Ad-H 25 cm, 5% MeOH, 5mL/min, 35ºC, 150 bar, 254 nm, tr (major) 
11.2, 15.2 min, tr (minor) 7.36, 8.24 min). 
 
 
Racemic trace 235a and 235b: 
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Part 2 
Synthesis of 2-bromobenzoic acids 
2-Bromo-3,4,5-trimethoxybenzoic acid258 and 2-bromo-3,5-dimethylbenzoic acid259 were 
synthesized according to literature procedures. 
Synthesis of 2-halobenzamides 
X
O
OH
X = Cl, Br, I
i. (COCl)2 (1.2 equiv), THF
DMF (cat), rt , 30 min
ii. cyclopropylamine (1.2 equiv)
then Et3N (2.5 equiv), rt, 16 h X
O
NH
NaH (1.5 equiv)
THF, 0 °C
then MeI (7 equiv)
0 °C to rt, 16 h X
O
N
 
Procedure J: To a solution of the corresponding 2-halobenzoic acid (1.0 equiv) in THF (0.2 
M), was added 2-3 drops DMF.  Oxalyl chloride (1.2 equiv) was slowly added over 15 
minutes, causing bubbling and the formation of a bright yellow solution.  The reaction was 
stirred for 30 min or until complete by TLC. Then, cyclopropylamine (1.2 equiv) was added 
dropwise. After 10 min, Et3N (2.5 equiv)) was added slowly, forming a faint yellow 
precipitate. The reaction was stirred overnight (16 h) at ambient temperature. The reaction was 
quenched with 10% HCl (50 mL), dissolving the white precipitate, and then transferred to a 
250 mL separatory funnel. The layers were separated, and the aqueous layer was extracted 
with DCM (3x50 mL). The combined organics were then washed with brine (50 mL), dried 
over anhydrous Na2SO4, filtered and concentrated in vacuo to give the desired product as an 
off-white solid. The crude intermediate was dissolved in 50 mL THF, cooled to 0 °C, and NaH 
was added (1.5 equiv) forming a grey solution. After 15 min, MeI (7.0 equiv) was added 
dropwise. The reaction was allowed to warm up to ambient temperature and stirred overnight 
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(16 h). The reaction was quenched with water (50 mL), EtOAc (50 mL), and transferred to a 
250 mL separatory funnel. The layers were separated, and the aqueous layer was extracted 
with EtOAc (3x50 mL). The combined organics were washed with brine (50 mL), dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude was purified via column 
chromatography over silica gel to provide the desired product.  
 
2-Bromo-N-cyclopropyl-N-methylbenzamide (258): Synthesized according to Procedure J 
on a 8.25 mmol scale and then purified via column chromatography over silica gel (RediSep® 
Rf Gold 24g) in 10-50% EtOAc/Hex to give a yellow oil in 100% yield (2.09 g, 8.25 mmol). 
Mixture of rotamers. 1H NMR (CDCl3, 400 MHz): δ 7.49-7.44 (m, 1H), 7.29-7.23 (m, 1H), 
7.18-7.11 (m, 2H), 3.05 (s, 2.38H), 2.85-2.73 (m, 0.24H), 2.69 (s, 0.63H), 2.67-2.59 (m, 
0.80H), 0.84-0.74 (m, 0.86H), 0.41-0.39 (m, 2.93H) ppm. 13C NMR (CDCl3, 75 MHz): δ 
171.1, 170.6, 139.9, 138.9, 132.63, 132.50, 130.1, 129.8, 127.85, 127.71, 127.61, 127.2, 
118.98, 118.92, 36.3, 34.0, 31.9, 29.9, 9.3 (br), 7.68 (br), 6.7 (br) ppm. FTIR (cm-1) (neat): 
3012, 1637, 1455, 1362, 1076, 766. HRMS (APPI, Pos): calc. for C11H13BrNO [M+H]+: 
254.0182, found 254.0175 m/z. 
 
2-Iodo-N-cyclopropyl-N-methylbenzamide (258a): Synthesized according to Procedure J 
on a 12.4 mmol scale and then purified via column chromatography (5% EtOAc/Hex) to give 
a brown oil in 85% yield (3.17 g, 10.5 mmol). 1H NMR (CDCl3, 400 MHz): δ 7.80-7.76 (m, 
1H), 7.37-7.32 (m, 1H), 7.19-7.16 (m, 1H), 7.06-7.00 (m, 1H), 3.10 (s, 2.32H), 2.87-2.84 (m, 
0.26H), 2.74 (s, 0.76H), 2.69-2.66 (m, 0.79H), 0.87-0.84 (br m, 1.02H), 0.53-0.45 (br m, 
3.12H) ppm. 13C NMR (CDCl3, 75 MHz): δ 171.6, 171.2, 143.2, 142.2, 138.24, 138.12, 129.5, 
129.1, 127.8, 127.2, 126.75, 126.58, 126.3, 92.0, 91.7, 77.6, 77.2, 76.7, 36.0, 33.5, 31.6, 29.3, 
8.2 (br), 6.0 (br) ppm. FTIR (cm-1) (neat): 3050, 1634, 1381, 1210, 930. HRMS (APPI, Pos): 
calc. for C11H13INO [M+H]+: 302.0042, found 302.0036 m/z. 
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2-Chloro-N-cyclopropyl-N-methylbenzamide (258b): Synthesized according to Procedure 
J on a 12 mmol scale and then purified via column chromatography (5% EtOAc/Hex) to give 
a yellow oil in 91% yield (2.06 g, 9.82 mmol). 1H NMR (CDCl3, 400 MHz): δ 7.35-7.22 (m, 
4H), 3.07 (s, 2.35 H), 2.8-2.83 (m, 0.20 H), 2.73 (s, 0.58 H), 2.70-2.63 (m, 0.79H), 0.81-0.75 
(br m, 0.85H), 0.44-0.42 (br m, 3.17H) ppm. 13C NMR (CDCl3, 75 MHz): δ 169.3, 168.9, 
137.1, 136.1, 129.3, 129.09, 128.98, 128.63, 128.50, 127.04, 126.86, 126.5, 126.0, 35.2, 33.1, 
30.9, 29.0, 7.6 (br), 5.9 (br) ppm. FTIR (cm-1) (neat): 3060, 1637, 1482, 1433, 1319, 859 ppm. 
HRMS (APPI, Pos): calc. for C11H13ClNO [M+H]+: 210.0688, found 210.0680 m/z.  
 
 
2-Bromo-N-cyclopropyl-N,4-dimethylbenzamide (C1): Synthesized according to 
Procedure J on a 2.3 mmol scale and then purified via column chromatography (5% 
EtOAc/Hex) to give a yellow solid in 79% yield (0.49 g, 1.82 mmol). mp: 53 °C. 1H NMR 
(CDCl3, 400 MHz): δ 7.40 (dd, 1H, J = 8.0, 5.1 Hz), 7.05-7.00 (m, 2H), 3.10 (s, 2.17H), 2.90-
2.86 (m, 0.29H), 2.77 (s, 0.75H), 2.74-2.69 (m, 0.72H), 2.28 (s,3H), 0.91-0.80 (br m, 1.03H), 
0.49-0.47 (m, 2.9H) ppm. 13C NMR (CDCl3, 75 MHz ): δ 171.3, 170.8, 139.7, 138.7, 137.8, 
137.2, 132.3, 131.0, 128.2, 115.58, 115.48, 36.3, 32.0, 29.8, 20.8, 9.5 (br), 7.5 (br), 6.8 (br) 
ppm. FTIR (cm-1) (neat): 3002, 1635, 1508, 1020, 815, 630, 591. HRMS (APPI, Pos): calc. for 
C12H15BrNO [M+H]+: 268.0340, found 268.0332 m/z.  
 
2-Bromo-N-cyclopropyl-N,5-dimethylbenzamide (C2): Synthesized according to 
Procedure J on a 10.0 mmol scale and then purified via column chromatography (5% 
EtOAc/Hex) to give a brown oil in 21% yield (0.55 g, 2.05 mmol). 1H NMR (CDCl3, 400 
MHz): δ 7.38 (m, 1H), 7.13 (m, 2H), 3.10 (s, 2.33H), 2.89-2.87 (m, 0.29H), 2.77 (s, 0.68H), 
2.72-2.69 (m, 0.79H), 2.34 (s, 3H), 0.90-0.81 (br m, 1H), 0.50-0.47 (br m, 2.96H) ppm. 13C 
NMR (CDCl3, 75 MHz): δ 170.9, 170.5, 140.1, 139.7, 136.7, 135.7, 132.60, 132.49, 128.2, 
127.6, 127.3, 127.1, 118.43, 118.36, 36.0, 33.7, 31.6, 29.6, 20.6, 8.2 (br), 6.3 (br), 5.90 (br) 
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ppm. FTIR (cm-1) (neat): 2922, 1640, 1380, 1287, 1028, 821, 576. HRMS (APPI, Pos): calc. 
for C12H15BrNO [M+H]+: 268.0340, found 268.0332 m/z. 
 
2-Bromo-N-cyclopropyl-N, 3,5-trimethylbenzamide (C3): Synthesized according to 
Procedure J on a 8.1 mmol scale and then purified via column chromatography (5% 
EtOAc/Hex) to give a yellow oil in 83% yield (1.89 g, 6.69 mmol). 1H NMR (CDCl3, 400 
MHz): 7.07-6.85 (m, 2H), 3.08 (s, 1.14H), 3.04 (s, 0.70H), 2.91-2.83 (m, 0.26H), 2.74 (s, 
0.53H), 2.73-2.64 (m, 0.46H), 2.37-2.26 (m, 6H), 0.88-0.81 (m, 1.26H), 0.65-0.55 (br m, 
1.31H), 0.54-0.39 (br m, 2.21H) ppm. 13C NMR (CDCl3, 75 MHz) δ 172.1, 171.5, 140.4, 
139.4, 138.6, 138.3, 137.1, 131.8, 131.6, 131.2, 126.0, 125.6, 125.1, 118.1, 36.4, 34.1, 32.1, 
30.0, 23.2, 23.2, 21.4, 20.9, 9.7 (br), 7.4 (br), 6.7 (br) ppm. FTIR (cm-1) (neat): 3275, 2921, 
1672, 1602, 1417, 1113, 963, 835, 63. HRMS (APPI, Pos): calc. for C13H17BrNO [M+H]+: 
282.0481, found 282.0488 m/z.  
 
2-Bromo-N-cyclopropyl-4-fluoro-N-methylbenzamide (C4): Synthesized according to 
Procedure J on a 10.0 mmol scale and then purified via column chromatography (5% 
EtOAc/Hex) to give an off-white solid in 87% yield (2.36 g, 8. 66 mmol). mp: 54 °C. 1H NMR 
(CDCl3, 400 MHz): δ  7.32-7.28 (m, 1H), 7.26-7.20 (m, 1H), 7.05 (td, 1H, J = 8.0, 3.0 Hz), 
3.09 (s, 2.44H), 2.85 (dt, 0.21H, J = 12.0, 6.0 Hz), 2.76 (s, 0.64H), 2.68 (dt, 0.82 H, J = 11.5, 
5.5 Hz), 0.90-0.79 (br m, 0.88H), 0.51-0.48 (br m, 3.12H) ppm. 13C NMR (CDCl3, 75MHz): δ 
170.1, 169.6, 161.9 (d, JC-F = 252.0 Hz), 161.7 (d, JC-F = 252.0 Hz), 136.1 (d, JC-F = 4.0 Hz) 
135.1 (d, JC-F = 4.0 Hz), 129.0 (d, JC-F = 9.0 Hz), 128.8, 119.8 (d, JC-F = 25.0 Hz), 119.6 (d, JC-
F = 25.0 Hz), 119.3 (d, JC-F = 9.0 Hz), 119.3 (d, JC-F = 9.0 Hz), 115.0 (d, JC-F = 22.0 Hz), 114.4 
(d, JC-F = 22.0 Hz), 36.1, 33.9, 31.7, 29.7, 8.5 (br), 6.5 (br) ppm. 19F NMR (CDCl3, 282 MHz): 
δ -109.9 (m), -110.4 (m) ppm. FTIR (cm-1) (neat): 3016, 1637, 1418, 931, 826. HRMS (APPI, 
Pos): calc. for C11H12BrFNO [M+H]+: 272.0087, found 272.0081 m/z.  
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2-Bromo-N-cyclopropyl-5-fluoro-N-methylbenzamide (C5): Synthesized according to 
Procedure J on a 2.0 mmol scale and then purified via column chromatography (5% 
EtOAc/Hex) to give a light pink solid in 32% yield (0.17 g, 0.63 mmol). mp: 52 °C. 1H NMR 
(CDCl3, 400 MHz): δ 7.51-7.48 (m, 1H), 6.98-6.93 (m, 2H), 3.10 (m, 2.35 H), 2.87-2.85 (m, 
0.24H), 2.77 (s, 0.59H), 2.72-2.67 (m, 0.79H), 0.90-0.80 (br m, 0.90H), 0.64-0.45 (br m, 
3.21H) ppm. 13C NMR (CDCl3, 75 MHz): δ 170.0, 162.1 (d, JC-F = 249.0 Hz), 161.8 (d, JC-F = 
249.0 Hz), 141.7 (d, JC-F = 7.0 Hz), 140.6 (d, JC-F = 7.0 Hz), 134.5 (d, JC-F = 8.0 Hz), 134.3 (d, 
JC-F = 8.0 Hz), 117.6 (d, JC-F = 23.0 Hz), 117.4 (d, JC-F = 23.0 Hz), 115.4 (d, JC-F = 24.0 Hz), 
115.3 (d, JC-F = 24.0 Hz), 113.6, 36.4, 34.3, 32.0, 30.14, 30.14, 6.94 (br). 19F NMR (CDCl3, 
282 MHz): δ -113.4 (ddd, JC-F = 8.0, 5.0, 5.0 Hz),-114.2 (ddd, JC-F = 8.0, 5.0, 5.0 Hz) ppm. 
FTIR (cm-1) (neat): 2923, 1638, 1433, 1361, 1026, 893, 815, 588. HRMS (APPI, Pos): calc. 
for C11H12BrFNO [M+H]+: 272.0087, found 272.0081 m/z.  
Br
O
NF
F  
 
2-Bromo-N-cyclopropyl-4,5-difluoro-N-methylbenzamide (C6): Synthesized according to 
Procedure J on a 7.8 mmol scale and then purified via column chromatography (5% 
EtOAc/Hex) to give a light orange solid in 68% yield (1.55 g, 5.34 mmol). mp: 61 °C. 1H 
NMR (CDCl3, 400 MHz): δ 7.43-7.38 (m, 1H), 7.13-7.07 (m, 1H), 3.08 (s, 2.42H), 2.86-2.85 
(m, 0.29H), 2.79 (s, 0.66H), 2.72-2.68 (m, 0.82H), 0.93-0.77 (br m, 0.90H), 0.55-0.50 (m, 
2.91H) ppm. 13C NMR (CDCl3, 75 MHz): δ 150.2 (dd, JC-F = 255.0, 14.0 Hz), 149.7 (dd, JC-F 
= 252.0, 13.0 Hz), 136.8 (t, JC-F = 5.0 Hz),122.1 (dd, JC-F = 20.0 Hz), 117.0 (dd, JC-F = 20.0 
Hz),  113.3 (dd, JC-F = 7.0, 4.0 Hz), 36.5, 34.4, 32.0, 30.2, 9.0 (br) ppm. 19F NMR (282 MHz, 
CDCl3): δ -133.5 (m), -134.0 (m), -136.8 (m), -137.6 (m) ppm. FTIR (cm-1) (neat): 2924, 
1638, 1430, 1293, 887, 797, 594. HRMS (APPI, Pos): calc. for C11H11BrF2NO [M+H]+: 
289.9990, found 289.9987 m/z.  
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2-Bromo-N-cyclopropyl-4-methoxy-N-methylbenzamide (C7): Synthesized according to 
Procedure J on a 12.5 mmol scale and then purified via column chromatography (5% 
EtOAc/Hex) to give a yellow oil in 90% yield (3.20 g, 11.3 mmol). 1H NMR (CDCl3, 400 
MHz): δ 7.45-7.40 (m, 1H), 6.79-6.76 (m, 2H), 3.80 (s, 3.83H), 3.11 (s, 3H), 2.91-2.86 (m, 
0.51H), 2.80 (s, 1.22H), 2.76-2.73 (m, 1.11H), 0.96-0.81 (m, 3.58H), 0.53-0.50 (m, 2.88H) 
ppm. 13C NMR (CDCl3, 75 MHz): δ 170.6, 170.2, 158.9, 158.5, 140.4, 139.4, 133.2, 133.1, 
116.2, 115.7, 113.1, 112.6, 109.1, 108.9, 55.4, 36.0, 33.8, 31.7, 29.7, 9.1 (br), 7.6 (br), 6.5 (br) 
ppm. FTIR (cm-1) (neat): 3009, 1638, 1462, 1304, 12355, 1014, 815, 597. HRMS (APPI, Pos): 
calc. for C12H15BrNO2 [M+H]+: 284.0287, found 284.0281 m/z.  
 
2-Bromo-N-cyclopropyl-3,4,5-trimethoxy-N-methylbenzamide (C8): Synthesized 
according to Procedure J on a 10.0 mmol scale and then purified via column chromatography 
(5% EtOAc/Hex) to give a pink solid in 50% yield (1.70 g, 4.95 mmol). mp: 52 °C. 1H NMR 
(CDCl3, 400 MHz): δ 6.58 (s, 1H), 3.86-3.82 (m, 6 H), 3.82-3.81 (m, 3H), 3.07 (s, 2.17H), 
2.89-2.82 (m, 3.29H), 2.76 (s, 0.82H), 2.73-2.68 (m, 0.72H), 0.90-0.75 (m, 1.24H), 0.63-0.56 
(m, 0.72H), 0.56-0.48 (m, 2.31H) ppm. 13C NMR (CDCl3, 75 MHz): δ 171.0, 170.5, 153.6, 
153.2, 151.17, 151.06, 143.48, 143.34, 135.5, 134.5, 106.9, 106.4, 105.9,  61.3, 61.3, 56.4, 
56.4 36.4, 34.2, 32.0, 30.1, 7.2 (br), 6.5 (br) ppm. FTIR (cm-1) (neat): 3263, 3006, 1643, 1421, 
1193, 1053, 752, 532 ppm. HRMS (APPI, Pos): calc. for C14H19BrNO4 [M+H]+: 344.0503, 
found 344.0492 m/z.  
 
N-Benzyl-2-bromo-N-cyclopropylbenzamide (263):  
Following the first part of Procedure J, the intermediate 2-bromo-N-cyclopropylbenzamide 
was benyzlated as follows: 
The intermediate (0.50 g, 2.08 mmol) was dissolved in DMF (10 mL) in a 50-mL round-
bottom flask. Cs2CO3 (1.35 g, 4.16 mmol, 2.0 equiv) was then added, followed by 
tetrabutylammonium iodide (TBAI) (77.0 mg, 0.02 mmol, 0.1 equiv). After stirring for 10 
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min, benzyl bromide (0.27 mL, 2.29 mmol, 2.0 equiv) was added to the cloudy cream-colored 
solution. The reaction was stirred for 16 h at ambient temperature, then quenched with 25 mL 
water and transferred to a 125-mL separatory funnel. The aqueous layer was extracted with 
EtOAc (3x25mL). The combined organic layers were washed with 5% LiCl solution (25 mL) 
to remove any trace DMF, and with brine (25 mL); then, dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo to give a brown oil. The crude product was purified via 
column chromatography over silica gel (RediSep® Rf Gold 24g) in 5-50% EtOAc/Hex. The 
desired product 263 was isolated as a yellow oil (0.44 g, 1.49 mmol, 72% yield). 1H NMR 
(CDCl3, 400 MHz): δ 7.47-7.06 (m, 9H), 4.73-4.61 (br m, 1.16H), 4.63 (s, 0.97H), 4.21 (d, J = 
9.5 Hz, 0.30H), 3.18 (br m, 0.43H) 2.62-2.54 (m, 0.14H), 2.48-2.40 (m, 0.60H), 0.90-0.30 (m, 
3.22H) ppm. 13C NMR (CDCl3, 75 MHz): δ 171.36, 171.17, 141.1, 139.8, 138.4, 137.6, 136.9, 
132.87, 132.84, 132.80, 130.5, 130.0, 128.75, 128.65, 128.62, 128.58, 128.00, 127.80, 127.67, 
127.62, 127.48, 127.35, 127.25, 127.06, 119.5, 119.2, 65.4, 53.2, 50.2, 30.7, 28.6, 9.8 (br), 8.7 
(br), 7.0 (br) ppm. FTIR (cm-1) (neat): 3435, 2923, 1639, 1454, 1046, 768, 697, 505. HRMS 
(APPI, Pos): calc. for C17H17BrNO [M+H]+: 330.0493, found 330.0488 m/z. 
Synthesis of Benzo[c]azepin-1-ones 
Procedure K: To a 5 mL microwave vial in a glovebox was added in the following order: 
Pd(OAc)2 (5.6 mg, 0.025 mmol), PtBu3•HBF4 (7.2 mg, 0.025 mmol), K2CO3 (76 mg, 0.55 
mmol) and Ag3PO4 (69.1 mg, 0.16 mmol). The vial was crimped shut and taken out of the 
glovebox. The corresponding cyclopropylbenzamide (0.50 mmol) was weighed into a vial, 
dissolved in 0.5 mL of toluene and added to the reaction vial. The vial was rinsed with 4x0.5 
mL of toluene for a total volume of 2.5 mL. The solution was then heated to 125 °C in an oil 
bath for 16 h. The reaction turned black within five minutes. The reaction was cooled to 
ambient temperature, filtered over a cotton-Celite® plug, and rinsed with EtOAc (25 mL). It 
was then concentrated in vacuo to give the crude product, which was purified via column 
chromatography over silica gel (RediSep® Rf Gold 24g) in 10-50% EtOAc/Hex to provide the 
cyclized products. 
 
2-methyl-2,5-dihydro-1H-benzo[c]azepin-1-one (259) and  
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2-methyl-2,3-dihydro-1H-benzo[c]azepin-1-one (260): Synthesized according to Procedure 
K to give 259 as an orange oil in 66% yield (58 mg, 0.34 mmol) and 260 as an orange oil in 
26% yield (23 mg, 0.13 mmol).  
259: 1H NMR (CDCl3, 400 MHz): δ 7.87-7.84 (m, 1H), 7.37 (td, 1H, J = 7.4, 1.4 Hz), 7.30-
7.25 (m, 2H), 7.06 (d, 1H, J = 7.6 Hz), 5.96 (d, 1H, J = 7.5 Hz), 5.62 (q, 1H, J = 7.3 Hz), 3.28 
(s, 3H), 3.21 (d, 2H, J = 7.2 Hz) ppm. 13C NMR (CDCl3, 75MHz): δ 169.5, 143.4, 134.0, 
131.6, 131.3, 130.7, 126.6, 126.2, 117.8, 36.4, 31.4 ppm. FTIR (cm-1) (neat): 2924, 1656, 
1364, 1285, 735, 609. HRMS (APPI, Pos): calc. for C11H12NO [M+H]+: 174.0914, found  
174.0913 m/z.  
260: 1H NMR (CDCl3, 400 MHz): δ 8.03-8.01 (m, 1H), 7.46-7.36 (m, 2H), 7.22-7.20 (m, 1H), 
6.81 (d, 1H, J = 9.9 Hz), 6.41-6.35 (m, 1H), 3.62 (d, 2H, J = 6.8 Hz), 3.22 (s, 3H) ppm. 13C 
NMR (CDCl3, 75 MHz): δ 168.8, 135.6, 134.7, 131.2, 130.3, 129.8, 128.5, 127.8, 106.2, 46.3, 
36.5 ppm. FTIR (cm-1) (neat): 2923, 1688, 1428, 756, 708, 595. HRMS (APPI, Pos): calc. for 
C11H12 NO [M+H]+: 174.0914, found 174.0913 m/z. 
 
2-methyl-1a,2-dihydro-1H-cyclopropa[c]isoquinolin-3(7bH)-one (261): Synthesized 
according to Procedure K, using PCy3 instead of PtBu3•HBF4 as a ligand at 135 oC, to give 
an orange oil in 39% yield (34 mg, 0.20 mmol). 1H NMR (CDCl3, 400 MHz): δ  8.15 (d, 1H, J 
= 7.6 Hz), 7.44-7.36 (m, 2H), 7.31-7.27 (m, 1H), 3.25 (s, 3H), 3.14 (ddd, 1H, J = 8.2, 6.5, 3.9 
Hz), 2.30 (ddd, 1H, J = 9.6, 8.3, 5.8 Hz), 1.34 (ddd, 1H, J = 9.8, 6.4, 5.2 Hz), 0.28-0.24 (m, 
1H) ppm. 13C NMR (CDCl3, 75 MHz): δ 161.5, 139.2, 131.8, 129.0, 128.2, 126.6, 125.5, 36.3, 
34.9, 15.0, 13.7 ppm. FTIR (cm-1) (neat): 2928, 1621, 1333, 903, 724, 649. HRMS (APPI, 
Pos): calc. for C11H12NO [M+H]+: 174.0914, found 174.0913 m/z.  
 
2'-methylspiro[cyclopropane-1,1'-isoindolin]-3'-one (262): Synthesized according to 
Procedure K, using PCy3 instead of PtBu3•HBF4 as a ligand at 135 oC,  to give an orange oil 
in 15% yield (13 mg, 0.075 mmol). 1H NMR (CDCl3, 400 MHz): δ 7.88 (d, 1H, J = 7.6 Hz), 
7.52-7.48 (m, 1H), 7.42 (td, 1H, J = 7.4, 0.7 Hz), 7.05 (d, 1H, J = 7.6 Hz), 2.87 (s, 3H), 1.59-
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1.56 (m, 2H), 1.36-1.33 (m, 2H) ppm. 13C NMR (CDCl3, 75 MHz): δ 168.1, 147.2, 131.8, 
131.4, 127.4, 123.6, 117.7, 45.1, 24.0, 10.3 ppm. FTIR (cm-1) (neat): 3502, 2926, 1722, 1591, 
1472, 765, 690. HRMS (APPI, Pos): calc. for C11H12NO [M+H]+: 174.0914, found 174.0913 
m/z.  
 
2,7-dimethyl-2,5-dihydro-1H-benzo[c]azepin-1-one (268) and 2,7-dimethyl-2,3-dihydro-
1H-benzo[c]azepin-1-one (269): Synthesized according to Procedure K to give 268 as a 
yellow oil in 71% yield (65 mg, 0.35 mmol) and 269 as a yellow oil in 27% yield (25 mg, 0.13 
mmol).  
268: 1H NMR (CDCl3, 400 MHz): δ 7.68 (s, 1H), 7.17 (d, 1H, J = 8.0 Hz), 6.95 (dd, 1H, J = 
7.7, 2.7 Hz), 5.94 (dd, 1H, J = 8.0, 3.0 Hz), 5.62 (qd, 1H, J = 7.0, 3.0 Hz), 3.27 (s, 3H), 3.17 
(dd, 2H, J = 7.0, 3.0 Hz), 2.33 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz):  δ 169.7, 140.6, 
136.3, 133.7, 132.4, 131.6, 130.5, 126.1, 118.1, 36.5, 30.9, 21.0 ppm. FTIR (cm-1) (neat): 
3325, 2952, 1626, 1602, 1405, 1098, 752, 681. HRMS (APPI, Pos): calc. for C12H14NO 
[M+H]+: 188.1079, found 188.1070 m/z.  
269: 1H NMR (CDCl3, 400 MHz): δ 7.82 (s, 1H), 7.23 (s, 1H), 7.11-7.09 (m, 1H), 6.78 (d, 1H, 
J = 9.8 Hz), 6.34-6.28 (m, 1H), 3.60 (d, 2H, J = 6.8 Hz), 3.21 (s, 3H), 2.40 (s, 3H) ppm. 13C 
NMR (CDCl3, 75 MHz): δ 168.8, 137.7, 135.2, 134.5, 132.0, 131.28, 131.21, 128.6, 128.4, 
46.3, 36.3, 21.2 ppm. FTIR (cm-1) (neat): 3339, 2921, 1626, 1603, 1391, 835, 713. HRMS 
(APPI, Pos): calc. for C12H14NO (M+H)+: 188.1077, found 188.1070 m/z.  
 
2,8-dimethyl-2,5-dihydro-1H-benzo[c]azepin-1-one (270) and 2,8-dimethyl-2,3-dihydro-
1H-benzo[c]azepin-1-one (271): Synthesized according to Procedure K to give 270 as an 
orange oil in 62% yield (57 mg, 0.31 mmol) and 271 as an orange oil in 30% yield (28 mg, 
0.15 mmol). 
270: 1H NMR (CDCl3, 400 MHz): δ  7.76 (d, 1H, J = 7.9 Hz), 7.09 (d, 1H, J = 7.9 Hz), 6.87 
(s, 1H), 5.95 (d, 1H, J = 7.6 Hz), 5.63-5.57 (m, 1H), 3.27 (s, 3H), 3.17 (d, 2H, J = 7.2 Hz), 
2.34 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): δ 169.4, 143.2, 142.0, 131.29, 131.11, 130.7, 
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127.4, 126.8, 117.5, 36.4, 31.3, 21.3 ppm. FTIR (cm-1) (neat): 3332.42, 2921, 1608, 1389, 
1282, 1151, 764. HRMS (APPI, Pos): calc. for C12H14NO [M+H]+: 188.1077, found 188.1070 
m/z. 
 271: 1H NMR (CDCl3, 400 MHz): δ  7.91 (d, 1H, J = 8.0 Hz), 7.19 (d, 1H, J = 8.0), 7.01 (s, 
1H), 6.76 (d, 1H, J = 10 Hz), 6.37-6.31 (m, 1H), 3.61 (d, 2H, J = 7.0 Hz,), 3.19 (s, 3H), 2.36 
(s, 3H) ppm. 13C NMR (CDCl3, 75 MHz):  δ 169.0, 140.6, 134.78, 134.71, 132.8, 131.2, 
129.5, 128.91, 128.81, 46.4, 36.4, 21.4 ppm. FTIR (cm-1) (neat): 3305, 2922, 1621, 1605, 
1394, 1064, 832, 755. HRMS (APPI, Pos): calc. for C12H14NO [M+H]+: 188.1077, found 
188.1070 m/z. 
 
2,6,8-trimethyl-2,5-dihydro-1H-benzo[c]azepin-1-one (272) and 2,6,8-Trimethyl-2,3-
dihydro-1H-benzo[c]azepin-1-one (273): Synthesized according to Procedure K to give 272 
as an orange oil in 81% yield (72 mg, 0.36 mmol) and  273 as an orange oil in 13% yield (12 
mg, 0.59 mmol).  
272: 1H NMR (CDCl3, 400 MHz): δ 7.48 (d, 1H, J = 1.0 Hz), 7.07 (d, 1H, J = 1.0 Hz), 5.98 (d, 
1H, J = 7.0 Hz), 5.62 (dt, 1H, J = 15.0, 7.0 Hz), 3.28 (s, 3H), 3.17 (d, 2H, J = 8.0 Hz), 2.33 (s, 
3H), 2.29 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): δ 170.4, 139.2, 135.6, 134.5, 134.1, 
132.3, 130.9, 129.3, 117.6, 36.3, 26.0, 20.9, 19.9. FTIR (cm-1) (neat): 3350, 2920, 1625, 1600, 
1385, 1119, 1042, 774, 722. HRMS (APPI, Pos): calc. for C13H16NO [M+H]+: 202.1236, 
found 202.1236 m/z.  
273:  1H NMR (CDCl3, 400 MHz): δ  7.60 (td, 1H, J = 0.7, 0.4 Hz), 7.08 (ddd, 1H, J = 1.1, 
0.8, 0.5 Hz), 6.83-6.80 (m, 1H), 6.37-6.31 (m, 1H), 3.56 (d, 2H, J = 7.0 Hz), 3.18 (s, 3H), 2.33 
(s, 3H), 2.29 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): δ 169.2, 141.9, 137.6, 136.9, 133.0, 
131.7, 128.9, 128.4, 123.0, 46.32, 46.30, 29.8, 21.2, 20.3 ppm. FTIR (cm-1) (neat): 3276, 2920, 
1629, 1601, 1094, 1035, 814. HRMS (APPI, Pos): calc. for C13H16NO [M+H]+: 202.1236, 
found 202.1226 m/z.  
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7-fluoro-2-methyl-2,5-dihydro-1H-benzo[c]azepin-1-one (274) and 7-fluoro-2-methyl-2,3-
dihydro-1H-benzo[c]azepin-1-one (275): Synthesized according to Procedure K to give 274 
as a yellow oil in 54% yield (51 mg, 0.27 mmol) and 275 as a yellow oil in 31% yield (29 mg, 
0.15 mmol).  
274: 1H NMR (CDCl3, 400 MHz): δ 7.86 (dd, 1H, J = 9.0, 6.0 Hz), 6.99-6.96 (m, 1H), 6.78-
6.75 (m, 1H), 5.98 (dt, 1H, J = 8.0, 1.0 Hz), 5.61-5.59 (m, 1H), 3.27 (s, 3H), 3.19 (d, 2H, J = 
7.0Hz) ppm. 13C NMR (CDCl3, 75 MHz): δ 168.3, 164.5 (d, JC-F = 252.1 Hz), 145.7 (d, JC-F = 
8.0 Hz), 133.7 (d, JC-F = 9.3 Hz), 131.0, 130.1 (d, JC-F = 3.0 Hz) 116.9, 113.6 (d, JC-F = 21.3 
Hz), 113.0 (d, JC-F = 21.8 Hz) 36.3, 31.2 ppm. 19F NMR (CDCl3, 282 MHz): δ -109.0 (ddd, J = 
2 3.0, 8.0, 6.0 Hz) ppm. FTIR (cm-1) (neat): 2922, 1621, 1604, 1276, 1060, 900, 742. HRMS 
(APPI, Pos): calc. for C11H11FNO [M+H]+: 192.0828, found: 192.0819 m/z.  
275: 1H NMR (CDCl3, 400 MHz): δ 8.03 (ddd, 1H, J = 9.0, 6.0, 0.3 Hz), 7.07 (td, 1H, J = 8.4, 
3.0 Hz), 6.88 (dd, 1H, J = 9.0, 3.0 Hz), 6.75 (d, 1H, J = 10.0 Hz), 6.44-6.40 (m, 1H), 3.63 (d, 
2H, J = 7.0 Hz), 3.20 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): δ 168.0, 163.5 (d, JC-F = 251.0 
Hz), 137.1 (d, JC-F = 8.4 Hz), 133.4, 133.9 (d, JC-F = 2.0 Hz), 133.8, 131.9 (d, JC-F = 2.8 Hz), 
130.9, 115.3 (d, JC-F = 21.7 Hz), 114.5 (d, JC-F = 21.6 Hz), 46.2, 36.5 ppm. 19F NMR (CDCl3, 
282 MHz): δ -110.3 (dd, J = 14.6, 8.2 Hz) ppm. FTIR (cm-1) (neat): 2925, 1619, 1600, 1478, 
1432, 1237, 936, 799, 760, 572, 432. HRMS (APPI, Pos): calc. for C11H11FNO [M+H]+: 
192.0817, found 192.0819 m/z.  
 
8-fluoro-2-methyl-2,5-dihydro-1H-benzo[c]azepin-1-one (276) and 8-fluoro-2-methyl-2,3-
dihydro-1H-benzo[c]azepin-1-one (277): Synthesized according to Procedure K to give 276 
as a yellow oil in 64% yield (59 mg, 0.31 mmol) and 277 as a yellow oil in 24% yield (22 mg, 
0.12 mmol). 
276: 1H NMR (CDCl3, 400 MHz):  δ 7.58 (dd, 1H, J = 10.0, 3.0 Hz), 7.10-7.04 (m, 2H), 5.97 
(d, 1H, J = 7.6 Hz), 5.69-5.63 (m, 1H), 3.30 (s, 3H), 3.20 (d, 2H, J = 7.0 Hz) ppm. δ 13C NMR 
(CDCl3, 75 MHz): δ 168.2, 161.4 (d, JC-F = 244.0 Hz), 139.3 (d, JC-F = 4.0 Hz), 135.6 (d, J= 
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7.0 Hz), 130.5, 127.8 (d, JC-F = 8.0 Hz), 118.5 (d, JC-F = 22.0 Hz), 118.0 117.9 (d, JC-F = 24.0 
Hz), 36.5, 30.5 ppm. 19F NMR (CDCl3, 282 MHz): δ -116.5 (m) ppm. FTIR (cm-1) (neat): 
3345, 2926, 1625, 1582, 1489, 1321, 719, 545. HRMS (APPI, Pos): calc. for C11H11FNO 
[M+H]+: 192.0828, found 192.0819 m/z.  
277: 1H NMR (CDCl3, 400 MHz):  δ 7.72-7.70 (m, 1H), 7.22-7.11 (m, 2H), 6.77 (d, 1H, J = 
10.0 Hz), 6.36-6.33 (m, 1H), 3.62 (d, 2H, J = 7.0 Hz), 3.20 (s, 3H) ppm. 13C NMR (CDCl3, 75 
MHz): δ 167.5, 161.9 (d, JC-F = 249.0 Hz), 137.7 (d, JC-F = 7.0 Hz), 133.8, 131.10 (d, JC-F = 
3.0 Hz), 130.7 (d, JC-F = 8.0 Hz), 129.2, 118.0 (d, JC-F = 22.0 Hz), 117.7 (d, JC-F = 23.0 Hz), 
46.3, 36.5 ppm. 19F NMR (CDCl3, 282 MHz): δ -113.0 (m) ppm. FTIR (cm-1) (neat): 3271, 
2923, 1627, 1606, 1484, 1393, 1026, 756, 557. HRMS (APPI, Pos): calc. for C11H11FNO 
([M+H]+: 192.0828, found 192.0819 m/z. 
 
7,8-difluoro-2-methyl-2,5-dihydro-1H-benzo[c]azepin-1-one (278) and 7,8-difluoro-2-
methyl-2,3-dihydro-1H-benzo[c]azepin-1-one (279): Synthesized according to Procedure K 
to give 278 as an orange oil in 69% yield (69 mg, 0.33 mmol) and 279 as an orange oil in 15% 
yield (15 mg, 0.73 mmol).  
278: 1H NMR (CDCl3, 400 MHz): δ 7.70 (dd, 1H, J = 11.1, 8.2 Hz), 6.88 (dd, 1H, J = 10.2, 
7.4 Hz), 5.98 (dt, 1H, J = 7.6, 0.9 Hz), 5.65-5.59 (m, 1H), 3.27 (s, 3H), 3.17 (d, 2H, J = 7.2 
Hz, 2H) ppm. 13C NMR (CDCl3, 75MHz): δ 167.3, 152.2 (dd, JC-F = 227.0, 13.0 Hz), 148.9 
(dd, JC-F = 220.0, 13.0 Hz), 140.3 (dd, JC-F = 6.0, 4.0 Hz), 131.0, 130.6 (dd, JC-F = 5.0, 3.5 Hz), 
122.0 (d, JC-F = 20.0 Hz),  120.5 (dd, JC-F = 19.0, 1.5 Hz), 117.2, 117.0 (d, JC-F = 20.0 Hz), 
115.0 (d, JC-F = 18.0 Hz), 36.6, 30.6 ppm. 19F NMR (CDCl3, 282 MHz): δ -133.3 (m), -140.8 
(m) ppm. FTIR (cm-1) (neat): 3280, 2920, 1658, 1615, 1508, 1439, 1387, 1157, 957, 758, 548. 
HRMS (APPI, Pos): calc. for C11H10F2NO [M+H]+ : 210.0724, found 210.0725 m/z.  
279: 1H NMR (CDCl3, 400 MHz): δ 7.85 (dd, 1H, J = 11.2, 8.2 Hz), 7.00 (dd, 1H, J = 10.7, 
7.6 Hz), 6.70 (d, 1H, J = 9.9 Hz), 6.42-6.36 (m, 1H), 3.63 (d, 1H, J = 6.9 Hz), 3.19 (s, 3H) 
ppm. 13C NMR (CDCl3, 75 MHz): δ 166.7, 151.3 (dd, JC-F = 254.0, 13.0 Hz), 149.6 (dd, JC-F = 
252.0, 13.0 Hz), 132.9 (d, JC-F = 1.0 Hz), 132.6 (dd, JC-F = 5.0, 3.0 Hz), 132.1 (dd, JC-F = 7.0, 
4.0 Hz), 130.3 (d, JC-F = 2.0 Hz), 120.3 (dd, JC-F = 19.0, 2.0 Hz), 116.7 (d, JC-F = 17.0 Hz), 
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46.1, 36.5 ppm. 19F NMR (CDCl3, 282 MHz): δ -134.1 (m), -137.2 (m) ppm. FTIR (cm-1) 
(neat): 3047, 2923, 1626, 1613, 1479, 1278, 886, 818, 754, 606. HRMS (APPI, Pos): calc. for 
C11H10F2NO [M+H]+ : 210.0733, found 210.0725 m/z.  
 
7-methoxy-2-methyl-2,5-dihydro-1H-benzo[c]azepin-1-one (280) and 7-methoxy-2-
methyl-2,3-dihydro-1H-benzo[c]azepin-1-one (281): Synthesized according to Procedure K 
to give 280 as an orange oil in 51% yield (51 mg, 0.25 mmol), and 281 as an orange oil in 
43% yield (43 mg, 0.21 mmol).  
280: 1H NMR (CDCl3, 400 MHz): δ 7.41 (d, 1H, J = 2.0 Hz), 6.98-6.91 (m, 2H), 5.93 (d, 1H, 
J = 8.0 Hz), 5.67-5.61 (dt, 1H, J = 15.0, 7.0 Hz), 3.81 (s, 3H), 3.28 (s, 3H), 3.15 (d, 2H, J = 
7.2 Hz) ppm. 13C NMR (CDCl3, 75 MHz): δ 169.4, 158.3, 136.0, 134.7, 130.34, 130.29, 
127.4, 118.60, 118.44, 115.0, 55.6, 36.6, 30.4 ppm. FTIR (cm-1) (neat): 3328, 1626, 1601, 
1282, 1032, 750. HRMS (APPI, Pos): calc. for C12H14NO2 [M+H]+: 204.1027, found 204.1019 
m/z.  
281: 1H NMR (CDCl3, 400 MHz): δ 7.51 (t, 1H, J = 2.5 Hz), 7.12 (dd, 1H, J = 8.7, 2.4 Hz), 
7.01-6.98 (m, 1H), 6.76-6.73 (m, 1H), 6.27-6.21 (m, 1H), 3.86, 3.60 (d, 2H, J = 6.8 Hz), 3.20 
(s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): δ 168.5, 158.9, 136.7, 134.3, 130.2, 128.0, 127.4, 
118.2, 114.2, 55.6, 46.5, 36.4 ppm. FTIR (cm-1) (neat): 3356, 2928, 1626, 1601, 1481, 1233, 
1030, 789. HRMS (APPI, Pos): calc. for C12H14NO2 [M+H]+: 204.1028, found 204.1019 m/z.  
 
6,7,8-trimethoxy-2-methyl-2,5-dihydro-1H-benzo[c]azepin-1-one (282) and 6,7,8-
trimethoxy-2-methyl-2,3-dihydro-1H-benzo[c]azepin-1-one (283): Synthesized according 
to Procedure K to give 282 as an orange oil in 17% yield (22 mg, 0.08 mmol), and 283 as an 
orange oil in 10% yield (12.8 mg, 0.05 mmol).  
282: 1H NMR (CDCl3, 400 MHz): δ 7.23 (s, 1H), 5.97 (d, 1H, J = 8.0 Hz), 5.61 (dt, 1H, J = 
15.0, 8.0 Hz), 3.90, (s, 3H), 3.87 (s, 3H), 3.82 (s, 3H), 3.28 (s, 3H), 3.23 (d, 2H, J = 7.3 Hz) 
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ppm. 13C NMR (CDCl3, 75 MHz): δ 169.1, 151.6, 148.2, 145.2, 131.1, 130.4, 129.5, 118.1, 
109.9, 61.0, 56.1, 36.6, 22.2 ppm. FTIR (cm-1) (neat): 2937, 1656, 1485, 1209, 1166, 1009, 
907, 760, 708. HRMS (APPI, Pos): calc. for C14H18NO4 [M+H]+: 264.1238, found 264.1230 
m/z.  
283: 1H NMR (CDCl3, 400 MHz):  δ 7.38 (s, 1H), 7.02-6.99 (m, 1H), 6.36-6.30 (m, 1H), 3.96-
3.94 (m, 6H), 3.88 (s, 3H), 3.65-3.63 (m, 2H), 3.23 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): 
169.2, 147.2, 143.0, 136.5, 136.4, 128.5, 128.4, 127.1, 108.9, 60.8, 60.5, 55.6, 46.0, 38.4 ppm. 
FTIR (cm-1) (neat): 2933, 1626, 1195, 1019, 972, 701. HRMS (APPI, Pos): calc. for 
C14H18NO4 [M+H]+: 264.1239, found 264.1230 m/z. 
 
2-benzyl-2,5-dihydro-1H-benzo[c]azepin-1-one (265) and 2-benzyl-2,3-dihydro-1H-
benzo[c]azepin-1-one (266): Synthesized according to Procedure K to give 265 as an orange 
oil in 59% yield (71.9 mg, 0.29 mmol), and 266 as an orange oil in 37% yield (45.5 g, 0.18 
mmol).  
265: 1H NMR (CDCl3, 400 MHz): δ 7.92 (dd, 1H, J = 7.7, 1.1 Hz), 7.41-7.26 (m, 7H), 7.07 (d, 
1H, J = 7.4 Hz), 5.99 (d, 1H, J = 7.6 Hz), 5.67 (q, 1H, J = 7.4 Hz), 4.95 (s, 2H), 3.20 (d, 2H, J 
= 7.2 Hz) ppm. 13C NMR (CDCl3, 75 MHz): δ 169.3, 143.5, 137.6, 133.9, 131.7, 131.4, 129.6, 
128.8, 128.0, 127.6, 126.7, 126.2, 119.0, 51.8, 31.6 ppm. FTIR (cm-1) (neat): 3060, 3030, 
2922, 1619, 1569, 1446, 1311, 724, 698, 463. HRMS (APPI, Pos): calc. for C17H16NO 
[M+H]+: 250.1231, found 250.1226 m/z.  
266: 1H NMR (CDCl3, 400 MHz): δ 8.13-8.11 (m, 1H), 7.50-7.30 (m, 7H), 7.24 (d, 1H, J = 
7.5 Hz), 6.78 (d, 1H, J = 9.9 Hz), 6.16-6.12 (m, 1H), 4.85 (s, 2H), 3.60 (d, 2H, J = 6.8 Hz) 
ppm. 13C NMR (CDCl3, 75 MHz): δ 171.7, 138.0, 134.3, 131.5, 130.5, 129.1, 128.8, 128.7, 
128.6, 128.3, 127.9, 127.7, 106.9, 51.9, 43.8 ppm. FTIR (cm-1) (neat): 3064, 3033, 2957, 1629, 
1495, 1421, 1277, 797, 700, 474. HRMS (APPI, Pos): calc. for C17H16NO [M+H]+: 250.1232, 
found 250.1226 m/z. 
Hydrogenation of benzazepinones 
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Pd on carbon (0.022 mmol) was placed in a 5 mL microwave vial, followed by 1.0 mL EtOH. 
After purging with H2 gas, benzazepinones 259 and 260 (0.22 mmol) were added as a solution 
in 1.5 mL EtOH. The reaction was stirred for 16 h under an H2 balloon (1 atm). It was then 
filtered over a celite/cotton plug, and concentrated in vacuo to give a pale yellow solid260 (35.6 
mg, 93%). 
Experimental section of Chapter 4 
Auxiliaries 319-321 (obtained via Procedure A and/or methylation with MeI) match reported 
literature data.195 
Synthesis of N-(cyclopropylmethyl)picolinamide (315) 
 
To a 250 mL round-bottom flask fitted with a stir bar (previously flame dried and cooled 
under Ar) was added LiAlH4 powder (1.06 g, 28 mmol, 1.4 equiv) and the flask was placed in 
an ice/water bath. Dry THF (100 mL) was added under Ar, and the mixture was stirred for 5 
min. Cyclopropanecarbonitrile (1.47 mL, 20 mmol, 1.0 equiv) was added dropwise. The 
reaction was stirred for 30 min at 0 °C, then fitted with a reflux condenser and refluxed for 18 
h under Ar. The reaction was allowed to cool down to room temperature, then cooled in an 
ice/water bath. Sodium sulfate decahydrate was added to the reaction, slowly at first. Extra 
THF was also added to the reaction. Enough sodium sulfate decahydrate was added to the 
heterogeneous reaction to quench all the LiAlH4 and the reaction was stirred at room 
temperature for another 2 h (until the gray solids turned white). Then, the mixture was filtered 
over a pad of anhydrous sodium sulfate directly into a 500 mL round-bottom flask, rinsing 
with about 150 mL dry THF. To the filtrate was directly added 4-dimethylaminopyridine 
(DMAP) (244 mg, 2 mmol, 0.1 equiv), 2-picolinic acid (2.46 g, 20 mmol, 1 equiv) and 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (3.72 g, 24 mmol, 1.2 equiv). The 
reaction turned red and was stirred at room temperature for 16 h. The reaction was quenched 
with a solution of citric acid (approx 0.8 M), then transferred to a separatory funnel where 
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EtOAc (100 mL) was added and the layers were separated. The organic layers was washed 
two more times with citric acid (15 mL), then saturated aqueous NaHCO3 (15 mL), and brine 
(10 mL). The organic layer was dried (Na2SO4), filtered and concentrated. The residue was 
flashed in 20% EtOAc/Hex. 2 g (57%) of a white solid were obtained. mp: <40 °C, 
decomposition. 1H NMR (CDCl3, 400 MHz): δ 8.56 (ddd, 1H, J = 4.8, 1.6, 0.9 Hz), 8.21 (dt, 
1H, J = 7.9, 1.1 Hz), 8.12 (br s, 1H), 7.83 (td, 1H, J = 7.7, 1.7 Hz), 7.40 (ddd, 1H, J = 7.6, 4.8, 
1.3 Hz), 3.33 (dd, 2H, J = 7.1, 5.9 Hz), 1.11-1.02 (m, 1H), 0.57-0.51 (m, 2H), 0.31-0.25 (m, 
2H) ppm. 13C NMR (CDCl3, 75 MHz): δ 164.2, 150.2, 148.1, 137.4, 126.1, 122.3, 44.3, 10.9, 
3.6 ppm. FTIR (cm–1) (neat): 3335, 3008, 2935, 1658, 1588, 1567, 1519, 1463, 1333, 1163. 
HRMS (ESI, Pos) calcd for C10H13N2O [M+H]+: 177.1022, found 177.1022 m/z.  
Palladium-catalyzed arylation of cyclopropanes 
Procedure L (or Condition A in Scheme 120): To a microwave vial (previously kept in an 
oven and cooled to room temperature under a stream of Ar) was added N-(pyridin-2-
ylmethyl)cyclopropanecarboxamide 315 (88.1 mg, 0.5 mmol, 1 equiv) and the corresponding 
iodoarene (if a solid, 0.75 mmol, 1.5 equiv). The vial was placed in a glove-box, where 
Pd(OAc)2 (5.6 mg, 0.025 mmol, 0.05 equiv), Na2CO3 (15.9 mg, 0.15 mmol, 0.3 equiv), and 
Ag3PO4 (104.6 mg, 0.25 mmol, 0.5 equiv) were added. The vial was crimped and taken out of 
the glove-box. Then, the iodoarene (if a liquid, 0.75 mmol, 1.5 equiv) was added via syringe, 
followed by 2.5 mL (0.2 M) dry toluene (via syringe). The reaction was placed in an oil bath 
and stirred at 130 °C for 15 h. The reaction was allowed to cool to room temperature and 
filtered over a pad of silica and celite, rinsing with EtOAc (10 mL) and MeOH (5 mL). The 
filtrate was concentrated, then trimethoxybenzene was added and the 1H NMR yield 
calculated. The residue was purified via flash chromatography.  
Procedure M (or Condition B in Scheme 120): To a microwave vial (previously kept in an 
oven and cooled to room temperature under a stream of Ar) was added N-(pyridin-2-
ylmethyl)cyclopropanecarboxamide (88.1 mg, 0.5 mmol, 1 equiv), trimethylacetic acid (15.3 
mg, 0.15 mmol, 0.3 equiv), and the corresponding iodoarene (if a solid, 0.75 mmol, 1.5 equiv). 
The vial was placed in a glove-box, where Pd(OAc)2 (5.6 mg, 0.025 mmol, 0.05 equiv), and 
K2CO3 (138.2 mg, 1.0 mmol, 2 equiv) were added. The vial was crimped and taken out of the 
glove-box. Then, the iodoarene (if a liquid, 0.75 mmol, 1.5 equiv) was added via syringe, 
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followed by 2.5 mL (0.2 M) dry toluene (via syringe). The reaction was placed in an oil bath 
and stirred at 130 °C for 15 h. The reaction was allowed to cool to room temperature and 
filtered over a pad of silica and celite, rinsing with EtOAc (10 mL) and MeOH (5 mL). The 
filtrate was concentrated, then trimethoxybenzene was added and the 1H NMR yield 
calculated. The residue was purified via flash chromatography.  
 
N-(((1R,2S)-2-(4-methoxyphenyl)cyclopropyl)methyl)picolinamide (316) and N-
(((2R,3R)-2,3-bis(4-methoxyphenyl)cyclopropyl)methyl)picolinamide (317): The reaction 
was performed according to Procedure L on a 0.5 mmol scale using 4-iodoanisole as the 
coupling partner. After work-up, trimethoxybenzene was added and the 1H NMR yield 
determined: 316 (78%), 317 (10%) and unreacted 315 (8%). The reaction was then purified 
via column chromatography over silica gel (RediSep® Rf Gold 12g) in 15-30% EtOAc/Hex to 
give 316 (100 mg, 71%), 317 (16 mg, 9%), along with recovered 315 (7 mg, 8%). The 
diarylated trans product 317 contained small traces (<5%) of the corresponding cis dimer.  
The reaction was performed according to Procedure M on a 0.5 mmol scale using 4-
iodoanisole as the coupling partner. After work-up, trimethoxybenzene was added and the 1H 
NMR yield determined: 316 (66%), 317 (16%) and unreacted 315 (6%).  The reaction was 
then purified via column chromatography over silica gel (RediSep® Rf Gold 12g) in 15-30% 
EtOAc/Hex to give 316 (102 mg, 72%), 317 (29 mg, 12%), along with recovered 315 (5 mg, 
5%). The diarylated trans product 317 contained small traces (<5%) of the corresponding cis 
dimer.  
316: white solid. mp: 61-62 °C. 1H NMR (CDCl3, 400 MHz): δ 8.53-8.52 (m, 1H), 8.14 (d, 
1H, J = 7.9 Hz), 7.96 (br s, 1H), 7.80 (td, 1H, J = 7.7, 1.8 Hz), 7.38 (ddd, 1H, J = 7.5, 4.8, 1.1 
Hz), 7.20 (d, 2H, J = 8.4 Hz), 6.84 (d, 2H, J = 8.4 Hz), 3.76 (s, 3H), 3.31-3.25 (m, 1H), 3.08-
3.05 (m, 1H), 2.23-2.20 (m, 1H), 1.45-1.43 (m, 1H), 1.04 (td, 1H, J = 8.4, 5.4 Hz), 0.88-0.84 
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(m, 1H) ppm. 13C NMR (CDCl3, 125 MHz): δ 164.1, 158.2, 150.1, 148.1, 137.3, 130.2, 130.1, 
126.0, 122.2, 113.8, 55.3, 39.7, 20.0, 18.0, 8.6 ppm. FTIR (cm–1) (neat): 3393, 3004, 1671, 
1512, 1464, 1434, 1245, 1178, 1033. HRMS (ESI, Pos) calcd for C17H18N2O2 [M+H]+: 
283.1441, found 283.1430 m/z.  
317: yellow oil. 1H NMR (CDCl3, 500 MHz): δ 8.53-8.51 (m, 1H), 8.16 (d, 1H, J = 7.9 Hz), 
8.04 (br s, 1H), 7.82 (td, 1H, J = 7.8, 1.7 Hz), 7.40 (ddd, 1H, J = 7.6, 4.7, 1.2 Hz), 7.29 (d, 2H, 
J = 8.4 Hz), 7.24 (d, 2H, J = 8.6 Hz), 6.89-6.83 (m, 4H), 3.81 (s, 3H), 3.79 (s, 3H), 3.49  (ddd, 
1H, J = 14.0, 7.2, 7.1 Hz), 3.25 (ddd, 1H, J = 14.0, 7.2, 5.4 Hz), 2.50 (dd, 1H, J = 9.0, 5.7 Hz), 
2.41-2.37 (m 1H), 1.81-1.77 (m, 1H) ppm. 13C NMR (CDCl3, 125 MHz): δ 164.3, 158.4, 
158.1, 150.1, 148.2, 137.4, 133.8, 130.1, 130.0, 127.7, 126.1, 122.3, 114.0, 113.4, 55.5, 55.4, 
39.4, 30.4, 28.1, 26.8 ppm. FTIR (cm–1) (neat): 3383, 2932, 2834, 1670, 1610, 1509, 1463, 
1433, 1031. HRMS (ESI, Pos) calcd for C24H25N2O3 [M+H]+: 389.1860, found 389.1860 m/z.  
 
N-(((1R,2S)-2-(p-tolyl)cyclopropyl)methyl)picolinamide (323a) and N-(((1s,2R,3S)-2,3-di-
p-tolylcyclopropyl)methyl)picolinamide (323b): The reaction was performed according to 
Procedure L on a 0.5 mmol scale using 4-iodotoluene as the coupling partner. After work-up, 
trimethoxybenzene was added and the 1H NMR yield determined: 323a (73%), 323b (4%) and 
unreacted 315 (10%). The reaction was then purified via column chromatography over silica 
gel in 15-30% EtOAc/Hex to give an inseparable mixture of 323a, 323b along with 315 (128 
mg, 1:0.05:0.15 ratio determined by 1H NMR). Isolated yields calculated based on 1H NMR 
ratio: 323a (82%), 323b (4%, cis:trans, >10:1), 315 (6%).  
The reaction was performed according to Procedure M on a 0.5 mmol scale using 4-
iodotoluene as the coupling partner, except the reaction was run for 45 h. After work-up, 
trimethoxybenzene was added and the 1H NMR yield determined: 323a (64%), 323b (21%) 
and unreacted 315 (<2%). The reaction was then purified via column chromatography over 
silica gel in 15-30% EtOAc/Hex to give an inseparable mixture of 323a and 323b (131 mg, 1: 
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0.41 ratio determined by 1H NMR). Isolated yields calculated based on 1H NMR ratio: 323a 
(64%), 323b (20%, cis:trans, 7:1).  
323a: yellow oil. 1H NMR (CDCl3, 400 MHz): δ 8.53 (d, 1H, J = 4.0 Hz), 8.15 (d, 1H, J = 7.9 
Hz), 7.96 (br. s, 1H), 7.80 (td, 1H, J = 7.7, 1.6 Hz), 7.41-7.37 (m, 1H), 7.19-7.17 (m, 2H), 
7.11-7.09 (m, 2H), 3.35-3.28 (m, 1H), 3.08-3.02 (m, 1H), 2.31 (s, 3H), 2.29-2.23 (m, 1H), 
1.48-1.44 (m, 1H), 1.05 (td, 1H, J = 8.3, 5.5 Hz), 0.99-0.85 (m, 1H) ppm. 13C NMR (CDCl3, 
125 MHz): δ 164.1, 150.2, 148.1, 137.3, 135.8, 135.0, 129.0, 126.4, 126.0, 122.2, 39.6, 21.1, 
20.4, 18.1, 8.4 ppm. FTIR (cm–1) (neat): 3393, 2922, 2866, 1672, 1590, 1569, 1516, 1464, 
1155. HRMS (ESI, Pos) calcd for C17H19N2O [M+H]+: 267.1492, found 267.1495 m/z. 
323b: HRMS (ESI, Pos) calcd for C24H25N2O [M+H]+: 357.1961, found 357.1967 m/z. 
 
N-(((1R,2S)-2-phenylcyclopropyl)methyl)picolinamide (324a) and N-(((1S,2R,3S)-2,3-
diphenylcyclopropyl)methyl)picolinamide (324b): The reaction was performed according to 
Procedure L on a 0.5 mmol scale using iodobenzene as the coupling partner. After work-up, 
trimethoxybenzene was added and the 1H NMR yield determined: 324a (73%), 324b (6%) and 
unreacted 315 (5%). The reaction was then purified via column chromatography over silica gel 
in 20-50% EtOAc/Hex to give an inseparable mixture of 324a, 324b along with 315 (116 mg, 
1: 0.15 : 0.15 ratio determined by 1H NMR). Yields calculated based on 1H NMR ratio: 324a 
(79%), 324b (6%, cis:trans, >10:1), 315 (6%).  
The reaction was performed according to Procedure M on a 0.5 mmol scale, using 
iodobenzene as the coupling partner, except the reaction was run for 45 h. After work-up, 
trimethoxybenzene was added and the 1H NMR yield determined: 324a (74%), 324b (21%) 
and unreacted 315 (<2%). The reaction was then purified via column chromatography over 
silica gel (RediSep® Rf Gold 12g) in 15-30% EtOAc/Hex to give an inseparable mixture of 
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324a and 324b (107 mg, 1:0.3 ratio determined by 1H NMR). Yields calculated based on 1H 
NMR ratio: 324a (61%), 324b (18%, cis:trans, 1:1.5). <1% 315 was observed in this case.  
324a: yellow oil. 1H NMR (CDCl3, 400 MHz): δ 8.55-8.53 (m, 1H), 8.15 (dt, 1H, J = 7.8, 1.2 
Hz), 7.94 (br. s, 1H), 7.82 (td, 1H, J = 7.7, 1.6 Hz), 7.40 (ddd, 1H, J = 7.6, 4.8, 1.2 Hz), 7.31-
7.28 (m, 4H), 7.21-7.20 (m, 1H), 3.32 (dt, 1H, J = 14.1, 7.0 Hz), 3.10-3.07 (m, 1H), 2.32-2.28 
(m, 1H), 1.53-1.50 (m, 1H), 1.09 (td, 1H, J = 8.3, 5.3 Hz), 1.00-0.87 (m, 1H) ppm. 13C NMR 
(CDCl3, 100 MHz): δ 183.8, 150.2, 138.2, 137.4, 129.2, 128.4, 126.4, 126.1, 122.3, 39.7, 20.9, 
18.4, 8.6 ppm. FTIR (cm–1) (neat): 3391, 2981, 2844, 1671, 1590, 1568, 1464, 1155. HRMS 
(ESI, Pos) calcd for C16H17N2O [M+H]+: 253.1335, found 253.1339 m/z.  
324b: HRMS (ESI, Pos) calcd for C22H21N2O [M+H]+: 329.1648, found 329.1652 m/z.  
 
N-(((1R,2S)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methyl)picolinamide (325a) and N-
(((1s,2R,3S)-2,3-bis(4-(trifluoromethyl)phenyl)cyclopropyl)methyl)picolinamide (325b): 
The reaction was performed according to Procedure L on a 0.5 mmol scale using 4-
iodobenzotrifluoride as the coupling partner. After work-up, trimethoxybenzene was added 
and the 1H NMR yield determined: 325a (73%), 325b (4%) and unreacted 315 (18%). The 
reaction was then purified via column chromatography over silica gel in 20-50% EtOAc/Hex 
to give 325a (108 mg, 67%), 325b (12 mg, 5%, cis), along with recovered 315 (15 mg, 17%). 
The reaction was performed according to Procedure M on a 0.5 mmol scale using 4-
iodobenzotrifluoride as the coupling partner. After work-up, trimethoxybenzene was added 
and the 1H NMR yield determined: 325a (68%), 325b (8%) and unreacted 315 (18%). The 
reaction was then purified via column chromatography over silica gel in 20-50% EtOAc/Hex 
(Silicycle 12 g) to give 325a (96 mg, 60%), 325b (17 mg, 7%, cis), along with recovered 315 
(25 mg, 28%). 
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325a: white solid. mp: 71-72 °C. 1H NMR (CDCl3, 700 MHz): δ 8.53 (ddd, 1H, J = 4.7, 1.6, 
0.9 Hz), 8.14 (dd, 1H, J = 7.8, 1.1 Hz), 7.93 (br s, 1H), 7.82 (td, 1H, J = 7.7, 1.7 Hz), 7.55 (d, 
2H, J = 8.1 Hz), 7.44-7.37 (m, 3H), 3.28 (ddd, 1H, J = 14.2, 7.6, 6.4 Hz), 3.15-3.06 (m, 1H), 
2.38-2.30 (m, 1H), 1.63-1.54 (m, 1H), 1.20-1.12 (m, 1H), 1.06-1.00 (m, 1H) ppm. 13C NMR 
(CDCl3, 175 MHz): δ 164.3, 150.0, 148.2, 142.7, 137.5, 129.4, 128.6 (q, JC-F = 32 Hz), 126.2, 
125.3 (q, JC-F = 4.0 Hz), 124.3(q, JC-F = 270 Hz), 122.3, 39.4, 20.9, 18.9, 9.2 ppm. 19F NMR 
(CDCl3, 376 MHz): δ - 62.3 ppm. FTIR (cm–1) (neat): 3297, 2924, 1670, 1615, 1568, 1434, 
1325, 1246, 1156. HRMS (ESI, Pos) calcd for C17H16F3N2O [M+H]+: 321.1209, found 
321.1210 m/z.  
325b: thick yellow oil. 1H NMR (CDCl3, 700 MHz): δ 8.42 (d, 1H, J = 4.3 Hz), 8.12 (d, 1H, J 
= 7.8 Hz), 7.81 (td, 1H, J = 7.7, 1.5 Hz), 7.76 (br s, 1H), 7.49 (d, 4H, J = 8.2 Hz), 7.38 (ddd, 
1H, J = 7.5, 4.8, 1.1 Hz), 7.11 (d, 4H, J = 8.1 Hz), 3.73 (dd, 2H, J = 7.7, 5.7 Hz), 2.80 (d, 2H, 
J = 9.2 Hz), 2.21-2.11 (m, 1H) ppm. 13C NMR (CDCl3, 175 MHz): δ 164.4, 149.6, 148.2, 
139.9, 137.4, 130.6, 128.8 (q, JC-F = 32.1 Hz), 126.3, 125.4 (q, JC-F = 4.0 Hz), 124.3 (q, JC-F = 
272.0 Hz), 122.2, 35.7, 26.4, 23.8 ppm. 19F NMR (CDCl3, 376 MHz): δ -62.5 ppm. FTIR (cm–
1) (neat): 3383, 2924, 1673, 1618, 1519, 1465, 1321, 1161, 1108. HRMS (ESI, Pos) calcd for 
C24H19F6N2O [M+H]+: 465.1396, found 465.1391 m/z.  
 
N-(((1R,2S)-2-(4-bromophenyl)cyclopropyl)methyl)picolinamide (326a) and N-(((1S,2R)-
2,3-bis(4-bromophenyl)cyclopropyl)methyl)picolinamide (326b): The reaction was 
performed according to Procedure L on a 0.5 mmol scale using 1-bromo-4-iodobenzene as 
the coupling partner. After work-up, trimethoxybenzene was added and the 1H NMR yield 
determined: 326a (68%), 326b (10%) and unreacted 315 (6%). The reaction was then purified 
via column chromatography over silica gel in 20-50% EtOAc/Hex to give 326a (96 mg, 68%), 
326b (29 mg, 11%, cis containing approx. 15% 326a), along with recovered 315 (18 mg, 
10%).  
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The reaction was performed according to Procedure M on a 0.5 mmol scale using 1-bromo-4-
iodobenzene as the coupling partner. After work-up, trimethoxybenzene was added and the 1H 
NMR yield determined: 326a (60%), 326b (9%) and unreacted 315 (13%). The reaction was 
then purified via column chromatography over silica gel in 20-50% EtOAc/Hex to give 326a 
(96 mg, 58%), 326b (34 mg, 11%, cis containing 23% 326a), along with recovered 315 (24 
mg containing 45% 326a). 326b was further purified by preparatory High Pressure Liquid 
Chromatography (prep-HPLC), in 1-2% iPrOH/Hex on a Zorbax RX silica column to obtain a 
pure sample. 
326a: white solid. mp: 86 °C. 1H NMR (CDCl3, 400 MHz): δ 8.53 (d, 1H, J = 4.6 Hz), 8.14 (d, 
1H, J = 7.9 Hz), 7.81 (td, 1H, J = 7.7, 1.6 Hz), 7.42-7.38 (m, 3H), 7.15 (d, 2H, J = 8.4 Hz), 
3.28 (dt, 1H, J = 14.2, 7.0 Hz), 3.09-3.02 (m, 1H), 2.25-2.20 (m, 1H), 1.54-1.49 (m, 1H), 1.09 
(td, 1H, J = 8.3, 5.5 Hz), 0.96-0.86 (m, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ 164.2, 
150.0, 148.1, 131.5, 130.9, 126.2, 122.2, 120.2, 39.5, 20.4, 18.4, 8.9 ppm. FTIR (cm–1) (neat): 
3290, 2921, 2866, 1657, 1587, 1567, 1490, 1460, 1332, 1286, 1154. HRMS (ESI, Pos) calcd 
for C16H16BrN2O [M+H]+: 331.0440, found 331.0444 m/z.  
326b: thick yellow oil. 1H NMR (CDCl3, 500 MHz): δ 8.46 (d, 1H, J = 4.6 Hz), 8.13 (d, 1H, J 
= 7.8 Hz), 7.81 (t, 1H, J = 7.8 Hz), 7.41-7.35 (m, 5H), 6.87 (d, 4H, J = 8.4 Hz), 3.72-3.66 (m, 
2H), 2.64 (d, 2H, J = 9.2 Hz), 2.08-1.96 (m, 1H) ppm. 13C NMR (CDCl3, 125 MHz): δ 164.4, 
149.8, 148.2, 137.4, 134.8, 132.1, 131.5, 126.2, 122.2, 120.5, 35.7, 25.7, 23.3 ppm. FTIR (cm–
1) (neat): 3382, 2867, 1669, 1590, 1568, 1518, 1487, 1241, 1197, 1163. HRMS (ESI, Pos) 
calcd for C22H19Br2N2O [M+H]+: 484.9859, found 484.9850 m/z.  
 
methyl 4-((1S,2R)-2-(picolinamidomethyl)cyclopropyl)benzoate (327a) and dimethyl 4,4'-
((1R,3S)-3-(picolinamidomethyl)cyclopropane-1,2-diyl)dibenzoate (327b): The reaction 
was performed according to Procedure L on a 0.5 mmol scale, using methyl 4-iodobenzoate 
 259 
as the coupling partner, except 0.4 equiv Ag3PO4 were used. After work-up, 
trimethoxybenzene was added and the 1H NMR yield determined: 327a (71%), 327b (8%) and 
unreacted 315 (14%). The reaction was then purified via column chromatography over silica 
gel in 20-50% EtOAc/Hex to give 327a (113 mg, 73%), 327b (19 mg, 9%, cis : trans, 1:0.6), 
along with recovered 315 (11 mg, 12%). 
The reaction was performed according to Procedure M on a 0.5 mmol scale, using methyl 4-
iodobenzoate as the coupling partner. After work-up, trimethoxybenzene was added and the 
1H NMR yield determined: 327a (66%), 327b (5%) and unreacted 315 (25%). The reaction 
was then purified via column chromatography over silica gel in 20-50% EtOAc/Hex to give 
327a (94 mg, 61%), 327b (11 mg, 5% trans and 13 mg, 6% cis, for a total of 11%), along with 
recovered 315 (19 mg, 22%). 
327a: white solid. mp: 88 °C. 1H NMR (CDCl3, 400 MHz): δ 8.52 (d, 1H, J = 4.8 Hz), 8.13 (d, 
1H, J = 7.9 Hz), 7.97 (d, 2H, J = 8.2 Hz), 7.91 (br s, 1H), 7.81 (td, 1H, J = 7.7, 1.6 Hz), 7.39 
(ddd, 1H, J = 7.6, 4.8, 1.2 Hz), 7.35 (d, 2H, J = 8.2 Hz), 3.9 (s, 3H), 3.34 (dt, 1H, J = 14.2, 7.1 
Hz), 3.07-3.00 (m, 1H), 2.36-2.30 (m, 1H), 1.62-1.56 (m, 1H), 1.15 (td, 1H, J = 8.3, 5.6 Hz), 
1.08-0.99 (m, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ 167.1, 164.2, 150.0, 148.2, 144.0, 
137.4, 129.7, 129.0, 128.3, 126.2, 122.2, 52.1, 39.4, 21.1, 19.2, 9.2 ppm. FTIR (cm–1) (neat): 
3379, 2950, 1717, 1657, 1611, 1587, 1523, 1437, 1276, 1165. HRMS (ESI, Pos) calcd for 
C18H19N2O3 [M+H]+: 311.1390, found 311.1392 m/z.  
327b: Cis; yellow oil. 1H NMR (CDCl3, 300 MHz): δ 8.42 (ddd, 1H, J = 4.7, 1.6, 0.9 Hz), 8.12 
(d, 1H, J = 7.8 Hz), 7.89 (d, 4H, J = 8.4 Hz), 7.83-7.75 (m, 1H), 7.36 (ddd, 1H, J = 7.6, 4.8, 
1.2 Hz), 7.06 (d, 4H, J = 8.4 Hz), 3.89 (s, 6H), 3.76 (dd, 2H, J = 7.7, 5.8 Hz), 2.80 (d, 2H, J = 
9.1 Hz), 2.23-2.09 (m, 1H) ppm. 13C NMR (CDCl3, 75 MHz): δ 167.1, 164.4, 149.7, 148.2, 
141.4, 137.4, 130.3, 129.6, 129.4, 128.9, 128.4, 126.2, 122.2, 106.2, 52.2, 35.8, 26.8, 24.2 
ppm. FTIR (cm–1) (neat): 3385, 2951, 1714, 1672, 1608, 1569, 1519, 1463, 1274, 1185. 
Trans; yellow oil. 1H NMR (CDCl3, 300 MHz): δ 8.51 (d, 1H, J = 4.3 Hz), 8.14 (d, 1H, J = 
7.8 Hz), 8.03 (d, 2H, J = 8.3 Hz), 7.96 (d, 2H, J = 8.4 Hz), 7.82 (d, 1H, J = 7.7, 1.6 Hz), 7.44 
(d, 2H, J =  8.3 Hz), 7.43-7.37 (m, 1H), 7.26 (d, 1H, J = 8.3 Hz), 3.92 (s, 3H), 3.90 (s, 3H), 
3.57 (dt, 1H, J = 14.3, 7.1 Hz), 3.24 (ddd, 1H, J = 14.2, 7.2, 5.5 Hz), 2.72 (dd, 1H, J = 9.3, 5.6 
Hz), 2.64 (t, 1H, J = 5.4 Hz), 2.10-1.98 (m, 1H) ppm. 13C NMR (CDCl3, 75 MHz): δ 167.0 
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(2), 164.4, 149.8, 148.2, 146.7, 142.6, 137.5, 130.0 (2), 129.0, 128.9, 126.3, 122.3, 52.3, 52.2, 
38.9, 32.3, 30.0, 27.8 ppm. FTIR (cm–1) (neat): 3385, 2951, 1714, 1669, 1607, 1570, 1519, 
1463, 1273. HRMS (ESI, Pos) calcd for C26H25N2O5 [M+H]+: 445.1758, found 445.1752 m/z.  
N
NHO
N
NHOO
O
O  
N-(((1R,2S)-2-(4-acetylphenyl)cyclopropyl)methyl)picolinamide (328a) and N-(((1S,2R)-
2,3-bis(4-acetylphenyl)cyclopropyl)methyl)picolinamide (328b): The reaction was 
performed according to Procedure L on a 0.5 mmol scale, using 4-iodoacetophenone as the 
coupling partner. After work-up, the reaction was purified via column chromatography over 
silica gel in 20-50% EtOAc/Hex to give 328a (111 mg, 75%), 328b (29 mg, 14%, cis:trans, 
1.7:1), along with recovered 315 (11 mg, 12%). 
The reaction was performed according to Procedure M on a 0.5 mmol scale, using 4-
iodoacetophenone as the coupling partner. After work-up, trimethoxybenzene was added and 
the 1H NMR yield determined: 328a (65%), 328b (5%) and unreacted 315 (25%).  and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 12g) in 20-100% 
EtOAc/Hex to give 328a (79 mg, 54%), 328b (19 mg, 9%, cis:trans, 1:1), along with 
recovered 315 (24 mg, 27%). 
328a: white solid. mp: 100-101 °C. 1H NMR (CDCl3, 400 MHz): δ 8.52 (d, 1H, J = 4.8 Hz), 
8.13 (d, 1H, J = 7.9 Hz), 7.90-7.88 (m, 3H), 7.81 (td, 1H, J = 7.7, 1.6 Hz), 7.42-7.36 (m, 3H), 
3.33 (td, 1H, J = 14.1, 7.0 Hz), 3.09-3.08 (m, 1H), 2.58 (s, 3H), 2.36-2.31 (m, 1H), 1.64-1.57 
(m, 1H), 1.19-1.16 (m, 1H), 1.08-1.04 (m, 1H) ppm. 13C NMR (CDCl3, 125 MHz): δ 197.9, 
164.2, 150.0, 148.1, 144.3, 137.4, 135.4, 129.2, 128.5, 126.2, 122.3, 39.4, 26.7, 21.1, 19.2, 9.3 
ppm. FTIR (cm–1) (neat): 3376, 2972, 2865, 2844, 1656, 1603, 1566, 1523, 1455, 1266, 1166. 
HRMS (ESI, Pos) calcd for C18H19N2O2 [M+H]+: 295.1441, found 295.1443 m/z.  
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328b: Characterized as approx. a 1:1 mixture of cis:trans. Thick yellow oil. 1H NMR (CDCl3, 
400 MHz): δ 8.52-8.51 (m, 1H), 8.43 (d, 1H, J = 4.8 Hz), 8.14 (dd, 2H, J = 12.6, 7.8 Hz), 7.95 
(d, 2H, J = 8.2 Hz), 7.90 (d, 2H, J = 8.2 Hz), 7.85-7.78 (m, 6H), 7.48 (d, 2H, J = 8.2 Hz), 
7.43-7.40 (m, 2H), 7.29 (d, 2H, J = 8.4 Hz), 7.09 (d, 4H, J = 8.4 Hz), 3.77 (dd, 2H, J = 7.8, 5.8 
Hz), 3.58-3.53 (m, 1H), 3.29-3.24 (m, 1H), 2.82 (d, 2H, J = 9.2 Hz), 2.75-2.71 (m, 1H), 2.69-
2.65 (m, 1H), 2.61 (s, 3H), 2.58 (s, 3H), 2.57 (s, 6H), 2.22-2.14 (m, 1H), 2.10-2.04 (m, 1H) 
ppm. 13C NMR (CDCl3, 75 MHz): δ 197.9, 197.8, 197.7, 164.4 (2), 149.7, 149.6, 148.2 (2), 
147.0, 141.7, 137.5, 137.4, 135.9, 135.4 (2), 130.5, 129.1, 128.8 (2), 128.4, 128.2, 126.4 (2), 
126.3, 122.3, 122.2, 38.9, 32.4, 31.1, 30.1, 27.9, 26.9, 26.7, 26.6, 24.2 ppm. FTIR (cm–1) 
(neat): 3382, 2972, 2866, 2844, 1673, 1603, 1568, 1519, 1464, 1357, 1266. HRMS (ESI, Pos) 
calcd for C26H25N2O3 [M+H]+: 413.1860, found 413.1866 m/z.  
 
 
N-(((1R,2S)-2-(3-chlorophenyl)cyclopropyl)methyl)picolinamide (329a) and N-(((1S,2R)-
2,3-bis(3-chlorophenyl)cyclopropyl)methyl)picolinamide (329b): The reaction was 
performed according to Procedure L on a 0.5 mmol scale, using 1-chloro-3-iodobenzene as 
the coupling partner. After work-up, trimethoxybenzene was added and the 1H NMR yield 
determined: 329a (76%), 329b (3%) and unreacted 315 (9%). The reaction was then purified 
via column chromatography over silica gel in 20-50% EtOAc/Hex to give 329a (96 mg, 67%), 
329b (15 mg, 8%, cis containing 50% 329a), along with recovered 315 (11 mg, 12%). 
The reaction was performed according to Procedure M on a 0.5 mmol scale, using 1-chloro-
3-iodobenzene as the coupling partner. After work-up, trimethoxybenzene was added and the 
1H NMR yield determined: 329a (61%), 329b (8%) and unreacted 315 (13%).The reaction 
was then purified via column chromatography over silica gel in 20-50% EtOAc/Hex to give 
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329a (64 mg, 43%), 329b (34 mg, 10%, cis containing 40% 329a), along with recovered 315 
(29 mg, containing with 50% 329a). 
329a: white solid. mp: 47-48 °C. 1H NMR (CDCl3, 400 MHz): δ 8.56 (dt, 1H, J = 4.7, 0.8 Hz), 
8.15 (d, 1H, J = 7.8 Hz), 7.86-7.79 (m, 1H), 7.41 (ddd, 1H, J = 7.5, 4.8, 1.2 Hz), 7.30 (s, 1H), 
7.25-7.14 (m, 3H), 3.33 (dt, 1H, J = 14.0, 7.0 Hz), 3.12-3.00 (m, 1H), 2.33-2.21 (m, 1H), 1.58-
1.48 (m, 1H), 1.15-1.06 (m, 1H), 1.02-0.95 (m, 1H) ppm. 13C NMR (CDCl3, 125 MHz): δ 
164.2, 150.0, 148.2, 140.5, 137.4, 129.6, 129.5, 127.2, 126.6, 122.2, 39.6, 20.6, 18.5, 8.9 ppm. 
FTIR (cm–1) (neat): 3680, 3309, 2939, 2865, 2844, 1651, 1595, 1567, 1462, 1393, 1153. 
HRMS (ESI, Pos) calcd for C16H16ClN2O [M+H]+: 287.0946, found 287.0948 m/z.  
329b: yellow oil. 1H NMR (CDCl3, 400 MHz): δ 8.47-8.46 (m, 1H), 8.13 (d, 1H, J = 7.9 Hz), 
7.80 (m, 1H), 7.76 (br. S, 1H), 7.39-7.37 (m, 1H), 7.22-7.17 (m, 6H), 6.81 (d, 2H, J = 7.5 Hz), 
3.72 (dd, 2H, J = 7.6, 6.0 Hz), 2.68 (d, 2H, J = 9.2 Hz), 2.11-1.98 (m, 1H) ppm. 13C NMR 
(CDCl3, 125 MHz): δ 164.4, 149.8, 148.2, 137.9, 137.4, 134.2, 130.7, 129.6, 128.2, 126.2, 
122.2, 35.8, 26.0, 23.4 ppm. FTIR (cm–1) (neat): 3382, 1671, 1593, 1567, 1517, 1433, 1163. 
HRMS (ESI, Pos) calcd for C22H19Cl2N2O [M+H]+: 397.0869, found 397.0870 m/z.  
 
N-(((1R,2S)-2-(benzo[d][1,3]dioxol-5-yl)cyclopropyl)methyl)picolinamide (330a) and N-
(((1S,2R)-2,3-bis(benzo[d][1,3]dioxol-5-yl)cyclopropyl)methyl)picolinamide (330b): The 
reaction was performed according to Procedure L on a 0.5 mmol scale, using 1-iodo-3,4-
methylenedioxybenzene as the coupling partner. After work-up, trimethoxybenzene was added 
and the 1H NMR yield determined: 330a (69%), 330b (4%) and unreacted 315 (5%). The 
reaction was then purified via column chromatography over silica gel in 20-50% EtOAc/Hex 
to give 330a (112 mg, 76%), 330b (17 mg, 8%, cis:trans, 1:5), along with recovered 315 (7 
mg, 8%). 
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The reaction was performed according to Procedure M on a 0.5 mmol scale, using 1-iodo-
3,4-methylenedioxybenzene as the coupling partner. After work-up, trimethoxybenzene was 
added and the 1H NMR yield determined: 330a (69%), 330b (4%) and unreacted 315 (9%). 
The reaction was then purified via column chromatography over silica gel (RediSep® Rf Gold 
12g) in 20-100% EtOAc/Hex to give 330a (97 mg, 65%), 330b (12 mg, 6%, trans), along with 
recovered 315 (22 mg, 23%). 
330a: yellow oil. 1H NMR (CDCl3, 300 MHz): δ 8.54 (ddd, 1H, J = 4.7, 1.7, 0.9 Hz), 8.17-
8.14 (m, 1H), 7.98 (br. s, 1H), 7.82 (td, 1H, J = 7.7, 1.7 Hz), 7.40 (ddd, 1H, J = 7.6, 4.8, 1.2 
Hz), 6.79-6.74 (m, 3H), 5.93 (s, 2H), 3.35-3.25 (m, 1H), 3.13-3.04 (m, 1H), 2.22 (td, 1H, J = 
8.5, 6.2 Hz), 1.48-1.40 (m, 1H), 1.04 (td, 1H, J = 8.4, 5.4 Hz), 0.89-0.78 (m, 1H) ppm. 13C 
NMR (CDCl3, 75 MHz): δ 164.2, 150.1, 148.1, 147.7, 146.2, 137.4, 132.0, 126.1, 122.2 (2), 
109.8, 108.2, 101.0, 39.7, 20.6, 18.1, 8.9 ppm. FTIR (cm–1) (neat): 3383, 2981, 2844, 1667, 
1590, 1569, 1520, 1502, 1347, 1288, 1232, 1213, 1174. HRMS (ESI, Pos) calcd for 
C17H17N2O3 [M+H]+: 297.1234, found 297.1237 m/z.  
330b: yellow oil. 1H NMR (CDCl3, 300 MHz): δ 8.46 (ddd, 1H, J = 4.8, 1.6, 0.9 Hz), 8.14 (dt, 
1H, J = 7.8, 1.0 Hz), 7.80 (td, 2H, J = 7.7, 1.7 Hz), 7.37 (ddd, 1H, J = 7.6, 4.8, 1.2 Hz), 6.70 
(d, 2H, J = 8.0 Hz), 6.57-6.51 (m, 4H), 5.91 (s, 4H), 3.74-3.70 (m, 2H), 2.57 (d, 2H, J = 9.2 
Hz), 1.94-1.86 (m, 1H) ppm. 13C NMR (CDCl3, 75 MHz): δ 164.3, 150.0, 148.1, 147.5, 146.0, 
137.4, 129.7, 126.1, 123.6, 122.3, 110.7, 108.2, 100.2, 36.1, 25.9, 22.8 ppm. FTIR (cm–1) 
(neat): 3382, 2922, 2845, 1672, 1590, 1569, 1520, 1503, 1346, 1285. HRMS (ESI, Pos) calcd 
for C24H21N2O5 [M+H]+: 417.1445, found 417.1446 m/z. 
 
N-(((1R,2S)-2-(1-methyl-1H-indol-5-yl)cyclopropyl)methyl)picolinamide (331a) and N-
(((1s,2R,3S)-2,3-bis(1-methyl-1H-indol-5-yl)cyclopropyl)methyl)picolinamide (331b): The 
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reaction was performed according to Procedure L on a 0.5 mmol scale, using 5-iodo-1-
methyl-1H-indole as the coupling partner. After work-up, trimethoxybenzene was added and 
the 1H NMR yield determined: 331a (77%), 331b (4%) and unreacted 315 (5%). The reaction 
was then purified via column chromatography over silica gel in 20-50% EtOAc/Hex to give 
331a (106 mg, 69%), 331b (30 mg, 14%, trans), along with recovered 315 (5 mg, 6%). 
The reaction was performed according to Procedure M on a 0.5 mmol scale, using 5-iodo-1-
methyl-1H-indole as the coupling partner. After work-up, trimethoxybenzene was added and 
the 1H NMR yield determined: 331a (29%), 331b (18%, cis:trans, 1:2) and unreacted 315 
(28%). 
331a: Red oil. 1H NMR (CDCl3, 400 MHz): δ 8.54 (d, 1H, J = 4.2), 8.15 (d, 1H, J = 7.9 Hz), 
8.00 (br. s, 1H), 7.81-7.78 (m, 1H), 7.53 (s, 1H), 7.38 (dd, 1H, J = 6.5, 5.0 Hz), 7.28-7.22 (m, 
1H), 7.03 (d, 1H, J = 3.0), 6.43 (d, 1H), J = 3.0 Hz), 3.77 (s, 3H), 3.35 (dt, 1H, J = 14.0, 7.0 
Hz), 3.08-3.03 (m, 1H), 2.46-2.40 (m, 1H), 1.54-1.45 (m, 1H), 1.09 (td, 1H, J = 8.3, 5.3 Hz), 
1.03-0.94 (m, 1H) ppm. 13C NMR (CDCl3, 125 MHz): δ 164.1, 150.3, 148.1, 137.3, 135.8, 
129.1, 128.8, 128.7, 126.0, 123.5, 122.2, 121.0, 109.1, 100.7, 39.8, 20.9, 18.1, 8.5 ppm. FTIR 
(cm–1) (neat): 3384, 2934, 2844, 1667, 1590, 1569, 1515, 1493, 1368, 1337, 1279, 1244. 
HRMS (ESI, Pos) calcd for C19H20N3O [M+H]+: 306.1601, found 306.1602 m/z.  
331b: red oil. 1H NMR (CDCl3, 400 MHz): δ 8.52 (ddd, 1H, J = 4.5, 1.7, 0.9 Hz), 8.16 (dt, 
1H, J = 7.8, 1.0 Hz), 7.80 (td, 1H, J = 7.7, 1.7 Hz), 7.68 (s, 1H), 7.55 (s, 1H), 7.38 (ddd, 1H, J 
= 7.6, 4.8, 1.2 Hz), 7.33-7.27 (m, 2H), 7.18 (dd, 1H, J = 8.5, 1.7 Hz), 7.04 (dd, 2H, J = 10.0, 
3.1 Hz), 6.46 (d, 1H, J = 3.0 Hz), 6.42 (d, 1H, J = 3.0 Hz), 3.80 (s, 3H), 3.77 (s, 3H), 3.57-
3.51 (m, 1H), 3.35-3.30 (m, 1H), 2.78 (dd, 1H, J = 9.0, 5.7 Hz), 2.67 (t, 1H, J = 5.3 Hz), 1.96-
1.92 (m, 1H) ppm. 13C NMR (CDCl3, 125 MHz): δ 164.2, 150.2, 148.1, 137.4, 135.9, 135.6, 
132.9, 129.3, 129.2, 128.8 (2), 128.7, 126.0, 123.5, 122.3, 121.2, 121.1, 118.5, 109.3, 109.2, 
100.8, 100.6, 39.8, 33.0 (2), 31.6, 28.0, 27.7 ppm. FTIR (cm–1) (neat): 3385, 2972, 2844, 
1667, 1568, 1513, 1490, 1432, 1338. HRMS (ESI, Pos) calcd for C28H27N4O [M+H]+: 
435.21794, found 435.2180 m/z.  
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N-(((1R,2S)-2-(thiophen-2-yl)cyclopropyl)methyl)picolinamide (332a) and N-(((1S,2S)-
2,3-di(thiophen-2-yl)cyclopropyl)methyl)picolinamide (332b): The reaction was performed 
according to Procedure L on a 0.5 mmol scale, using 2-iodothiophene as the coupling partner, 
except 10 mol % Pd(OAc)2 was used for the reaction. After work-up, trimethoxybenzene was 
added and the 1H NMR yield determined: 332a (55%), 332b (<5%) and unreacted 315 (10%). 
The reaction was then purified via column chromatography over silica gel in 15-50% 
EtOAc/Hex to give 332a (64 mg, 50%, containing small traces of 315 and 332b) and 
unreacted 315 (44 mg, containing >50% 332a).  
The reaction was performed according to Procedure M on a 0.5 mmol scale, using 2-
iodothiophene as the coupling partner, except 10 mol % Pd(OAc)2 was used for the reaction. 
After work-up, trimethoxybenzene was added and the 1H NMR yield determined: 332a (31%), 
332b (<5%) and unreacted 315 (43%). 
332a: yellow oil. 1H NMR (CDCl3, 400 MHz): δ 8.56 (dd, 1H, J = 4.1, 0.9 Hz), 8.17 (dd, 1H, 
J = 7.8, 1.0 Hz), 7.83 (td, 1H, J = 7.7, 1.7 Hz), 7.41 (ddd, 1H, J = 6.8, 5.5, 1.2 Hz), 7.14 (dd, 
1H, J = 5.1, 1.0 Hz), 6.97-6.92 (m, 1H), 6.87 (dd, 1H, J = 2.3, 1.1 Hz), 3.54 (ddd, 1H, J = 
14.0, 7.0, 6.8 Hz), 3.15-3.04 (m, 1H), 2.40-2.29 (m, 1H), 1.56-1.48 (m, 1H), 1.27-1.15 (m, 
1H), 0.96-0.87 (m, 1H) ppm. 13C NMR (CDCl3, 125 MHz): δ 164.3, 150.2, 148.2, 142.6, 
137.4, 127.0, 126.1, 125.9, 124.1, 122.3, 39.4, 19.2, 15.5, 11.3 ppm. FTIR (cm–1) (neat): 3384, 
2923, 2866, 2844, 1666, 1590, 1568, 1518, 1463, 1433, 1240, 1150. HRMS (ESI, Pos) calcd 
for C14H15N2OS [M+H]+: 259.0900, found 259.0910 m/z.  
332b: HRMS (ESI, Pos) calcd for C18H17N2OS2 [M+H]+: 341.0777, found 341.0780 m/z. 
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N-(((1R,2S)-2-(naphthalen-1-yl)cyclopropyl)methyl)picolinamide (333a) and N-
(((1s,2R,3S)-2,3-di(naphthalen-1-yl)cyclopropyl)methyl)picolinamide (333b): The reaction 
was performed according to Procedure L on a 0.5 mmol scale, using 1-iodonaphthalene as the 
coupling partner and then purified via column chromatography over silica gel in 15-30% 
EtOAc/Hex to give 333a  and 333b (67 mg, 44%, trans, as an inseparable 5:1 mixture of 
333a:333b), along with recovered 315 (46 mg, 52%). 
The reaction was performed according to Procedure M on a 0.5 mmol scale, using 1-
iodonaphthalene as the coupling partner. After work-up, trimethoxybenzene was added and 
the 1H NMR yield determined: 333a (19%) and unreacted 315 (80%). 
Yellow oil, characterized as a 5:1 mixture of monoarylation and diarylation (trans).  
333a: 1H NMR (CDCl3, 500 MHz): δ 8.40-8.36 (m, 2H), 8.05 (d, 1H, J = 7.9 Hz), 7.88-7.86 
(m, 1H), 7.78-7.75 (m, 2H), 7.70 (br. s, 1H), 7.54-7.48 (m, 1H), 7.43-7.40 (m, 1H), 7.37-7.34 
(m, 2H), 3.18 (dt, 1H, J = 14.2, 7.0 Hz), 2.95-2.89 (m, 1H), 2.65-2.61 (m, 1H), 1.84-1.77 (m, 
1H), 1.25 (td, 1H, J = 8.2, 5.3 Hz), 1.15-1.08 (q, 1H, J = 5.4 Hz) ppm. 333b: 1H NMR (CDCl3, 
500 MHz): δ 8.51-8.50 (m, 1H), 8.13 (d, 1H, J = 7.7 Hz), 7.96 (br. s, 1H), 3.41-3.34 (m, 1H), 
3.09-3.05 (m, 1H), 2.48-2.44 (m, 1H), 1.64-1.58 (m, 1H), 1.20-1.18 (m, 1H) ppm. 333a + 
333b: 13C NMR (CDCl3, 125 MHz): δ 164.1, 164.0, 150.0, 148.1, 147.9, 137.4, 137.2, 135.9, 
134.6, 133.8, 133.7, 132.4, 128.7, 128.1, 128.0, 127.7 (2), 127.4, 127.2, 126.4, 126.3, 126.1, 
126.0, 125.8, 125.5, 124.4, 122.1, 39.6, 21.1, 19.2, 18.6, 18.3, 8.7, 8.3 ppm.  FTIR (cm–1) 
(neat): 3370, 2923, 2867, 1667, 1591, 1568, 1518, 1463, 1433, 1330, 1286, 1151, 1087, 1054. 
333a: HRMS (ESI, Pos) calcd for C20H19N2O [M+H]+: 303.1492, found 303.1495 m/z. 333b: 
HRMS (ESI, Pos) calcd for C30H25N2O [M+H]+: 429.1967, found 429.2192 m/z. 
Synthesis of (R)-N-(1-cyclopropylethyl)picolinamide (334) 
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Adapted from a literature procedure,261 cyclopropanecarboxaldehyde (1.2 mL, 16 mmol, 2 
equiv) was dissolved in 16 mL dry DCM under argon. To the stirring solution was added (R)-
2-methylpropane-2-sulfinamide (Ellman’s auxiliary) (970 mg, 8 mmol, 1 equiv), Mg2SO4 
(9.86 g, 40 mmol, 5 equiv) and pyridinium para-toluenesulfonate (20 mg, 0.08 mmol, 1 mol 
%). The reaction was allowed to stir at room temperature overnight, then filtered over a pad of 
cotton and celite. The filtrate was concentrated and purified via flash chromatography over 
silica gel in 10-20% EtOAc/Hex, providing D1 866 mg (62%) clear oil, which corresponded to 
previously reported analytical data.261 
Adapted from a literature procedure,261 a solution of D1 (433 mg, 2.5 mmol, 1 equiv) in 15 
mL dry DCM was cooled to -75 °C in a dry ice/acetone bath under Ar. Methylmagnesium 
chloride (3.12 M in THF, 1.9 mL, 6 mmol, 2.4 equiv) was added dropwise over 5 min. The 
reaction was allowed to warm up to -50 °C over 15 min, then stirred at this temperature for 6 
h. The reaction was allowed to warm up to room temperature overnight, then quenched with 
sat. aqueous NH4Cl solution (10 mL), then transferred to a separatory funnel. The layers were 
separated and the aqueous layer was extracted with EtOAc (2x20 mL). The combined organic 
layers were washed with brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo. 
The residue was flashed in 40-80% EtOAc (product visible on TLC upon staining with 
KMnO4). 448 mg (95%) clear oil D2 were obtained, corresponding to previously reported 
analytical data.261  
To a solution of D2 (414 mg, 2.2 mmol, 1 equiv) in 1.5 mL freshly distilled methanol in a 10 
mL round-bottom flask under Argon was added a solution of HCl in dioxane (1.09 mL of a 6.0 
M solution, 3 equiv). The reaction was stirred at room temperature for 30 min, then 
concentrated. The resulting white solid was triturated with hexanes and dried under vacuum. 
The white solid (1.6 mmol) was taken and directly placed in a 100 mL dry round-bottom flask, 
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to which dry THF (15 mL) was added. Diisopropylethylamine (0.86 mL, 4.8 mmol, 3 equiv) 
was added and the reaction was stirred for 5 min at room temperature. Then, the following 
reagents were added: 2-picolinic acid (302.8 mg, 2.46 mmol, 1.5 equiv), 4-
dimethylaminopyridine (20.0 mg, 0.16 mmol, 0.1 equiv) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) (381.9 mg, 22.46 mmol, 1.5 equiv). The reaction 
was stirred at room temperature for 16 h, then quenched with a solution of citric acid (10 mL, 
0.8 M), transferred to a separatory funnel where EtOAc (30 mL) was added and the layers 
were separated. The organic layers was washed two more times with citric acid (10 mL), then 
saturated aqueous NaHCO3 (10 mL), and brine (5 mL). The organic layer was dried (Na2SO4), 
filtered and concentrated. The residue was flashed in 20-30% EtOAc/Hex to give 171 mg 
(55%) of a white solid.  
334: mp: 61-62 °C. 1H NMR (CDCl3, 400 MHz): δ 8.51 (d, 1H, J = 4.7 Hz), 8.15 (dd, 1H, J = 
7.8, 0.8 Hz), 8.01 (br. s, 1H), 7.79 (td, 1H, J = 7.7, 1.5 Hz), 7.37 (ddd, 1H, J = 7.5, 4.9, 1.0 
Hz), 3.59-3.51 (m, 1H), 1.29 (d, 3H, J = 6.6 Hz), 0.96-0.89 (m, 1H), 0.52-0.48 (m, 1H), 0.43-
0.41 (m, 1H), 0.39-0.35 (m, 1H), 0.27-0.22 (m, 1H) ppm. 13C NMR (CDCl3, 125 MHz): δ 
163.5, 150.2, 148.0, 137.3, 126.0, 122.2, 49.7, 20.5, 17.5, 3.3, 3.1 ppm. FTIR (cm–1) (neat): 
3373, 2972, 2866, 1656, 1588, 1567, 1510, 1454, 1293, 1144, 1055, 1033. HRMS (ESI, Pos) 
calcd for C11H15N2O [M+H]+: 191.1179, found 191.1182 m/z.  
Compound 335 was synthesized in a similar matter as 334 and isolated in 53% yield for the 
last step. 1H NMR (CDCl3, 400 MHz): δ 8.49 (dd, 1H, J = 4.7, 0.5 Hz), 8.13 (dd, 1H, J = 7.8, 
0.8 Hz), 7.76 (td, 1H, J = 7.7, 1.7 Hz), 7.34 (ddd, 1H, J = 7.5, 4.8, 1.2 Hz), 3.29 (td, 1H, J = 
9.4, 5.8 Hz, 2.00-1.89 (m, 1H), 0.97 (dd, 6H, J = 6.8, 3.4 Hz), 0.93-0.83 (m, 1H), 0.56-0.49 
(m, 1H), 0.38-0.30 (m, 1H) ppm. 13C NMR (CDCl3, 125 MHz): δ 163.7, 150.2, 148.0, 137.3, 
126.0, 122.3, 59.0, 33.4, 19.4, 18.6, 14.0, 4.9, 2.2 ppm. 
Synthesis of N-((R)-1-((1R,2S)-2-(4-methoxyphenyl)cyclopropyl)ethyl)picolinamide (334a) 
and N-((R)-1-((1R,2R)-2-(4-methoxyphenyl)cyclopropyl)ethyl)picolinamide (334b) 
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The reaction was performed according to Procedure L on a 0.2 mmol scale using 334 as the 
auxiliary and 4-iodoanisole as the coupling partner, and then purified via column 
chromatography over silica gel in 10-25% EtOAc/Hex. Obtained 334a (42 mg, 71%, 
containing traces of diarylation) and 334b (6 mg, 10%). The stereochemistry was determined 
via 1D nOe (it is difficult to know which diastereomer is which).  
HN
H2
H1
H3
PA
H4
H5
OMe
H1-H2-H6 nOe
H2-H3 nOe
H3-H4-H5 nOe
H5-H6 nOe
nOe
H6
H6
nOe
334a  
334a: clear oil. 1H NMR (CDCl3, 300 MHz): δ 8.56-8.52 (m, 1H), 8.04 (d, 1H, J = 7.8 Hz), 
7.86 (br. s, 1H), 7.79 (td, 1H, J = 7.7, 1.7 Hz), 7.39 (ddd, 1H, J = 7.6, 4.8, 1.2 Hz), 7.09 (d, 
2H, J = 8.4 Hz), 6.66-6.58 (m, 2H), 3.69 (s, 3H), 3.27-3.17 (m, 1H), 2.26-2.14 (m, 1H), 1.40-
1.13 (m, 4H), 1.08 (td, 1H, J = 8.6, 5.3 Hz), 0.86-0.80 (m, 1H) ppm. 13C NMR (CDCl3, 75 
MHz): δ 163.0, 158.0, 150.3, 148.0, 137.3, 130.3, 129.7, 125.9, 122.1, 113.5, 55.3, 46.7, 24.3, 
21.2, 20.7, 8.4 ppm. FTIR (cm–1) (neat): 3680, 2967, 2866, 2844, 1670, 1611, 1590, 1510, 
1463, 1290, 1178. HRMS (ESI, Pos) calcd for C18H21N2O2 [M+H]+: 297.1598, found 
297.1594 m/z.  
334b: clear oil. 1H NMR (CDCl3, 500 MHz): δ 8.56 (d, 1H, J = 4.1 Hz), 8.18 (d, 1H, J = 7.8 
Hz), 8.08 (br d), 7.84 (td, 1H, J = 7.7, 1.7 Hz), 7.41 (ddd, 1H, J = 7.6, 4.8, 1.2 Hz), 7.21 (d, 
2H, J = 8.5 Hz), 6.86 (d, 2H, J = 8.7 Hz), 3.8 (s, 3H), 3.48-3.38 (m, 1H), 2.27-2.18 (m, 1H), 
1.27-1.20 (m, 1H), 1.18-1.12 (m, 1H), 1.10 (d, 3H, J = 6.6 Hz), 0.97 (td, 1H, J = 8.4, 5.4 Hz) 
ppm. 13C NMR (CDCl3, 125 MHz): δ 163.5, 158.1, 150.4, 148.1, 137.5, 129.9, 129.8, 126.1, 
122.4, 113.8, 55.4, 46.0, 26.1, 20.9 (2), 8.5 ppm. FTIR (cm–1) (neat): 3680, 2972, 2844, 1669, 
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1569, 1455, 1433, 1033. HRMS (ESI, Pos) calcd for C18H21N2O2 [M+H]+: 297.1598, found 
297.1595 m/z.  
Synthesis of N-((R)-1-((1R,2S)-2-(4-
(trifluoromethyl)phenyl)cyclopropyl)ethyl)picolinamide (334c) 
 
The reaction was performed according to Procedure L on a 0.2 mmol scale using 334 as the 
auxiliary and 4-iodobenzotrifluoride as the coupling partner, and then purified via column 
chromatography over silica gel in 10-50% EtOAc/Hex. Obtained 334c and 334d as an 
inseparable mixture (46 mg, 69%, 8:1). Traces of diarylation <3% also observed. 
334c: white solid. mp 55-56 °C. 1H NMR (CDCl3, 500 MHz): δ 8.43 (ddd, 1H, J = 4.8, 1.6, 
0.9 Hz), 7.89 (dt, 1H, J = 7.8, 1.0 Hz), 7.70 (dt, 1H, J =7.7, 1.7 Hz), 7.69 (br. s, 1H), 7.31 
(ddd, J = 7.5, 4.8, 1.2 Hz), 7.23 (d, 2H, J = 8.3 Hz), 7.18 (d, 2H, J = 8.3 Hz), 3.27-3.15 (m, 
1H), 2.26-2.17 (m, 1H), 1.45-1.36 (m, 1H), 1.29 (d, 3H, J = 6.6 Hz), 1.12 (td, 1H, J = 8.5, 5.6 
Hz), 0.94-0.89 (m, 1H) ppm. 19F NMR (CDCl3, 282 MHz): δ -63.8 ppm. 13C NMR (CDCl3, 
125 MHz): δ 162.8, 150.0, 147.9, 142.2, 137.4, 129.3, 129.0, 128.4 (q, JC-F = 32 Hz), 124.9 (q, 
JC-F = 3.5 Hz), 122.1, 46.5, 25.2, 21.4, 21.3, 9.0 ppm. FTIR (cm–1) (neat): 3680, 2973, 2866, 
1656, 1618, 1569, 1510, 1456, 1157. HRMS (ESI, Pos) calcd for C18H18F3N2O [M+H]+: 
335.1366, found 335.1367 m/z. 
Reaction Scale Up 
To a 20 mL microwave vial (previously kept in an oven and cooled to room temperature under 
a stream of Argon) was added N-(pyridin-2-ylmethyl)cyclopropanecarboxamide (881.1 mg, 5 
mmol, 1 equiv) and 4-iodoanisole (1.75 g, 7.5 mmol, 1.5 equiv). The vial was placed in a 
glove-box, where Pd(OAc)2 (22.4 mg, 0.01 mmol, 0.02 equiv), sodium carbonate (159 mg, 1.5 
mmol, 0.3 equiv), and silver phosphate (1.05 g, 2.5 mmol, 0.5 equiv) were added. The vial 
was crimped and taken out of the glove-box. Then, 10 mL dry toluene was added via syringe. 
The reaction was placed in an oil bath and stirred at 130 °C for 24 h. The reaction was allowed 
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to cool to room temperature and filtered over a pad of silica and celite, rinsing with EtOAc (20 
mL) and MeOH (5 mL). The filtrate was concentrated, then purified via flash chromatography 
in 15-30% EtOAc/Hex to provide 1.05 g 316 (74%), 110 mg 317 (6%), along with 148 mg 
315 (17%).  
Auxiliary cleavage 
 
Adapted from a literature procedure;262 to a 10 mL round-bottom flask, previously flame-dried 
and cooled to room temperature under a stream of Ar, was added 316 (56.5 mg, 0.2 mmol, 1 
equiv), 4-dimethylaminopyridine (4.9 mg, 0.04 mmol, 0.2 equiv), di-tert-butyl dicarbonate 
(87.3 mg, 0.4 mmol, 2 equiv) and dry acetonitrile (1.0 mL). The reaction was stirred for one 
day at room temperature. As the reaction was not complete, further 4-dimethylaminopyridine 
(4.9 mg, 0.04 mmol, 0.2 equiv) and di-tert-butyl dicarbonate (87.3 mg, 0.4 mmol, 2 equiv) 
were added for the next two days. The reaction was then concentrated in vacuo and flashed in 
10% EtOAc/Hex to provide 25 mg (33%) desired product D3.  
1H NMR (CDCl3, 400 MHz): δ 8.59-8.52 (m, 1H), 7.78 (td, 1H, J = 7.7, 1.6 Hz), 7.63 (d, 1H, 
J = 7.9 Hz), 7.39-7.32 (m, 1H), 7.23 (d, 2H, J = 8.5 Hz), 6.84 (d, 2H, J = 8.6 Hz), 3.83 (dd, 
1H, J = 14.1, 4.1 Hz), 3.78 (s, 3H), 3.20 (dd, 1H, J = 14.1, 10.7 Hz), 2.21 (d, 1H, J = 6.4 Hz), 
1.67-1.56 (m 1H), 1.17 (s, 9H), 1.14-1.06 (m, 2H) ppm. 13C NMR (CDCl3, 125 MHz): δ 
171.8, 158.1, 155.1, 153.6, 148.3, 136.8, 130.3, 130.1, 125.2, 122.7, 113.7, 82.9, 55.4, 46.3, 
27.5, 20.0, 17.5, 9.3 ppm. FTIR (cm–1) (neat): 2978, 2935, 1734, 1669, 1612, 1588, 1514, 
1457, 1034. HRMS (ESI, Pos) calcd for C22H27N2O4 [M+H]+: 383.1965, found 383.1949 m/z.  
Adapted from a literature procedure;262 to a 10 mL round-bottom flask, previously flame-dried 
and cooled under a stream of Ar, was added D3 (25 mg, 0.065 mmol, 1 equiv) as a solution in 
0.8 mL THF, followed by 0.2 mL distilled H2O. The solution was cooled in an ice/water bath, 
then lithium hydroxide monohydrate (8.3 mg, 0.2 mmol, 3 equiv) and 30% H2O2 (37.1 mg, 
0.33 mmol, 5 equiv) were added. The reaction was allowed to warm up to room temperature, 
then stirred at this temperature for 16 h. The reaction was quenched by the addition of a 
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solution of saturated aqueous Na2SO3 (5 mL) and extracted with EtOAc (3x10 mL). The 
combined organic layers were dried (Na2SO4), filtered and concentrated. The residue was 
purified by flash chromatography in 10% EtOAc/Hex to provide 16.9 mg (93%) of a clear oil. 
322: 1H NMR (CDCl3, 400 MHz): δ 7.12 (d, 2H, J = 8.2 Hz), 6.82 (d, 2H, J = 8.7 Hz), 4.36 
(br. s, 1H), 3.78 (s, 3H), 2.95 (ddd, 1H, J = 13.9, 6.9, 6.8), 2.78-2.69 (m, 1H), 2.15 (td, 1H, J = 
8.5, 6.2 Hz), 1.40 (s, 9H), 1.35-1.26 (m, 1H), 0.97 (td, 1H, J = 8.4, 5.3 Hz), 0.73 (q, 1H, J = 
5.6 Hz) ppm. 13C NMR (CDCl3, 75 MHz): δ 158.2, 155.9, 130.2, 130.0, 113.9, 79.2, 55.4, 
40.8, 28.5, 19.9, 18.4, 8.4 ppm. FTIR (cm–1) (neat): 3357, 2976, 2930, 1701, 1456, 1391, 
1246. HRMS (ESI, Pos) calcd for C16H23NO3 [M+Na]+: 300.1570, found 300.1559 m/z.  
Experimental section of chapter 5 
Aryl ether synthesis 
The aryl ether substrates 145 and 378 were prepared according to the literature procedure and 
145 matches the literature data.263  
378: Synthesized on a 2.27 mmol scale. Obtained 378 as a white solid (686 mg, 83%), mp: 64-
66 °C. 1H NMR (CDCl3, 300 MHz): δ 7.82 (dd, 1H, J  = 7.7, 1.6 Hz), 7.45 (d, 4H, J = 1.6 Hz), 
7.32-7.29 (m, 2H), 6.90 (dd, 1H, J = 8.3, 1.3 Hz), 6.75 (td, 1H, J = 7.7, 1.3 Hz), 5.15 (s, 2H), 
1.36 (s, 9H) ppm. 13C NMR (CDCl3, 100 MHz): δ 157.0, 150.4, 139.2, 133.1, 129.1, 126.5, 
125.2, 122.3, 112.4, 86.5, 70.6, 34.3, 31.1 ppm. FTIR (cm-1) (neat): 3060, 2961, 1471, 1275. 
HRMS (ESI Pos): expe. for C17H19INaO [M+Na]+: 389.0374, calc. 389.0373 m/z. 
Aryl amine synthesis 
 
Procedure N: In a flame-dried 100 mL round bottom flask, 2-iodoaniline (1.0 equiv) and the 
corresponding aldehyde (1.5 equiv) were dissolved in 20 mL MeOH. Acetic acid (1.5 equiv) 
was added and the reaction was stirred at rt for 30 min. Then, the reaction was cooled down to 
0 °C and sodium cyanoborohydride (1.3 equiv) was added in two portions over 30 min. The 
reaction was allowed to stir from 0 °C to rt overnight (or until complete by TLC). The reaction 
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was quenched with a saturated aqueous solution of NaHCO3 (30 mL) and then extracted with 
Et2O (3x30 mL). The combined organic layers were dried with Na2SO4, filtered and the 
solvent was removed under reduced pressure. The crude was flashed in 5% DCM/petroleum 
ether.  
Procedure O: In a flame-dried 100 mL round bottom flask, E1-8 (1.0 equiv) and 37% 
aqueous paraformaldehyde (10 equiv) were dissolved in 20 mL MeCN. Acetic acid (15 equiv) 
was added and the reaction was stirred at rt for 30 min. Then, the reaction was cooled down to 
0 °C and sodium cyanoborohydride (1.3 equiv) was added in two portions over 30 min. The 
reaction was allowed to stir from 0 °C to rt overnight (or until complete by TLC). The reaction 
was quenched with a saturated aqueuos solution of NaHCO3 (30 mL) and then extracted with 
Et2O (3x30 mL). The combined organic layers were dried with Na2SO4, filtered and the 
solvent was removed under reduced pressure. The crude was flashed in 5% DCM/petroleum 
ether to give the title compound. 
For R = H,264 4-OMe,265 4-Me,266 the intermediates E1-2,4-5 matched the reported literature 
data. For R = H,267 the methylated amine also matched the reported literature data.  
 
N-(4-tert-butylbenzyl)-2-iodoaniline (E3): Synthesized according to Procedure N on a 2.28 
mmol scale to give a white solid (624 mg, 75 %), mp: 81-83 °C. 1H NMR (CDCl3, 300 MHz): 
δ 7.69 (dd, 1H, J = 8.0, 1.6 Hz), 7.42-7.30 (m, 4H), 7.22-7.16 (m, 1H), 6.60 (dd, 1H, J = 8.0, 
1.6 Hz), 6.50-6.45 (m, 1H), 4.60 (br s, 1H), 4.37 (s, 2H), 1.35 (s, 9H) ppm. 13C NMR (CDCl3, 
300 MHz): δ 151.4, 148.0, 140.2, 136.8, 130.3, 127.8, 126.7, 119.7, 111.6, 85.9, 49.0, 35.5, 
32.2 ppm. FTIR (cm-1) (neat): 3382, 2953, 1586, 1491, 1315, 1006. HRMS (ESI Pos): expe. 
for C17H21IN [M+H]+: 366.0709, calc. 366.0713 m/z. 
 
2-iodo-N-(3-methoxybenzyl)aniline (E6): Synthesized according to Procedure N on a 4.57 
mmol scale to give a yellow oil (1.32 g, 85%). 1H NMR (CDCl3, 300 MHz): δ 7.68 (dd, 1H, J 
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= 7.8, 1.4 Hz), 7.42-7.30 (t, 1H, J = 7.8 Hz), 7.16 (td, 1H, J = 8.3, 1.1 Hz), 6.95 (d, 1H, J = 8.2 
Hz), 6.92 (s, 1H), 6.82 (dd, 1H, J = 8.2, 2.4 Hz), 6.54 (dd, 1H, J = 8.1, 1.3 Hz), 6.45 (td, 1H, J 
= 7.4, 1.4 Hz), 4.63 (br s, 1H), 4.38 (d, 2H, J = 5.6 Hz), 3.81 (s, 3H) ppm. 13C NMR (CDCl3, 
100 MHz): δ 160.3, 147.4, 140.7, 139.3, 130.1, 129.7, 119.7, 119.2, 113.1, 113.0, 111.3, 85.6, 
55.5, 48.6 ppm. FTIR (cm-1) (neat): 3399, 2933, 1589, 1491, 1317, 1263, 743. HRMS (ESI 
Pos): expe. for C14H15INO [M+H]+: 340.0184, calc. 340.0193 m/z. 
 
N-(3,5-dimethoxybenzyl)-2-iodoaniline (E7): Synthesized according to Procedure N on a 
2.28 mmol scale to give a white solid (651 mg, 77%). mp: 64-65 °C. 1H NMR (CDCl3, 400 
MHz): δ 7.71 (dd, 1H, J = 7.9, 1.5 Hz), 7.20 (t, 1H, J  = 7.9 Hz), 6.58-6.55 (m, 3H), 6.49 (t, 
1H, J = 7.8 Hz), 6.45-6.41 (m, 1H), 4.68 (br s, 1H), 4.37 (d, 2H, J = 6.3 Hz), 3.82 (s, 6H) ppm. 
13C NMR (CDCl3, 100 MHz): δ 160.8, 146.7, 141.0, 138.7, 129.3, 118.6, 110.6, 104.7, 98.9, 
85.0, 55.2, 48.2 ppm. FTIR (cm-1) (neat): 3393, 2934, 1587, 1451, 1426, 1315, 1202, 1149. 
HRMS (ESI Pos): expe. for C15H17INO2 [M+H]+: 370.0297, calc. 370.0298 m/z.    
 
2-iodo-N-(2-methylbenzyl)aniline (E8): Synthesized according to Procedure N on a 2.28 
mmol scale to give a white solid (469 mg, 64%). mp: 64-66 °C. 1H NMR (CDCl3, 400 MHz): 
δ 7.71 (dd, 1H, J = 7.8, 1.4 Hz), 7.33 (d, 1H, J = 6.7 Hz), 7.25-7.19 (m, 4H), 6.58 (dd, 1H, J = 
8.2, 1.0 Hz), 6.49 (td, 1H, J = 7.7, 1.4 Hz), 4.45 (bs, 1H), 4.33 (d, 2H,  J = 5.3 Hz), 2.39 (s, 
3H) ppm. 13C NMR (CDCl3, 100 MHz): δ 147.5, 139.3, 136.5, 130.8, 129.8, 128.1, 127.8, 
126.6, 119.1, 111.1, 85.5, 46.9, 19.3 ppm. FTIR (cm-1) (neat): 3398, 1588, 1501, 1315. HRMS 
(ESI Pos): expe. for C14H15IN [M+H]+: 324.0244, calc. 324.0244 m/z. 
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N-benzyl-2-bromo-N-methylaniline (E10): Synthesized according to Procedure O to give a 
clear oil (95%). 1H NMR (CDCl3, 300 MHz): δ 7.60 (dd, 1H, J = 7.9, 1.6 Hz), 7.45-7.41 (dm, 
2H, J = 5.9 Hz), 7.36-7.31 (tm, 2H, J = 8.5 Hz), 7.28-7.23 (m, 2H), 7.09 (dd, 1H, J = 8.0, 1.6 
Hz), 6.92 (td, 2H, J = 7.3, 1.6 Hz), 4.19 (s, 2H), 2.67 (s, 3H) ppm. 13C NMR (CDCl3, 100 
MHz): δ 151.3, 138.4, 134.0, 128.6, 128.4, 128.3, 128.1, 127.2, 124.4, 122.3, 120.2, 60.6, 40.6 
ppm. FTIR (cm-1) (neat): 2793, 1585, 1474, 1025, 753, 696. HRMS (ESI Pos): expe. for 
C14H15BrN [M+H]+: 276.0388, calc. 276.0382 m/z. 
 
N-(4-tert-butylbenzyl)-2-iodo-N-methylaniline (380): Synthesized according to Procedure 
O on a 1.37 mmol scale to give a white solid (480 mg, 92%). mp: 51-52 °C. 1H NMR (CDCl3, 
300 MHz): δ 7.90 (dd, 1H, J = 7.9, 1.6 Hz), 7.45-7.31 (m, 5H), 7.13 (dd, 1H, J = 8.0, 1.0 Hz), 
6.81 (td, 1H, J = 7.8, 1.3 Hz), 4.10 (s, 2H), 2.63 (s, 3H), 1.35 (s, 9H) ppm. 13C NMR (CDCl3, 
75 MHz): δ 155.3, 150.7, 140.8, 136.3, 129.9, 126.2, 125.9, 123.0, 99.4, 61.7, 42.4, 35.3, 32.3 
ppm. FTIR (cm-1) (neat): 2959, 1579, 1467, 1360, 1014. HRMS (ESI Pos): expe. for C18H23IN 
[M+H]+: 380.0870, calc. 380.0870 m/z.    
 
2-iodo-N-methyl-N-(4-methylbenzyl)aniline (382): Synthesized according to Procedure O 
on a  1.25 mmmol scale to give a white solid (332 mg, 80%). mp: 51-52 °C. 13H NMR 
(CDCl3, 300 MHz): δ 7.90 (dd, 1H, J = 7.8, 1.5 Hz), 7.30-7.40 (m, 3H), 7.18-7.08 (m, 3H), 
6.80 (td, 1H, J = 7.8, 1.6 Hz), 4.10 (s, 2H), 2.63 (s, 3H), 2.36 (s, 3H) ppm. 13C NMR (CDCl3, 
75MHz): δ 155.0, 140.9, 137.5, 135.9, 129.8, 129.7, 129.5, 126.2, 123.1, 99.4, 61.7, 42.3, 22.0 
ppm. FTIR (cm-1) (neat): 2844, 1579, 1467, 1360, 1097. HRMS (ESI Pos): expe. for C15H17N 
[M+H]+: 338.0398, calc. 338.0400 m/z. 
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2-iodo-N-(4-methoxybenzyl)-N-methylaniline (384): Synthesized according to Procedure O 
on a 1.47 mmol scale to give a clear oil (451 mg, 87%). 1H NMR (CDCl3, 400 MHz): δ 7.89 
(dd, 1H, J = 7.9, 1.5 Hz), 7.41-7.37 (m, 2H), 7.35-7.29 (m, 1H), 7.10 (dd, 1H, J = 8.0, 1.5 Hz), 
6.90-6.80 (m, 2H), 4.08 (s, 2H), 3.83 (s, 3H), (2.63 (s, 3H) ppm. 13C NMR (CDCl3, 300 MHz): 
δ159.6, 154.9, 140.9, 131.0, 130.7, 129.8, 126.2, 123.2, 114.4, 99.5, 61.3, 56.1, 42.3 ppm. 
FTIR (cm-1) (neat): 2920, 1609, 1569, 1457, 1219. HRMS (ESI, Pos): expe. for C15H17NO 
[M+H]+: 354.0351, found 354.0349 m/z.  
 
2-iodo-N-(3-methoxybenzyl)-N-methylaniline (386): Synthesized according to Procedure O 
on a 0.59 mmol scale, to give a light yellow oil (205 mg,  95%). 1H NMR (CDCl3, 400 MHz): 
δ 7.89 (dd, 1H, J = 7.8, 1.4 Hz), 7.31 (td, 1H, J = 8.5, 1.4 Hz), 7.23 (t, 1H, J = 7.8 Hz), 7.11 
(dd, 2H, J = 7.9, 1.4 Hz), 7.01 (d, 1H, J = 7.5 Hz), 6.83-6.79 (m, 2H), 4.11 (s, 2H), 3.81 (s, 
3H), 2.64 (s, 3H) ppm. 13C NMR (CDCl3, 100 MHz): δ 160.0, 154.4, 140.4, 140.3, 129.4, 
125.9, 122.7, 121.2, 114.1, 113.3, 99.0, 61.3, 55.6, 42.2 ppm. FTIR (cm-1) (neat): 2832, 1600, 
1583, 1466, 1258, 1044. HRMS (ESI Pos): expe. for C15H17INO [M+H]+: 354.0349, calc. 
354.0350 m/z. 
 
N-(3,5-dimethoxybenzyl)-2-iodo-N-methylaniline (388): Synthesized according to 
Procedure O on a 1.25 mmol scale to give a clear oil (381 mg, 80%). 1H NMR (CDCl3, 300 
MHz): δ 7.91 (dd, 1H, J = 8.1, 1.5 Hz), 7.35-7.29 (m, 1H), 7.14 (dd, 1H, J = 8.1, 2.2 Hz), 6.82 
(td, 1H, J = 7.5, 1.7 Hz), 6.70 (d, 2H, J = 2.2 Hz), 6.37-6.34 (m, 1H), 4.09 (s, 2H), 3.81 (s, 
6H), 3.06 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): δ 161.6, 154.8, 141.7, 140.9, 129.9, 126.4, 
123.4, 107.1 100.1, 99.5, 61.8, 56.2, 42.9 ppm. FTIR (cm-1) (neat): 2936, 1595, 1465, 1202, 
1151. HRMS (ESI Pos): expe. for C16H19INO2 [M+H]+: 384.0454, calc. 384.0455 m/z. 
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2-iodo-N-methyl-N-(2-methylbenzyl)aniline (400): Synthesized according to Procedure O 
on a 0.93 mmol scale to give a clear oil (96%). 1H NMR (CDCl3, 400 MHz): δ 7.90 (dd, 1H, J 
= 7.9, 1.3 Hz), 7.57-7.54 (m, 1H), 7.36 (td, 1H, J = 7.3, 1.5 Hz), 7.23-7.19 (m, 4H), 6.83 (td, 
1H, J = 7.8, 1.6 Hz), 4.14 (s, 2H), 2.67 (s, 3H), 2.36 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): 
δ 155.0, 140.6, 137.3, 136.4, 130.6, 129.9, 129.4, 127.4, 126.0, 125.7, 122.4, 98.6, 58.7, 42.8, 
19.8 ppm.  FTIR (cm-1) (neat): 2841, 1578, 1470, 1093. HRMS (ESI Pos): expe. for C15H17IN 
[M+H]+: 338.0403, calc. 338.0400 m/z. 
Synthesis of N,N-dibenzyl-2-iodoaniline (E12) 
I
NH Ph
BzCl, pyr
MeCN,
I
N Ph
OPh
BH3·DMS
PhMe, 60 °C
I
N Ph
Ph
E12E11E1  
N-benzyl-N-(2-iodophenyl)benzamide (E11): A solution of benzoyl chloride (3.9 mmol) in 
CH3CN (13 mL) was added to a suspension of E1 (3.2 mmol) and pyridine (9.7 mmol) in 
CH3CN (22 mL) at 0 °C dropwise.  The mixture was warmed up to rt, and refluxed overnight 
and then cooled down to rt. The reaction mixture was diluted with H2O, and extracted with 
EtOAc (3x15 mL). The combined organic layers were washed with brine, and dried over 
anhydrous MgSO4. The filtrate was concentrated, and purified by flash chromatography (10-
15% EtOAc/Hex), affording a white solid in 84%. mp: 88-89 °C. 1H NMR (CDCl3, 400 
MHz): δ 7.77 (d, 1H, J = 7.8 Hz), 7.37 (d, 1H, J = 7.3 Hz), 7.27 (s, 6H), 7.20 (t, 1H, J = 7.2 
Hz), 7.13 (t, 1H, J = 7.2 Hz), 7.00 (t, 1H, J = 7.4 Hz), 6.83 (t, 1H, J = 7.3 Hz), 6.62 (d, 1H, J = 
7.8 Hz), 5.82 (d, 1H, J = 14.2 Hz), 4.27 (d, 1H, J = 14.2 Hz) ppm. 13C NMR (CDCl3, 100 
MHz): δ 170.6, 144.8, 140.4, 137.1, 136.1, 132.4, 130.0, 129.8, 129.4, 128.9, 128.7, 128.5, 
127.9, 127.8, 100.3, 52.7 ppm.  FTIR (cm-1) (neat): 3028, 1641, 1467, 1378, 1292, 696. 
HRMS (ESI Pos): expe. for C20H17INO [M+H]+: 414.0357, calc. 414.0349 m/z. 
N,N-dibenzyl-2-iodoaniline (E12): A BH3⋅DMS solution (6 mmol) was added to a solution of 
E11 (1.9 mmol) in toluene (8 mL). The resulting mixture was heated at 60 °C overnight, and 
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then cooled down to rt.  The reaction was quenched by adding H2O at 0 °C, and stirred until 
the evolution of H2 gas ceased.  The mixture was extracted with DCM (3x10 mL), and the 
combined organic layers were washed with brine.  After drying the organic layers with 
anhydrous MgSO4, the crude was concentrated and purified by flash chromatography (5% 
EtOAc/Hex), affording a pale yellow oil in 87% yield. 1H NMR (CDCl3, 400 MHz): δ 7.88 (d, 
1H, J = 7.8 Hz), 7.35-7.16 (m, 11H), 6.88 (d, 1H, J = 8.0 Hz), 6.76 (t, 1H, J = 7.8 Hz), 4.14 (s, 
4H) ppm. 13C NMR (CDCl3, 100 MHz): δ 151.9, 140.4, 138.1, 129.3, 128.8, 128.5, 127.4, 
126.1, 124.9, 100.1, 57.4 ppm. FTIR (cm-1) (neat): 3026, 2923, 1579, 1466, 719, 695. HRMS 
(ESI Pos): expe. for C20H19IN [M+H]+: 400.0567, calc. 400.0557 m/z. 
Synthesis of N-benzyl-2-iodo-N,4-dimethylaniline (E15) 
 
2-Iodo-4-methylaniline (E13): p-Toluidine (5 mmol), iodine (5 mmol) and NaHCO3 (15 
mmol) were dissolved in a mixture of DCM (20 mL) and H2O (10 mL), and stirred overnight 
at rt.  The organic layer was separated and the aqueous layer was extracted with DCM (2x10 
mL).  The combined organic layers were washed with brine (20 mL) and dried over anhydrous 
MgSO4. The filtrate was concentrated and the crude mixture was purified by flash 
chromatography (5% EtOAc/Hex), affording a white solid in 79%. The observed 
characterization data (1H and 13C) were consistent with the one previously reported in the 
literature.268 
N-benzyl-2-iodo-4-methylaniline (E14): Synthesized according to Procedure N to give a 
yellow oil in >95% yield. 1H NMR (CDCl3, 400 MHz): δ 7.54 (d, 1H, J = 1.3 Hz), 7.36-7.33 
(m, 4H), 7.31-7.27 (m, 1H), 6.97 (d, 1H, J = 7.9 Hz), 6.45 (d, 1H, J = 8.2 Hz), 4.46 (br. s, 1H), 
4.38 (d, 2H, J = 5.6 Hz), 2.21 (s, 3H) ppm. 13C NMR (CDCl3, 100 MHz): δ 145.2, 139.6, 
139.2, 130.3, 129.0, 128.6, 127.6, 127.5, 111.2, 85.7, 48.9, 20.1 ppm.  FTIR (cm-1) (neat): 
3402, 2918, 1603, 1508, 1026, 695. HRMS (ESI Pos): expe. for C14H15IN [M+H]+: 324.0244, 
calc. 324.0244 m/z. 
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N-benzyl-2-iodo-N,4-dimethylaniline (E15) : Synthesized according to Procedure O to give 
a pale yellow oil (>95%). 1H NMR (CDCl3, 400 MHz): δ 7.72 (s, 1H), 7.47 (d, 2H, J = 7.3 
Hz), 7.33 (t, 2H, J = 7.3 Hz), 7.26 (t, 1H, J = 7.3 Hz), 7.11 (d, 1H, J = 8.0 Hz), 7.00 (d, 1H, J 
= 8.0 Hz), 4.08 (s, 2H), 2.59 (s, 3H), 2.27 (s, 3H) ppm. 13C NMR (CDCl3, 100 MHz): δ 151.9, 
140.7, 138.7, 135.7, 130.1, 129.1, 128.5, 127.4, 122.2, 99.1, 61.7, 42.1, 20.5 ppm.  FTIR (cm-
1) (neat): 3025, 2792, 1484, 1450, 1032, 696. HRMS (ESI Pos): expe. for C15H17IN [M+H]+: 
338.0410, calc. 338.0400 m/z. 
 
2-Iodo-4-trifluoromethylaniline (E16): Using a literature procedure,269 the title intermediate 
E16 was obtained as an orange solid in 72% yield. The observed characterization data (1H and 
13C) were consistent with the one previously reported in the literature. 
N-benzyl-2-iodo-4-(trifluoromethyl)aniline (E17): Synthesized according to Procedure N 
to give a yellow oil (25%). 1H NMR (CDCl3, 400 MHz): δ 7.90 (d, 1H, J = 1.4 Hz), 7.40-7.29 
(m, 6H), 6.52 (d, 1H, J = 8.6 Hz), 4.99 (br s, 1H), 4.45 (d, 2H, J = 5.6 Hz) ppm. 13C NMR 
(CDCl3, 100 MHz): δ 149.6, 137.9, 136.3, 129.1, 127.9, 127.3, 127.0, 125.3, 122.6, 120.7, 
120.4, 109.9, 83.9, 48.3 ppm.  FTIR (cm-1) (neat): 3396, 3031, 1603, 1525, 1316, 729. HRMS 
(ESI Pos): expe. for C14H12F3IN [M+H]+: 377.9962, calc. 377.9961 m/z. 
N-benzyl-2-iodo-N-methyl-4-(trifluoromethyl)aniline (E18): Synthesized according to 
Procedure O to give a pale orange oil (83%). 1H NMR (CDCl3, 400 MHz): δ 8.13 (d, 1H, J = 
1.4 Hz), 7.55 (dd, 1H, J = 8.4, 1.4 Hz), 7.43 (dd, 2H, J = 8.3, 1.4 Hz), 7.35 (td, 2H, J = 7.0, 1.2 
Hz), 7.31-7.27 (m, 1H), 7.10 (d, 1H, J = 8.4 Hz), 4.22 (s, 2H), 2.70 (s, 3H) ppm. 13C NMR 
(CDCl3, 100 MHz): δ 157.5, 137.7, 128.8, 128.7, 127.7, 127.1, 126.8, 126.3, 124.9, 122.2, 
121.9, 119.5, 96.8, 60.8, 41.6 ppm.  FTIR (cm-1) (neat): 3029, 2802, 1601, 1320, 1121, 697. 
HRMS (ESI Pos): expe. for C15H14F3IN [M+H]+: 392.0123, calc. 392.0118 m/z. 
Synthesis of carbon iodoarenes 
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Procedure P: To a flame-dried 100 mL round-bottom flask was added NaHMDS (1 equiv) in 
a dry box. The flask was fitted with a septum and taken outside of the dry box. THF (20 mL) 
were added and the solution was cooled down to 0 °C. A solution of the corresponding 
phosphonate (1 equiv) in THF (2 mL) was added to the reaction dropwise. The reaction was 
stirred for a further 10 min at 0 °C, then a solution of the haloaldehyde (1 equiv) in THF (2 
mL) was added to the reaction dropwise. The reaction was stirred from 0 °C to rt overnight (or 
until complete by TLC). The reaction was quenched with water (10 mL), and the aqueous 
layer was extracted with Et2O (3x25 mL). The combined organic layers were washed with 
10% aq NaHSO3 (2x10 mL) and brine (10 mL). The crude was purified by flash 
chromatography in 5% DCM/Pet. Et2O to give E19-21 as a mixture of E/Z isomers.  
Procedure Q: E19-20 (1 equiv) was dissolved in 2 mL o-xylenes. Hydrazide270 (1 equiv) was 
added. The reaction was refluxed for 10 min, then an additional equivalent of hydrazide was 
added to the reaction every 15 min until complete reduction (usually a total of 4 equiv). The 
reaction was filtered through a pad of celite and purified by flash chromatography (2% 
EtOAc/Hex) to give the title compound.  
 
(E)-1-iodo-2-styrylbenzene (E19): Synthesized according to Procedure P on a 4.13 mmol 
scale, to give a white solid (957 mg, 76%, E/Z >10:1, mixture). mp: <50 °C (decomposition). 
E isomer: 1H NMR (CDCl3, 400 MHz): δ 7.91 (dd, 1H, J = 7.9, 1.3 Hz), 7.65 (dd, 1H, J = 7.8, 
1.3 Hz), 7.61-7.58 (m, 2H), 7.44-7.31 (m, 5H), 7.02-6.97 (m, 2H) ppm. 13C NMR (CDCl3, 100 
MHz): δ 140.0, 139.3, 136.6, 132.1, 131.3, 128.7, 128.4, 128.1, 127.7, 126.5, 126.0, 99.9 ppm. 
FTIR (cm-1) (neat): 2922, 1461, 1010, 957. HRMS (ESI Pos): expe. for C14H11AgI [M+Ag]+: 
412.8949, calc. 412.8951 m/z. 
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(E)-1-bromo-2-styrylbenzene (E20 Synthesized according to Procedure P on a 5.4 mmol 
scale to give a clear oil (966 mg, 72%, E/Z >10:1, mixture). 1H NMR (CDCl3, 400 MHz): δ 
7.71 (d, 1H, J = 8.0 Hz), 7.64-7.59 (m, 3H), 7.52 (d, 1H, J = 16.2 Hz), 7.43 (t, 2H, J = 7.6 Hz), 
7.37-7.32 (m, 2H), 7.18-7.14 (m, 1H), 7.08 (d, 1H, J = 16.2 Hz) ppm. 13C NMR (CDCl3, 75 
MHz): δ 138.0, 137.9, 133.9, 132.3, 129.7, 129.6, 128.9, 128.3, 127.7, 127.6, 125.0 ppm. 
FTIR (cm-1) (neat): 3057, 1585, 1464, 1022, 957. HRMS (ESI Pos): expe. for C14H11AgBr 
[M+Ag]+: 364.9094, calc. 364.9090 m/z. 
 
(E)-1-iodo-2-(4-methylstyryl)benzene (E21): Synthesized according to Procedure P on a 4.3 
mmol scale to give a clear oil (688 mg, 50%). 1H NMR (CDCl3, 400 MHz): δ 7.87 (dd, 1H, J 
= 7.8, 1.1 Hz), 7.62 (dd, 1H, J = 7.9, 1.5 Hz), 7.46 (dd, 1H, J = 7.9 Hz), 7.37-7.30 (m, 1H), 
7.27-7.25 (m, 1H), 7.20 (d, 2H, J = 8.3 Hz), 7.00-6.93 (m, 2H), 2.39 (s, 3H) ppm. 13C NMR 
(CDCl3, 75 MHz): δ 141.4, 140.5, 138.9, 135.0, 132.4, 132.3, 130.3, 129.6, 129.2, 127.6, 
127.0, 101.2, 22.1 ppm. FTIR (cm-1) (neat): 2921, 1514, 1464, 1011. HRMS (ESI Pos): expe. 
for C15H13AgI [M+Ag]+: 426.9101, calc. 426.9107 m/z. 
 
1-iodo-2-phenethylbenzene (E22): Synthesized according to Procedure Q on a 1.5 mmol 
scale to give a clear oil (355 mg, 70%). 1H NMR (CDCl3, 400 MHz): δ 7.88 (d, 1H, J = 7.8 
Hz), 7.38-7.21 (m, 7H), 6.94 (t, 1H, J = 7.4 Hz), 3.08-3.04 (m, 2H), 2.95-2.91 (m, 2H) ppm. 
13C NMR (CDCl3, 100 MHz): δ 143.9, 141.0, 139.2, 129.3, 128.2, 128.1, 127.6, 125.8, 100.2, 
42.8, 36.0 ppm. FTIR (cm-1) (neat): 2925, 1561, 1453, 1009. HRMS (ESI Pos): expe. for 
C14H13AgI [M+Ag]+: 414.9121, calc. 414.9107 m/z.  
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1-bromo-2-phenethylbenzene (E23): Synthesized according to Procedure Q on a 1.5 mmol 
scale to give a clear oil (322 mg, 82%). 1H NMR (CDCl3, 400 MHz): δ 7.59 (dd, 1H, J = 8.0, 
1.0 Hz), 7.36-7.19 (m, 7H), 7.11 (td, 1H, J = 8.0, 2.0 Hz), 3.09-3.05 (m, 2H), 2.97-2.93 (m, 
2H) ppm. 13C NMR (CDCl3, 75 MHz): δ 142.3, 141.8, 131.3, 129.3, 129.2, 128.6, 128.3, 
126.9, 125.3, 39.3, 37.1 ppm. FTIR (cm-1) (neat): 3025, 1602, 1470, 1024. HRMS (ESI Pos): 
expe. for C14H13AgBr [M+Ag]+: 366.9254, calc. 366.9246 m/z. 
 
 
1-iodo-2-(4-methylphenethyl)benzene (392): Synthesized according to Procedure Q on a 
1.25 mmol scale to give a clear oil (314 mg, 78%). 1H NMR (CDCl3, 400 MHz): δ 7.88 (dd, 
1H, J = 8.0, 1.2 Hz), 7.31 (td, 1H, J = 7.5, 1.5 Hz), 7.24-7.16 (m, 5H), 6.94 (td, 1H, J = 7.6, 
1.7 Hz), 3.07-3.02 (m, 2H), 2.92-2.88 (m, 2H), 2.39 (s, 3H) ppm. 13C NMR (CDCl3, 100 
MHz): δ 144.0, 139.2, 138.0, 135.2, 129.2, 128.8, 128.0, 127.5, 100.2, 42.8, 35.7, 20.7 ppm. 
FTIR (cm-1) (neat): 2921, 1514, 1464, 1443, 1010. HRMS (ESI Pos): expe. for C15H15AgI 
[M+Ag]+: 428.9267, calc. 428.9264 m/z.  
The amide substrates were prepared according to the literature procedure and matched the 
reported spectra.271,89a 
KOtBu-promoted intramolecular arylation 
Procedure R: A microwave vial was charged with a stir bar and freshly sublimed KOtBu (1 
mmol, 2 equiv) in a glove box. The vial was crimped and taken out of the glove box. A 
solution of the starting material (0.5 mmol, 1 equiv) in freshly distilled pyridine (3.7 mL, 0.13 
M) was added to the vial via syringe under a positive pressure of Ar. The reaction was stirred 
at rt for 1 min, then heated in a microwave at 160 °C for 10 min. The reaction mixture was 
filtered on a pad of silica and celite, rinsing with EtOAc (20 mL). The solvent was removed in 
 283 
vacuo, and the crude was purified by flash chromatography in 1-2% Et2O/Pet. ether. The 
product was occasionally recovered with a small impurity of reduced starting material.  
Procedure S: A microwave vial was charged with a stir bar, phenanthroline (0.05 mmol, 0.1 
equiv), and freshly sublimed KOtBu (1 mmol, 2 equiv) in a glove box. The vial was crimped 
and taken out of the glove box. A solution of the starting material (0.5 mmol, 1 equiv) in 
freshly distilled pyridine (3.7 mL, 0.13 M) was added to the vial via syringe under a positive 
pressure of Ar. The reaction was stirred at rt for 1 min, then heated in a microwave at 160 °C 
for 10 min. The reaction mixture was filtered on a pad of silica and celite, rinsing with EtOAc 
(20 mL). The solvent was removed in vacuo, and the crude was purified by flash 
chromatography in 1-2% Et2O/Pet. ether. The product was occasionally recovered with a small 
impurity of reduced starting material.  
The phenanthridine products had a high propensity to oxidize at room temperature,210b but 
were stable at –20 °C for several weeks. 
 
6H-benzo[c]chromene (152): Synthesized according to Procedure R to give a clear oil (72 
mg, 79%, for X = I, along with 2% 368). Matches reported literature data.272 Synthesized 
according to Procedure S to give a clear oil (68 mg, 75%, for X = Br, along with 2% 368). 
 
9,10-dihydrophenanthrene (373): Synthesized according to Procedure R to give a clear oil 
(X = I, 80 mg, 89%). Synthesized according to Procedure S to give a clear oil (X = Br, 63 
mg, 71%). Matches reported data.273 
N
Me  
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5-methyl-5,6-dihydrophenanthridine (375): Synthesized according to Procedure R to give 
a clear oil (80 mg, 82% for X = I). Synthesized according to Procedure S to give a clear oil 
(62 mg, 64% for X = Br). Matches reported data.274 
 
5-benzyl-5,6-dihydrophenanthridine (374): Synthesized according to Procedure R to give a 
yellow oil (88 mg, 65%).1H NMR (CDCl3, 400 MHz): δ 7.82 (t, 1H, J = 6.4 Hz), 7.42-7.21 
(m, 8H), 7.10 (d, 1H, J = 7.4 Hz), 6.87 (t, 1H, J = 7.3 Hz), 6.83 (d, 1H, J = 8.1 Hz), 4.56 (s, 
2H), 4.36 (s, 2H) ppm. 13C NMR (CDCl3, 75 MHz): δ 147.2, 138.6, 133.8, 133.0, 129.9, 
129.5, 128.5, 127.9, 127.8, 126.4, 124.5, 124.0, 123.3, 119.2, 113.9, 55.7, 53.4 ppm. FTIR 
(cm-1) (neat): 3027, 1649, 1603, 1493, 1442, 1286. HRMS (ESI Pos): expe. for C20H18N 
[M+H]+: 272.1431, calc. 272.1434 m/z. 
 
2,5-dimethyl-5,6-dihydrophenanthridine (376):  Synthesized according to Procedure R to 
give a yellow oil in 64% yield, along with traces of dehalogenated arene. 1H NMR (CDCl3, 
400 MHz): δ 7.77 (d, 1H, J = 7.8 Hz), 7.60 (s, 1H), 7.36 (t, 1H, J = 7.4 Hz), 7.26 (t, 1H, J = 
7.3 Hz), 7.18 (d, 1H, J = 7.4 Hz), 7.11 (d, 1H, J = 8.2 Hz), 6.72 (d, 1H, J = 8.2 Hz), 4.17 (s, 
2H), 2.94 (s, 3H), 2.40 (s, 3H) ppm. 13C NMR (CDCl3, 100 MHz): δ 145.4, 133.8, 132.5, 
129.9, 128.0, 127.9, 127.2, 125.9, 124.5, 123.7, 122.7, 112.7, 55.6, 39.0, 21.0 ppm.  FTIR (cm-
1) (neat): 3027, 2788, 1504, 1446, 1283, 1203. HRMS (ESI Pos): expe. for C15H16N [M+H]+: 
210.1279, calc. 210.1277 m/z. 
 
5-methyl-2-(trifluoromethyl)-5,6-dihydrophenanthridine (377): Synthesized according to 
Procedure R to give a yellow oil in 31% yield (41 mg), along with dehalogenated arene 
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(~13%). 1H NMR (CDCl3, 400 MHz): δ 7.91 (d, 1H, J = 1.6 Hz), 7.73 (d, 1H, J = 7.8 Hz), 
7.44 (dd, 1H, J = 8.4, 1.5 Hz), 7.35 (q, 1H, J = 7.8 Hz), 7.27 (td, 1H, J = 7.4, 1.1 Hz), 7.13 (d, 
1H, J = 7.4 Hz), 6.74 (d, 1H, J = 8.5 Hz), 4.31 (s, 2H), 2.97 (s, 3H) ppm. 13C NMR (CDCl3, 
100 MHz): δ 149.7, 133.0, 131.3, 129.2, 128.4, 128.2, 126.8, 126.4, 126.2, 123.1, 123.0, 
120.8, 112.2, 55.0, 38.9 ppm.  FTIR (cm-1) (neat): 2959, 1617, 1330, 1272, 1106, 815. HRMS 
(ESI Pos): expe. for C15H13F3N [M+H]+: 264.1001, calc. 264.0995 m/z. 
 
8-tert-butyl-6H-benzo[c]chromene (379a) and 9-(tert-butyl)-6H-benzo[c]chromene 
(379b): Synthesized according to Procedure S to give a clear oil (108 mg, 91%) 5:1 mixture 
of inseparable regioisomers, along with 7% reduced starting material. 379a: 1H NMR (CDCl3, 
400 MHz): δ 7.75 (dd, 1H, J = 7.9, 1.6 Hz), 7.65 (d, 1H, J = 8.2 Hz), 7.43 (m, 1H), 7.24 (m, 
1H), 7.19 (d, 1H, J = 1.5 Hz), 7.07 (td, 1H, J = 7.5, 1.2 Hz), 7.01 (dd, 1H, J = 8.0, 1.2 Hz), 
5.15 (s, 2H), 1.38 (s, 9H) ppm. 13C NMR (CDCl3, 75 MHz): δ 155.5, 151.9, 132.0, 129.8, 
128.2, 126.3, 123.9, 123.8, 122.9, 122.6, 122.4, 118.0, 69.7, 35.5, 32.2 ppm. FTIR (cm-1) 
(neat): 2960, 1607, 1479, 1241. HRMS (ESI Pos): expe. for C17H19O [M+H]+: 239.1428, calc. 
239.1430 m/z. Structure was assigned based on 1D nOe experiments.275 379b (mass confirmed 
by GC-MS) could not be characterized. Structure was assigned based on proposed mechanism 
for para isomer.   
 
8-tert-butyl-5-methyl-5,6-dihydrophenanthridine (381a) and 8-tert-butyl-5-methyl-5,6-
dihydrophenanthridine (381b): Synthesized according to Procedure R to give a yellow oil 
(107 mg, 86%) 10:1 inseparable mixture of isomers, with <2% reduced starting material). 
381a: 1H NMR (CDCl3, 300 MHz): δ 7.72-7.66 (m, 2H), 7.36 (dd, 1H, J = 8.2, 2.0 Hz), 7.26-
7.20 (m, 1H), 7.17 (d, 1H, J = 2.0 Hz), 6.87 (td, 1H, J = 7.7, 1.3 Hz), 6.75 (d, 1H, J = 8.3 Hz), 
4.20 (s, 2H), 2.93 (s, 3H), 1.34 (s, 9H) ppm. 13C NMR (CDCl3, 75 MHz): δ 150.6, 147.5, 
 286 
133.2, 129.8, 129.1, 125.1, 123.8, 123.0, 122.6, 119.0, 112.7, 112.6, 55.9, 39.1, 35.0, 31.8 
ppm. FTIR (cm-1) (neat): 2959, 1651, 1604, 1271, 1206. HRMS (ESI Pos): expe. for C18H22N 
[M+H]+: 252.1747, calc. 252.1747 m/z. Structure was assigned based on 1D nOe 
experiments.275 381b (mass confirmed by GC-MS) could not be characterized. Structure was 
assigned based on proposed mechanism for para isomer.   
 
5,8-dimethyl-5,6-dihydrophenanthridine (383a) and 5,9-dimethyl-5,6-
dihydrophenanthridine (383b): Synthesized according to Procedure R to give a clear oil 
(107 mg, 82%, inseparable mixture of two isomers, >15:1). 383a: 1H NMR (CDCl3, 400 
MHz): δ 7.72 (dd, 1H, J = 7.8, 1.7 Hz), 7.65 (d, 1H, J = 8.0 Hz), 7.28-7.24 (m, 1H), 7.18-7.16 
(m, 1H), 6.99 (s, 1H), 6.90 (td, 1H, J = 7.6, 1.4 Hz), 6.80-6.77 (m, 1H), 4.2 (s, 3H), 2.95 (s, 
3H), 2.40 (s, 3H) ppm. 13C NMR (CDCl3, 100 MHz): δ 146.6, 136.5, 132.8, 129.0, 128.3, 
125.9, 123.2, 122.9, 122.1, 118.2, 111.9, 54.5, 38.3, 20.9 ppm. FTIR (cm-1) (neat): 1648, 1492, 
1291, 1204. HRMS (ESI Pos): expe. for C15H16N [M+H]+: 210.1274, calc. 210.1273 m/z. 
Structure was assigned based on 1D nOe experiments.275 383b (mass confirmed by GC-MS) 
could not be characterized. Structure was assigned based on proposed mechanism for para 
isomer.   
 
8-methoxy-5-methyl-5,6-dihydrophenanthridine (385a) and 9-methoxy-5-methyl-5,6-
dihydrophenanthridine (385b): Synthesized according to Procedure R to give white solids 
(93 mg, 83%, 385a:385b, 10:1).  
385a: mp: 78-80 °C. 1H NMR (CDCl3, 300 MHz): δ 7.69-7.65 (m, 2H), 7.22 (t, 1H, J = 7.7 
Hz), 6.92-6.87 (m, 2H), 6.76 (d, 1H, J = 8.3 Hz), 6.71 (d, 1H, J = 2.3 Hz), 4.2 (s, 2H), 3.86 (s, 
3H), 2.94 (s, 2H) ppm. 13C NMR (CDCl3, 75 MHz): δ 158.6, 146.0, 134.4, 127.8, 124.7, 
 287 
123.5, 123.1, 122.4, 118.3, 113.1, 111.9, 110.5, 55.0, 54.9, 38.3 ppm. FTIR (cm-1) (neat): 
1611, 1493, 1291, 1035. HRMS (ESI Pos): expe. for C15H16NO [M+H]+: 226.1217, calc. 
226.1226 m/z. Structure was assigned based on 1D nOe experiments.275  
385b: mp: 57-58 °C. 1H NMR (CDCl3, 300 MHz): δ 7.69 (dd, 1H, J = 7.8, 1.3 Hz), 7.27-7.23 
(m, 2H), 7.07 (d, 1H, J = 8.4 Hz), 6.88 (t, 1H, J = 7.5 Hz), 6.82-6.75 (m, 2H), 4.15 (s, 2H), 
3.88 (s, 3H), 2.94 (s, 3H) ppm. 13C NMR (CDCl3, 75 MHz): δ 160.2, 148.2, 134.1, 130.1, 
127.5, 126.7, 124.4, 124.1, 119.3, 113.6, 113.2, 108.7, 56.2, 55.4, 39.5 ppm. FTIR (cm-1) 
(neat): 1646, 1610, 1500, 1207, 1039. HRMS (ESI Pos): expe. for C15H16NO [M+H]+: 
226.1223, calc. 226.1226 m/z. Structure was assigned based on comparison to literature 
spectra of oxidized 385b.276    
 
7-methoxy-5-methyl-5,6-dihydrophenanthridine (387a): Synthesized according to 
Procedure R to give a yellow oil in 67% yield (75 mg), along with dehalogenated arene. 1H 
NMR (CDCl3, 400 MHz): δ 7.69 (dd, 1H, J = 7.7, 1.3 Hz), 7.36 (d, 1H, J = 7.8 Hz), 7.28 (t, 
1H, J = 8.0 Hz), 7.24 (t, 1H, J = 7.2 Hz), 6.86 (td, 1H, J = 7.5, 1.0 Hz), 6.80 (d, 1H, J = 8.1 
Hz), 6.74 (d, 1H, J = 8.1 Hz), 4.29 (s, 2H), 3.87 (s, 3H), 2.94 (s, 3H) ppm. 13C NMR (CDCl3, 
100 MHz): δ 155.2, 147.4, 133.6, 129.5, 128.2, 124.2, 123.4, 122.3, 119.3, 115.2, 112.7, 
109.0, 55.8, 48.9, 38.9 ppm.  FTIR (cm-1) (neat): 2953, 1606, 1467, 1255. HRMS (ESI Pos): 
expe. for C15H16NO [M+H]+: 226.1226, calc. 226.1226 m/z. 
N
Me
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MeO OMe
 
7,9-dimethoxy-5-methyl-5,6-dihydrophenanthridine (389a) and 8,10-dimethoxy-5-
methyl-5,6-dihydrophenanthridine (389b): Synthesized according to Procedure R to give a 
clear oil (78 mg, 62%, 389a:389b, 7:1).  
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389a: mp: 61-62 °C. 1H NMR (CDCl3, 300 MHz): δ 7.67 (dd, 1H, J = 7.7, 1.5 Hz), 7.27-7.21 
(m, 1H), 6.88-6.82 (m, 1H), 6.75 (d, 1H, J = 2.4 Hz), 4.22 (s, 2H), 3.90 (s, 3H), 3.85 (s, 3H), 
2.94 (s, 3H) ppm. 13C NMR (CDCl3, 100 MHz): δ 160.8, 156.8, 148.2, 134.5, 130.1, 124.6, 
123.9, 118.9, 115.7, 112.9, 99.4, 98.0, 56.3, 49.2, 39.4 ppm. FTIR (cm-1) (neat): 1607, 1422, 
1204. HRMS (ESI Pos): expe. for C16H18NO2 [M+H]+: 256.1327, calc. 256.1332 m/z.  
389b: mp: 64-65 °C. 1H NMR (CDCl3, 300 MHz): δ 8.31 (dd, 1H, J = 8.3, 1.5 Hz), 7.24-7.19 
(m, 1H), 6.91 (t, 1H, J = 7.4 Hz), 6.79 (d, 1H, J = 7.7 Hz), 6.51 (d, 1H, J = 2.3 Hz), 6.37 (d, 
1H, J = 2.3 Hz), 4.02 (s, 2H), 3.91 (s, 3H), 3.87 (s, 3H), 2.92 (s, 3H) ppm. 13C NMR (CDCl3, 
75 MHz): δ 160.3, 158.9, 148.2, 138.5, 128.8, 128.2, 123.8, 119.5, 115.2, 112.9, 103.4, 99.3, 
57.1, 56.5, 56.2, 39.7 ppm. FTIR (cm-1) (neat): 1607, 1455, 1422, 1277. HRMS (ESI Pos): 
expe. for C16H18NO2 [M+H]+: 256.1328, calc. 256.1332 m/z. Structures assigned based on 1D 
nOe experiments.275   
 
5,10-dimethyl-5,6-dihydrophenanthridine  (391a): Synthesized according to Procedure R 
to give a clear oil (26 mg, 25%). 1H NMR (CDCl3, 400 MHz): δ 7.71 (dd, 1H, J = 7.8, 1.5 Hz), 
7.31-7.16 (m, 2H), 7.09-7.05 (m, 1H), 6.95 (t, 1H, J = 7.6 Hz), 6.86 (d, 1H, J = 8.1 Hz), 3.99 
(s, 2H), 2.94 (s, 3H), 2.66 (s, 3H) ppm. 13C NMR (CDCl3, 100 MHz): δ 149.1, 136.5, 133.8, 
131.1, 128.0, 126.0, 124.6, 122.9, 117.8, 112.1, 56.2, 38.3, 22.9 ppm. FTIR (cm-1) (neat): 
2952, 1600, 1496, 1281, 1203. HRMS (ESI Pos): expe. for C15H16N [M+H]+: 210.1281, calc. 
210.1277 m/z. Structure was assigned based on 1D nOe experiments of 391a and oxidized 
391a.275  
 
3-methyl-9,10-dihydrophenanthrene (393a) and 2-methyl-9,10-dihydrophenanthrene 
(393b): Synthesized according to Procedure R to give a clear oil ( mg, 92%, 393a:393b, 
1:2.3, inseparable, with <5% reduced starting material). Mixture: 1H NMR (CDCl3, 500 
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MHz): δ 7.81 (d, 1H, J = 8.0 Hz, major), 7.78 (d, 1H, J = 8.0 Hz, minor), 7.71 (d, 1H, J = 8.0 
Hz, minor), 7.64 (s, 1H, major), 7.38-7.34 (m, 1H, major; m, 1H, minor), 7.30-7.24 (m, 2H, 
major; m, 1H, minor), 7.19-7.16 (m, 1H, major; m, 2H, minor), 7.12-7.10 (m, 1H, major; m, 
1H, minor), 2.96-2.88 (m, 4H, major; m, 4H, minor), 2.47 (s, 3H, major), 2.43 (s, 3H, minor) 
ppm. 13C NMR (CDCl3, 75 MHz): δ 137.2, 137.0, 136.8, 136.7, 136.0, 134.2, 134.1, 134.0, 
131.4, 128.7, 128.5, 128.1, 128.0, 127.8, 17.7, 127.7, 127.6, 127.3, 126.9, 126.6, 126.5, 124.1, 
123.3, 123.1, 28.9, 28.8, 28.7, 28.3, 21.1, 20.8 ppm. FTIR (cm-1) (neat): 3025, 2930, 1491, 
1448. HRMS (ESI Pos): expe. for C15H14  [M*+]: 194.1085, calc. 194.1090 m/z. 
 
5-methylphenanthridin-6(5H)-one (399): Synthesized according to Procedure S to give a 
light brown solid (45 mg, 43%). Matches reported literature data.277 
Oxidation to phenanthridone 
 
A microwave vial was charged with a stir bar and freshly sublimed KOtBu (1 mmol, 2 equiv) 
in a dry box. The vial was capped and taken out of the dry box. A solution of N-benzyl-2-iodo-
N-methylaniline (0.5 mmol, 1 equiv) in freshly distilled pyridine (3.7 mL, 0.13 M) was added 
to the vial via syringe under a positive pressure of Ar. The reaction was stirred at rt for 1 min, 
then heated in a microwave at 160 °C for 10 min. The reaction mixture was filtered on a pad 
of silica and celite, rinsing with EtOAc (20 mL). The solvent was removed in vacuo, and the 
crude dihydrophenanthridine 374 (1 equiv) was dissolved in DCM (0.1 M) in a microwave 
vial. Ba(MnO4)2 (5 equiv) was added, the vial was crimped and reaction was refluxed at 45 °C 
overnight (or until complete by TLC). The reaction was allowed to cool down to rt, and 
filtered through a celite cake. Purification by flash chromatography in 30-50% EtOAc/Hex 
provided 70 mg of the phenanthridone 399 (67% overall yield).  
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Radical Scavenging Studies 
Using Procedure R, except that one equivalent of the corresponding radical inhibitor was 
added to the reaction as a solution in pyridine. Yields determined by 1H NMR using 
trimethoxybenzene as internal standard. 
Experiment section of Chapter 6 
Synthesis of phenylsulfanes 
 
Procedure T: To a flask charged with NaOH (1.0 equiv) in EtOH (0.5 mL/mmol NaOH) was 
added thiophenol (1.0 equiv) in one portion at rt. The reaction mixture was refluxed until 
dissolution of the NaOH. A solution of 1,3-diiodo-2,2-dimethylpropane278 (4.0 equiv) in 
dioxane (0.17 mL/mmol 1,3-diiodo-2,2-dimethylpropane) was added in one portion and the 
yellow solution was refluxed for 16 h. The reaction was cooled to rt and then poured into ice 
water (20 mL). Et2O (20 mL) was added and the layers were separated. The aqueous layer was 
extracted with Et2O (2x20 mL). The combined organic layers were dried over MgSO4, filtered, 
then concentrated in vacuo.   
 
(3-iodo-2,2-dimethylpropyl)(phenyl)sulfane (450): Synthesized according to Procedure T 
on a 3 mmol scale. The crude product was purified by flash chromatography (2-3% 
EtOAc/Hex) affording the title compound (817 mg, 89%) as a pale yellow oil. 1H NMR 
(CDCl3, 400 MHz): δ 7.41-7.16 (m, 5H), 3.33 (s, 2H), 3.03 (s, 2H), 1.15 (s, 6H). 13C NMR 
(CDCl3, 100 MHz): δ 137.3, 129.8, 129.0, 126.3, 46.1, 35.5, 26.7, 22.2. IR (film) cm-1 2960, 
1582, 1479, 1438, 1381, 1365, 1088, 1024. HRMS (ESI, Pos) calcd for C11H15Ag1I1S1 
[M+Ag]+: 412.8985, found 412.8990 m/z.  
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(3-iodo-2,2-dimethylpropyl)(4-methoxyphenyl)sulfane (453): Synthesized according to 
Procedure T on a 4 mmol scale. The residue was purified by flash chromatography (2-3% 
EtOAc/Hex), affording the title compound (945 mg, 70%) as a clear oil. 1H NMR (CDCl3, 300 
MHz): δ 7.38 (d, 2H, J = 8.8 Hz), 6.83 (d, 2H, J = 8.8 Hz), 3.79 (s, 3H), 3.30 (s, 2H), 2.94 (s, 
2H), 1.13 (s, 6H). 13C NMR (CDCl3, 75 MHz): δ 158.7, 133.6, 127.7, 114.5, 55.6, 48.5, 36.2, 
26.7, 22.5. IR (film) cm-1 2958, 1592, 1492, 1461, 1283, 1240, 1172, 1030, 822, 639, 604, 
522.  HRMS (ESI, Pos) calcd for C12H17I1O1S1 [M]+: 336.0039, found 336.0038 m/z. 
Route 1 
 
Mono-protected diol F1 was synthesized according to the literature procedure and is in 
accordance to the given spectra.279 
 
2-(3-iodo-2,2-dimethylpropoxy)tetrahydro-2H-pyran (F2): To a solution of F1 (28.5 
mmol, 1.0 equiv) in toluene (100 mL) was added I2 (31.3 mmol, 1.1 equiv), PPh3 (31.3 mmol, 
1.1 equiv) and imidazole (113.8 mmol, 4.0 equiv). The reaction was stirred under reflux for 12 
h (or until complete by TLC). The reaction was allowed to cool down to rt, then quenched 
with a saturated aqueous solution of NaHSO3. The layers were separated, and the organic layer 
was concentrated. The resulting solid suspension was triturated several times with hexanes. 
The filtrate was concentrated and then purified by flash chromatography in 0-5% EtOAc/Hex, 
giving 6.26 g (74%) of a clear, colourless oil. 1H NMR (CDCl3, 300 MHz): δ 4.56 (s, 1H), 
3.86-3.78 (m, 1H), 3.54-3.45 (m, 2H), 3.21 (q, 2H, J = 9.7 Hz), 3.09 (d, 1H, J = 9.7 Hz), 1.82-
1.46 (m, 6H), 1.04 (s, 3H), 0.99 (s, 3H). 13C NMR (CDCl3, 75 MHz): δ 98.9, 74.4, 61.9, 34.9, 
30.5, 25.5, 24.5, 24.4, 20.7, 19.3. IR (film) cm–1 2939, 2869, 1473, 1379, 1350, 1200, 1121, 
1063, 1032. HRMS (ESI, Pos) calcd for C10H19Na2O2 [M+Na]+: 321.0322, found 321.0320 
m/z. 
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Procedure U: To a solution of F2 (6.9 mmol, 2.3 equiv) in Et2O (7.0 mL) in a flame-dried 
flask under Argon was cannulated tBuLi (1.5 M in pentane, 14.4 mmol, 4.8 equiv) at – 78 °C. 
The reaction was stirred at – 78 °C for 1 h, then allowed to warm up to rt in 5 min. The 
resulting organolithium was then cannulated to a suspension of CuI (3.6 mmol, 1.2 equiv) in 
THF (6 mL) at – 78 °C. The reaction was transferred to a cryostat bath at – 40 °C. After 30 
min, the corresponding benzyl bromide (3.0 mmol, 1.0 equiv) was added dropwise (neat, or as 
a solution in THF if solid), and the reaction was stirred at – 40 °C for 16 h. The reaction was 
quenched with a saturated aqueous ammonium sulfate solution (20 mL), filtered, and extracted 
with ether (3x25 mL). The combined organic layers were washed with brine, dried with 
Na2SO4, and concentrated. The concentrate was dissolved in 6 mL MeOH, and 225 mg of 
HSO4•silica was added. The reaction was stirred for 30 min at rt, then filtered and 
concentrated.   
Procedure V: To a solution of the corresponding alcohol (1.0 equiv) in toluene was added I2 
(1.1 equiv), PPh3 (1.1 equiv) and imidazole (4.0 equiv). The reaction was stirred under reflux 
for 12 h (or until complete by TLC). The reaction was allowed to cool down to rt, then 
quenched with a saturated aqueous solution of NaHSO3. The layers were separated, and the 
organic layer was concentrated. The residue was purified by flash chromatography.  
 
4-(4-methoxyphenyl)-2,2-dimethylbutan-1-ol (F3): Synthesized according to Procedure U. 
The residue was purified by flash chromatography (5% EtOAc/Hex), affording the title 
compound (251 mg, 40%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.14–7.08 (m, 2H), 
6.85–6.80 (m, 2H), 3.78 (s, 3H), 3.37 (s, 2H), 2.56–2.49 (m, 2H), 1.56–1.50 (m, 2H), 1.40 (br 
s, 1H), 0.95 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 157.7, 135.3, 129.2, 113.8, 71.8, 55.3, 
41.2, 35.3, 29.6, 23.9 (2). IR (film) cm–1 3428, 2954, 1512, 1245, 1036. HRMS (ESI, Pos) 
calcd for C13H20AgO2 [M+Ag]+: 315.0509, found 315.0509 m/z. 
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1-(4-iodo-3,3-dimethylbutyl)-4-methoxybenzene (457): Synthesized according to 
Procedure V on a 1.2 mmol scale. The residue was purified by flash chromatography (2% 
EtOAc/Hex), affording the title compound (282 mg, 74%) as a clear oil. 1H NMR (CDCl3, 400 
MHz): δ 7.18–7.10 (m, 2H), 6.90–6.82 (m, 2H), 3.81 (s, 3H), 3.24 (s, 2H), 2.55–2.47 (m, 2H), 
1.67–1.60 (m, 2H), 1.12 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 157.8, 134.6, 129.3, 113.9, 
55.4, 43.7, 33.6, 30.0, 26.8, 24.0. IR (film) cm–1 2956, 1612, 1510, 1463, 1243, 1176, 1035. 
HRMS (ESI, Pos) calcd for C13H19NAgIO [M+Ag]+: 424.9526, found 424.9515 m/z. 
 
4-(4-tert-butylphenyl)-2,2-dimethylbutan-1-ol (F4): Synthesized according to Procedure 
U. The residue was purified by flash chromatography (5% EtOAc/Hex), affording the title 
compound (241 mg, 35%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.38 (d, 2H, J = 8.0 
Hz), 7.21 (d, 2H, J = 8.0 Hz), 3.44 (s, 2H), 2.65-2.60 (m, 2H), 1.90 (br s, 1H), 1.66-1.62 (m, 
2H), 1.39 (s, 9H), 1.03 (s, 6H) ppm. 13C NMR (CDCl3, 100 MHz): δ 148.5, 140.2, 128.0, 
125.3, 71.9, 40.9, 35.4, 34.4, 31.6, 30.0, 23.9. IR (film) cm-1 3355, 2955, 2867, 1109. HRMS 
(ESI Pos): calc. for C16H26NaO [M+Na]+: 257.1876, found 257.1872 m/z.  
 
1-tert-butyl-4-(4-iodo-3,3-dimethylbutyl)benzene (459): Synthesized according to 
Procedure V on a 1 mmol scale. The residue was purified by flash chromatography (Hex), 
affording the title compound (279 mg, 81%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.38 
(d, 2H, J = 8.2 Hz), 7.20 (d, 2H, J = 8.2 Hz), 3.23 (s, 2H), 2.60-2.55 (m, 2H), 1.73-1.69 (m, 
2H), 1.38 (s, 9H), 1.17 (s, 6H) ppm. 13C NMR (CDCl3, 100 MHz): δ 148.7, 139.5, 128.1, 
125.4, 43.4, 34.4, 33.7, 31.6, 30.4, 26.8, 24.0 ppm. IR (film) cm-1 2958, 1364, 1268. LRMS 
(CI, Pos) calcd for C16H26I1  [M+H]+ : 345.3 m/z, found 345.2 m/z.  
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2,2-dimethyl-4-p-tolylbutan-1-ol (F5): Synthesized according to Procedure U. The residue 
was purified by flash chromatography (5% EtOAc/Hex), affording the title compound (208 
mg, 36%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.17 (s, 4H), 3.41 (s, 2H), 2.64-2.58 
(m, 2H), 2.39 (s, 3H), 1.65-1.59 (m, 2H), 1.02 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 140.2, 
135.0, 129.1, 128.2, 71.9, 41.2, 35.3, 30.1, 23.9, 21.1. IR (film) cm-1 2959, 1514, 1466, 807. 
LRMS (CI, Pos): calc. for C13H19• [M-OH•]: 175.2 m/z, found 175.1 m/z.  
 
1-(4-iodo-3,3-dimethylbutyl)-4-methylbenzene (461): Synthesized according to Procedure 
V on a 1.1 mmol scale. The residue was purified by flash chromatography (Hex), affording the 
title compound (243 mg, 75%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.15 (s, 4H), 3.26 
(s, 2H), 2.57-2.53 (m, 2H), 2.38 (s, 3H), 1.70-1.65 (m, 2H), 1.15 (s, 6H). 13C NMR (CDCl3, 
100 MHz): δ 139.5, 135.3, 129.2, 128.3, 43.6, 33.7, 30.5, 26.9, 24.0, 21.1. IR (film) cm-1 2959, 
2861, 1514, 1466, 1383, 1365, 1207, 1162. LRMS (CI, Pos) calcd for C13H20I1 [M+H]+: 303.1, 
found 303.0 m/z. 
 
N,N-diethyl-4-(4-hydroxy-3,3-dimethylbutyl)benzamide (F6): Synthesized according to 
Procedure U.  The residue was purified by flash chromatography (20-30% EtOAc/Hex), 
affording the title compound (371 mg, 45%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.27 
(d, 2H, J = 8.1 Hz), 7.20 (d, 2H, J = 8.1 Hz), 3.53-3.27 (m, 4H), 3.34 (s, 2H), 2.60-2.56 (m, 
2H), 2.16 (br s, 1H), 1.57-1.52 (m, 2H). 1.23-1.11 (m, 6H), 0.94 (s, 6H) ppm. 13C NMR 
(CDCl3, 100 MHz): δ 171.7, 144.6, 134.6, 128.4, 126.5, 71.6, 40.8, 35.4, 30.5, 25.8, 24.0, 
14.3, 13.1 ppm. IR (film) cm-1 3407, 2937, 1608, 1460. HRMS (ESI Pos): expe. for 
C17H27NNaO2 [M+Na]+: 300.1938, calc. 300.1934 m/z.  
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N,N-diethyl-4-(4-iodo-3,3-dimethylbutyl)benzamide (465): Synthesized according to 
Procedure V on a 1.3 mmol scale. The residue was purified by flash chromatography (10-
20% EtOAc/Hex), affording the title compound (318 mg, 63%) as a clear oil. 1H NMR 
(CDCl3, 400 MHz): δ 7.27 (d, 2H, J = 7.9 Hz), 7.20 (d, 2H, J = 7.9 Hz), 3.53-3.27 (m, 4H), 
3.21 (s, 2H), 2.56-2.52 (m, 2H), 1.64-1.60 (m, 2H), 1.22-1.11 (m, 6H), 1.11 (s, 6H) ppm. 13C 
NMR (CDCl3, 100 MHz): δ 171.1, 143.9, 134.6, 128.2, 126.6, 43.4, 33.7, 31.1, 27.8, 23.5, 
14.3, 12.9 ppm. IR (film) cm-1 2961, 1608, 1462, 1282, 1094. HRMS (ESI Pos): expe. for 
C17H26INNaO [M+Na]+: 410.0963, calc. 410.0951 m/z.  
OHMe  
2,2-dimethyl-4-m-tolylbutan-1-ol (F7): Synthesized according to Procedure U. The residue 
was purified by flash chromatography (5% EtOAc/Hex), affording the title compound (189 
mg, 32%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.19 (t, 1H, J = 7.0 Hz), 7.04-7.01 (m, 
3H), 3.39 (s, 2H), 2.59-2.54 (m, 2H), 2.36 (s, 3H), 1.67 (br s, 1H), 1.60-1.56 (m, 2H), 0.98 (s, 
6H). 13C NMR (CDCl3, 100 MHz): δ 143.2, 137.9, 129.2, 128.3, 126.4, 125.4, 71.9, 41.1, 
35.4, 30.6, 23.9, 21.5. IR (film) cm-1 3469, 2943, 2869, 1753, 1445, 1378, 1038, 1018. HRMS 
(ESI Pos): expe. for C13H19 [M-H2O]+: 175.1475, calc. 175.1481 m/z.  
 
1-(4-iodo-3,3-dimethylbutyl)-3-methylbenzene (469): Synthesized according to Procedure 
V on a 0.96 mmol scale. The residue was purified by flash chromatography (Hex), affording 
the title compound (190 mg, 62%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.25 (t, 1H, J 
= 7.5 Hz), 7.09-7.06 (m, 3H), 3.26 (s, 2H), 2.59-2.55 (m, 2H), 2.41 (s, 3H), 1.72-1.68 (m, 2H), 
1.17 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 142.5, 138.1, 129.3, 128.4, 126.6, 125.5, 43.5, 
33.7, 30.9, 26.8, 23.9, 21.5. IR (film) cm-1 2959, 1608, 1466, 1383, 1365, 1225, 1206. LRMS 
(CI, Pos) calcd for C13H20I1 [M+H]+: 303.1, found 303.0 m/z. 
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2,2-dimethyl-4-o-tolylbutan-1-ol (F8): Synthesized according to Procedure U. The residue 
was purified by flash chromatography (5% EtOAc/Hex), affording the title compound (90 mg, 
16%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.15-7.08 (m, 4H), 3.43 (s, 2H), 2.60-2.56 
(m, 2H), 2.37 (s, 3H), 1.55 (br s, 1H), 1.55-1.48 (m, 2H), 1.04 (s, 6H) ppm. 13C NMR (CDCl3, 
100 MHz): δ 141.4, 135.8, 130.3, 128.9, 126.2, 126.0, 72.0, 39.7, 35.5, 28.0, 23.8, 19.4 ppm. 
IR (film) cm-1 3457, 2942, 2868, 1732, 1363, 1125, 1105, 1017. HRMS (ESI Pos): expe. for 
C13H20AgO [M+Ag]+: 299.0556, calc. 299.0560 m/z.  
 
1-(4-iodo-3,3-dimethylbutyl)-2-methylbenzene (471): Synthesized according to Procedure 
V on a 0.83 mmol scale. The residue was purified by flash chromatography (Hex), affording 
the title compound (150 mg, 60%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.18-7.11 (m, 
4H), 3.27 (s, 3H), 2.58-2.52 (m, 2H), 2.37 (s, 3H), 1.62-1.55 (m, 2H), 1.18 (s, 6H) ppm. 13C 
NMR (CDCl3, 100 MHz): δ 140.6, 135.8, 130.4, 129.0, 126.3, 126.1, 42.2, 33.8, 28.3, 26.8, 
23.8, 19.4 ppm. IR (film) cm-1 2958, 2860, 1608, 1466, 1383, 1366, 1255, 1130. LRMS (CI, 
Pos) calcd for C13H20I1 [M+H]+: 303.1, found 303.0 m/z. 
Route 2 
 
Procedure W: To a solution of iPr2NH (1.2 equiv) in THF (0.33 mL/mmol iPr2NH) at 0 °C 
was added nBuLi (2.5 M in hexanes, 1.25 equiv). The reaction was stirred for 15 min at 0 °C, 
then cooled down to - 78 °C. Then, the LDA solution was slowly cannulated to a solution of 
methyl isobutyrate (1.0 equiv) in THF (15 mL), previously cooled down to - 78 °C. The 
resulting reaction was stirred for 30 min, then the corresponding phenethyl bromide (1.2 
equiv) was added dropwise. The reaction was stirred for another 15 min at - 78 °C, then 
allowed to warm up to rt overnight. The reaction was acidified with 2M HCl, extracted with 
O
OMe
i. nBuLi, iPr2NH
THF, - 78 °C, 30 min
ii. Br
R CO2Me
R LiAlH4, THF0 °C, then reflux
OH
R
I
R
I2, PPh3
imidazole
PhMe, reflux
12 h
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Et2O (3x30 mL). The combined organic layers were washed with brine, dried with Na2SO4, 
filtered and concentrated under vacuum.   
Procedure X: To a suspension of LiAlH4 (2.0 equiv) in THF (12 mL) at 0 °C, a solution of 
the methyl ester (1.0 equiv), in THF (5 mL) was added dropwise. The reaction was fitted with 
a reflux condenser and refluxed for 2 h. The reaction was then cooled down to 0 °C, where 
water and 15% NaOH were added (n mL H2O, n mL 15% NaOH, and 3n mL H2O, where n = 
grams of LiAlH4 used). The mixture was filtered on a pad of celite, eluted with Et2O, dried 
with Na2SO4, filtered and concentrated in vacuo. 
 
methyl 4-(4-chlorophenyl)-2,2-dimethylbutanoate (F9): Synthesized according to 
Procedure W on a 10 mmol scale. The residue was purified by flash chromatography (2-3% 
EtOAc/Hex), affording the title compound (84 mg, 88%) as a clear oil. 1H NMR (CDCl3, 300 
MHz): δ 7.23–7.16 (m, 2H), 7.11–7.02 (m, 2H), 3.65 (s, 3H), 2.54–2.43 (m, 2H), 1.83–1.73 
(m, 2H), 1.23 (s, 6H). 13C NMR (CDCl3, 75 MHz): δ 177.8, 140.6, 131.4, 129.6, 128.3, 51.6, 
42.4, 42.2, 30.8, 25.1 (2). IR (film) cm–1 2951, 1721, 1492, 1453, 1259, 1192, 1170, 1130, 
1088, 1041, 811, 520. HRMS (ESI, Pos) calcd for C13H17Cl1Na1O2 [M+Na]+: 263.0809, found 
263.0806 m/z.  
 
4-(4-chlorophenyl)-2,2-dimethylbutan-1-ol (F10): Synthesized according to Procedure X 
on a 2.5 mmol scale. The title compound (539 mg, quant.) was obtained as a clear oil. 1H 
NMR (CDCl3, 300 MHz): δ 7.14–7.06 (m, 2H), 7.02–6.94 (m, 2H), 3.22 (s, 2H), 2.46–2.37 
(m, 2H), 2.33 (br s, 1H), 1.45–1.35 (m, 2H), 0.82 (s, 6H). 13C NMR (CDCl3, 75 MHz): δ 
141.6, 131.2, 129.7, 128.4, 71.6, 40.7, 35.2, 29.9, 23.8 (2). IR (film) cm–1 3322, 2954, 2865, 
1572, 1492, 1304, 1260, 1159, 1093, 1015, 807. HRMS (ESI, Pos) calcd for C12H17Cl1Li1O1 
[M+Li]+: 218.1114, found 218.1113 m/z. 
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1-chloro-4-(4-iodo-3,3-dimethylbutyl)benzene (463): Synthesized according to Procedure 
V on a 2.5 mmol scale. The residue was purified by flash chromatography (Hex), affording the 
title compound (699 mg, 87%) as a clear oil. 1H NMR (CDCl3, 300 MHz): δ 7.16–7.08 (m, 
2H), 7.04–6.97 (m, 2H), 3.08 (s, 2H), 2.42–2.33 (m, 2H), 1.53–1.43 (m, 2H), 0.98 (s, 6H). 13C 
NMR (CDCl3, 75 MHz): δ 140.9, 131.5, 129.7, 128.5, 43.3, 33.5, 30.2, 26.7(2C), 23.6. IR 
(film) cm–1 2959, 2865, 1491, 1467, 1384, 1365, 1204, 1162, 1092, 1014, 805, 660, 607, 519. 
LRMS (EI) calcd for C14H19Cl1I1 [M]: 322.0, found 322.0 m/z. 
 
methyl 4-(3-methoxyphenyl)-2,2-dimethylbutanoate (F11): Synthesized according to 
Procedure W on a 1.2 mmol scale. The residue was purified by flash chromatography (5% 
EtOAc/Hex), affording the title compound (219 mg, 77%) as a clear oil. 1H NMR (CDCl3, 300 
MHz): δ 7.27-7.18 (m, 1H), 6.80-6.74 (m, 3H), 3.81 (s, 3H), 3.70 (s, 3H), 2.58-2.52 (m, 2H), 
1.90-1.83 (m, 2H), 1.28 (s, 6H). 13C NMR (CDCl3, 75 MHz): δ 178.2, 159.8, 143.9, 129.4, 
120.7, 114.2, 111.2, 55.1, 51.7, 42.7, 42.3, 31.6, 25.2. IR (film) cm–1 2950, 1730, 1602, 1489, 
1455, 1262, 1193, 1151, 1128, 1046. HRMS (ESI, Pos) calcd for C14H20Na1O3 [M+Na]+: 
259.1305, found 259.1300 m/z. 
 
4-(3-methoxyphenyl)-2,2-dimethylbutan-1-ol (F12): Synthesized according to Procedure X 
on a 0.75 mmol scale. The title compound (158 mg, quant.) was obtained as a clear oil.  1H 
NMR (CDCl3, 300 MHz): δ 7.23 (t, 1H, J = 7.9 Hz), 6.84-6.76 (m, 3H), 3.82 (s, 3H), 3.40 (s, 
2H), 2.62-2.58 (m, 2H), 1.94 (br s, 1H), 1.62-1.58 (m, 2H), 1.00 (s, 6H). 13C NMR (CDCl3, 75 
MHz): δ 159.8, 145.1, 129.5, 120.9, 114.1, 111.1, 71.8, 55.2, 40.8, 35.2, 30.7, 23.9. IR (film) 
cm–1 3373, 2950, 2871, 1601, 1585, 1489, 1455, 1259, 1152, 1048. HRMS (ESI, Pos) calcd 
for C13H20Na2O2 [M+Na]+: 231.1356, found 231.1347 m/z. 
IOMe  
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1-(4-iodo-3,3-dimethylbutyl)-3-methoxybenzene (467): Synthesized according to 
Procedure V on a 0.73 mmol scale. The residue was purified by flash chromatography (Hex), 
affording the title compound (203 mg, 87%) as a clear oil. 1H NMR (CDCl3, 300 MHz): δ 7.22 
(t, 1H, J = 7.8 Hz), 6.83-6.73 (m, 3H), 3.81 (s, 3H), 3.22 (s, 2H), 2.57-2.51 (m, 2H), 1.69-1.63 
(m, 2H), 1.12 (s, 6H). 13C NMR (CDCl3, 75 MHz): δ 159.8, 144.2, 129.6, 120.8, 114.2, 111.1, 
55.2, 43.3, 39.7, 31.0, 26.8, 23.6. IR (film) cm–1  2957, 1601, 1489, 1465, 1260, 1152, 1048. 
HRMS (ESI, Pos) calcd for C13H19INaO [M+Na]+: 341.0373, found 341.0364 m/z. 
 
ethyl 1-phenethylcyclohexanecarboxylate (F13): Synthesized according to Procedure W on 
a 7.6 mmol scale. The residue was purified by flash chromatography (2-3% EtOAc/Hex), 
affording the title compound (1.34 g, 68%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.31-
7.27 (m, 2H), 7.21-7.16 (m, 3H), 4.20 (q, 2H, J = 7.2 Hz), 2.55-2.51 (m, 2H), 2.17-2.14 (m, 
2H), 1.84-1.79 (m, 2H), 1.59-1.56 (m, 3H), 1.46-1.27 (m, 5H), 1.32 (t, 3H, J = 7.2 Hz). 13C 
NMR (CDCl3, 100 MHz): δ 176.1, 142.2, 128.2, 128.1, 126.6, 59.5, 46.7, 42.4, 34.1, 30.5, 
25.8, 23.1, 14.2. IR (film) cm–1 2930, 2854, 1722, 1452, 1173, 1129, 1026. HRMS (ESI, Pos) 
calcd for C17H24Na1O2 [M+Na]+: 283.1669, found 283.1659 m/z. 
 
(1-phenethylcyclohexyl)methanol (F14): Synthesized according to Procedure X on a 5.0 
mmol scale. The residue was purified by flash chromatography (5-20% EtOAc/Hex), 
affording the title compound (966 mg, 88%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 
7.36-7.21 (m, 5H), 3.55 (s, 2H), 2.64-2.59 (m, 2H), 1.94 (br s, 1H), 1.75-1.63 (m, 2H), 1.55-
1.45 (m, 10H). 13C NMR (CDCl3, 100 MHz): δ 143.5, 128.4 (2), 125.6, 68.4, 37.3, 37.0, 32.4, 
29.7, 26.5, 21.6. IR (film) cm–1 3344, 2922, 2850, 1452, 1031. HRMS (ESI, Pos) calcd for 
C15H22Na1O1 [M+Na]+: 241.1563, found 241.1565 m/z. 
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(2-(1-(iodomethyl)cyclohexyl)ethyl)benzene (473): Synthesized according to Procedure V 
on a 3.0 mmol scale. The residue was purified by flash chromatography (Hex), affording the 
title compound (777 mg, 79%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.30-7.14 (m, 
5H), 3.31 (s, 2H), 2.48-2.42 (m, 2H), 1.66-1.60 (m, 2H), 1.53-1.37 (m, 10 H). 13C NMR 
(CDCl3, 100 MHz): δ 142.5, 128.4 (2 C’s), 125.8, 40.5, 35.1, 35.0, 29.3, 2621, 21.9, 21.8. IR 
(film) cm-1 2923, 2848, 1496, 1452, 1220, 1168. HRMS (ESI Pos): expe. for C15H21Ag 
[M+Ag]+: 434.9741, calc. 434.9733 m/z.  
Route 3 
 
Procedure Y: To a solution of NaH (1.1 equiv) and iPr2NH (1.0 equiv) in THF (2.5 mL/mmol 
iPr2NH) was added dropwise isobutyric acid (1.0 equiv) at rt. The reaction was refluxed for 15 
min, then cooled down to 0 °C. nBuLi (2.5 M in hexanes, 1.0 equiv) was added dropwise. The 
reaction was stirred at 0 °C for 20 min, then at 35 °C for 30 min. The reaction was cooled 
down to 0 °C, and the alkyl bromide (1.0 equiv) was added dropwise. The reaction was stirred 
at 0 °C for 30 min, then at 35 °C for 1 h. Then, the reaction was cooled to 0 °C and quenched 
slowly with water (20 mL). The layers were separated. The organic layer was washed with 
water (20 mL). The combined organic layers were extracted with 20 mL Et2O. The combined 
aqueous layers were acidified with 2 M HCl, then back-extracted with 2x30 mL Et2O. The 
combined organic layers from the back-extraction were washed with brine, dried with Na2SO4, 
filtered and concentrated in vacuo.  
Procedure Z: To a solution of the carboxylic acid (1.0 equiv) in THF (0.23 mL/mmol 
carboxylic acid) at 0 °C was added dropwise a solution of BH3•DMS (1.5 equiv) in THF (0.48 
mL/mmol BH3•DMS). The reaction was stirred at 0 °C for 1 h, then allowed to warm up to rt 
overnight (or when complete by TLC). The reaction was cooled down to 0 °C, then quenched 
slowly with water (20 mL). The reaction was extracted with DCM 3x20 mL. The combined 
organic layers were dried with Na2SO4, filtered and concentrated in vacuo.  
O
OH
i. NaH, iPr2NH
THF, rt
ii. nBuLi
iii. alkyl bromide
16 h
CO2H
n
BH3*DMS
THF, 12 h
n
OH
I2, PPh3
imidazole
PhMe, reflux
12 h
n
I
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2,2-dimethyl-4-phenylbutanoic acid (F15): Synthesized according to Procedure Y on a 55 
mmol scale. The residue was purified by flash chromatography (5% EtOAc/Hex), affording 
the title compound (7.43 g, 71%) as a white solid. mp: 80-83 °C. 1H NMR (CDCl3, 400 MHz): 
δ 12.05 (br s, 1H), 7.35-7.31 (m, 2H), 7.25-7.21 (m, 3H), 2.69-2.65 (m 2H), 1.95-1.91 (m, 
2H), 1.34 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ  185.1, 142.4, 128.5 (2 C’s), 125.0, 42.6, 
42.4, 31.6, 25.1. IR (film) cm–1 2973, 2933, 1698, 1473, 1236, 1203, 935, 744, 698, 546, 501. 
HRMS (ESI, Pos) calcd for C13H18Na1O2 [M+Na]+: 215.1043, found 215.1041 m/z. 
 
2,2-dimethyl-4-phenylbutan-1-ol (F16): Synthesized according to Procedure Z on a 35 
mmol scale. The residue was purified by flash chromatography (5% EtOAc/Hex), affording 
the title compound (4.62 g, 74%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.34-7.29 (m, 
2H), 7.25-7.20 (m, 3H), 3.42 (s, 2H), 2.65-2.60 (m, 2H), 1.64 (br s, 1H), 1.63-1.59 (m, 2H), 
1.01 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 143.3, 128.5, 128.4, 125.8, 71.9, 41.0, 35.4, 
30.6, 24.5, 23.9. IR (film) cm–1 3353, 2952, 2868, 1496, 1454, 1415, 1382, 1337, 1047, 736, 
697. HRMS (ESI, Pos) calcd for C12H18Li1O1 [M+Li]+: 184.1503, found 184.1503 m/z. 
 
(4-iodo-3,3-dimethylbutyl)benzene (455): Pyridine (10 mL) was cooled in an ice/salt bath 
and p-TsCl (4.82 g, 23.0 mmol) was added as a solid portionwise. A solution of F16 in 
pyridine (10 mL) was added and the reaction was allowed to warm to rt. The reaction mixture 
was stirred at rt for 16 h, then partitioned between DCM (100 mL) and 1 M aqueous HCl 
solution (50 mL). The layers were separated and the organic layer was sequentially washed 
with 1 M aqueous HCl solution (25 mL), H2O (25 mL), 1 M aqueous NaOH solution (25 mL) 
and H2O (25 mL). The organic layer was then dried over MgSO4 and concentrated in vacuo 
affording the crude tosylate (8.00 g, 93%) as a red oil, which was used as such in the 
iodination reaction. The crude tosylate (7.85 g, 23.6 mmol) was dissolved in 2-ethoxyethanol 
 302 
(25 mL) and NaI (7.08 g, 47.2 mmol) was added as a solid in one portion. The reaction 
mixture was heated to reflux for 16 h. The reaction was allowed to cool to room temperature 
and diluted with H2O (50 mL) and Et2O (100 mL). The layers were separated and the organic 
layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash 
chromatography (Hex), affording the title compound (4.30 g, 66%) as a pale red oil. 1H NMR 
(CDCl3, 400 MHz): δ 7.29-7.19 (m, 5H), 3.22 (s, 2H), 2.57-2.51 (m, 2H), 1.67-1.61 (m, 2H), 
1.11 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ  142.5, 128.5, 128.4, 125.9, 43.5, 33.7, 31.0, 
26.8, 23.9. IR (film) cm-1 3025, 2959, 1497, 1454, 1384, 1365, 1204, 1163.  LRMS (CI, Pos) 
calcd for C12H18I1 [M+H]+: 289.0, found 289.0 m/z. 
 
2,2-dimethyl-3-phenylpropanoic acid (F17): Synthesized according to Procedure Y on a 55 
mmol scale. The residue was purified by flash chromatography (5% EtOAc/Hex), affording 
the title compound (8.14 g, 84%) as a white solid. mp: 50-51 °C. 1H NMR (CDCl3, 400 MHz): 
δ 7.29-7.13 (m, 5H), 2.88 (s, 2H), 1.20 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 184.8, 137.8, 
130.4, 128.2, 126.7, 46.0, 43.6, 24.8. IR (film) cm–1 2972, 1685, 1470, 1456, 1289, 1223, 
1134.  HRMS (ESI, Pos) calcd for C11H14Na1O2 [M+Na]+: 201.0886, found 201.0889 m/z.  
 
2,2-dimethyl-3-phenylpropan-1-ol (F18): Synthesized according to Procedure Z, on a 30 
mmol scale. The residue was purified by flash chromatography (5% EtOAc/Hex), affording 
the title compound (4.90 g, 99%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.28-7.12 (m, 
5H), 3.30 (d, 2H, J = 6.0 Hz), 2.56 (s, 2H), 0.87 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 
138.9, 130.6, 128.0, 126.1, 71.3, 44.9, 36.6, 24.1. IR (film) cm–1 3239, 2866, 1467, 1385, 
1361, 1040. HRMS (ESI, Pos) calcd for C11H16Na1O1 [M+Na]+: 187.1093, found 187.1092 
m/z. 
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(3-iodo-2,2-dimethylpropyl)benzene (F19): Pyridine (20 mL) was cooled in an ice/salt bath 
and p-TsCl (5.80 g, 30.4 mmol) was added as a solid portionwise. A solution of F18 in 
pyridine (10 mL) was added and the reaction was allowed to warm to rt. The reaction mixture 
was stirred at rt for 16 h, then partitioned between DCM (100 mL) and 1 M aqueous HCl 
solution (50 mL). The layers were separated and the organic layer was sequentially washed 
with 1 M aqueous HCl solution (25 mL), H2O (25 mL), 1 M aqueous NaOH solution (25 mL) 
and H2O (25 mL). The organic layer was then dried over MgSO4 and concentrated in vacuo 
affording the crude tosylate (7.99 g, 91%) as a pale yellow solid, which was used as such in 
the iodination reaction. The crude tosylate (7.99 g, 25.1 mmol) was dissolved in 2-
ethoxyethanol (75 mL) and NaI (7.52 g, 50.2 mmol) was added as a solid in one portion. The 
reaction mixture was heated to reflux for 16 h. The reaction was allowed to cool to room 
temperature and diluted with H2O (50 mL) and Et2O (100 mL). The layers were separated and 
the organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified 
by flash chromatography (Hex), affording the title compound (3.97 g, 58%) as a clear oil. 1H 
NMR (CDCl3, 400 MHz): δ 7.32-7.19 (m, 5H), 3.14 (s, 2H), 2.66 (s, 2H), 1.06 (s, 6H). 13C 
NMR (CDCl3, 100 MHz): δ 138.3, 130.4, 128.0, 126.4, 46.4, 34.8, 27.2, 24.3. IR (film) cm-1 
2959, 1453, 1364, 1212, 773.  LRMS (CI, Pos) calcd for C11H16I1 [M+H]+: 275.0, found 275.0 
m/z. 
 
2,2-dimethyl-5-phenylpentanoic acid (F20): Synthesized according to Procedure Y on a 9.0 
mmol scale. The residue was purified by flash chromatography (5% EtOAc/Hex), affording 
the title compound (310 mg, 17%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 12.18 (br s, 
1H), 7.37-7.33 (m, 2H), 7.28-7.24 (m, 3H), 2.70-2.66 (m, 2H), 1.71-1.67 (m, 4H), 1.27 (s, 
6H). 13C NMR (CDCl3, 100 MHz): δ 185.3, 142.3, 128.5, 125.6, 42.2, 40.3, 36.4, 26.9, 25.41. 
IR (film) cm-1 2942, 1697, 1475, 1453, 1278, 1199. HRMS (ESI, Pos) calcd for C13H18Na1O2 
[M+Na]+: 229.1202, found 229.1199 m/z.  
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2,2-dimethyl-5-phenylpentan-1-ol (F21): Synthesized according to Procedure Z on a 1.5 
mmol scale. The residue was purified by flash chromatography (5-10% EtOAc/Hex), 
affording the title compound (212 mg, 76%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 
7.35-7.32 (m, 2H), 7.25-7.23 (m, 3H), 3.35 (s, 2H), 2.65 (t, 2H, J = 8.2 Hz), 1.69-1.61 (m, 
3H), 1.37-1.33 (m, 2H), 0.92 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 142.8, 128.5 (2), 125.8, 
72.0, 38.4, 37.0, 35.2, 26.1, 24.0. IR (film) cm-1 3354, 2936, 2864, 1495, 1471, 1453, 1389, 
1363, 1028. HRMS (ESI Pos): expe. for C13H20NaO [M+Na]+: 215.1410, calc. 215.1406 m/z.  
 
(5-iodo-4,4-dimethylpentyl)benzene (F22): Synthesized according to Procedure V, on a 1.1 
mmol scale. The residue was purified by flash chromatography (Hex), affording the title 
compound (232 mg, 72%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.38-7.34 (m, 2H), 
7.27-7.25 (m, 3H), 3.21 (s, 2H), 2.68 (t, 2H, J = 7.6 Hz), 1.68-1.60 (m, 2H), 1.48-1.44 (m, 
2H), 1.08 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 142.5, 128.4 (2C), 125.9, 40.8, 36.7, 33.6, 
26.9, 26.6, 24.4. IR (film) cm-1 2958, 2934, 2858, 1495, 1466, 1453, 1384, 1365, 1222, 1205, 
1161, 1030. LRMS (CI, Pos) calcd for C13H20I1 [M+H]+: 303.1, found 303.0 m/z. 
Nickel-catalyzed cyclization 
Procedure AA: In a glovebox, Ni(PPh3)4 (27.7 mg, 0.025 mmol, 0.05 equiv) and NaHMDS 
(137.5 mg, 0.75 mmol, 1.5 equiv) were added to a microwave vial containing a stir bar. The 
vial was crimped and taken out of the glovebox. A solution of the corresponding iodide (0.5 
mmol, 1.0 equiv) in 1.5 mL dry benzene was cannulated into the microwave vial. The flask 
was rinsed with 2x1.5 mL benzene for a total volume of 4.5 mL. The reaction was stirred at 80 
°C for 20 h. The reaction was allowed to cool down to rt, then filtered through a pad of silica 
and celite, concentrated and purified by flash chromatography.   
 
3,3-dimethylthiochroman (451): Synthesized according to Procedure AA. The residue was 
purified by flash chromatography (Hex), affording the title compound (62 mg, 70%) and 
dimer 452 (7 mg, 8%) as clear oils. 1H NMR (CDCl3, 300 MHz): δ 7.13-6.94 (m, 4H), 2.76 (s, 
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2H), 2.58 (s, 2H), 1.13 (s, 6H). 13C NMR (CDCl3, 75 MHz): δ 132.9, 132.4, 130.8, 127.1, 
126.0, 124.0, 43.5, 39.6, 28.5, 28.1. IR (film) cm-1 2953, 2913, 1467, 1437, 1249, 1070, 1039.  
LRMS (CI, Pos) calcd for C11H15S1 [M+H]+: 179.1, found 179.1 m/z. 
 
(2,2,5,5-tetramethylhexane-1,6-diyl)bis(phenylsulfane) (452): 1H NMR (CDCl3, 400 MHz): 
δ 7.36-7.34 (m, 4H), 7.28-7.24 (m, 3H), 7.16-7.13 (m, 3H), 2.88 (s, 4H), 1.30 (s, 4H), 1.00 (s, 
6H). 13C NMR (CDCl3, 100 MHz): δ 138.5, 129.2, 128.9, 125.7, 49.9, 35.2, 34.8, 27.0. IR 
(film) cm-1 2956, 2056, 1583, 1479, 1438, 1384, 1365, 1089, 1025. HRMS (ESI, Pos) calcd 
for C22H31S2 [M+H]+: 359.1862, found 359.1874 m/z. 
 
6-methoxy-3,3-dimethylthiochroman (454): Synthesized according to Procedure AA. The 
residue was purified by flash chromatography (Hex), affording the title compound (92 mg, 
88%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.03-7.01 (m, 1H), 6.69-6.66 (m, 1H), 
6.58-6.59 (m, 1H), 3.75 (s, 3H), 2.72 (s, 2H), 2.54 (s, 2H), 1.10 (s, 6H). 13C NMR (CDCl3, 100 
MHz): δ 156.8, 134.4, 127.0, 123.3, 116.1, 112.8, 55.7, 43.9, 39.3, 29.1, 28.2. IR (film) cm-1 
2953, 2933, 1599, 1482, 1312, 1230, 1151, 1034. HRMS (ESI, Pos) calcd for C12H17O1S1 
[M+H]+: 209.0995, found 209.0990 m/z.  
 
2,2-dimethyl-1,2,3,4-tetrahydronaphthalene (456): Synthesized according to Procedure 
AA. The residue was purified by flash chromatography (Hex), affording the title compound 
(59 mg,74%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.15-7.04 (m, 4H), 2.84 (t, 2H, J = 
6.9 Hz), 2.58 (s, 2H), 1.60 (t, 2H, J = 6.9 Hz), 1.04 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 
136.7, 135.9, 129.6, 128.9, 125.6 (2), 43.7, 36.1, 29.6, 28.3, 26.8. IR (film) cm-1 2949, 2911, 
1494, 1452, 1364. LRMS (CI, Pos) calcd for C12H17 [M+H]+: 161.1, found 161.1 m/z. 
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7-methoxy-2,2-dimethyl-1,2,3,4-tetrahydronaphthalene (458): Synthesized according to 
Procedure AA. The residue was purified by flash chromatography (Hex), affording the title 
compound (84 mg, 88%) as a clear oil. 1H NMR (CDCl3, 300 MHz): δ 7.04–6.99 (m, 1H), 
6.73–6.67 (m, 1H), 6.61–6.57 (m, 1H), 3.78 (s, 3H), 2.74 (t, 2H, J = 6.8 Hz), 2.52 (s, 2H), 1.56 
(t, 2H, J = 6.8 Hz), 1.00 (s, 6H). 13C NMR (CDCl3, 75 MHz): δ 157.6, 137.7, 129.7, 128.0, 
114.1, 111.8, 55.3, 43.9, 36.3, 29.5, 28.2 (2), 25.8. IR (film) cm–1 2948, 2908, 1610, 1502, 
1463, 1364, 1269, 1242, 1219, 1156, 1042. LRMS (CI, Pos) calcd for C14H19O1 [M+H]+: 
191.1, found 191.1 m/z. 
 
7-tert-butyl-2,2-dimethyl-1,2,3,4-tetrahydronaphthalene (460): Synthesized according to 
Procedure AA. The residue was purified by flash chromatography (Hex), affording the title 
compound (92 mg, 85%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.22-7.07 (m, 3H), 2.82 
(t, 2H, J = 6.8 Hz), 2.60 (s, 2H), 1.61 (t, 2H, J = 6.8 Hz), 1.37 (s, 9H), 1.05 (s, 6H) ppm. 13C 
NMR (CDCl3, 100 MHz): δ 148.4, 136.1, 132.9, 128.5, 126.3, 122.6, 43.9, 36.2, 31.6, 28.5, 
26.2 ppm. IR (film) cm-1 2950, 2906, 2868, 1460, 1433, 1363, 1339, 1256, 1089. LRMS (EI) 
calcd for C16H24 [M]: 216.2, found 216.2 m/z. 
 
2,2,7-trimethyl-1,2,3,4-tetrahydronaphthalene (462): Synthesized according to Procedure 
AA. The residue was purified by flash chromatography (Hex), affording the title compound 
(75 mg, 86%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.05-6.90 (m, 3H), 2.81 (t, 2H, J = 
6.8 Hz), 2.54 (s, 2H), 2.33 (s, 3H), 1.60 (t, 2H , J = 6.8 Hz), 1.03 (s, 6H). 13C NMR (CDCl3, 
100 MHz): δ 136.4, 134.9, 132.7, 130.2, 128.8, 126.4, 43.6, 36.2, 29.6, 28.3, 26.2, 21.1. IR 
(film) cm-1 2949, 2913, 2868, 1504, 1450, 1433, 1383, 1364, 1167. LRMS (CI, Pos) calcd for 
C13H19 [M+H]+: 175.2, found 175.2 m/z. 
 
7-chloro-2,2-dimethyl-1,2,3,4-tetrahydronaphthalene (464): Synthesized according to 
Procedure AA. The residue was purified by flash chromatography (Hex), affording the title 
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compound (72 mg, 74%) as a clear oil. 1H NMR (CDCl3, 300 MHz): δ 7.13–6.90 (m, 3H), 
2.75 (t, 2H, J = 6.6 Hz), 2.49 (s, 2H), 1.55 (t, 2H, J = 6.8 Hz), 0.97 (s, 6H). 13C NMR (CDCl3, 
75 MHz): δ 138.5, 134.3, 131.0, 130.2, 129.3, 125.6, 43.4, 35.8, 29.4, 28.1 (2), 26.1. IR (film) 
cm–1 2950, 2918, 2869, 1486, 1449, 1431, 1365, 1089. LRMS (CI, Pos) calcd for C12H16Cl1 
[M+H]+: 195.1, found 195.0 m/z. 
 
N,N-diethyl-7,7-dimethyl-5,6,7,8-tetrahydronaphthalene-2-carboxamide (466): 
Synthesized according to Procedure AA. The residue was purified by flash chromatography 
(10-15% EtOAc/Hex), affording the title compound (90 mg, 70%) as a clear oil. 1H NMR 
(CDCl3, 400 MHz): δ 7.10-7.00 (m, 3H), 3.52-3.28 (m, 4H), 2.79 (t, 2H, J = 6.7 Hz), 2.52 (s, 
2H), 1.56 (t, 2H, J = 6.7 Hz), 1.21-1.12 (m, 6H), 0.97 (s, 6H) ppm. 13C NMR (CDCl3, 100 
MHz): δ 171.7, 137.9, 137.1, 136.1, 134.7, 129.3, 128.6, 127.6, 126.9, 123.5, 43.5, 35.9, 29.5, 
28.2, 26.5, 14.3, 13.0 ppm. IR (film) cm-1 2915, 1627, 1425, 1381, 1364, 1315, 1290, 1255, 
1221, 1162, 1118. HRMS (ESI Pos): expe. for C17H25NNaO [M+Na]+: 282.1836, calc. 
282.1828 m/z.  
 
8-methoxy-2,2-dimethyl-1,2,3,4-tetrahydronaphthalene (468a) and 6-methoxy-2,2-
dimethyl-1,2,3,4-tetrahydronaphthalene (468b): Synthesized according to Procedure AA. 
The residue was purified by flash chromatography (Hex), affording 468a (59 mg, 62%) and 
468b (22 mg, 23%) as clear oils.  
468a: 1H NMR (CDCl3, 400 MHz): δ 7.14 (t, 1H, J = 8.1 Hz), 6.80 (d, 1H, J = 7.8 Hz), 6.71 
(d, 2H, J = 8.1 Hz), 3.87 (s, 3H), 2.85 (t, 2H, J = 6.8 Hz), 2.51 (s, 2H), 1.59 (t, 2H, J = 6.8 
Hz), 1.06 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 157.7, 137.3, 125.8, 125.4, 121.2, 106.8, 
55.3, 37.0, 35.6, 29.0, 28.7, 26.8. IR (film) cm-1 2948, 2914, 2869, 2843, 1585, 1467, 1252. 
LRMS (CI, Pos) calcd for C13H19O1 [M+H]+: 191.1, found 191.1 m/z. 
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468b: 1H NMR (CDCl3, 400 MHz): δ 6.97 (d, 1H, J = 8.5 Hz), 6.71-6.67 (m, 2H), 3.77 (s, 
3H), 2.77 (t, 2H, J = 6.7 Hz), 2.47 (s, 2H), 1.54 (t, 2H, J = 6.7 Hz), 0.99 (s, 6H). 13C NMR 
(CDCl3, 100 MHz): δ 157.5, 136.9, 130.4, 128.7, 113.4, 111.9, 55.5, 42.9, 36.0, 29.7, 28.2, 
27.0. IR (film) cm-1 2949, 2917, 1610, 1503, 1466, 1261, 1243, 1043. LRMS (CI, Pos) calcd 
for C13H19O1 [M+H]+: 191.1, found 191.1 m/z. 
 
 
2,2,8-trimethyl-1,2,3,4-tetrahydronaphthalene (470a) and 2,2,6-trimethyl-1,2,3,4-
tetrahydronaphthalene (470b): Synthesized according to Procedure AA. The residue was 
purified by flash chromatography (Hex), affording an inseparable 3:1 mixture of 470a and 
470b (71 mg, 81%) as a clear oil.  
470a: 1H NMR (CDCl3, 400 MHz): δ 7.10-6.98 (m, 3H), 2.87 (t, 2H, J = 6.7 Hz), 2.45 (s, 2H), 
2.30 (s, 3H), 1.61 (t, 2H, J = 6.7 Hz), 1.07 (s, 6H). Minor: 1H NMR (CDCl3, 400 MHz): δ 
7.10-6.98 (m, 3H), 2.82 (t, 2H, J = 6.7 Hz), 2.58 (s, 2H), 2.35 (s, 3H), 1.62-1.59 (m, 2H), 1.04 
(s, 6H). Major + minor 13C NMR (CDCl3, 100 MHz): δ 136.8, 135.7, 135.6, 135.0, 134.8, 
133.4, 129.4 (2 C’s), 127.1, 126.7, 125.0, 43.2, 40.8, 36.1, 35.5, 29.6, 28.7, 27.0, 26.6, 21.0, 
19.7. IR (film) cm-1 2948, 2911, 2864, 1458, 1384, 1363. LRMS (CI, Pos) calcd for C13H19 
[M+H]+: 175.2, found 175.1 m/z. 
 
2,2,5-trimethyl-1,2,3,4-tetrahydronaphthalene (472a) + 2,2,8-trimethyl-1,2,3,4-
tetrahydronaphthalene (472b): Synthesized according to Procedure AA. The residue was 
purified by flash chromatography (Hex), affording an inseparable 10:1 mixture of 472a and 
472b (59 mg, 71%) as a clear oil.  
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472a: 1H NMR (CDCl3, 400 MHz): δ 7.07-6.89 (m, 3H), 2.65 (t, 2H, J = 6.7 Hz), 2.57 (s, 2H), 
2.24 (s, 3H), 1.62 (t, 2H, J = 6.7 Hz), 0.99 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 136.4 (2), 
134.3, 127.4, 127.1, 125.4, 44.1, 36.2, 29.2, 28.1, 24.5, 19.7. IR (film) cm-1 2948, 2909, 2866, 
1460, 1430, 1384, 1364. LRMS (CI, Pos) calcd for C13H19 [M+H]+: 175.2, found 175.1 m/z. 
472b: 1H NMR (CDCl3, 300 MHz): δ 7.07-6.89 (m, 3H), 2.83 (t, 2H, J = 6.4 Hz), 2.40 (s, 2H), 
2.23 (s, 3H), 1.56 (t, 2H, J = 6.7 Hz), 1.02 (s, 6H). 
 
 
3',4'-dihydro-1'H-spiro[cyclohexane-1,2'-naphthalene] (474): Synthesized according to 
Procedure AA. The residue was purified by flash chromatography (Hex), affording the title 
compound (94 mg, 94%) as a clear oil. 1H NMR (CDCl3, 400 MHz): δ 7.15-7.08 (m, 4H), 2.82 
(t, 2H, J = 6.7 Hz), 2.63 (s, 2H), 1.68 (t, 2H, J = 6.7 Hz), 1.57-1.47 (m, 6H), 1.40-1.37 (m, 
4H). 13C NMR (CDCl3, 100 MHz): δ 136.4 (2), 129.7, 128.8, 125.6, 125.5, 41.4, 36.5, 33.4, 
32.0, 26.9, 25.7, 21.9. IR (film) cm-1 2918, 2845, 1494, 1449, 745, 712. LRMS (CI, Pos) calcd 
for C15H21 [M+H]+: 201.2, found 201.1 m/z. 
O N
 
1-(2,2-dimethyl-4-phenylbutoxy)-2,2,6,6-tetramethylpiperidine (479): Synthesized 
according to Procedure AA in presence of TEMPO (78.1 mg, 1 mmol). The residue was 
purified by flash chromatography (Hex), affording the TEMPO-adduct 479 (52 mg, 33%) as a 
clear oil and recovery of 455 (90 mg, 63%). 1H NMR (CDCl3, 400 MHz): δ 7.33-7.29 (m, 
2H), 7.24-7.19 (m, 3H), 3.60 (s, 2H), 2.67-62 (m, 2H), 1.66-1.62 (m, 2H), 1.56-1.30 (m, 6H), 
1.23 (s, 6H), 1.18 (s, 6H), 1.06 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 143.9, 128.7, 125.9, 
84.9, 60.7, 42.7, 40.3, 35.8, 33.9, 31.3, 25.6, 20.6, 17.3. IR (film) cm-1 2928, 2870, 1470, 
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1373, 1133, 1059. HRMS (ESI, Pos) calcd for C21H36N1O1 [M+H]+: 318.2791, found 
318.2793 m/z. 
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Annex 1: X-Ray Data for Compounds 242a and 241b 
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242a: 
 
      Table 1.  Crystal data and structure refinement for C17 H14 Cl N O.  
    
      Identification code               cha217  
   
      Empirical formula                 C17 H14 Cl N O  
   
      Formula weight                    283.74  
   
      Temperature                       150K  
   
      Wavelength                        1.54178 Å  
   
      Crystal system                    Orthorhombic  
   
      Space group                       Pna21  
   
      Unit cell dimensions              a = 12.5875(8) Å    α = 90°  
                                        b = 17.8684(12) Å    β = 90°  
                                        c = 6.0173(4) Å    γ = 90°  
   
      Volume                            1353.40(15)Å3  
   
      Z                                 4  
   
      Density (calculated)              1.393  g/cm3  
   
      Absorption coefficient            2.440 mm-1  
   
      F(000)                            592  
   
      Crystal size                      0.25 x 0.15 x 0.15 mm  
   
      Theta range for data collection   4.30 to 69.70°  
   
      Index ranges                      -15 ≤ h ≤ 15, -21 ≤ k ≤ 21, -5 ≤  ≤ 7  
   
      Reflections collected             39869  
   
      Independent reflections           1968 [Rint = 0.039]  
xxxii 
 
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.6935 and 0.5640  
   
      Refinement method                 Full-matrix least-squares on F2  
   
      Data / restraints / parameters    1968 / 1 / 183  
   
      Goodness-of-fit on F2             1.080  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0299, wR2 = 0.0791  
   
      R indices (all data)              R1 = 0.0299, wR2 = 0.0791  
   
      Absolute structure parameter      0.127(18)  
   
      Largest diff. peak and hole       0.254 and -0.251 e/Å3  
241b: 
 
  Table 2.  Crystal data and structure refinement for C18 H14 F3 N O.  
   
   
      Identification code               cha227  
   
      Empirical formula                 C18 H14 F3 N O  
   
      Formula weight                    317.30  
   
      Temperature                       100K  
   
      Wavelength                        1.54178 Å  
   
      Crystal system                    Monoclinic  
   
      Space group                       P21/n  
   
      Unit cell dimensions              a = 15.2477(7) Å    α = 90°  
                                        b = 5.8321(3) Å    β = 90.669(3)°  
                                        c = 16.7963(9) Å    γ = 90°  
xxxiii 
 
   
      Volume                            1493.53(13)Å3  
   
      Z                                 4  
   
      Density (calculated)              1.411  g/cm3  
   
      Absorption coefficient            0.964 mm-1  
   
      F(000)                            656  
   
      Crystal size                      0.22 x 0.04 x 0.02 mm  
   
      Theta range for data collection   3.89 to 70.51°  
   
      Index ranges                      -18 ≤ h ≤ 18, -6 ≤ k ≤ 7, -20 ≤  ≤ 20  
   
      Reflections collected             18994  
   
      Independent reflections           2813 [Rint = 0.042]  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9809 and 0.7716  
   
      Refinement method                 Full-matrix least-squares on F2  
   
      Data / restraints / parameters    2813 / 84 / 219  
   
      Goodness-of-fit on F2             1.112  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0453, wR2 = 0.1269  
   
      R indices (all data)              R1 = 0.0515, wR2 = 0.1323  
   
      Largest diff. peak and hole       0.358 and -0.253 e/Å3 
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